Note: Descriptions are shown in the official language in which they were submitted.
CA 02489091 2004-12-08
SPECIFICATION
Inhibitors against activation of NF- rc B
Field of Invention
The present invention relates to a medicament having inhibitory activity
against activation of NF- r~ B.
Background Art
Inflammation is a basic defense mechanism to various infestations, where
inflammatory cytokine such as interleukin (IL)-1, TNF- a (tumor necrosis
factor) and
prostaglandin E2 (PGE2) are known to play important roles. Due to the progress
of
gene analysis of inflammatory cytokines and inflammatory cell adhesion
factors, it has
been revealed that these cytokines are controlled by a common transcription
factor
(also called as transcription regulatory factor). This transcription factor is
a protein
called as NF- r~ B (also described as NF r~ B, Nucleic Acids Research,
(England), 1986,
Vo1.14, No.20, p.7897-1914; Cold Spring Harbor Symposia on Quantitative
Biology,
(USA), 1986, Vo1.51, No.l, p.611-624).
The NF- rc B is a hetero dimer (also called as complex) of p65 (also called as
Rel
A) and p50 (also called as NF- ~ B- 1 ), usually binds to I- ~c B when
external
stimulation does not exist, and exists in cytoplasm as an inactive form. I- ~
B is
phosphorated by various external stimulations such as oxidative stress,
cytokine,
lipopolysaccharide, virus, UV, free radical, protein kinase C to become
ubiquitin, and
then decomposed by proteasome (Genes & Development, (USA), 1995, Vol.9, No.22,
p.2723-2735). NF- rc B separated from I- r~ B immediately move into nucleus,
and
plays a role as a transcription factor by binding to a promoter region which
has
recognition sequence of NF- ~ B.
In 1997, phosphoenzyme (called as I r~ B kinase abbreviated as "IKK"), which
participates in phosphorylation of I- ~ B, was identified (Nature, (England),
1997,
Vo1.388, p.548-554; Cell, (USA), 1997, Vo1.90, No.2, p.373-383). IKK- a (also
called
as IKK1) and IKK- ~3 (also called as IKK2) which resemble to each other exist
among a
class of IKK, and they are known to form a complex to bind directly to I ~ B
and
phosphorize I rc B (Science, (USA), 1997, Vo1.278, p.866-869; Cell, (USA),
1997, Vo1.91,
1
CA 02489091 2004-12-08
No.2, p.243-252).
Recently, a mechanism except cyclooxygenase inhibition is suggested for
aspirin, a widely used anti-inflammatory agent, which is known to be based on
inhibition of NF- ~ B activation (Science, (USA), 1994, Vo1.265, p.956-959).
Moreover,
it Was revealed that aspirin regulates release and activation of NF- ~ B by
binding
reversibly to IKK- a which is I- rc B kinase competing with ATP and by
inhibiting
phosphorylation of I- ~c B (Nature, (England), 1998, Vo1.396, p.77-80).
However, a
huge amount of aspirin needs to be administered to sufficiently suppress NF- ~
B
activation, and as a result, side effects such as gastrointestinal disorders
by
prostaglandin synthesis inhibition and increase of bleeding tendency by
anticoagulation action are expected to be caused with high probability.
Accordingly,
aspirin is not suitable for long term application.
Besides aspirin, some pharmaceuticals are known to have inhibitory action
against NF- ~ B activation. Glucocorticoids (steroid hormones) such as
dexamethasone supprress NF- x B activation by binding to their receptors
(called as
glucocorticoid receptor, Science, (USA), 1995, Vo1.270, p.283-286). However,
long
term use is not suitable, because they have serious side effects such as
aggravation of
an infectious disease, generation of peptic ulcer, degradation of bone
density, and
central action. Leflunomide as an immunosuppressive agent, an isoxazole-type
agent,
also has NF- ~c B inhibitory action (Journal of Immunology, (USA), 1999,
Vo1.162, No.4,
p.2095-2102), however, the drug is also not suitable for long term use due to
serious
side effects. Furthermore, substituted pyrimidine derivatives (Japanese Patent
Publication of International Application (KOHYO) No.(Hei)11-512399, and
Journal of
Medicinal Chemistry, (USA), 1998, Vo1.41, No.4, p.413-419), xanthine
derivatives
(Japanese Patent Unexamined Publication (KOKAI) No.(Hei)9-227561),
isoquinoline
derivatives (Japanese Patent Unexamined Publication (KOKAI) No.(Hei)10-87491),
indan derivatives (International Patent Publication WO00/05234 pamphlet),
N-phenylsalicylamide derivatives (International Patent Publication W099/65499
pamphlet and International Patent Publication W002/076918 pamphlet),
epoxyquinomycin C, D, and their derivatives (Japanese Patent Unexamined
Publication (KOKAI) No.(Hei)10-45738, and Bioorganic & Medicinal Chemistry
Letters, (England), 2000, Vo1.10, No.9, p.865-869) are known as inhibitors
against NF-
x B activation. Moreover, in the pamphlet of International Patent Publication
2
CA 02489091 2004-12-08
W002/051397, N-phenylsalicylamide derivatives are disclosed as inhibitors
against
the production of cytokines.
Disclosure of the Invention
An object of the present invention is to provide medicaments having inhibitory
activity against activation of NF- rc B.
The inventors of the present invention carried out search for compounds
having inhibitory activity against activation of NF- r~ B by a virtual
screening out of
compounds registered in databases of compounds commercially available from
suppliers such as Sigma-Aldrich, Aldrich, Maybridge, Specs, Bionet, Labotest,
Lancaster, Tocris, Tokyo Kasei Kogyo Co., Wako Pure Chemical Industries and
the like,
by using an automatic search program of a ligand from a three-dimensional
compound
database based on the three-dimensional structure of the protein. Using
candidate
compounds selected by the screening, the inventors of the present invention
investigated whether they have inhibitory activity against NF- rc B activation
by a
reporter assay method under TNF- a stimulation. They further conducted
syntheses
of their analogous compounds and investigation whether they have inhibitory
activity
against release of inflammatory mediators under TNF- a stimulation. The
present
invention was achieved on the basis of these findings.
The present invention thus provides:
(1) A medicament having inhibitory activity against NF- r~ B activation which
comprises as an active ingredient a substance selected from the group
consisting of a
compound represented by the following general formula (I) and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof:
A
~O O
\ NiE (I)
Z
H
wherein A represents hydrogen atom or acetyl group,
E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a
monocyclic
or a fused polycyclic heteroaryl group which may be substituted, provided that
the
compound wherein said heteroaryl group is 1~ a fused polycyclic heteroaryl
group
wherein the ring which binds directly to -CONH- group in the formula (I) is a
CA 02489091 2004-12-08
benzene ring, 2~ unsubstituted thiazol-2-yl group, or 3~ unsubstituted
benzothiazol-2-yl group is excluded,
ring Z represents an arene which may have one or more substituents in addition
to the
group represented by formula -O-A wherein A has the same meaning as that
defined above and the group represented by formula -CONH-E wherein E has the
same meaning as that defined above, or a heteroarene which may have one or
more
substituents in addition to the group represented by formula -O-A wherein A
has
the same meaning as that defined above and the group represented by formula -
CONH-E wherein E has the same meaning as that defined above.
Examples of preferred medicaments of the present invention include:
(2) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
A is a
hydrogen atom;
(3) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
ring Z is a
Cs to Cio arene which may have one or more substituents in addition to the
group
represented by formula -O-A wherein A has the same meaning as that defined in
the general formula (I) and the group represented by formula -CONH-E wherein E
has the same meaning as that defined in the general formula (I), or a 5 to 10-
membered
heteroarene which may have one or more substituents in addition to the group
represented by formula -0-A wherein A has the same meaning as that defined in
the general formula (I) and the group represented by formula -CONH-E wherein E
has the same meaning as that defined in the general formula (I);
(4) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
ring Z is a
benzene ring which may have one or more substituents in addition to the group
represented by formula -O-A wherein A has the same meaning as that defined in
the general formula (I) and the group represented by formula -CONH-E wherein E
has the same meaning as that defined in the general formula (I), or a
naphthalene ring
which may have one or more substituents in addition to the group represented
by
4
CA 02489091 2004-12-08
formula -O-A wherein A has the same meaning as that defined in the general
formula (I) and the group represented by formula -CONH-E wherein E has the
same meaning as that defined in the general formula (I);
(5) a medicament having inhibitory activity against NF- r~ B activation which
comprises as an active ingredient a substance selected from the group
consisting of a
compound represented by the following general formula (I) and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
ring Z is a
benzene ring which is substituted with halogen atoms) in addition to the group
represented by formula -O-A wherein A has the same meaning as that defined in
the general formula (I) and the group represented by formula -CONH-E wherein E
has the same meaning as that defined in the general formula (I);
(6) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
ring Z is a
naphthalene ring which may have one or more substituents in addition to the
group
represented by formula -O-A wherein A has the same meaning as that defined in
the general formula (I) and the group represented by formula -CONH-E wherein E
has the same meaning as that defined in the general formula (I);
(7) a medicament having inhibitory activity against NF- ~ B activation which
comprises as an active ingredient a substance selected from the group
consisting of a
compound represented by the following general formula (I) and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
E is a
2,5-di-substituted phenyl group or a 3,5-di-substituted phenyl group;
(8) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
E is a
2,5-di-substituted phenyl group wherein at least one of said substituents is
trifluoromethyl group, or a 3,5-di-substituted phenyl group wherein at least
one of said
substituents is trifluoromethyl group;
(9) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
E is
3,5-bis(trifluoromethyl)phenyl group;
CA 02489091 2004-12-08
(10) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
E is a
monocyclic or a fused polycyclic heteroaryl group which may be substituted,
provided
that the compound wherein said heteroaryl group is ~l a fused polycyclic
heteroaryl
group wherein the ring which binds directly to -CONH- group in the formula (I)
is
a benzene ring, 2~ unsubstituted thiazol-2-yl group, or 3~ unsubstituted
benzothiazol-2-yl group is excluded;
(11) the aforementioned medicament which comprises as an active ingredient a
substance selected from the group consisting of the compound and a
pharmacologically
acceptable salt thereof, and a hydrate thereof and a solvate thereof, wherein
E is a
5-membered monocyclic heteroaryl group which may be substituted, provided that
the
compound wherein said heteroaryl group is unsubstituted thiazol-2-yl group is
excluded.
From another aspect, the present invention provides use of each of the
substances for manufacture of the medicament according to the aforementioned
(1) to
(11) and an inhibitor which comprises each of the aforementioned substances
against
NF- r~ B activation.
The present invention further provides a method for inhibiting NF- ~c B
activation in a mammal including a human, which comprises the step of
administering
effective dose of each of the aforementioned substances to a mammal including
a
human.
Brief Explanation of the Drawings
Fig.l shows inhibitory activity of the medicament of the present invention
against the collagenous arthritis in mouse.
Fig.2 shows inhibitory activity of the medicament of the present invention
against the immediate type allergy.
Best Mode for Carrying out the Invention
Reference to the disclosure of the pamphlet of International Publication
W002/49632 is useful for better understanding of the present invention. The
entire
disclosure of the aforementioned pamphlet of International Publication
W002/49632 is
6
CA 02489091 2004-12-08
incorporated by reference in the disclosures of the present specification.
The terms used in the present specification have the following meanings.
As the halogen atom, any of fluorine atom, chlorine atom, bromine atom, or
iodine atom may be used unless otherwise specifically referred to.
Examples of the hydrocarbon group include, for example, an aliphatic
hydrocarbon group, an aryl group, an arylene group, an aralkyl group, a
bridged cyclic
hydrocarbon group, a spiro cyclic hydrocarbon group, and a terpene
hydrocarbon.
Examples of the aliphatic hydrocarbon group include, for example, alkyl group,
alkenyl group, alkynyl group, alkylene group, alkenylene group, alkylidene
group and
the like which are straight chain or branched chain monovalent or bivalent
acyclic
hydrocarbon groups; cycloalkyl group, cycloalkenyl group, cycloalkanedienyl
group,
cycloalkyl-alkyl group, cycloalkylene group, and cycloalkenylene group, which
are
saturated or unsaturated monovalent or bivalent alicyclic hydrocarbon groups.
Examples of the alkyl group include, for example, methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-
methylbutyl,
1-methylbutyl, neopentyl, 1,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 4-
methylpentyl,
3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-
dimethylbutyl,
1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl,
2-ethylbutyl, 1-ethylbutyl, 1-ethyl-1-methylpropyl, n-heptyl, n-octyl, n-
nonyl, n-decyl,
n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, and n-pentadecyl, which are Ci
to Cis
straight chain or branched chain alkyl groups.
Examgles of the alkenyl group include, for example, vinyl, prop-1-en-1-yl,
allyl,
isopropenyl, but-1-en-1-yl, but-2-en-1-yl, but-3-en-1-yl, 2-methylprop-2-en-1-
yl,
1-methylprop-2-en-1-yl, pent-1-en-1-yl, pent-2-en-1-yl, pent-3-en-1-yl, pent-4-
en-1-yl,
3-methylbut-2-en-1-yl, 3-methylbut-3-en-1-yl, hex-1-en-1-yl, hex-2-en-1-yl,
hex-3-en-1-yl, hex-4-en-1-yl, hex-5-en-1-yl, 4-methylpent-3-en-1-yl,
4-methylpent-3-en-1-yl, hept-1-en-1-yl, hept-6-en-1-yl, oct-1-en-1-yl, oct-7-
en-1-yl,
non-1-en-1-yl, non-8-en-1-yl, dec-1-en-1-yl, dec-9-en-1-yl, undec-1-en-1-yl,
undec-10-en-1-yl, dodec-1-en-1-yl, dodec-11-en-1-yl, tridec-1-en-1-yl, tridec-
12-en-1-yl,
tetradec-1-en-1-yl, tetradec-13-en-1-yl, pentadec-1-en-1-yl, and pentadec-14-
en-1-yl,
which are Cz to Cis straight chain or branched chain alkenyl groups.
Examples of the alkynyl group include, for example, ethynyl, prop-1-yn-1-yl,
prop-2-yn-1-yl, but-1-yn-1-yl, but-3-yn-1-yl, 1-methylprop-2-yn-1-yl, pent-1-
yn-1-yl,
7
CA 02489091 2004-12-08
pent-4-yn-1-yl, hex-1-yn-1-yl, hex-5-yn-1-yl, hept-1-yn-1-yl, hept-6-yn-1-yl,
oct-1-yn-1-yl, oct-7-yn-1-yl, non-1-yn-1-yl, non-8-yn-1-yl, dec-1-yn-1-yl, dec-
9-yn-1-yl,
undec-1-yn-1-yl, undec-10-yn-1-yl, dodec-1-yn-1-yl, dodec-11-yn-1-yl, tridec-1-
yn-1-yl,
tridec-12-yn-1-yl, tetradec-1-yn-1-yl, tetradec-13-yn-1-yl, pentadec-1-yn-1-
yl, and
pentadec-14-yn-1-yl, which are Ca to Cis straight chain or branched chain
alkynyl
groups.
Examgles of the alkylene group include, for example, methylene, ethylene,
ethane-1,1-diyl, propane-1,3-diyl, propane-1,2-diyl, propane-2,2-diyl, butane-
1,4-diyl,
pentane-1,5-diyl, hexane-1,6-diyl, and 1,1,4,4-tetramethylbutane-1,4-diyl
group, which
are Ci to Cs straight chain or branched chain alkylene groups.
Examples of the alkenylene group include, for example, ethene-1,2-diyl,
propene-1,3-diyl, but-1-ene-1,4-diyl, but-2-ene-1,4-diyl, 2-methylpropene-1,3-
diyl,
pent-2-ene-1,5-diyl, and hex-3-ene-1,6-diyl, which are Ci to Cs straight chain
or
branched chain alkylene groups.
Examples of the alkylidene group include, for example, methylidene,
ethylidene, propylidene, isopropylidene, butylidene, pentylidene, and
hexylidene,
which are Ci to Cs straight chain or branched chain alkylidene groups.
Examples of the cycloalkyl group include, for example, cyclopropyl,
cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl, which are Ca to Ca
cycloalkyl
groups.
The aforementioned cycloalkyl group may be fused with benzene ring,
naphthalene ring and the like, and examples include, for example, 1-indanyl, 2-
indanyl,
1,2,3,4-tetrahydronaphthalen-1-yl, and 1,2,3,4-tetrahydronaphthalen-2-yl.
Examples of the cycloalkenyl group include, for example, 2-cyclopropen-1-yl,
2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl,
3-cyclohexen-1-yl, 1-cyclobuten-1-yl, and 1-cyclopenten-1-yl, which are Ca to
Cs
cycloalkenyl grougs.
The aforementioned cycloalkenyl group may be fused with benzene ring,
naphthalene ring and the like, and examples include, for example, 1-indanyl, 2-
indanyl,
1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, 1-
indenyl, and
2-indenyl.
Examples of the cycloalkanedienyl group include, for example,
2,4-cyclopentadien-1-yl, 2,4-cyclohexanedien-1-yl, and 2,5-cyclohexanedien-1-
yl, which
8
CA 02489091 2004-12-08
are Cs to Cs cycloalkanedienyl groups.
The aforementioned cycloalkanedienyl group may be fused with benzene ring,
naphthalene ring and the like, and examples include, for example, 1-indenyl
and
2-indenyl.
Examples of the cycloalkyl-alkyl group include the groups in which one
hydrogen atom of the alkyl group is substituted with a cycloalkyl group, and
include,
for example, cyclopropylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl,
3-cyclopropylpropyl, 4-cycloprogylbutyl, 5-cyclopropylpentyl, 6-
cyclopropylhexyl,
cyclobutylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopentylmethyl,
cyclohexylmethyl, cyclohexylpropyl, cyclohexylbutyl, cycloheptylmethyl,
cyclooctylmethyl, and 6-cyclooctylhexyl, which are C4 to Ci4 cycloalkyl-alkyl
groups.
Examples of the cycloalkylene group include, for example,
cyclopropane-1,1-diyl, cyclopropane-1,2-diyl, cyclobutane-1,1-diyl,
cyclobutane-1,2-diyl,
cyclobutane-1,3-diyl, cyclopentane-1,1-diyl, cyclopentane-1,2-diyl,
cyclopentane-1,3-diyl, cyclohexane-1,1-diyl, cyclohexane-1,2-diyl, cyclohexane-
1,3-diyl,
cyclohexane-1,4-diyl, cycloheptane-1,1-diyl, cycloheptane-1,2-diyl,
cyclooctane-1,1-diyl,
and cyclooctane-1,2-diyl, which are Cs to Cs cycloalkylene groups.
Examples of the cycloalkenylene group include, for example,
2-cyclopropene-1,1-diyl, 2-cyclobutene-1,1-diyl, 2-cyclopentene-1,1-diyl,
3-cyclopentene-1,1-diyl, 2-cyclohexene-1,1-diyl, 2-cyclohexene-1,2-diyl,
2-cyclohexene-1,4-diyl, 3-cyclohexene-1,1-diyl, 1-cyclobutene-1,2-diyl,
1-cyclopentene-1,2-diyl, and 1-cyclohexene-1,2-diyl, which are Cs to Cs
cycloalkenylene
groups.
Examples of the aryl group include a monocyclic or a fused polycyclic aromatic
hydrocarbon group, and include, for example, phenyl, 1-naphthyl, 2-naphthyl,
anthryl,
phenanthryl, and acenaphthylenyl, which are Cs to Ci4 aryl groups.
The aforementioned aryl group may be fused with the aforementioned Cs to Cs
cycloalkyl group, Cs to Cs cycloalkenyl group, Cs to Cs cycloalkanedienyl
group or the
like, and examples include, for example, 4-indanyl, 5-indanyl,
1,2,3,4-tetrahydronaphthalen-5-yl, 1,2,3,4-tetrahydronaphthalen-6-yl,
3-acenaphthenyl, 4-acenaphthenyl, inden-4-yl, inden-5-yl, inden-6-yl, inden-7-
yl,
4-phenalenyl, 5-phenalenyl, 6-phenalenyl, 7-phenalenyl, 8-phenalenyl, and
9-phenalenyl.
9
CA 02489091 2004-12-08
Examples of the arylene group include, for example, 1,2-phenylene,
1,3-phenylene, 1,4-phenylene, naphthalene-1,2-diyl, naphthalene-1,3-diyl,
naphthalene-1,4-diyl, naphthalene-1,5-diyl, naphthalene-1,6-diyl, ,
naphthalene-1,7-diyl, naphthalene-1,8-diyl, naphthalene-2,3-diyl,
naphthalene-2,4-diyl, naphthalene-2,5-diyl, naphthalene-2,6-diyl,
naphthalene-2,7-diyl, naphthalene-2,8-diyl, and anthracene-1,4-diyl, which are
Cs to
Ci4 arylene groups.
Examples of the aralkyl group include the groups in which one hydrogen atom
of the alkyl group is substituted with an aryl group, and include, for
example, benzyl,
1-naphthylmethyl, 2-naphthylmethyl, anthracenylmethyl, phenanthrenylmethyl,
acenaphthylenylmethyl, diphenylmethyl, 1-phenethyl, 2-phenethyl,
1-(1-naphthyl)ethyl, 1-(2-naphthyl)ethyl, 2-(1-naphthyl)ethyl, 2-(2-
naphthyl)ethyl,
3-phenylpropyl, 3-(1-naphthyl)propyl, 3-(2-naphthyl)propyl, 4-phenylbutyl,
4-(1-naphthyl)butyl, 4-(2-naphthyl)butyl, 5-phenylpentyl, 5-(1-
naphthyl)pentyl,
5-(2-naphthyl)pentyl, 6-phenylhexyl, 6-(1-naphthyl)hexyl, and 6-(2-
naphthyl)hexyl,
which are C~ to Cis aralkyl groups.
Examples of the bridged cyclic hydrocarbon group include, for example,
bicyclo[2.1.0]pentyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]octyl, and
adamantyl.
Examples of the spiro cyclic hydrocarbon group include, for example,
spiro[3.4]octyl, and spiro[4.5]deca-1,6-dienyl.
Examples of the terpene hydrocarbon include, for example, geranyl, neryl,
linalyl, phytyl, menthyl, and bornyl.
Examples of the halogenated alkyl group include the groups in which one
hydrogen atom of the alkyl group is substituted with a halogen atom, and
include, for
example, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl,
dichloromethyl,
trichloromethyl, bromomethyl, dibromomethyl, tribromomethyl, iodomethyl,
diiodomethyl, triiodomethyl, 2,2,2-trifluoroethyl, pentafluoroethyl,
3,3,3-trifluoropropyl, heptafluoropropyl, heptafluoroisogropyl,
nonafluorobutyl, and
perfluorohexyl, which are Ci to Cs straight chain or branched chain
halogenated alkyl
groups substituted with 1 to 13 halogen atoms.
Examples of the heterocyclic group include, for example, a monocyclic or a
fused polycyclic hetero aryl group which comprises at least one atom of 1 to 3
kinds of
hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the
like as
CA 02489091 2004-12-08
ring-constituting atoms (ring forming atoms), and a monocyclic or a fused
polycyclic
non-aromatic heterocyclic group which comprises at least one atom of 1 to 3
kinds of
hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and the
like as
ring-constituting atoms (ring forming atoms).
Examples of the monocyclic heteroaryl group include, for example, 2-furyl,
3-furyl, 2-thienyl, 3-thienyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-oxazolyl,
4-oxazolyl,
5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-
thiazolyl, 5-thiazolyl,
3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1-imidazolyl, 2-imidazolyl, 4-
imidazolyl,
5-imidazolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, (1,2,3-
oxadiazol)-4-yl,
(1,2,3-oxadiazol)-5-yl, (1,2,4-oxadiazol)-3-yl, (1,2,4-oxadiazol)-5-yl,
(1,2,5-oxadiazol)-3-yl, (1,2,5-oxadiazol)-4-yl, (1,3,4-oxadiazol)-2-yl,
(1,3,4-oxadiazol)-5-yl, furazanyl, (1,2,3-thiadiazol)-4-yl, (1,2,3-thiadiazol)-
5-yl,
(1,2,4-thiadiazol)-3-yl, (1,2,4-thiadiazol)-5-yl, (1,2,5-thiadiazol)-3-yl,
(1,2,5-thiadiazol)-4-yl, (1,3,4-thiadiazolyl)-2-yl, (1,3,4-thiadiazolyl)-5-yl,
(1H-1,2,3-triazol)-1-yl, (1H-1,2,3-triazol)-4-yl, (1H-1,2,3-triazol)-5-yl,
(2H-1,2,3-triazol)-2-yl, (2H-1,2,3-triazol)-4-yl, (1H-1,2,4-triazol)-1-yl,
(1H-1,2,4-triazol)-3-yl, (1H-1,2,4-triazol)-5-yl, (4H-1,2,4-triazol)-3-yl,
(4H-1,2,4-triazol)-4-yl, (1H-tetrazol)-1-yl, (1H-tetrazol)-5-yl, (2H-tetrazol)-
2-yl,
(2H-tetrazol)-5-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 3-pyridazinyl, 4-
pyridazinyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, (1,2,3-triazin)-4-
yl,
(1,2,3-triazin)-5-yl, (1,2,4-triazin)-3-yl, (1,2,4-triazin)-5-yl, (1,2,4-
triazin)-6-yl,
(1,3,5-triazin)-2-yl, 1-azepinyl, 2-azepinyl, 3-azepinyl, 4-azepinyl, (1,4-
oxazepin)-2-yl,
(1,4-oxazepin)-3-yl, (1,4-oxazepin)-5-yl, (1,4-oxazepin)-6-yl, (1,4-oxazepin)-
7-yl,
(1,4-thiazepin)-2-yl, (1,4-thiazepin)-3-yl, (1,4-thiazepin)-5-yl, (1,4-
thiazepin)-6-yl, and
(1,4-thiazepin)-7-yl, which are 5 to 7-membered monocyclic heteroaryl groups.
Examples of the fused polycyclic heteroaryl group include, for example,
2-benzofuranyl, 3-benzofuranyl, 4-benzofuranyl, 5-benzofuranyl, 6-
benzofuranyl,
7-benzofuranyl, 1-isobenzofuranyl, 4-isobenzofuranyl, 5-isobenzofuranyl,
2-benzo[b]thienyl, 3-benzo[b]thienyl, 4-benzo[b]thienyl, 5-benzo[b]thienyl,
6-benzo[b]thienyl, 7-benzo[b]thienyl, 1-benzo[c]thienyl, 4-benzo[c]thienyl,
5-benzo[c]thienyl, 1-indolyl, 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-
indolyl,
6-indolyl, 7-indolyl, (2H-isoindol)-1-yl, (2H-isoindol)-2-yl, (2H-isoindol)-4-
yl,
(2H-isoindol)-5-yl, (1H-indazol)-1-yl, (1H-indazol)-3-yl, (1H-indazol)-4-yl,
11
CA 02489091 2004-12-08
(1H-indazol)-5-yl, (1H-indazol)-6-yl, (1H-indazol)-7-yl, (2H-indazol)-1-yl,
(2H-indazol)-2-yl, (2H-indazol)-4-yl, (2H-indazol)-5-yl, 2-benzoxazolyl, 2-
benzoxazolyl,
4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl, 7-benzoxazolyl, (1,2-
benzisoxazol)-3-yl,
(1,2-benzisoxazol)-4-yl, (1,2-benzisoxazol)-5-yl, (1,2-benzisoxazol)-6-yl,
(1,2-benzisoxazol)-7-yl, (2,1-benzisoxazol)-3-yl, (2,1-benzisoxazol)-4-yl,
(2,1-benzisoxazol)-5-yl, (2,1-benzisoxazol)-6-yl, (2,1-benzisoxazol)-7-yl,
2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl,
7-benzothiazolyl, (1,2-benzisothiazol)-3-yl, (1,2-benzisothiazol)-4-yl,
(1,2-benzisothiazol)-5-yl, (1,2-benzisothiazol)-6-yl, (1,2-benzisothiazol)-7-
yl,
(2,1-benzisothiazol)-3-yl, (2,1-benzisothiazol)-4-yl, (2,1-benzisothiazol)-5-
yl,
(2,1-benzisothiazol)-6-yl, (2,1-benzisothiazol)-7-yl, (1,2,3-benzoxadiazol)-4-
yl,
(1,2,3-benzoxadiazol)-5-yl, (1,2,3-benzoxadiazol)-6-yl, (1,2,3-benzoxadiazol)-
7-yl,
(2,1,3-benzoxadiazol)-4-yl, (2,1,3-benzoxadiazol)-5-yl, (1,2,3-
benzothiadiazol)-4-yl,
(1,2,3-benzothiadiazol)-5-yl, (1,2,3-benzothiadiazol)-6-yl, (1,2,3-
benzothiadiazol)-7-yl,
(2,1,3-benzothiadiazol)-4-yl, (2,1,3-benzothiadiazol)-5-yl, (1H-benzotriazol)-
1-yl,
(1H-benzotriazol)-4-yl, (1H-benzotriazol)-5-yl, (1H-benzotriazol)-6-yl,
(1H-benzotriazol)-Z-yl, (2H-benzotriazol)-2-yl, (2H-benzotriazol)-4-yl,
(2H-benzotriazol)-5-yl, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-
quinolyl,
7-quinolyl, 8-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-
isoquinolyl,
6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl, 3-cinnolinyl, 4-cinnolinyl, 5-
cinnolinyl,
6-cinnolinyl, 7-cinnolinyl, 8-cinnolinyl, 2-quinazolinyl, 4-quinazolinyl, 5-
quinazolinyl,
6-quinazolinyl, 7-quinazolinyl, 8-quinazolinyl, 2-quinoxalinyl, 5-
quinoxalinyl,
6-quinoxalinyl, 1-phthalazinyl, 5-phthalazinyl, 6-phthalazinyl, 2-
naphthyridinyl,
3-naphthyridinyl, 4-naphthyridinyl, 2-purinyl, 6-purinyl, 7-purinyl, 8-
purinyl,
2-pteridinyl, 4-pteridinyl, 6-pteridinyl, 7-pteridinyl, 1-carbazolyl, 2-
carbazolyl,
3-carbazolyl, 4-carbazolyl, 9-carbazolyl, 2-( a -carbolinyl), 3-( a -
carbolinyl), 4-( a
-carbolinyl), 5-( a -carbolinyl), 6-( a -carbolinyl), 7-( a -carbolinyl), 8-(
a -carbolinyl),
9-( a -carbolinyl), 1-( ~3 -carbolinyl), 3-( /3 -carbolinyl), 4-( (3 -
carbolinyl), 5-( (3 -carbolinyl),
6-( a -carbolinyl), 7-( (3 -carbolinyl), 8-( a -carbolinyl), 9-( (3 -
carbolinyl), 1-( y -carbolinyl),
2-( y -carbolinyl), 4-( y -carbolinyl), 5-( y -carbolinyl), 6-( y -
carbolinyl), 7-( y -carbolinyl),
8-( y -carbolinyl), 9-( y -carbolinyl), 1-acridinyl, 2-acridinyl, 3-acridinyl,
4-acridinyl,
9-acridinyl, 1-phenoxazinyl, 2-phenoxazinyl, 3-phenoxazinyl, 4-phenoxazinyl,
10-phenoxazinyl, 1-phenothiazinyl, 2-phenothiazinyl, 3-phenothiazinyl,
12
CA 02489091 2004-12-08
4-phenothiazinyl, 10-phenothiazinyl, 1-phenazinyl, 2-phenazinyl, 1-
phenanthridinyl,
2-phenanthridinyl, 3-phenanthridinyl, 4-phenanthridinyl, 6-phenanthridinyl,
7-phenanthridinyl, 8-phenanthridinyl, 9-phenanthridinyl, 10-phenanthridinyl,
2-phenanthrolinyl, 3-phenanthrolinyl, 4-phenanthrolinyl, 5-phenanthrolinyl,
6-phenanthrolinyl, 7-phenanthrolinyl, 8-phenanthrolinyl, 9-phenanthrolinyl,
10-phenanthrolinyl, 1-thianthrenyl, 2-thianthrenyl, 1-indolizinyl, 2-
indolizinyl,
3-indolizinyl, 5-indolizinyl, 6-indolizinyl, 7-indolizinyl, 8-indolizinyl, 1-
phenoxathiinyl,
2-phenoxathiinyl, 3-phenoxathiinyl, 4-phenoxathiinyl, thieno[2,3-b]furyl,
pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridyl, imidazo[11,2-a]pyridyl,
imidazo[1,5-a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl,
1,2,4-triazolo[4,3-a]pyridyl, and 1,2,4-triazolo[4,3-a]pyridazinyl, which are
8 to
14-membered fused polycyclic heteroaryl groups.
Examples of the monocyclic non-aromatic heterocyclic group include, for
example, 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-
pyrrolidinyl, 2-
tetrahydrofuryl, 3-tetrahydrofuryl, thiolanyl, 1-imidazolidinyl, 2-
imidazolidinyl,
4-imidazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 1-(2-
pyrrolinyl),
1-(2-imidazolinyl), 2-(2-imidazolinyl), 1-(2-pyrazolinyl), 3-(2-pyrazolinyl),
piperidino,
2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1-homopiperidinyl, 2-
tetrahydropyranyl,
morpholino, (thiomorpholin)-4-yl, 1-piperazinyl, and 1-homopiperazinyl, which
are 3 to
7-membered saturated or unsaturated monocyclic non-aromatic heterocyclic
groups.
Examples of the fused polycyclic non-aromatic heterocyclic group include, for
example, 2-quinuclidinyl, 2-chromanyl, 3-chromanyl, 4-chromanyl, 5-chromanyl,
6-chromanyl, 7-chromanyl, 8-chromanyl, 1-isochromanyl, 3-isochromanyl,
4-isochromanyl, 5-isochromanyl, 6-isochromanyl, 7-isochromanyl, 8-
isochromanyl,
2-thiochromanyl, 3-thiochromanyl, 4-thiochromanyl, 5-thiochromanyl,
6-thiochromanyl, 7-thiochromanyl, 8-thiochromanyl, 1-isothiochromanyl,
3-isothiochromanyl, 4-isothiochromanyl, 5-isothiochromanyl, 6-
isothiochromanyl,
7-isothiochromanyl, 8-isothiochromanyl, 1-indolinyl, 2-indolinyl, 3-indolinyl,
4-indolinyl, 5-indolinyl, 6-indolinyl, 7-indolinyl, 1-isoindolinyl, 2-
isoindolinyl,
4-isoindolinyl, 5-isoindolinyl, 2-(4H-chromenyl), 3-(4H-chromenyl), 4-(4H-
chromenyl),
5-(4H-chromenyl), 6-(4H-chromenyl), 7-(4H-chromenyl), 8-(4H-chromenyl),
1-isochromenyl, 3-isochromenyl, 4-isochromenyl, 5-isochromenyl, 6-
isochromenyl,
7-isochromenyl, 8-isochromenyl, 1-(1H-pyrrolidinyl), 2-(1H-pyrrolidinyl),
13
CA 02489091 2004-12-08
3-(1H-pyrrolidinyl), 5-(1H-pyrrolidinyl), 6-(1H-pyrrolidinyl), and 7-(1H-
pyrrolidinyl),
which are 8 to 10-membered saturated or unsaturated fused polycyclic non-
aromatic
heterocyclic groups.
Among the aforementioned heterocyclic groups, a monocyclic or a fused
polycyclic hetero aryl groups which may have 1 to 3 kinds of hetero atoms
selected
from oxygen atom, sulfur atom, nitrogen atom and the like, in addition to the
nitrogen
atom that has the bond, as ring-constituting atoms (ring forming atoms), and a
monocyclic or a fused polycyclic non-aromatic heterocyclic groups which may
have 1 to
3 kinds of hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom
and the
like, in addition to the nitrogen atom that has the bond, as ring-constituting
atoms
(ring forming atoms) are referred to as "cyclic amino group." Examples
include, for
example, 1-pyrrolidinyl, 1-imidazolidinyl, 1-pyrazolidinyl, 1-oxazolidinyl,
1-thiazolidinyl, piperidino, morpholino, 1-piperazinyl, thiomorpholin-4-yl,
1-homopiperidinyl, 1-homopiperazinyl, 2-pyrolin-1-yl, 2-imidazolin-1-yl,
2-pyrazolin-1-yl, 1-indolinyl, 2-isoindolinyl, 1,2,3,4-tetrahydroquinolin-1-
yl,
1,2,3,4-tetrahydroisoquinolin-2-yl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, 1-
indolyl,
1-indazolyl, and 2-isoindolyl.
The aforementioned cycloalkyl group, cycloalkenyl group, cycloalkanedienyl
group, aryl group, cycloalkylene group, cycloalkenylene group, arylene group,
bridged
cyclic hydrocarbon group, spiro cyclic hydrocarbon group, and heterocyclic
group are
generically referred to as "cyclic group." Furthermore, among said cyclic
groups,
particularly, aryl group, arylene group, monocyclic heteroaryl group, and
fused
polycyclic heteroaryl group are generically referred to as "aromatic ring
group."
Examples of the hydrocarbon-oxy group include the groups in which a
hydrogen atom of the hydroxy group is substituted with a hydrocarbon group,
and
examples of the hydrocarbon include similar groups to the aforementioned
hydrocarbon groups. Examples of the hydrocarbon-oxy group include, for
example,
alkoxy group (alkyl-oxy group), alkenyl-oxy group, alkynyl-oxy group,
cycloalkyl-oxy
group, cycloalkyl-alkyl-oxy group and the like, which are aliphatic
hydrocarbon-oxy
groups; aryl-oxy group; aralkyl-oxy group; and alkylene-dioxy group.
Examples of the alkoxy (alkyl-oxy group) include, for example, methoxy,
ethoxy,
n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-
pentyloxy,
isopentyloxy, 2-methylbutoxy, 1-methylbutoxy, neopentyloxy, 1,2-
dimethylpropoxy,
14
CA 02489091 2004-12-08
1-ethylpropoxy, n-hexyloxy, 4-methylpentyloxy, 3-methylpentyloxy, 2-
methylpentyloxy,
1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethybutoxy, 1,1-dimethylbutoxy,
1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy, 2-ethylbutoxy,
1-ethylbutoxy, 1-ethyl-1-methylpropoxy, n-heptyloxy, n-octyloxy, n-nonyloxy, n-
decyloxy,
n-undecyloxy, n-dodecyloxy, n-tridecyloxy, n-tetradecyloxy, and n-
pentadecyloxy, which
are Ci to Cis straight chain or branched chain alkoxy groups.
Examples of the alkenyl-oxy group include, for example, vinyloxy,
(prop-1-en-1-yl)oxy, allyloxy, isopropenyloxy, (but-1-en-1-yl)oxy, (but-2-en-1-
yl)oxy,
(but-3-en-1-yl)oxy, (2-methylprop-2-en-1-yl)oxy, (1-methylprop-2-en-1-yl)oxy,
(pent-1-en-1-yl)oxy, (pent-2-en-1-yl)oxy, (pent-3-en-1-yl)oxy, (pent-4-en-1-
yl)oxy,
(3-methylbut-2-en-1-yl)oxy, (3-methylbut-3-en-1-yl)oxy, (hex-1-en-1-yl)oxy,
(hex-2-en-1-yl)oxy, (hex-3-en-1-yl)oxy, (hex-4-en-1-yl)oxy, (hex-5-en-1-
yl)oxy,
(4-methylpent-3-en-1-yl)oxy, (4-methylpent-3-en-1-yl)oxy, (hept-1-en-1-yl)oxy,
(hept-6-en-1-yl)oxy, (oct-1-en-1-yl)oxy, (oct-7-en-1-yl)oxy, (non-1-en-1-
yl)oxy,
(non-8-en-1-yl)oxy, (dec-1-en-1-yl)oxy, (dec-9-en-1-yl)oxy, (undec-1-en-1-
yl)oxy,
(undec-10-en-1-yl)oxy, (dodec-1-en-1-yl)oxy, (dodec-11-en-1-yl)oxy, (tridec-1-
en-1-yl)oxy,
(tridec-12-en-1-yl)oxy, (tetradec-1-en-1-yl)oxy, (tetradec-13-en-1-yl)oxy,
(pentadec-1-en-1-yl)oxy, and (pentadec-14-en-1-yl)oxy, which are Cz to Cis
straight
chain or branched chain alkenyl-oxy groups.
Examples of the alkynyl-oxy group include, for example, ethynyloxy,
(prop-1-yn-1-yl)oxy, (prop-2-yn-1-yl)oxy, (but-1-yn-1-yl)oxy, (but-3-yn-1-
yl)oxy,
(1-methylprop-2-yn-1-yl)oxy, (pent-1-yn-1-yl)oxy, (pent-4-yn-1-yl)oxy,
(hex-1-yn-1-yl)oxy, (hex-5-yn-1-yl)oxy, (hept-1-yn-1-yl)oxy, (kept-6-yn-1-
yl)oxy,
(oct-1-yn-1-yl)oxy, (oct-7-yn-1-yl)oxy, (non-1-yn-1-yl)oxy, (non-8-yn-1-
yl)oxy,
(dec-1-yn-1-yl)oxy, (dec-9-yn-1-yl)oxy, (undec-1-yn-1-yl)oxy, (undec-10-yn-1-
yl)oxy,
(dodec-1-yn-1-yl)oxy, (dodec-11-yn-1-yl)oxy, (tridec-1-yn-1-yl)oxy, (tridec-12-
yn-1-yl)oxy,
(tetradec-1-yn-1-yl)oxy, (tetradec-13-yn-1-yl)oxy, (pentadec-1-yn-1-yl)oxy,
and
(pentadec-14-yn-1-yl)oxy, which are Cz to Cis straight chain or branched chain
alkynyl-oxy groups.
Examples of the cycloalkyl-oxy group include, for example, cyclopropoxy,
cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, and cyclooctyloxy,
which are
Ca to Cs cycloalkyl-oxy groups.
Examples of the cycloalkyl-alkyl-oxy group include, fox example,
CA 02489091 2004-12-08
cyclopropylmethoxy, 1-cyclopropylethoxy, 2-cyclopropylethoxy, 3-
cyclopropylpropoxy,
4-cyclopropylbutoxy, 5-cyclopropylpentyloxy, 6-cyclopropylhexyloxy,
cyclobutylmethoxy,
cyclopentylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy,
2-cyclohexylethoxy, 3-cyclohexylpropoxy, 4-cyclohexylbutoxy,
cycloheptylmethoxy,
cyclooctylmethoxy, and 6-cyclooctylhexyloxy, which are C4 to Ci4 cycloalkyl-
alkyl-oxy
groups.
Examples of the aryl-oxy group include, for example, phenoxy, 1-naphthyloxy,
2-naphthyloxy, anthryloxy, phenanthryloxy, and acenaphthylenyloxy, which are
Cs to
Ci4 aryl-oxy groups.
Examples of the aralkyl-oxy group include, for example, benzyloxy,
1-naphthylmethoxy, 2-naphthylmethoxy, anthracenylmethoxy,
phenanthrenylmethoxy,
acenaphthylenylmethoxy, diphenylmethoxy, 1-phenethyloxy, 2-phenethyloxy,
1-(1-naphthyl)ethoxy, 1-(2-naphthyl)ethoxy, 2-(1-naphthyl)ethoxy,
2-(2-naphthyl)ethoxy, 3-phenylpropoxy, 3-(1-naphthyl)propoxy, 3-(2-
naphthyl)propoxy,
4-phenylbutoxy, 4-(1-naphthyl)butoxy, 4-(2-naphthyl)butoxy, 5-phenylpentyloxy,
5-(1-naphthyl)pentyloxy, 5-(2-naphthyl)pentyloxy, 6-phenylhexyloxy,
6-(1-naphthyl)hexyloxy, and 6-(2-naphthyl)hexyloxy, which are C~ to Cis
aralkyl-oxy
groups.
Examples of the alkylenedioxy group include, for example, methylenedioxy,
ethylenedioxy, 1-methylmethylenedioxy, and 1,1-dimethylmethylenedioxy.
Examples of the halogenated alkoxy group (halogenated alkyl-oxy group)
include the groups in which a hydrogen atom of the hydroxy groug is
substituted with
a halogenated alkyl group, and include, for example, fluoromethoxy,
difluoromethoxy,
chloromethoxy, bromomethoxy, iodomethoxy, trifluoromethoxy, trichloromethoxy,
2,2,2-trifluoroethoxy, pentafluoroethoxy, 3,3,3-trifluoropropoxy,
heptafluoropropoxy,
heptafluoroisopropoxy, nonafluorobutoxy, and perfluorohexyloxy, which are Ci
to Cs
straight chain or branched chain halogenated alkoxy groups substituted with 1
to 13
halogen atoms.
Examples of the heterocyclic-oxy group include the groups in which a hydrogen
atom of the hydroxy group is substituted with a heterocyclic group, and
examples of
the heterocyclic ring include similar groups to the aforementioned
heterocyclic groups.
Examples of the heterocyclic-oxy group include, for example, a monocyclic
heteroaryl-oxy group, a fused polycyclic heteroaryl-oxy group, a monocyclic
16
CA 02489091 2004-12-08
non-aromatic heterocyclic-oxy group, and a fused polycyclic non-aromatic
heterocyclic-oxy group.
Examples of the monocyclic heteroaryl-oxy group include, for example,
3-thienyloxy, (isoxazol-3-yl)oxy, (thiazol-4-yl)oxy, 2-pyridyloxy, 3-
pyridyloxy,
4-pyridyloxy, and (pyrimidin-4-yl)oxy.
Examples of the fused polycyclic heteroaryl-oxy group include, for example,
5-indolyloxy, (benzimidazol-2-yl)oxy, 2-quinolyloxy, 3-quinolyloxy, and 4-
quinolyloxy.
Examples of the monocyclic non-aromatic heterocyclic-oxy group include, for
example, 3-pyrrolidinyloxy, and 4-piperidinyloxy.
Examples of the fused polycyclic non-aromatic heterocyclic-oxy group include,
for example, 3-indolynyloxy, and 4-chromanyloxy.
Examples of the hydrocarbon-sulfanyl group include the groups in which a
hydrogen atom of the sulfanyl group is substituted with a hydrocarbon group,
and
examples of the hydrocarbon include similar groups to the aforementioned
hydrocarbon groups. Examples of the hydrocarbon-sulfanyl groups include, for
example, alkyl-sulfanyl group, alkenyl-sulfanyl group, alkynyl-sulfanyl group,
cycloalkyl-sulfanyl group, cycloalkyl-alkyl-sulfanyl group and the like, which
are
aliphatic hydrocarbon-sulfanyl groups; aryl-sulfanyl group, and aralkyl-
sulfanyl
group.
Examples of the alkyl-sulfanyl group include, for example, methylsulfanyl,
ethylsulfanyl, n-propylsulfanyl, isopropylsulfanyl, n-butylsulfanyl,
isobutylsulfanyl,
sec-butylsulfanyl, tert-butylsulfanyl, n-pentylsulfanyl, isopentylsulfanyl,
(2-methylbutyl)sulfanyl, (1-methylbutyl)sulfanyl, neopentylsulfanyl,
(1,2-dimethylpropyl)sulfanyl, (1-ethylpropyl)sulfanyl, n-hexylsulfanyl,
(4-methylpentyl)sulfanyl, (3-methylpentyl)sulfanyl, (2-methylpentyl)sulfanyl,
(1-methylpentyl)sulfanyl, (3,3-dimethylbutyl)sulfanyl, (2,2-
dimethylbutyl)sulfanyl,
(1,1-dimethylbutyl)sulfanyl, (1,2-dimethylbutyl)sulfanyl, (1,3-
dimethylbutyl)sulfanyl,
(2,3-dimethylbutyl)sulfanyl, (2-ethylbutyl)sulfanyl, (1-ethylbutyl)sulfanyl,
(1-ethyl-1-methylpropyl)sulfanyl, n-heptylsulfanyl, n-octylsulfanyl, n-
nonylsulfanyl,
n-decylsulfanyl, n-undecylsulfanyl, n-dodecylsulfanyl, n-tridecylsulfanyl,
n-tetradecylsulfanyl, and n-pentadecylsulfanyl, which are Ci to Cis straight
chain or
branched chain alkyl-sulfanyl groups.
Examples of the alkenyl-sulfanyl group include, for example, vinylsulfanyl,
17
CA 02489091 2004-12-08
(prop-1-en-1-yl)sulfanyl, allylsulfanyl, isopropenylsulfanyl, (but-1-en-1-
yl)sulfanyl,
(but-2-en-1-yl)sulfanyl, (but-3-en-1-yl)sulfanyl, (2-methylprop-2-en-1-
yl)sulfanyl,
(1-methylprop-2-en-1-yl)sulfanyl, (pent-1-en-1-yl)sulfanyl, (pent-2-en-1-
yl)sulfanyl,
(pent-3-en-1-yl)sulfanyl, (pent-4-en-1-yl)sulfanyl, (3-methylbut-2-en-1-
yl)sulfanyl,
(3-methylbut-3-en-1-yl)sulfanyl, (hex-1-en-1-yl)sulfanyl, (hex-2-en-1-
yl)sulfanyl,
(hex-3-en-1-yl)sulfanyl, (hex-4-en-1-yl)sulfanyl, (hex-5-en-1-yl)sulfanyl,
(4-methylpent-3-en-1-yl)sulfanyl, (4-methylpent-3-en-1-yl)sulfanyl,
(hept-1-en-1-yl)sulfanyl, (kept-6-en-1-yl)sulfanyl, (oct-1-en-1-yl)sulfanyl,
(oct-7-en-1-yl)sulfanyl, (non-1-en-1-yl)sulfanyl, (non-8-en-1-yl)sulfanyl,
(dec-1-en-1-yl)sulfanyl, (dec-9-en-1-yl)sulfanyl, (undec-1-en-1-yl)sulfanyl,
(undec-10-en-1-yl)sulfanyl, (dodec-1-en-1-yl)sulfanyl, (dodec-11-en-1-
yl)sulfanyl,
(tridec-1-en-1-yl)sulfanyl, (tridec-12-en-1-yl)sulfanyl, (tetradec-1-en-1-
yl)sulfanyl,
(tetradec-13-en-1-yl)sulfanyl, (pentadec-1-en-1-yl)sulfanyl, and
(pentadec-14-en-1-yl)sulfanyl, which are Cz to Cis straight chain or branched
chain
alkenyl-sulfanyl groups.
Examples of the alkynyl-sulfanyl group include, for example, ethynylsulfanyl,
(prop-1-yn-1-yl)sulfanyl, (prop-2-yn-1-yl)sulfanyl, (but-1-yn-1-yl)sulfanyl,
(but-3-yn-1-yl)sulfanyl, (1-methylprop-2-yn-1-yl)sulfanyl, (pent-1-yn-1-
yl)sulfanyl,
(pent-4-yn-1-yl)sulfanyl, (hex-1-yn-1-yl)sulfanyl, (hex-5-yn-1-yl)sulfanyl,
(hept-1-yn-1-yl)sulfanyl, (hept-6-yn-1-yl)sulfanyl, (oct-1-yn-1-yl)sulfanyl,
(oct-7-yn-1-yl)sulfanyl, (non-1-yn-1-yl)sulfanyl, (non-8-yn-1-yl)sulfanyl,
(dec-1-yn-1-yl)sulfanyl, (dec-9-yn-1-yl)sulfanyl, (undec-1-yn-1-yl)sulfanyl,
(undec-10-yn-1-yl)sulfanyl, (dodec-1-yn-1-yl)sulfanyl, (dodec-11-yn-1-
yl)sulfanyl,
(tridec-1-yn-1-yl)sulfanyl, (tridec-12-yn-1-yl)sulfanyl, (tetradec-1-yn-1-
yl)sulfanyl,
(tetradec-13-yn-1-yl)sulfanyl, (pentadec-1-yn-1-yl)sulfanyl, and
(pentadec-14-yn-1-yl)sulfanyl, which are C2 to Cis straight chain or branched
chain
alkynyl-sulfanyl groups.
Examples of the cycloalkyl-sulfanyl group include, for example,
cyclopropylsulfanyl, cyclobutylsulfanyl, cyclopentylsulfanyl,
cyclohexylsulfanyl,
cycloheptylsulfanyl, and cyclooctylsulfanyl, which are Ca to Cs cycloalkyl-
sulfanyl
groups.
Examples of the cycloalkyl-alkyl-sulfanyl group include, for example,
(cyclopropylmethyl)sulfanyl, (1-cyclopropylethyl)sulfanyl, (2-
cyclopropylethyl)sulfanyl,
18
CA 02489091 2004-12-08
(3-cyclopropylpropyl)sulfanyl, (4-cyclopropylbutyl)sulfanyl,
(5-cyclopropylpentyl)sulfanyl, (6-cyclopropylhexyl)sulfanyl,
(cyclobutylmethyl)sulfanyl,
(cyclopentylmethyl)sulfanyl, (cyclobutylmethyl)sulfanyl,
(cyclopentylmethyl)sulfanyl,
(cyclohexylmethyl)sulfanyl, (2-cyclohexylethyl)sulfanyl, (3-
cyclohexylpropyl)sulfanyl,
(4-cyclohexylbutyl)sulfanyl, (cycloheptylmethyl)sulfanyl,
(cyclooctylmethyl)sulfanyl,
and (6-cyclooctylhexyl)sulfanyl, which are C4 to Ci4 cycloalkyl-alkyl-sulfanyl
groups.
Examples of the aryl-sulfanyl group include, for example, phenylsulfanyl,
1-naphthylsulfanyl, 2-naphthylsulfanyl, anthrylsulfanyl, fenanthrylsulfanyl,
and
acenaphthylenylsulfanyl, which are Cs to Ci4 aryl-sulfanyl groups.
Examples of the aralkyl-sulfanyl group include, fox example, benzylsulfanyl,
(1-naphthylmethyl)sulfanyl, (2-naphthylmethyl)sulfanyl,
(anthracenylmethyl)sulfanyl,
(phenanthrenylmethyl)sulfanyl, (acenaphthylenylmethyl)sulfanyl,
(diphenylmethyl)sulfanyl, (1-phenethyl)sulfanyl, (2-phenethyl)sulfanyl,
(1-(1-naphthyl)ethyl)sulfanyl, (1-(2-naphthyl)ethyl)sulfanyl,
(2-(1-naphthyl)ehyl)sulfanyl, (2-(2-naphthyl)ethyl)sulfanyl, (3-
phenylpropyl)sulfanyl,
(3-(1-naphthyl)propyl)sulfanyl, (3-(2-naphthyl)propyl)sulfanyl,
(4-phenylbutyl)sulfanyl, (4-(1-naphthyl)butyl)sulfanyl, (4-(2-
naphthyl)butyl)sulfanyl,
(5-phenylpentyl)sulfanyl, (5-(1-naphthyl)pentyl)sulfanyl,
(5-(2-naphthyl)pentyl)sulfanyl, (6-phenylhexyl)sulfanyl, (6-(1-
naphthyl)hexyl)sulfanyl,
and (6-(2-naphthyl)hexyl)sulfanyl, which are C~ to Cis aralkyl-sulfanyl
groups.
Examples of the halogenated alkyl-sulfanyl group include the groups in which
a hydrogen atom of the sulfanyl group is substituted with a halogenated alkyl
group,
and include, for example, (fluoromethyl)sulfanyl, (chloromethyl)sulfanyl,
(bromomethyl)sulfanyl, (iodomethyl)sulfanyl, (difluoromethyl)sulfanyl,
(trifluoromethyl)sulfanyl, (trichloromethyl)sulfanyl, (2,2,2-
trifluoroethyl)sulfanyl,
(pentafluoroethyl)sulfanyl, (3,3,3-trifluoropropyl)sulfanyl,
(heptafluoropropyl)sulfanyl,
(heptafluoroisopropyl)sulfanyl, (nonafluorobutyl)sulfanyl, and
(perfluorohexyl)sulfanyl, which are Ci to Cs straight chain or branched chain
halogenated alkyl-sulfanyl groups substituted with 1 to 13 halogen atoms.
Examples of the heterocyclic-sulfanyl group include the groups in which a
hydrogen atom of the sulfanyl group is substituted with a heterocyclic group,
and
examples of the heterocyclic ring include similar groups to the aforementioned
heterocyclic groups. Examples of the heterocyclic-sulfanyl group include, for
example,
19
CA 02489091 2004-12-08
a monocyclic heteroaryl-sulfanyl group, a fused polycyclic heteroaryl-sulfanyl
group, a
monocyclic non-aromatic heterocyclic-sulfanyl group, and a fused polycyclic
non-aromatic heterocyclic-sulfanyl group.
Examples of the monocyclic heteroaryl-sulfanyl group include, for example,
(imidazol-2-yl)sulfanyl, (1,2,4-triazol-2-yl)sulfanyl, (pyridin-2-yl)sulfanyl,
(pyridin-4-yl)sulfanyl, and (pyrimidin-2-yl)sulfanyl.
Examples of the fused polycyclic heteroaryl-sulfanyl group include, for
example, (benzimidazol-2-yl)sulfanyl, (quinolin-2-yl)sulfanyl, and
(quinolin-4-yl)sulfanyl.
Examples of the monocyclic non-aromatic heterocyclic-sulfanyl groups include,
for example, (3-pyrrolidinyl)sulfanyl, and (4-piperidinyl)sulfanyl.
Examples of the fused polycyclic non-aromatic heterocyclic-sulfanyl group
include, for example, (3-indolinyl)sulfanyl, and (4-chromanyl)sulfanyl.
Examples of the acyl group include, for example, formyl group, glyoxyloyl
group, thioformyl group, carbamoyl group, thiocarbamoyl group, sulfamoyl
group,
sulfinamoyl group, carboxy group, sulfo group, phosphono group, and grougs
represented by the following formulas:
CA 02489091 2004-12-08
-C -Rai _ _ a1
_ R
O
(o' -lA) C (u' -2A)
O ~ O >
-C -C Rai -C -C O Rai
- - -
(u'-3A) ~~ ~) (cr'-4A)
O O > O O ,
_ _ a1 _ _
C _ R C a1
S R
(o'-5A) (~-6 A)
O > S
-C O Rai -C -S Rai
- - -
(u'-7A) ~~ (U' -8A)
S ~ S >
_ _ a1
_ N R -C- N- Rai
C
( 9 A) ( - 1 0
o' ~ A )
-
O H , ~ Rbi
-C N- Rai -C N Rai
- - -
S H (~'-1 lA) (0' -1 2A)
S Rbi
O O
-S- N- Rai ( 1 3 A) -S- N- Rai( - 1 4
v' u, A)
-
O H > ~ Rb1 ,
_ _ ai -S- N- R
_ R ai
H (u'-1 5A) (~''-1 6A)
O Rbi
O
ai
-s-O-Rai (u'-1 7A) -S-O R (0'-1 8A)
O >
O '
O -Rai O
-P=O ( v, - 1 9 A) -g-Rai ( ~ - 2 0 A)
O-Rbi O
-S -Ra 1 ( u~ - 2 1 A )
O
wherein R81 and Rbl may be the same or different and represent a hydrocarbon
group
or a heterocyclic group, or Ral and Rbl combine to each other, together with
the
nitrogen atom to which they bind, to form a cyclic amino group.
In the definition of the aforementioned acyl group, among the groups
represented by the formula ( w -lA), those groups in which Ral is a
hydrocarbon group
are referred to as "hydrocarbon-carbonyl group" whose examples include, for
example,
21
CA 02489091 2004-12-08
acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl,
lauroyl, myristoryl,
palmitoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, isocrotonoyl,
cyclohexylcarbonyl, cyclohexylmethylcarbonyl, benzoyl, 1-naphthoyl, 2-
naphthoyl, and
phenylacetyl, and those groups in which Ral is a heterocyclic group are
referred to as
"heterocyclic ring-carbonyl group" whose examples include, for example, 2-
thenoyl,
3-furoyl, nicotinoyl, and isonicotinoyl.
Among the groups represented by the formula ( c~ -2A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-oxy-carbonyl group"
whose
examples include, for example, methoxycarbonyl, ethoxycarbonyl,
phenoxycarbonyl,
and benzyloxycarbonyl, and those groups in which Ral is a heterocyclic group
are
referred to as "heterocyclic ring-oxy-carbonyl group" whose examples include,
for
example, 3-pyridyloxycarbonyl.
Among the groups represented by the formula ( w -3A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-carbonyl-carbonyl
group"
whose examples include, for example, pyruvoyl, and those groups in which R81
is a
heterocyclic group are referred to as "heterocyclic ring-carbonyl-carbonyl
group."
Among the groups represented by the formula ( w -4A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-oxy-carbonyl-
carbonyl
group" whose examples include, for example, methoxalyl and ethoxalyl groups,
and
those groups in which R81 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-carbonyl-carbonyl group."
Among the groups represented by the formula ( c~ -5A), those groups in which
R81 is a hydrocarbon group are referred to as "hydrocarbon-sulfanyl-carbonyl
group,"
and those groups in which R81 is a heterocyclic group are referred to as
"heterocyclic
ring-sulfanyl-carbonyl group."
Among the groups represented by the formula ( c~ -6A), those groups in which
R81 is a hydrocarbon group are referred to as "hydrocarbon-thiocarbonyl
group," and
those groups in which Ral is a heterocyclic group are referred to as
"heterocyclic
ring-thiocarbonyl group."
Among the groups represented by the formula ( cu -7A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-oxy-thiocarbonyl
group,"
and those groups in which Ral is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-thiocarbonyl group."
22
CA 02489091 2004-12-08
Among the groups represented by the formula ( c~ -8A), those groups in which
R81 is a hydrocarbon group are referred to as "hydrocarbon-sulfanyl-
thiocarbonyl
group," and those groups in which Ral is a heterocyclic group are referred to
as
"heterocyclic ring-sulfanyl-thiocarbanyl group."
Among the groups represented by the formula ( w -9A), those groups in which
Ral is a hydrocarbon group are referred to as referred to as "N-hydrocarbon-
carbamoyl
group" whose examples include, for example, N-methylcarbamoyl group, and those
groups in which Ral is a heterocyclic group are referred to as "N-heterocyclic
ring-carbamoyl group."
Among the groups represented by the formula ( ~ -l0A), those groups in which
both Ral and Rbl are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-carbamoyl group" whose examples include, for example,
N,N-dimethylcarbamoyl group, those groups in which both R81 and Rbl are
heterocyclic
groups are referred to as "N,N-di(heterocyclic ring)-carbamoyl group," those
groups in
which R81 is a hydrocarbon group and Rbl is a heterocyclic group are referred
to as
"N-hydrocarbon-N-heterocyclic ring-substituted carbamoyl group," and those
groups in
which Ral and Rbl combine to each other, together with the nitrogen atom to
which they
bind, to form a cyclic amino group are referred to as "cyclic amino-carbonyl
group"
whose examples include, for example, morpholino-carbonyl.
Among the groups represented by the formula ( c~ -11A), those groups in which
Ral is a hydrocarbon group are referred to as "N-hydrocarbon-thiocarbamoyl
group,"
and those groups in which R$1 is a heterocyclic group are referred to as "N-
heterocyclic
ring-thiocarbamoyl group."
Among the groups represented by the formula ( w -12A), those groups in which
both Ral and Rbl are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-thiocarbamoyl group," those groups in which both Ral and
Rbi
are heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-
thiocarbamoyl
group," those groups in which Ral is a hydrocarbon group and Rbl is a
heterocyclic
group are referred to as "N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl
group,"
and those groups in which Ral and Rbl combine to each other, together with the
nitrogen atom to which they bind, to form a cyclic amino group are referred to
as "cyclic
amino-thiocarbonyl group."
Among the groups represented by the formula ( cu -13A), those groups in which
23
CA 02489091 2004-12-08
Ral is a hydrocarbon group are referred to as "N-hydrocarbon-sulfamoyl group,"
and
those groups in which Ral is a heterocyclic group are referred to as "N-
heterocyclic
ring-sulfamoyl group."
Among the groups represented by the formula ( c~ -14A), those groups in which
both Ral and Rbl are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfamoyl group" whose examples include, for example,
N,N-dimethylsulfamoyl group, those groups in which both R$1 and Rbl are
heterocyclic
groups are referred to as "N,N-di(heterocyclic ring)-sulfamoyl group," those
groups in
which Ral is a hydrocarbon group and Rbl is a heterocyclic group are referred
to as
"N-hydrocarbon-N-heterocyclic ring-sulfamoyl group," and those groups in which
Ral
and Rbl combine to each other, together with the nitrogen atom to which they
bind, to
form a cyclic amino group are referred to as "cyclic amino-sulfonyl group"
whose
examples include, for example 1-pyrrolylsulfonyl.
Among the groups represented by the formula ( w -15A), those groups in which
Ral is a hydrocarbon group are referred to as "N-hydrocarbon-sulfinamoyl
group," and
those groups in which Ral is a heterocyclic group are referred to as "N-
heterocyclic
ring-sulfinamoyl group."
Among the groups represented by the formula ( w -16A), those groups in which
both Ral and Rbl are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfinamoyl group," those groups in which both Ral and
Rbl are
heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-sulfinamoyl
group,"
those groups in which Ral is a hydrocarbon group and Rbi is a heterocyclic
group are
referred to as "N-hydrocarbon-N-heterocyclic ring-sulfinamoyl group," and
those
groups in which Ral and Rbl combine to each other, together with the nitrogen
atom to
which they bind, to form a cyclic amino group are referred to as "cyclic amino-
sulfinyl
group."
Among the groups represented by the formula ( w -17A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfonyl
group," and
those groups in which Ral is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-sulfonyl group."
Among the groups represented by the formula ( cu -18A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfinyl
group," and
those groups in which R81 is a heterocyclic group are referred to as
"heterocyclic
24
CA 02489091 2004-12-08
ring-oxy-sulfinyl group."
Among the groups represented by the formula ( c~ -19A), those groups in which
both Ral and Rbl are hydrocarbon groups are referred to as
"O,O'-di(hydrocarbon)-phosphono group," those groups in which both Ral and Rbl
are
heterocyclic groups are referred to as "O,O'-di(heterocyclic ring)-phosphono
group,"
and those groups in which R$1 is a hydrocarbon group and Rbl is a heterocyclic
group
are referred to as "O-hydrocarbon-O'-heterocyclic ring-phosphono group."
Among the groups represented by the formula ( c~ -20A), those groups in which
Ral is a hydrocarbon group are referred to as "hydrocarbon-sulfonyl group"
whose
examples include, for example, methanesulfonyl and benzenesulfonyl, and those
groups in which Ral is a heterocyclic group are referred to as "heterocyclic
ring-sulfonyl
group."
Among the groups represented by the formula ( w -21A), those groups in which
R81 is a hydrocarbon group are referred to as "hydrocarbon-sulfinyl group"
whose
examples include, for example, methylsulfinyl and benzenesulfinyl, and those
groups
in which R81 is a heterocyclic group are referred to as "heterocyclic ring-
sulfinyl
group."
Examples of the hydrocarbon in the groups represented by the aforementioned
formulas ( cu -lA) through ( c~ -21A) include the similar groups to the
aforementioned
hydrocarbon group. Examples of the hydrocarbon-carbonyl group represented by
the
formula ( c~ -1A) include, for example, an alkyl-carbonyl group, an alkenyl-
carbonyl
group, an alkynyl-carbonyl group, a cycloalkyl-carbonyl group, a cycloalkenyl-
carbonyl
group, a cycloalkanedienyl-carbonyl group, a cycloalkyl-alkyl-carbonyl group,
which
are aliphatic hydrocarbon-carbonyl groups; an aryl-carbonyl group; an
aralkyl-carbonyl group; a bridged cyclic hydrocarbon-carbonyl group; a
spirocyclic
hydrocarbon-carbonyl group; and a terpene family hydrocarbon-carbonyl group.
In
the following, groups represented by the formulas ( c~ -2A) through ( c~ -21A)
are similar
to those explained above.
Examples of the heterocyclic ring in the groups represented by the
aforementioned formulas ( cu -lA) through ( cu -21A) include similar groups to
the
aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl
group
represented by the formula ( ~ -lA) include, for example, a monocyclic
heteroaryl-carbonyl group, a fused polycyclic heteroaryl-carbonyl group, a
monocyclic
CA 02489091 2004-12-08
non-aromatic heterocyclic ring-carbonyl group, and a fused polycyclic non-
aromatic
heterocyclic ring-carbonyl group. In the following, groups represented by the
formulas ( w -2A) through ( w -21A) are similar to those explained above.
Examples of the cyclic amino in the groups represented by the aforementioned
formulas ( cu -l0A) through ( w -16A) include similar groups to the
aforementioned cyclic
amino group.
In the present specification, when a certain functional group is defined as
"which may be substituted," the definition means that the functional group may
sometimes have one or more substituents at chemically substitutable positions,
unless
otherwise specifically mentioned. Kind of substituents, number of
substituents, and
the position of substituents existing in the functional groups are not
particularly
limited, and when two or more substituents exist, they may be the same or
different.
Examples of the substituent existing in the functional group include, for
example,
halogen atoms, oxo group, thioxo group, vitro group, nitroso group, cyano
group,
isocyano group, cyanato group, thiocyanato group, isocyanato group,
isothiocyanato
group, hydroxy group, sulfanyl group, carboxy group, sulfanylcarbonyl group,
oxalo
group, methooxalo group, thiocarboxy group, dithiocarboxy group, carbamoyl
group,
thiocarbamoyl group, sulfo group, sulfamoyl group, sulfino group, sulfinamoyl
group,
sulfeno group, sulfenamoyl group, phosphono group, hydroxyphosphonyl group,
hydrocarbon group, heterocyclic group, hydrocarbon-oxy group, heterocyclic
ring-oxy
group, hydrocarbon-sulfanyl group, heterocyclic ring-sulfanyl group, acyl
group, amino
group, hydrazine group, hydrazono group, diazenyl group, ureido group,
thioureido
group, guanidine group, carbamoimidoyl group (amidino group), azido group,
imino
group, hydroxyamino group, hydroxyimino group, aminooxy group, diazo group,
semicarbazino group, semicarbazono group, allophanyl group, hydantoyl group,
phosphano group, phosphoroso group, phospho group, beryl group, silyl group,
stannyl
group, selanyl group, oxide group and the like.
When two or more substituents exist according to the aforementioned
definition of "which may be substituted," said two or more substituents may
combine to
each other, together with atoms) to which they bind, to form a ring. For these
cyclic
groups, as ring-constituting atoms (ring forming atoms), one to three kinds of
one or
more hetero atoms selected from oxygen atom, sulfur atom, nitrogen atom and
the like
may be included, and one or more substituents may exist on the ring. The ring
may
26
CA 02489091 2004-12-08
be monocyclic or fused polycyclic, and aromatic or non-aromatic.
The above substituents according to the aforementioned definition of "which
may be substituted" may further be substituted with the aforementioned
substituents
at the chemically substitutable positions on the substituent. Kind of
substituents,
number of substituents, and positions of substituents are not particularly
limited, and
when the substituents are substituted with two or more substituents, they may
be the
same or different. Examples of the substituent include, for example, a
halogenated
alkyl-carbonyl group whose examples include, for example, trifluoroacetyl, a
halogenated alkyl-sulfonyl group whose examples include, for example,
trifluoromethanesulfonyl, an acyl-oxy group, an acyl-sulfanyl group, an
N-hydrocarbon-amino group, an N,N-di(hydrocarbon)-amino group, an N-
heterocyclic
ring-amino group, an N-hydrocarbon-N-heterocyclic ring-amino group, an acyl-
amino
group, and a di(acyl)-amino group. Moreover, substitution on the
aforementioned
substituents may be repeated multiple orders.
Examples of the acyl-oxy group include the groups in which hydrogen atom of
hydroxy group is substituted with acyl group, and include, for example,
formyloxy
group, glyoxyloyloxy group, thioformyloxy group, carbamoloxy group,
thiocarbamoyloxy group, sulfamoyloxy group, sulfinamoloxy group, carboxyoxy
group,
sulphooxy group, phosphonooxy group, and groups represented by the following
formulas:
27
CA 02489091 2004-12-08
-O -C -Ra2 -O -C -O -Ra2
(o~- 1 B) ~~ (u~-2 B)
'
O ~ O
-O -C-C -Ra2 -O -C -C O -Ra2
-
(~- 3 B) ~~ ~~ (0~-4 B)
O O ' O O '
_ _ a2 _ _ _
_ C _ R O C a2
O S R
(~,-5 B) (~-6 B)
O , S
-O -C-O -Ra2 -O -C -S Ra2
- BB)
(
(UJ-7B) Uw
S ' S '
a2 a2
-O- C - R -O -C -N- R
-
~ (u~-9 B) (~~- 1 0 B)
O H > O Rb2 '
_ _ _ _ _ _ _ a2
O a2 O _ R
R
C I (U~ - 1 1 B) ~ ~~ (u~- 1 2 B)
S H > SRb2
O O
-O -S -N-Ra2 ( o, - 1 3 B ) -O -S -N-Raz ( U, - 1 4 B )
O H , O Rb2 ,
_ _ _ _ a2 _ _ _ _ a2
O S i R (o~- 1 5 B) O S N R (~- 1 6 B)
O H ~ O Rb2
O
-O -S -O -Ra2
O-S-O-Ra2 (u~-1 7B) ~~ (~-1 8B)
O '
O '
O -Ra2 O
-O-P=O (m- 1 9 B) -O-S-Ra2 (U~-2 0 B)
O -Rb2 ' O >
-O -S -RaZ ( ~~ - 2 1 B )
O
wherein Ra2 and Rb2 may be the same or different and represent a hydrocarbon
group
or a heterocyclic group, or R$2 and Rb2 combine to each other, together with
the
nitrogen atom to which they bind, to form a cyclic amino group.
In the definition of the aforementioned acyl-oxy group, among the groups
represented by the formula ( c~ -1B ), those groups in which Ra2 is a
hydrocarbon group
are referred to as "hydrocarbon-carbonyl-oxy group" whose examples include,
for
28
CA 02489091 2004-12-08
example, acetoxy and benzoyloxy, and those groups in which Ra2 is a
heterocyclic group
are referred to as "heterocyclic ring-carbonyl-oxy group."
Among the groups represented by the formula ( w -2B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-oxy-carbonyl-oxy
group,"
and those groups in which Ra2 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-carbonyl-oxy group."
Among the groups represented by the formula ( w -3B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-carbonyl-carbonyl-
oxy
group," and those groups in which Ra2 is a heterocyclic group are referred to
as
"heterocyclic ring-carbonyl-carbonyl-oxy group."
Among the groups represented by the formula ( c~ -4B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-oxy-carbonyl-
carbonyl-oxy
group," and those groups in which Ra2 is a heterocyclic group are referred to
as
"heterocyclic ring-oxy-carbonyl-carbonyl-oxy group."
Among the groups represented by the formula ( c~ -5B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-sulfanyl-carbonyl-
oxy
group," and those groups where Ra2 is a heterocyclic group are referred to as
"heterocyclic ring-sulfanyl-carbonyl-oxy group."
Among the groups represented by the formula ( ~ -6B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-thiocarbonyl-oxy
group,"
and those groups where Ra2 is a heterocyclic group are referred to as
"heterocyclic
ring-thiocarbonyl-oxy group."
Among the groups represented by the formula ( w -7B), those groups in which
R82 is a hydrocarbon group are referred to as "hydrocarbon-oxy-thiocarbonyl-
oxy
group," and those groups in which Ra2 is a heterocyclic group are referred to
as
"heterocyclic ring-oxy-thiocarbonyl-oxy group."
Among the groups represented by the formula ( w -8B), those groups in which
Raz is a hydrocarbon group are referred to as "hydrocarbon-sulfanyl-
thiocarbonyl-oxy
group," and those groups wherein Ra2 is a heterocyclic group are referred to
as
"heterocyclic ring-sulfanyl-thiocarbonyl-oxy group."
Among the groups represented by the formula ( ~ -9B), those groups in which
Ra2 is a hydrocarbon group are referred to as "N-hydrocarbon-carbamoyl-oxy
group,"
and those groups in which Ra2 is a heterocyclic group are referred to as "N-
heterocyclic
29
CA 02489091 2004-12-08
ring-carbamoyl-oxy group."
Among the groups represented by the formula ( cu -lOB), those groups in which
both Ra2 and Rbz are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-carbamoyl-oxy group," those groups in which both Ra2 and
Rbz
are heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-
carbamoyl-oxy
group," those groups in which Ra2 is a hydrocarbon group and Rb2 is a
heterocyclic
group are referred to as "N-hydrocarbon-N-heterocyclic ring-carbamoyl-oxy
group,"
and those groups in which Ra2 and Rb2 combine to each other, together with the
nitrogen atom to which they bind, to form a cyclicic amino group are referred
to as
"cyclicamino-carbonyl-oxy group."
Among the groups represented by the formula ( ~-11B), those groups in which
Ra2 is a hydrocarbon group are referred to as "N-hydrocarbon-thiocarbamoyl-oxy
group," and those groups in which Ra2 is a heterocyclic group are referred to
as
"N-heterocyclic ring-thiocarbamoyl-oxy group."
Among the groups represented by the formula ( cu -12B), those groups in which
both Ra2 and Rb2 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-thiocarbamoyl-oxy group," those groups in which both R82
and
Rb2 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-thiocarbamoyl-oxy group," those groups in which Ra2 is a hydrocarbon
group and
Rbz is a heterocyclic group are referred to as "N-hydrocarbon-N-heterocyclic
ring-thiocarbamoyl-oxy group," and those groups in which R82 and Rbz combine
to each
other, together with the nitrogen atom to which they bind, to form a cyclic
amino group
are referred to as "cyclicamino-thiocarbonyl-oxy group."
Among the groups represented by the formula ( ~ -13B), those groups in which
Ra2 is a hydrocarbon group are referred to as "N-hydrocarbon-sulfamoyl-oxy
group,"
and those groups in which Ra2 is a heterocyclic group are referred to as "N-
heterocyclic
ring-sulfamoyl-oxy group."
Among the groups represented by the formula ( cu -14B), those groups in which
both Ra2 and Rb2 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfamoyl-oxy group," those groups in which both Ra2 and
Rbz
are heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-
sulfamoyl-oxy
group," those groups in which Ra2 is a hydrocarbon group and Rb2 is a
heterocyclic
group are referred to as "N-hydrocarbon-N-heterocyclic ring-sulfamoyl-oxy
group," and
CA 02489091 2004-12-08
those groups in which Ra2 and Rb2 combine to each other, together with the
nitrogen
atom to which they bind, to form a cyclic amino group are referred to as
"cyclic
amino-sulfonyl-oxy group."
Among the groups represented by the formula ( w -15B), those groups in which
Raz is a hydrocarbon group are referred to as "N-hydrocarbon-sulfinamoyl-oxy
group,"
and those groups where Ra2 is a heterocyclic group are referred to as "N-
heterocyclic
ring-sulfinamoyl-oxy group."
Among the groups represented by the formula ( c~ -16B), those groups in which
both Ra2 and R62 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfinamoyl-oxy group," those groups in which both Ra2
and Rbz
are heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-
sulfinamoyl-oxy
group," those groups in which Ra2 is a hydrocarbon group and Rb2 is a
heterocyclic
group are referred to as "N-hydrocarbon-N-heterocyclic ring-sulfinamoyl-oxy
group,"
and those groups in which Ra2 and Rb2 combine to each other, together with the
nitrogen atom to which they bind, to form a cyclic amino group are referred to
as "cyclic
amino-sulfinyl-oxy group."
Among the groups represented by the formula ( w -17B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfonyl-oxy
group,"
and those groups in which Ra2 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-sulfonyl-oxy group."
Among the groups represented by the formula ( W -18B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfinyl-oxy
group,"
those groups in which R82 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-sulfinyl-oxy group."
Among the groups represented by the formula ( c~ -19B), those groups in which
both Ra2 and Rb2 are hydrocarbon groups are referred to as
"O,O'-di(hydrocarbon)-phosphono-oxy group," those groups in which both Ra2 and
Rb2
are heterocyclic groups are referred to as "O,O'-di(heterocyclic ring)-
phosphono-oxy
group," and those groups in which Ra2 is a hydrocarbon group and Rb2 is a
heterocyclic
group are referred to as "O-hydrocarbon substituted-O'-heterocyclic ring
substituted
phophono-oxy group."
Among the groups represented by the formula ( w -20B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-sulfonyl-oxy
group," and
31
CA 02489091 2004-12-08
those groups in which Ra2 is a heterocyclic group referred to as "heterocyclic
ring-sulfonyl-oxy group."
Among the groups represented by the formula ( w-21B), those groups in which
Ra2 is a hydrocarbon group are referred to as "hydrocarbon-sulfinyl-oxy
group," and
those groups in which Ra2 is a heterocyclic group are referred to as
"heterocyclic
ring-sulfinyl-oxy group."
Examples of the hydrocarbon in the groups represented by the aforementioned
formulas ( c~ -1B) through ( c~ -21B) include the similar groups to the
aforementioned
hydrocarbon group. Examples of the hydrocarbon-carbonyl-oxy group represented
by
the formula ( c~-1B) include, for example, an alkyl-carbonyl-oxy group, an
alkenyl-carbonyl-oxy group, an alkynyl-carbonyl-oxy group, a cycloalkyl-
carbonyl-oxy
group, a cycloalkenyl-carbonyl-oxy group, a cycloalkanedienyl-carbonyl-oxy
group, and
a cycloalkyl-alkyl-carbonyl-oxy group, which are aliphatic hydrocarbon-
carbonyl-oxy
groups; an aryl-carbonyl-oxy group; an aralkyl-carbonyl-oxy group; a bridged
cyclic
hydrocarbon-carbonyl-oxy group; a spirocyclic hydrocarbon-carbonyl-oxy group;
and a
terpene family hydrocarbon-carbonyl-oxy group. In the following, groups
represented
by the formulas ( w -2B) through ( w -21B) are similar to those explained
above.
Examples of the heterocyclic ring in the groups represented by the
aforementioned formulas (~-1B) through (w-21B) include similar groups to the
aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl
group
represented by the formula ( c~ -1B) include, for example, a monocyclic
heteroaryl-carbonyl group, a fused polycyclic heteroaryl-carbonyl group, a
monocyclic
non-aromatic heterocyclic ring-carbonyl group, and a fused polycyclic non-
aromatic
heterocyclic ring-carbonyl group. In the following, groups represented by the
formulas ( ~ -2B) through ( ~ -21B) are similar to those groups explained
above.
Examples of the cyclic amino in the groups represented by the aforementioned
formulas ( c~ -lOB) through ( ~ -16B) include similar groups to the
aforementioned cyclic
amino group.
The aforementioned acyl-oxy group, hydrocarbon-oxy group, and
heterocyclic-oxy group are generically referred to as "substituted oxy group."
Moreover, these substituted oxy group and hydroxy group are generically
referred to as
"hydroxy group which may be substituted."
Examples of the acyl-sulfanyl group include the groups in which hydrogen
32
CA 02489091 2004-12-08
atom of sulfanyl group is substituted with acyl group, and include, for
example,
formylsulfanyl group, glyoxyloylsulfanyl group, thioformylsulfanyl group,
carbamoyloxy group, thicarbamoyloxy group, sulfamoyloxy group, sulfinamoyloxy
group, carboxyoxy group, sulphooxy group, phosphonooxy group, and groups
represented by the following formulas:
-S-C-Ra3 -S-C-O-Ra3 ( cu - 2 C )
II (u~- 1 C) (I
O > O ,
-S -C -C -Ra3 -S -C -C -O -Ra3
II II (~- s C) II II (~~-4 C)
O O ' O O ,
_ _ _ _ a3 _ _ _ a3
S C S R (~,,-5C) S C R (o~-6C)
O , S
-S -C -O -Ra3 -S -C -S -Ra3 ( ~ - 8 C )
(~~-7C) II
S ' S ,
-S -C -N-Ra3 -S -C -N-Ra3
O H (~"-9C) ' O Rb3 (u~-1 OC)
_ _ _ _ a3 _ _ _ _ a3
S C H R (~,-11C)' S C RbsR (u,-12C)'
O O
-S-S-N-Ra3 (~~- 1 3 C) -S-S-N-Ra3 (w- 1 4 C)
O H ' O Rb3 ,
_ _ _ _ a3 _ _ _ _ a3
S S I R (~- 1 5 C) S S N R (~- 1 6 C)
O H ' O Rba '
O
_ _ _ _ a3
-S -S -O -Ra3 ( w _ 1 7 C ) S S O R ( w - 1 8 C )
II O '
O '
O -Ra3 O
-S - i =O ( u~ - 1 9 C ) -S -S -Ra3 ( u.~ - 2 0 C )
O -Rbs ' O >
-S -S -Ra3 ( w _ 2 1 C )
I I
O
33
CA 02489091 2004-12-08
wherein Ra3 and Rb3 may be the same or different and represent a hydrocarbon
group
which may be substituted or a heterocyclic group which may be substituted, or
Ra3 and
Rb3 combine to each other, together with the nitrogen atom to which they bind,
to form
a cyclic amino group which may be substituted.
In the definition of the aforementioned acyl-sulfanyl group, among the groups
represented by the formula ( W -1C), those groups in which R83 is a
hydrocarbon group
are referred to as "hydrocarbon-carbonyl-sulfanyl group," and those groups in
which
R83 is a heterocyclic group are referred to as "heterocyclic ring-carbonyl-
sulfanyl
group."
Among the groups represented by the formula ( w-2C), those groups in which
R$3 is a hydrocarbon group are referred to as "hydrocarbon-oxy-carbonyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"heterocyclic ring-oxy-carbonyl-sulfanyl group."
Among the groups represented by the formula ( c~-3C), those groups in which
R83 is a hydrocarbon group are referred to as "hydrocarbon-carbonyl-carbonyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"heterocyclic ring-carbonyl-carbonyl-sulfanyl group."
Among the groups represented by the formula ( w -4C), those groups in which
Ra3 is a hydrocarbon group are referred to as
"hydrocarbon-oxy-carbonyl-carbonyl-sulfanyl group," and those groups in which
R83 is
a heterocyclic group are referred to as "heterocyclic
ring-oxy-carbonyl-carbonyl-sulfanyl group."
Among the groups represented by the formula ( ~ -5C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-sulfanyl-carbonyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"heterocyclic ring-sulfanyl-carbonyl-sulfanyl group."
Among the groups represented by the formula ( ~ -6C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-thiocarbonyl-
sulfanyl
group," and those groups in which R83 is a heterocyclic group are referred to
as
"heterocyclic ring-thiocarbonyl-sulfanyl group."
Among the groups represented by the formula ( c~ -7C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-oxy-thiocarbonyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
34
CA 02489091 2004-12-08
"heterocyclic ring-oxy-thiocarbonyl-sulfanyl group."
Among the groups represented by the formula ( c~ -8C), those groups in which
Ra3 is a hydrocarbon group are referred to as
"hydrocarbon-sulfanyl-thiocarbonyl-sulfanyl group," and those groups in which
R83 is a
heterocyclic group are referred to as "heterocyclic ring-sulfanyl-thiocarbonyl-
sulfanyl
group."
Among the groups represented by the formula ( cu -9C), those groups in which
Ra3 is a hydrocarbon group are referred to as "N-hydrocarbon-carbamoyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"N-heterocyclic ring-carbamoyl-sulfanyl group."
Among the groups represented by the formula ( c~ -lOC), those groups in which
both Ra3 and Rb3 are a hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-carbamoyl-sulfanyl group," those groups in which both Ra3
and
Rb3 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-carbamoyl-sulfanyl group," those groups in which Ra3 is a hydrocarbon
group and
Rb3 is a heterocyclic group are referred to as "N-hydrocarbon-N-heterocyclic
ring-carbamoyl-sulfanyl group," and those groups in which R83 and Rb3 combine
to each
other, together with the nitrogen atom to which they bind, to form a cyclic
amino group
are referred to as "cyclicamino-carbonyl-sulfamoyl group."
Among the groups represented by the formula ( ~ -11C), those groups in which
Ra3 is a hydrocarbon group are referred to as "N-hydrocarbon-thiocarbamoyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"N-heterocyclic ring-thiocarbamoyl-sulfanyl group."
Among the groups represented by the formula ( w -12C), those groups in which
both Ra3 and Rb3 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-thiocarbamoyl-sulfanyl group," those groups in which and
Raa
and Rb3 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-thiocarbamoyl-sulfanyl group," those groups in which Ra3 is a
hydrocarbon group
and Rb3 is a heterocyclic group are referred to as "N-hydrocarbon-N-
heterocyclic
ring-thiocarbamoyl-sulfanyl group," and those groups in which R83 and Rb3
combine to
each other, together with the nitrogen atom to which they bind, to form a
cyclic amino
group are referred to as "cyclicamino-thiocarbonyl-sulfamoyl group."
Among the groups represented by the formula ( w -13C), those groups in which
CA 02489091 2004-12-08
Ra3 is a hydrocarbon group are referred to as "N-hydrocarbon-sulfamoyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"N-heterocyclic ring-sulfamoyl-sulfanyl group."
Among the groups represented by the formula ( cu -14C), those groups in which
both Ra3 and Rb3 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfamoyl-sulfanyl group," those groups in which both Ra3
and
Rb3 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-sulfamoyl-sulfinyl group," those groups in which Ra3 is a hydrocarbon
group and
Rb3 is a heterocyclic group are referred to as "N-hydrocarbon-N-heterocyclic
ring-sulfamoyl-sulfanyl group," and those groups in which Ra3 and Rb3 combine
to each
other, together with the nitrogen atom to which they bind, to form a cyclic
amino group
are referred to as "cyclicamino-sulfonyl-sulfanyl group."
Among the groups represented by the formula ( cu-15C), those groups in which
R83 is a hydrocarbon group are referred to as "N-hydrocarbon-sulfinamoyl-
sulfanyl
group," and those groups in which R83 is a heterocyclic group are referred to
as
"N-heterocyclic ring-sulfinamoyl-sulfanyl group."
Among the groups represented by the formula ( w -16C), those groups in which
both Ra3 and Rb3 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfinamoyl-sulfanyl group," those groups in which both
Ra3 and
R63 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-sulfinamoyl-sulfanyl group," those groups in which Ra3 is a hydrocarbon
group
and Rb3 is a heterocyclic group are referred to as "N-hydrocarbon-N-
heterocyclic
ring-sulfinamoyl-sulfanyl group," and those groups in which Ra3 and Rb3
combine to
each other, together with the nitrogen atom to which they bind, to form a
cyclic amino
group are referred to as "cyclicamino-sulfanyl-sulfanyl group."
Among the groups represented by the formula ( c~ -17C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfonyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"heterocyclic ring-oxy-sulfonyl-sulfanyl group."
Among the groups represented by the formula ( w -18C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfinyl-
sulfanyl
group," and those groups in which Ra3 is a heterocyclic group are referred to
as
"heterocyclic ring-oxy-sulfinyl-sulfanyl group."
36
CA 02489091 2004-12-08
Among the groups represented by the formula ( cu -19C), those groups in which
both Ra3 and Rb3 are hydrocarbon groups are referred to as
"O,O'-di(hydrocarbon)-phosphono-sulfanyl group," those groups in which both
Ra3 and
Rb3 are heterocyclic groups are referred to as "O,O'-di(heterocyclic
ring)-phosphono-sulfanyl group," and those groups in which R83 is a
hydrocarbon group
and Rb3 is a heterocyclic group are referred to as "O-hydrocarbon-O'-
heterocyclic
ring-phosphono-sulfanyl group."
Among the groups represented by the formula ( w-20C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-sulfonyl-sulfanyl
group,"
and those groups in which Ra3 is a heterocyclic group are referred to as
"heterocyclic
ring-sulfonyl-sulfanyl group."
Among the groups represented by the formula ( c~ -21C), those groups in which
Ra3 is a hydrocarbon group are referred to as "hydrocarbon-sulfinyl-sulfanyl
group,"
and those groups in which R83 is a heterocyclic group are referred to as
"heterocyclic
ring-sulfinyl-sulfanyl group."
Examples of the hydrocarbon in the groups represented by the aforementioned
formulas ( w-1C) through ( c~-21C) include similar groups to the
aforementioned
hydrocarbon group. Examples of the hydrocarbon-carbonyl-sulfanyl group
represented by the formula ( cu -1C) include, for example, an alkyl-carbonyl-
sulfanyl
group, an alkenyl-carbonyl-sulfanyl group, an alkynyl-carbonyl-sulfanyl group,
a
cycloalkyl-carbonyl-sulfanyl group, a cycloalkenyl-carbonyl-sulfanyl group, a
cycloalkanedienyl-carbonyl-sulfanyl group, a cycloalkyl-alkyl-carbonyl-
sulfanyl group
which are aliphatic hydrocarbon-carbonyl-sulfanyl groups; an aryl-carbonyl-
sulfanyl
group; an aralkyl-carbonyl-sulfanyl group; a bridged cyclic
hydrocarbon-carbonyl-sulfanyl group; a spiro cyclic hydrocarbon-carbonyl-
sulfanyl
group; and a terpene family hydrocarbon-carbonyl-sulfanyl group. In the
following,
groups represented by the formulas ( w -2C) through ( c~ -21C) are similar to
those
explained above.
Examples of the heterocyclic ring in the groups represented by the
aforementioned formulas ( cu -1C) through ( c~ -21C) include similar groups to
the
aforementioned heterocyclic group. Examples of the heterocyclic
ring-carbonyl-sulfanyl group represented by the formula ( cu -1C) include, for
example,
a monocyclic heteroaryl-carbonyl-sulfanyl group, a fused polycyclic
37
CA 02489091 2004-12-08
heteroaryl-carbonyl-sulfanyl group, a monocyclic non-aromatic heterocyclic
ring-carbonyl-sulfanyl group, and a fused polycyclic non-aromatic heterocyclic
ring-carbonyl-sulfanyl group. In the following, groups represented by the
formula ( ~
-2C) through ( ~-21C) are similar to those groups explained above.
Examples of the cyclic amino in the groups represented by the aforementioned
formulas ( cu-lOC) through ( w-16C) include similar groups to the
aforementioned cyclic
amino group.
The aforementioned acyl-sulfanyl group, hydrocarbon-sulfanyl group, and
heterocyclic-sulfanyl group are generically referred to as "substituted
sulfanyl group."
Moreover, these substituted sulfanyl group and sulfanyl group are generically
referred
to as "sulfanyl group which may be substituted."
Examples of the N-hydrocarbon-amino group include the groups in which one
hydrogen atom of amino group is substituted with a hydrocarbon group, and
include,
for example, an N-alkyl-amino group, an N-alkenyl-amino group, an N-alkynyl-
amino
group, an N-cycloalkyl-amino group, an N-cycloalkyl-alkyl-amino group, an
N-aryl-amino group, and an N-aralkyl-amino group.
Examples of the N-alkyl-amino group include, for example, methylamino,
ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino,
sec-butylamino, tert-butylamino, n-pentylamino, isopentylamino,
(2-methylbutyl)amino, (1-methylbutyl)amino, neopentylamino,
(1,2-dimethylpropyl)amino, (1-ethylpropyl)amino, n-hexylamino,
(4-methylpentyl)amino, (3-methylpentyl)amino, (2-methylpentyl)amino,
(1-methylpentyl)amino, (3,3-dimethylbutyl)amino, (2,2-dimethylbutyl)amino,
(1,1-dimethylbutyl)amino, (1,2-dimethylbutyl)amino, (1,3-dimethylbutyl)amino,
(2,3-dimethylbutyl)amino, (2-ethylbutyl)amino, (1-ethylbutyl)amino,
(1-ethyl-1-methylpropyl)amino, n-heptylamino, n-octylamino, n-nonylamino,
n-decylamino, n-undecylamino, n-dodecylamino, n-tridecylamino, n-
tetradecylamino,
and n-pentadecylamino, which are Ci to Cis straight chain or branched chain N-
alkyl
amino groups.
Examples of the N-alkenyl-amino group include, for example, vinyl amino,
(prop-1-en-1-yl)amino, allylamino, isopropenylamino, (but-1-en-1-yl)amino,
(but-2-en-1-yl)amino, (but-3-en-1-yl)amino, (2-methylprop-2-en-1-yl)amino,
(1-methylprop-2-en-1-yl)amino, (pent-1-en-1-yl)amino, (pent-2-en-1-yl)amino,
38
CA 02489091 2004-12-08
(pent-3-en-1-yl)amino, (pent-4-en-1-yl)amino, (3-methylbut-2-en-1-yl)amino,
(3-methylbut-3-en-1-yl)amino, (hex-1-en-1-yl)amino, (hex-2-en-1-yl)amino,
(hex-3-en-1-yl)amino, (hex-4-en-1-yl)amino, (hex-5-en-1-yl)amino,
(4-methylpent-3-en-1-yl)amino, (4-methylpent-3-en-1-yl)amino, (hept-1-en-1-
yl)amino,
(hept-6-en-1-yl)amino, (oct-1-en-1-yl)amino, (oct-7-en-1-yl)amino,
(non-1-en-1-yl)amino, (non-8-en-1-yl)amino, (dec-1-en-1-yl)amino, (dec-9-en-1-
yl)amino,
(undec-1-en-1-yl)amino, (undec-10-en-1-yl)amino, (dodec-1-en-1-yl)amino,
(dodec-11-en-1-yl)amino, (tridec-1-en-1-yl)amino,
(tridec-12-en-1-yl)amino, (tetradec-1-en-1-yl)amino, (tetradec-13-en-1-
yl)amino,
(pentadec-1-en-1-yl)amino, and (pentadec-14-en-1-yl)amino, which are Cz to Cis
straight chain or branched chain N-alkenyl amino groups.
Examples of the N-alkynyl-amino group include, for example, ethynylamino,
(prop-1-yn-1-yl)amino, (prop-2-yn-1-yl)amino, (but-1-yn-1-yl)amino,
(but-3-yn-1-yl)amino, (1-methylprop-2-yn-1-yl)amino, (pent-1-yn-1-yl)amino,
(pent-4-yn-1-yl)amino, (hex-1-yn-1-yl)amino, (hex-5-yn-1-yl)amino,
(hept-1-yn-1-yl)amino, (kept-6-yn-1-yl)amino, (oct-1-yn-1-yl)amino,
(oct-7-yn-1-yl)amino, (non-1-yn-1-yl)amino, (non-8-yn-1-yl)amino, (dec-1-yn-1-
yl)amino,
(dec-9-yn-1-yl)amino, (undec-1-yn-1-yl)amino, (undec-10-yn-1-yl)amino,
(dodec-1-yn-1-yl)amino, (dodec-11-yn-1-yl)amino, (tridec-1-yn-1-yl)amino,
(tridec-12-yn-1-yl)amino, (tetradec-1-yn-1-yl)amino, (tetradec-13-yn-1-
yl)amino,
(pentadec-1-yn-1-yl)amino, and (pentadec-14-yn-1-yl)amino, which are Cz to Cis
straight chain or branched chain N-alkynyl-amino groups.
Examples of the N-cycloalkyl-amino group include, for example,
cyclopropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino,
cycloheptylamino, and cyclooctylamino, which are Ca to Cs N-cycloalkyl-amino
groups.
Examples of the N-cycloalkyl-alkyl-amino group include, for example,
(cyclopropylmethyl)amino, (1-cyclopropylethyl)amino, (2-
cyclopropylethyl)amino,
(3-cyclopropylpropyl)amino, (4-cyclopropylbutyl)amino, (5-
cyclopropylpentyl)amino,
(6-cyclopropylhexyl)amino, (cyclobutylmethyl)amino, (cyclopentylmethyl)amino,
(cyclobutylmethyl)amino, (cyclopentylmethyl)amino, (cyclohexylmethyl)amino,
(2-cyclohexylethyl)amino, (3-cyclohexylpropyl)amino, (4-cyclohexylbutyl)amino,
(cycloheptylmethyl)amino, (cyclooctylmethyl)amino, and (6-
cyclooctylhexyl)amino,
which are C4 to Ci4 N-cycloalkyl-alkyl-amino groups.
39
CA 02489091 2004-12-08
Examples of the N-aryl-amino group include, for example, phenylamino,
1-naphthylamino, 2-naphtylamino, anthrylamino, phenanthrylamino, and
acenaphthylenylamino, which are Cs to Ci4 N-mono-arylamino groups.
Examples of the N-aralkyl-amino group include, for example, benzylamino,
(1-naphthylmethyl)amino, (2-naphthylmethyl)amino, (anthracenylmethyl)amino,
(phenanthrenylmethyl)amino, (acenaphthylenylmethyl)amino,
(diphenylmethyl)amino,
(1-phenethyl)amino, (2-phenethyl)amino, (1-(1-naphthyl)ethyl)amino,
(1-(2-naphthyl)ethyl)amino, (2-(1-naphthyl)ethyl)amino, (2-(2-
naphthyl)ethyl)amino,
(3-phenylpropyl)amino, (3-(1-naphthyl)propyl)amino, (3-(2-
naphthyl)propyl)amino,
(4-phenylbutyl)amino, (4-(1-naphthyl)butyl)amino, (4-(2-naphthyl)butyl)amino,
(5-phenylpentyl)amino, (5-(1-naphthyl)pentyl)amino, (5-(2-
naphthyl)pentyl)amino,
(6-phenylhexyl)amino, (6-(1-naphthyl)hexyl)amino, and (6-(2-
naphthyl)hexyl)amino,
which are C~ to Cis N-aralkyl-amino groups.
Examples of the N,N-di(hydrocarbon)-amino group include the groups in which
two hydrogen atoms of amino group are substituted with hydrocarbon groups, and
include, for example, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-
methylamino,
N,N-di-n-propylamino, N,N-diisopropylamino, N-allyl-N-methylamino,
N-(prop-2-yn-1-yl)-N-methylamino, N,N-dicyclohexylamino,
N-cyclohexyl-N-methylamino, N-cyclohexylmethylamino-N-methylamino,
N,N-diphenylamino, N-methyl-N-phenylamino, N,N-dibenzylamino, and
N-benzyl-N-methylamino.
Examples of the N-heterocyclic ring-amino group include the groups in which
one hydrogen atom of amino group is substituted with a heterocyclic group, and
include, for example, (3-pyrrolizinyl)amino, (4-piperidinyl)amino,
(2-tetrahydropyranyl)amino, (3-indolinyl)amino, (4-chromanyl)amino,
(3-thienyl)amino, (3-pyridyl)amino, (3-quinolyl)amino, and (5-indolyl)amino.
Examples of the N-hydrocarbon-N-heterocyclic ring-amino group include the
groups in which two hydrogen atoms of amino group are substituted with
hydrocarbon
group and heterocyclic group respectively, and include, for example,
N-methyl-N-(4-piperidinyl)amino, N-(4-chromanyl)-N-methylamino,
N-methyl-N-(3-thienyl)amino, N-methyl-N-(3-pyridyl)amino,
N-methyl-N-(3-quinolyl)amino.
Examples of the acyl-amino group include the groups in which one hydrogen
CA 02489091 2004-12-08
atom of the amino group is substituted with an acyl group, and include, for
example,
formylamino group, glyoxyloylamino group, thioformylamino group,
carbamoylamino
group, thiocarbamoylamino group, sulfamoylamino group, sulfinamoylamino group,
carboxyamino group, sulphoamino group, phosphonoamino group, and groups
represented by the following formulas
a4 a4
-N C R (v'-1D) -~-C-O R (v'-2D)
H O > H O
-N -CC -Ra4 -N- C C O -Ra4
- - -
(v'-3D) H (u'-4D)
H O p > O O >
_ _ a4 _ _ a4
-N- C S R (v'-5D) N-C R (v'-6D)
H O ~ H S
-N -CO -Ra4 -N- C Ra4
- -S (v'-SD)
-
(v'-7D) H SI
H S ~ '
_ _ a4 _ _ _ a4
_ C-N R r _ R
N '
(v'-9D) I II I (v'-l OD)
H O H ~ H O Rba.
_ _ _ _ _
a4 - C _
R a4
N
R
N (v'-1 1D) N (~-12D)
H S H H S Rb4
O O
-N -S -N -Ra4 ( v' - 1 3 D ) -N -S -N -Ra4 ( v' - 1 4 D )
H O H , H O Rb4 ,
_ _ _ a4 _ _ _ _ a4
I-S I R (v'-1 5D) N S N R (v'-1 6D)
H O H ~ H O R~
O
-N -S -O -Ra4
-N -S -O -Ra4 ( v' - 1 7 D ) ( I I ( v' - 1 8 D )
II H O '
H O '
O -Ra4 O
-N -P =O ( v' - 1 9 D ) ' -N -S -Raa ( v' _ 2 0 D )
H O -Rb4 H O
-N-S-Ra4 ( ~ - 2 1 D)
I II
H O
41
CA 02489091 2004-12-08
wherein Ra4 and Rb4 may be the same or different and represent a hydrocarbon
group
which may be substituted or a heterocyclic group which may be substituted, or
Ra4 and
Rb4 combine to each other, together with the nitrogen atom to which they bind,
to form
a cyclic amino group which may be substituted.
In the definition of the aforementioned acyl-amino group, among the groups
represented by the formula ( ~ -1D), those groups in which Ra4 is a
hydrocarbon group
are referred to as "hydrocarbon-carbonyl-amino group," and those groups in
which Ray
is a heterocyclic group are referred to as "heterocyclic ring-carbonyl-amino
group."
Among the groups represented by the formula ( w -2D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-oxy-carbonyl-amino
group,"
and those groups in which Ra4 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-carbonyl-amino group."
Among the groups represented by the formula ( w-3D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-carbonyl-carbonyl-
amino
group," and those groups in which Ra4 is a heterocyclic group are referred to
as
"heterocyclic ring-carbonyl-carbonyl-amino group."
Among the groups represented by the formula ( c~ -4D), those groups in which
R$4 is a hydrocarbon group are referred to as
"hydrocarbon-oxy-carbonyl-carbonyl-amino group," and those groups in which Ra4
is a
heterocyclic group are referred to as "heterocyclic ring-oxy-carbonyl-carbonyl-
amino
group."
Among the groups represented by the formula ( cu -5D), those groups in which
Ra4 is a hydrocarbon group axe referred to as "hydrocarbon-sulfanyl-carbonyl-
amino
group," and those groups in which Ra4 is a heterocyclic group are referred to
as
"heterocyclic ring-sulfanyl-carbonyl-amino group."
Among the groups represented by the formula ( ~ -6D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-thiocarbonyl-amino
group,"
and those groups in which Ra4 is a heterocyclic group are referred to as
"heterocyclic
ring-thiocarbonyl-amino group."
Among the groups represented by the formula ( cu -7D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-oxy-thiocarbonyl-
amino
group," and those groups in which R$4 is a heterocyclic group are referred to
as
42
CA 02489091 2004-12-08
"heterocyclic ring-oxy-thiocarbonyl-amino group."
Among the groups represented by the formula ( ~ -8D), those groups in which
Ra4 is a hydrocarbon group are referred to as
"hydrocarbon-sulfanyl-thiocarbonyl-amino group," and those groups in which Ra4
is a
heterocyclic group are referred to as "heterocyclic ring-sulfanyl-thiocarbonyl-
amino
group."
Among the groups represented by the formula ( w -9D), those groups in which
R$4 is a hydrocarbon group are referred to as "N-hydrocarbon-carbamoyl group,"
and
those groups in which Ra4 is a heterocyclic group are referred to as "N-
heterocyclic
ring-carbamoyl-amino group."
Among the groups represented by the formula ( r~ -lOD), those groups in which
both Ra4 and Rb4 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-carbamoyl-amino group," those groups in which both R84
and Rb4
axe heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-
carbamoyl-amino
group," those groups in which Ra4 is a hydrocarbon group and Rb4 is a
heterocyclic
group are referred to as "N-hydrocarbon-N-heterocyclic ring-carbamoyl-amino
group,"
and those groups in which Ra4 and Rb4 combine to each other, together with the
nitrogen atom to which they bind, to form a cyclic amino group are referred to
as "cyclic
amino-carbonyl-amino group."
Among the groups represented by the formula ( c~ -11D), those groups in which
Ra4 is a hydrocarbon group are referred to as "N-hydrocarbon-thiocarbamoyl-
amino
group," and those groups in which Ra4 is a heterocyclic ring group are
referred to as
"N-heterocyclic-thiocarbamoyl-amino group."
Among the groups represented by the formula ( w -12D), those groups in which
both Ra4 and Rb4 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-thiocarbamoyl-amino group," those groups in which both
Ra4 and
Rb4 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-thiocarbamoyl-amino group," those groups in which Ra4 is a hydrocarbon
group
and Rb4 is a heterocyclic group are referred to as "N-hydrocarbon-N-
heterocyclic
ring-thiocarbamoyl-amino group," and those groups in which Ra4 and Rb4 combine
to
each other, together with the nitrogen atom to which they bind, to form a
cyclic amino
group are referred to as "cyclic amino-thiocarbonyl-amino group."
Among the groups represented by the formula ( cu -13D), those groups in which
43
CA 02489091 2004-12-08
Ra4 is a hydrocarbon group are referred to as "N-hydrocarbon-sulfamoyl-amino
group,"
and those groups in which Ra4 is a heterocyclic group are referred to as "N-
heterocyclic
ring-sulfamoyl-amino group."
Among the groups represented by the formula ( c~ -14D), those groups in which
both Ra4 and Rb4 are hydrocarbon groups are referred to as
"di(hydrocarbon)-sulfamoyl-amino group," those groups in which both Ra4 and
Rb4 are
heterocyclic groups are referred to as "N,N-di(heterocyclic ring)-sulfamoyl-
amino
group," those groups in which Ra4 is a hydrocarbon group and Rb4 is a
heterocyclic
group axe referred to as "N-hydrocarbon-N-heterocyclic ring-sulfamoyl-amino
group,"
and those groups in which R$4 and Rb4 combine to each other, together with the
nitrogen atom to which they bind, to form a cyclic amino group are referred to
as "cyclic
amino-sulfonyl-amino group."
Among the groups represented by the formula ( ~ -15D), those groups in which
Ra4 is a hydrocarbon group are referred to as "N-hydrocarbon-sulfinamoyl-amino
group," and those groups in which Ra4 is a heterocyclic group are referred to
as
"N-heterocyclic ring-sulfinamoyl-amino group."
Among the groups represented by the formula ( cu -16D), those groups in which
both R84 and Rb4 are hydrocarbon groups are referred to as
"N,N-di(hydrocarbon)-sulfinamoyl-amino group," those groups in which both Ra4
and
Rb4 are heterocyclic groups are referred to as "N,N-di(heterocyclic
ring)-sulfinamoyl-amino group," groups in which Ra4 is a hydrocarbon group and
Rb4 is
a heterocyclic group are referred to as "N-hydrocarbon-N-heterocyclic
ring-sulfinamoyl-amino group," and those groups in which Ra4 and Rb4 combine
to each
other, together with the nitrogen atom to which they bind, to form a cyclic
amino group
are referred to as "cyclic amino-sulfinyl-amino group."
Among the groups represented by the formula ( ~ -17D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfonyl-amino
group,"
and those groups in which Ra4 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-sulfoyl-amino group."
Among the groups represented by the formula ( cu -18D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-oxy-sulfinyl-amino
group,"
and those groups in which R84 is a heterocyclic group are referred to as
"heterocyclic
ring-oxy-sulfinyl-amino group."
44
CA 02489091 2004-12-08
Among the groups represented by the formula ( ~ -19D), those groups in which
both Ra4 and Rb4 are hydrocarbon groups are referred to as
"O,O'-di(hydrocarbon)-phosphono-amino group," those groups in which both Ra4
and
Rb4 are heterocyclic groups are referred to as "O,O'-di(heterocyclic
ring)-phosphono-amino group," and those groups in which R84 is a hydrocarbon
group
and Rb4 is a heterocyclic group are referred to as "O-hydrocarbon-O'-
heterocyclic
ring-phosphono-amino group."
Among the groups represented by the formula ( c~ -20D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-sulfonyl-amino
group," and
those groups in which Ra4 is a heterocyclic group are referred to as
"heterocyclic
ring-sulfonyl-amino group."
Among the groups represented by the formula ( c~ -21D), those groups in which
Ra4 is a hydrocarbon group are referred to as "hydrocarbon-sulfinyl-amino
group," and
those groups in which Ra4 is a heterocyclic group are referred to as
"heterocyclic
ring-sulfinyl-amino group."
Examples of the hydrocarbon in the groups represented by the aforementioned
formulas ( c~ -1D) through ( c~ -21D) include the similar groups to the
aforementioned
hydrocarbon group. Examples of the hydrocarbon-carbonyl-amino groups
represented
by the formula ( c~ -1D) include, for example, an alkyl-carbonyl-amino group,
an
alkenyl-carbonyl-amino group, an alkynyl-carbonyl-amino group, a
cycloalkyl-carbonyl-amino group, a cycloalkenyl-carbonyl-amino group, a
cycloalkanedienyl-carbonyl-amino group, a cycloalkyl-alkyl-carbonyl-amino
group
which are aliphatic hydrocarbon-carbonyl-amino groups; an aryl-carbonyl-amino
group; an aralkyl-carbonyl-amino group; a bridged cyclic hydrocarbon-carbonyl-
amino
group; a spiro cyclic hydrocarbon-carbonyl-amino group; and a terpene family
hydrocarbon-carbonyl-amino group. In the following, groups represented by the
formulas ( c~ -2D) through ( w -21D) are similar to those explained above.
Examples of the heterocyclic ring in the groups represented by the
aforementioned formulas ( c~ -1D) through ( cu -21D) include similar groups to
the
aforementioned heterocyclic group. Examples of the heterocyclic ring-carbonyl-
amino
group represented by the formula ( c~ -1D) include, for example, a monocyclic
heteroaryl-carbonyl-amino group, a fused polycyclic heteroaryl-carbonyl-amino
group,
a monocyclic non-aromatic heterocyclic-carbonyl-amino group, and a fused
polycyclic
CA 02489091 2004-12-08
non-aromatic heterocyclic-carbonyl-amino group. In the following, groups
represented by the formulas ( w -2D) through ( c~ -21D) are similar to those
groups
explained above.
Examples of the cyclic amino in the groups represented by the aforementioned
formulas ( w -lOD) through ( w -16D) include similar groups to the
aforementioned
cyclic amino group.
Examples of the di(acyl)-amino group include the groups in which two
hydrogen atoms of amino group are substituted with acyl groups in the
definitions of
the aforementioned substituents according to "which may be substituted."
Examples
include, for example, di(formyl)-amino group, di(glyoxyloyl)-amino group,
di(thioformyl)-amino group, di(carbamoyl)-amino group, di(thiocarbamoyl)-amino
group, di(sulfamoyl)-amino group, di(sulfinamoyl)-amino group, di(carboxy)-
amino
group, di(sulfo)-amino group, di(phosphono)-amino group, and groups
represented by
the following formulas
46
CA 02489091 2004-12-08
-N C -N C -O Ra5
-Ra5 - (v~-2E)
(v~-1 E) , II ,
O 2 O 2
-N C -C Ra5 -N C -C O Ra5
- - - (cv-4E)
(v~-3E) O p ,
,
O p 2 2
-N C-S- Ra5 -N C-Ra5 ( ~ - 6 E
)
,
II (W-5E), S
p 2 2
-N C -O Ra5 -N C -S
- -Ra5
(v~-7E) II (v~-8E)
,
S 2 , S 2
-N C -N-Ra5 -N C -N Ra5
-
(v~-9E) O Rb5 (v~-1 OE)
>
O H 2 , 2
-N C- N- Ra5 -N C-N- Ra5
I (v'- 1 1 S Rb5 (v~- 1 2
E) , E) ,
S H 2 2
O O
-N S- N- Ra5 ( v~ - 1 -N S-N- Ra5 ( v~ - 1
3 E ) 4 E ) ,
O H , O Rb5
2
-N S- N- Ra5 -N S-N- Ra5
(v~-15E), O I (a~-16E),
bS
2 R 2
O
_ a5
-N S Ra5 ( v~ - 1 ~N S -O R ( ~ - 1
-O 7 E ) , 8 E ) ,
- -
O O 2
2
O Ra5 O
-
-N P O ( - 1 9 E -N $-Ra5 (
= v~ ) , v>
-
2
0
E
)
,
O Rn52 O 2
-
-N S -Ra5
(I (v~-2 1 E)
O 2
wherein R$5 and Rb5 may be the same or different and represent hydrogen atom,
a
hydrocarbon group which may be substituted or a heterocyclic group which may
be
substituted, or Ra5 and Rb5 combine to each other, together with the nitrogen
atom to
which they bind, to form a cyclic amino group which may be substituted.
In the definition of aforementioned di(acyl)-amino group, among the groups
represented by the formula ( w -lE), those groups in which Ra5 is a
hydrocarbon group
are referred to as "bis(hydrocarbon-carbonyl)-amino group," and those groups
in which
R85 is a heterocyclic group are referred to as "bis(heterocyclic ring-
carbonyl)-amino
47
CA 02489091 2004-12-08
group."
Among the groups represented by the formula ( c~ -2E), those groups in which
Ra5 is a hydrocarbon group are referred to as "bis(hydrocarbon-oxy-carbonyl)-
amino
group," and those groups in which Ra5 is a heterocyclic group are referred to
as
"bis(heterocyclic ring-oxy-carbonyl)-amino group."
Among the groups represented by the formula ( c~ -3E), those groups in which
Ra5 is a hydrocarbon group are referred to as
"bis(hydrocarbon-carbonyl-carbonyl)-amino group," and those groups in which
Ra5 is a
heterocyclic group are referred to as "bis(heterocyclic ring-carbonyl-
carbonyl)-amino
group."
Among the groups represented by the formula ( cu -4E), those groups in which
Ra5 is a hydrocarbon group are referred to as
"bis(hydrocarbon-oxy-carbonyl-carbonyl)-amino group," and those groups in
which Ra5
is a heterocyclic group are referred to as "bis(heterocyclic
ring-oxy-carbonyl-carbonyl)-amino group."
Among the groups represented by the formula ( c~ -5E), those groups in which
Ra5 is a hydrocarbon group are referred to as
"bis(hydrocarbon-sulfanyl-carbonyl)-amino group," and those groups in which
Ra5 is a
heterocyclic group are referred to as "bis(heterocyclic ring-sulfanyl-
carbonyl)-amino
group."
Among the groups represented by the formula ( cu-6E), those groups in which
R85 is a hydrocarbon group are referred to as "bis(hydrocarbon-thiocarbonyl)-
amino
group," and those groups in which Ra5 is a heterocyclic group are referred to
as
"bis(heterocyclic ring-thiocarbonyl)-amino group."
Among the groups represented by the formula ( c~ -7E), those groups in which
Ra5 is a hydrocarbon group are referred to as
"bis(hydrocarbon-oxy-thiocarbonyl)-amino group," and those groups in which Ra5
is a
heterocyclic group are referred to as "bis(heterocyclic ring-oxy-thiocarbonyl)-
amino
group."
Among the groups represented by the formula ( ~ -8E), those groups in which
R$5 is a hydrocarbon group are referred to as
"bis(hydrocarbon-sulfanyl-thiocarbonyl)-amino group," and those groups in
which Ras
is a heterocyclic group are referred to as "bis(heterocyclic
48
CA 02489091 2004-12-08
ring-sulfanyl-thiocarbonyl)-amino group."
Among the groups represented by the formula ( c~ -9E), those groups in which
Ra5 is a hydrocarbon group are referred to as "bis(N-hydrocarbon-carbamoyl)-
amino
group," and those groups in which Ra5 is a heterocyclic group are referred to
as
"bis(N-heterocyclic ring-carbamoyl)-amino group."
Among the groups represented by the formula (c~-10E), those groups in which
both Ra5 and Rb5 are hydrocarbon groups are referred to as
"bis[N,N-di(hydrocarbon)-carbamoyl]-amino group," those groups in which both
Ras
and Re5 are heterocyclic groups are referred to as "bis[N,N-di(heterocyclic
ring)-carbamoyl]-amino group," groups in which R85 is a hydrocarbon group and
Rb5 is
a heterocyclic group are referred to as "bis(N-hydrocarbon-N-heterocyclic
ring-carbamoyl)-amino group," and those groups in which Ra5 and Rb5 combine to
each
other, together with the nitrogen atom to which they bind, to form a cyclic
amino
groups are referred to as "bis(cyclic amino-carbonyl)amino group."
Among the groups represented by the formula ( ~ -11E), those groups in which
R85 is a hydrocarbon group are referred to as
"bis(N-hydrocarbon-thiocarbamoyl)-amino group," and those groups in which Ra5
is a
heterocyclic group are referred to as "bis(N-heterocyclic ring-thiocarbamoyl)-
amino
group."
Among the groups represented by the formula ( c~ -12E), those groups in which
both R$5 and Rb5 are hydrocarbon groups are referred to as
"bis[N,N-di(hydrocarbon)-thiocarbamoyl]-amino group," those groups in which
both
R85 and Rb5 are heterocyclic groups are referred to as "bis[N,N-
di(heterocyclic
ring)-thiocarbamoyl]-amino group," those groups in which R85 is a hydrocarbon
group
and Rb5 is a heterocyclic group axe referred to as "bis(N-hydrocarbon-N-
heterocyclic
ring-thiocarbamoyl)-amino group," and those groups in which R85 and Rb5
combine to
each other, together with the nitrogen atom to which they bind, to form a
cyclic amino
group are referred to as "bis(cyclic amino-thiocarbonyl)-amino group."
Among the groups represented by the formula ( w-13E), those groups in which
Ra5 is a hydrocarbon group are referred to as "bis(N-hydrocarbon-sulfamoyl)-
amino
group," and those groups in which R~5 is a heterocyclic group are referred to
as
"bis(N-heterocyclic ring-sulfamoyl)-amino group."
Among the groups represented by the formula ( w -14E), those groups in which
49
CA 02489091 2004-12-08
both Ra5 and Rb5 are hydrocarbon groups are referred to as
"bis[N,N-di(hydrocarbon)-sulfamoyl]-amino group," those groups in which both
Ra5 and
Rb5 are heterocyclic groups are referred to as "bis[N,N-di(heterocyclic
ring)-sulfamoyl]-amino group," those groups in which R$5 is a hydrocarbon
group and
R~5 is a heterocyclic group are referred to as "bis(N-hydrocarbon-N-
heterocyclic
ring-sulfamoyl)-amino group," and those groups in which Ra5 and Rb5 combine to
each
other, together with the nitrogen atom to which they bind, to form a cyclic
amino group
are referred to as "bis(cyclic amino-sulfonyl)amino group."
Among the groups represented by the formula ( cu -15E), those groups in which
Ra5 is a hydrocarbon group are referred to as "bis(N-hydrocarbon-sulfinamoyl)-
amino
group," and those groups in which Ra5 is a heterocyclic group are referred to
as
"bis(N-heterocyclic ring-sulfinamoyl)-amino group."
Among the groups represented by the formula ( w -16E), those groups in which
R85 and Rb5 are hydrocarbon groups are referred to as
"bis[N,N-di(hydrocarbon)-sulfinamoyl]-amino group," those groups in which Ra5
and
Rb5 are heterocyclic groups are referred to as "bis[N,N-di(heterocyclic
ring)-sulfinamoyl]-amino group," those groups in which R85 is a hydrocarbon
group and
Rb5 is a heterocyclic group are referred to as "bis(N-hydrocarbon-N-
heterocyclic
ring-sulfinamoyl)-amino group," and those groups in which Ra5 and Rb~ combine
to
each other, together with the nitrogen atom to which they bind, to form a
cyclic amino
group are referred to as "bis(cyclic amino-sulfinyl)amino group."
Among the groups represented by the formula ( ~ -17E), those groups in which
R85 is a hydrocarbon group are referred to as "bis(hydrocarbon-oxy-sulfonyl)-
amino
group," and those groups in which Ra5 is a heterocyclic group are referred to
as
"bis(heterocyclic ring-oxy-sulfonyl)-amino group."
Among the groups represented by the formula ( ~ -18E), those groups in which
R$5 is a hydrocarbon group are referred to as "bis(hydrocarbon-oxy-sulfinyl)-
amino
group," and those groups in which Ra5 is a heterocyclic group are referred to
as
"bis(heterocyclic ring-oxy-sulfinyl)-amino group."
Among the groups represented by the formula ( w -19E), those groups in which
both Ra5 and Rb5 are hydrocarbon groups are referred to as
"bis[O,O'-di(hydrocarbon)-phosphono]-amino group," those groups in which both
Rab
and Rb5 are heterocyclic groups are referred to as "bis[O,O'-di(heterocyclic
CA 02489091 2004-12-08
ring)-phosphono]-amino group," and those groups in which R85 is a hydrocarbon
group
and Rb5 is a heterocyclic group are referred to as "bis(O-hydrocarbon-O'-
heterocyclic
ring-phosphono)-amino group."
Among the groups represented by the formula ( w-20E), those groups in which
R85 is a hydrocarbon group are referred to as "bis(hydrocarbon-sulfonyl)-amino
group,"
and those groups in which R85 is a heterocyclic group are referred to as
"bis(heterocyclic ring-sulfonyl)-amino group."
Among the groups represented by the formula ( cu -21E), those groups in which
Ra5 is a hydrocarbon group are referred to as "bis(hydrocarbon-sulfinyl)-amino
group,"
and those groups in which Ra5 is a heterocyclic group are referred to as
"bis(heterocyclic ring-sulfinyl)-amino group."
Examples of the hydrocarbon in the groups represented by the aforementioned
formulas ( c~ -lE) through ( cu -21E) include the similar groups to the
aforementioned
hydrocarbon group. Examples of the bis(hydrocarbon-carbonyl)-amino groups
represented by the formula ( u~ -lE) include, for example, a bis(alkyl-
carbonyl)-amino
group, a bis(alkenyl-carbonyl)-amino group, a bis(alkynyl-carbonyl)-amino
group, a
bis(cycloalkyl-carbonyl)-amino group, a bis(cycloalkenyl-carbonyl)-amino
group, a
bis(cycloalkanedienyl-carbonyl)-amino group, a bis(cycloalkyl-alkyl-carbonyl)-
amino
group which are bis(aliphatic hydrocarbon-carbonyl)-amino groups; a
bis(aryl-carbonyl)-amino group; a bis(aralkyl-carbonyl)-amino group; a
bis(bridged
cyclic hydrocarbon-carbonyl)-amino group; a bis(spiro cyclic
hydrocarbon-carbonyl)-amino group; and a bis(terpene family
hydrocarbon-carbonyl)-amino group. In the following, groups represented by the
formulas ( c~-2E) through ( c~-21E) are similar to those explained above.
Examples of the heterocyclic ring in the groups represented by the
aforementioned formulas ( c~ -lE) through ( w -21E) include similar groups to
the
aforementioned heterocyclic group. Examples of the bis(heterocyclic
ring-carbonyl)-amino group represented by the formula ( ~ -lE) include, for
example, a
bis(monocyclic heteroaryl-carbonyl)-amino group, a bis(fused polycyclic
heteroaryl-carbonyl)-amino group, a bis(monocyclic non-aromatic
heterocyclic-carbonyl)-amino group, and a bis(fused polycyclic non-aromatic
heterocyclic-carbonyl)-amino group. In the following, groups represented by
the
formulas ( ~ -2E) through ( c~ -21E) are similar to those groups explained
above.
51
CA 02489091 2004-12-08
Examples of the cyclic amino in the groups represented by the aforementioned
formulas ( c~ -l0E) through ( cu -16E) include similar groups to the
aforementioned cyclic
amino group.
The aforementioned acyl-amino group and di(acyl)-amino group are
generically referred to as "acyl substituted amino group." Furthermore, the
aforementioned N-hydrocarbon-amino group, N,N-di(hydrocarbon)-amino group,
N-heterocyclic-amino group, N-hydrocarbon-N-heterocyclic-amino group, cyclic
amino
group, acyl-amino group, and di(acyl)-amino group are generically referred to
as
"substituted amino group."
The compounds represented by the aforementioned general formula (I) are
explained in details.
In the aforementioned general formula (I), examples of "A" include hydrogen
atom or acetyl group, and hydrogen atom is preferred.
Examples of the "arene" in "an arene which may have one or more substituents
in addition to the group represented by formula -O-A Wherein A has the same
meaning as that defined above and the group represented by formula -CONH-E
wherein E has the same meaning as that defined above" in the definition of
ring Z
include a monocyclic or fused heterocyclic aromatic hydrocarbon, and include,
for
example, benzene ring, naphthalene ring, anthracene ring, phenanthrene ring,
and
acenaphylene ring. Cs to Cio arenes such as benzene ring, naphthalene ring and
the
like are preferred, benzene ring, and naphthalene ring are more preferred, and
benzene ring is most preferred.
Examples of the substituent in the definition of "an arene which may have one
or more substituents in addition to the group represented by formula -O-A
wherein
A has the same meaning as that defined above and the group represented by
formula
-CONH-E wherein E has the same meaning as that defined above" in the
aforementioned definition of ring Z include similar groups to the substituent
explained
for the definition "which may be substituted." The position of substituents
existing on
the arene is not particularly limited, and when two or more substituents
exist, they
may be the same or different.
When "an arene which may have one or more substituents in addition to the
group represented by formula -O-A wherein A has the same meaning as that
defined above and the group represented by formula -CONH-E wherein E has the
52
CA 02489091 2004-12-08
same meaning as that defined above" in the aforementioned definition of ring Z
is "a
benzene ring which may have one or more substituents in addition to the group
represented by formula -O-A wherein A has the same meaning as that defined
above and the group represented by formula -CONH-E wherein E has the same
meaning as that defined above," "a benzene ring which has one to three
substituents in
addition to the group represented by formula -O-A wherein A has the same
meaning
as that defined above and the group represented by formula -CONH-E wherein E
has the same meaning as that defined above" is preferred, and "a benzene ring
which
has one substituent in addition to the group represented by formula -O-A
wherein A
has the same meaning as that defined above and the group represented by
formula
-CONH-E wherein E has the same meaning as that defined above" is more
preferred.
Preferred examples of said substituents include groups selected from the
following
Substituent Group y -1z. A halogen atom and tert-butyl group [(1,1-
dirnethyl)ethyl
group] are more preferred, and a halogen atom is most preferred.
(Substituent Group y -lz] a halogen atom, nitro group, cyano group, hydroxy
group,
methoxy group, methyl group, isopropyl group, tert-butyl group,
1,1,3,3-tetrarnethylbutyl group, 2-phenylethen-1-yl group, 2,2-dicyanoethen-1-
yl group,
2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl
group,
ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group,
trifluoromethyl
group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group,
4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-
hydroxyethyl
group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl
group
[thiophen-2-yl group], 3-thienyl group (thiophen-3-yl group), 1-pyrrolyl group
[pyrrol-1-yl group], 2-methylthiazol-4-yl group, imidazo(1,2-a]pyridin-2-yl
group,
2-pyridyl group [pyridin-2-yl group], acetyl group, isobutyryl group,
piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-
yl)sulfonyl
group, carboxy group, methoxycarbonyl group,
N-[3,5-bis(trifluoromethyl)phenyl)carbamoyl group, N,N-dimethylcarbamoyl
group,
sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfarnoyl group,
N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino
group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino
group, 3-phenylureido group, (3-phenyl)thioureido group, (4-
nitrophenyl)diazenyl
group, and {[4-(pyridin-2-yl)sulfamoyl)phenyl}diazenyl group
53
CA 02489091 2004-12-08
When "an arene which may have one or more substituents in addition to the
group represented by formula -O-A wherein A has the same meaning as that
defined above and the group represented by formula -CONH-E wherein E has the
same meaning as that defined above" in the aforementioned definition of ring Z
is "a
benzene ring which may have one or more substituents in addition to the group
represented by formula -O-A wherein A has the same meaning as that defined
above and the group represented by formula -CONH-E wherein E has the same
meaning as that defined above," it is most preferable that one substituent
exists and
locates on the position of RZ when the following partial formula (Iz-1) in the
general
formula containing ring Z
~'O
\ (I z-1)
z
is represented by the following formula (Iz-2).
~O
\' (I z-2)
RZ
In this embodiment, said substituents can be defined as RZ. Preferred examples
of RZ
include a group selected from the following Substituent Group y -2z. A halogen
atom
and tert-butyl group are more preferred, and a halogen atom is most preferred.
[Substituent Group y -2z] a halogen atom, nitro group, cyano group, methoxy
group,
methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl
group,
2-phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group,
2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl
group,
ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group,
trifluoromethyl
group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group,
4-fluorophenyl group, 2,4-difluorophenyl group, 2-phenethyl group, 1-
hydroxyethyl
group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino)ethyl group, 2-thienyl
group,
3-thienyl group, 1-pyrrolyl group, 2-methylthiazol-4-yl group,
imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group, acetyl group, isobutyryl
group,
54
CA 02489091 2004-12-08
piperidinocarbonyl group, 4-benzylpiperidinocarbonyl group, (pyrrol-1-
yl)sulfonyl
group, carboxy group, methoxycarbonyl group,
N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl
group,
sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group,
N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino
group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino
group, 3-phenylureido group, (3-phenyl)thioureido group, (4-
nitrophenyl)diazenyl
group, and ([4-(pyridin-2-yl)sulfamoyl]phenyl}diazenyl group
When "an arene which may have one or more substituents in addition to the
group represented by formula -O-A wherein A has the same meaning as that
defined above and the group represented by formula -CONH-E wherein E has the
same meaning as that defined above" in the aforementioned definition of ring Z
is "a
naphthalene ring which may have one or more substituents in addition to the
group
represented by formula -O-A wherein A has the same meaning as that defined
above and the group represented by formula -CONH-E wherein E has the same
meaning as that defined above," naphthalene ring is preferred.
Examples of the "hetero arene" in "a hetero arene which may have one or more
substituents in addition to the group represented by formula -O-A wherein A
has
the same meaning as that defined above and the group represented by formula
-CONH-E wherein E has the same meaning as that defined above" in the
aforementioned definition of ring Z include a monocyclic or a fused polycyclic
aromatic
heterocyclic rings containing at least one of 1 to 3 kinds of heteroatoms
selected from
oxygen atom, sulfur atom and nitrogen atom and the like as ring-constituting
atoms
(ring forming atoms), and include, for example, furan ring, thiophene ring,
pyrrole ring,
oxazole ring, isoxazole ring, thiazole ring, isothiazole ring, imidazole ring,
pyrazole
ring, 1,2,3-oxadiazole ring, 1,2,3-thiadiazole ring, 1,2,3-triazole ring,
pyridine ring,
pyridazine ring, pyrimidine ring, pyrazine ring, 1,2,3-triazine ring, 1,2,4-
triazine ring,
1H-azepine ring, 1,4-oxepine ring, 1,4-thiazepine ring, benzofuran ring,
isobenzofuran
ring, benzo[b]thiophene ring, benzo[c]thiophene ring, indole ring, 2H-
isoindole ring,
1H-indazole ring, 2H-indazole ring, benzoxazole ring, 1,2-benzisoxazole ring,
2,1-benzisoxazole ring, benzothiazole ring, 1,2-benzisothiazole ring,
2,1-benzisothiazole ring, 1,2,3-benzoxadiazol ring, 2,1,3-benzoxadiazol ring,
1,2,3-benzothiadiazole ring, 2,1,3-benzothiadiazole ring, 1H-benzotriazole
ring,
CA 02489091 2004-12-08
2H-benzotriazole ring, quinoline ring, isoquinoline ring, cinnoline ring,
quinazoline
ring, quinoxaline ring, phthalazine ring, naphthyridine ring, 1H-1,5-
benzodiazepine
ring, carbazole ring, a -carboline ring, (3 -carboline ring, y -carboline
ring, acridine
ring, phenoxazine ring, phenothiazine ring, phenazine ring, phenanthridine
ring,
phenanthroline ring, thianthrene ring, indolizine ring, and phenoxathiine
ring, which
are 5 to 14-membered monocyclic or fused polycyclic aromatic heterocyclic
rings. 5 to
10-membered monocyclic or fused polycyclic aromatic heterocyclic rings are
preferred,
and thiophene ring, pyridine ring, indole ring, and quinoxaline ring are more
preferred.
Examples of the substituent in the definition of "a hetero arene which may
have one or more substituents in addition to the group represented by formula -
O-A
wherein A has the same meaning as that defined above and the group represented
by
formula -CONH-E wherein E has the same meaning as that defined above" in the
aforementioned definition of ring Z include similar groups to the substituent
explained
for the aforementioned definition "which may be substituted." The position of
substituents existing on the hetero arene is not particularly limited, and
when two or
more substituents exist, they may be the same or different.
A halogen atom is preferred as the substituent in the definition of "a hetero
arene which may have one or more substituents in addition to the group
represented
by formula -O-A wherein A has the same meaning as that defined above and the
group represented by formula -CONH-E wherein E has the same meaning as that
defined above" in the aforementioned definition of ring Z.
Examples of the substituent in the definition of "a 2,5-di-substituted phenyl
group" in the definition of E include similar groups to the substituent
explained for the
definition "which may be substituted."
Preferred examples of the "2,5-di-substituted phenyl group" in the definition
of
E include groups represented by the following Substituent Group 8 -1e.
[Substituent Group b -le] 2,5-dimethoxyphenyl group,
2-chloro-5-(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl
group,
2-fluoro-5-(trifluoromethyl)phenyl group, 2-nitro-5-(trifluoromethyl)phenyl
group,
2-methyl-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl
group,
2-methylsulfanyl-5-(trifluoromethyl)phenyl group,
2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group,
56
CA 02489091 2004-12-08
2-morpholino-5-(trifluoromethyl)phenyl group, 2,5-dichlorophenyl group,
2,5-bis[(1,1-dimethyl)ethyl]phenyl group, 5-((1,1-dimethyl)ethyl]-2-
methoxyphenyl
group, 4-methoxybiphenyl-3-yl group, 2-bromo-5-(trifluoromethyl)phenyl group,
2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group,
2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group,
2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group,
2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group,
2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group,
2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group,
2-piperidino-5-(trifluoromethyl)phenyl group,
2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group,
2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group, 5-isopropyl-2-
methylphenyl
group, 2,5-diethoxyphenyl group, 2,5-dimethylphenyl group, 5-chloro-2-cyano
group,
5-diethylsulfamoyl-2-methoxyphenyl group, 2-chloro-5-nitrophenyl group,
2-methoxy-5-(phenylcarbamoyl)phenyl group, 5-acetylamino-2-methoxyphenyl
group,
5-methoxy-2-methylphenyl group, 2,5-dibutoxyphenyl group, 2,5-diisopentyloxy
group,
5-carbamoyl-2-methoxyphenyl group, 5-[(1,1-dimethyl)propyl]-2-phenoxyphenyl
group,
2-hexyloxy-5-methanesulfonyl group, 5-(2,2-dimethylpropionyl)-2-methylphenyl
group,
5-methoxy-2-(1-pyrrolyl)phenyl group, 5-chloro-2-(p-toluenesulfonyl)phenyl
group,
2-chloro-5-(p-toluenesulfonyl)phenyl group, 2-fluoro-5-methanesulfonyl group,
2-methoxy-5-phenoxy group, 2-methoxy-5-(1-methyl-1-phenylethyl)phenyl group,
5-morpholino-2-nitrophenyl group, 5-fluoro-2-(1-imidazolyl)phenyl group,
2-butyl-5-nitrophenyl group, 5-((1,1-dimethyl)propyl]-2-hydroxyphenyl group,
2-methoxy-5-methylphenyl group, 2,5-difluorophenyl group, 2-benzoyl-5-
methylphenyl
group, 2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, and
2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group
"A 2,5-di-substituted phenyl group wherein at least one of said substituents
is
trifluoromethyl group" is more preferred, a group selected from the following
Substituent Group 8 -2e is further preferred, and 2,5-
bis(trifluoromethyl)phenyl
group is most preferred.
[Substituent Group b -2e] 2-chloro-5-(trifluoromethyl)phenyl group,
2,5-bis(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl
group,
2-nitro-5-(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl
group,
57
CA 02489091 2004-12-08
2-methoxy-5-(trifluoromethyl)phenyl group,
2-methylsulfanyl-5-(trifluoromethyl)phenyl group,
2-(1-pyrrolidinyl)-5-(trifluoromethyl)phenyl group,
2-morpholino-5-(trifluoromethyl)phenyl group, 2-bromo-5-
(trifluoromethyl)phenyl
group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group,
2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group,
2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group,
2-(2,2,2-trifluoroethoxy)-5-(trifluoromethyl)phenyl group,
2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group,
2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group,
2-piperidino-5-(trifluoromethyl)phenyl group,
2-(4-methylphenoxy)-5-(trifluoromethyl)phenyl group,
2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group,
2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, and
2-(4-methoxyphenoxy)-5-(trifluoromethyl)phenyl group
Examples of the substituent in the definition of "a 3,5-di-substituted phenyl
group" in the definition of E include similar groups to the substituent
explained for the
definition "which may be substituted."
Preferred examples of the "3,5-di-substituted phenyl group" in the definition
of
E include groups represented by the following Substituent Group b -3e.
[Substituent Group b -3e] 3,5-bis(trifluoromethyl)phenyl group, 3,5-
dichlorophenyl
group, 3,5-bis[(1,1-dimethyl)ethyl]phenyl group, 3-fluoro-5-
(trifluoromethyl)phenyl
group, 3-bromo-5-(trifluoromethyl)phenyl group, 3-methoxy-5-
(trifluoromethyl)phenyl
group, 3,5-difluorophenyl group, 3,5-dinitrophenyl group, 3,5-dimethylphenyl
group,
3,5-dimethoxyphenyl group, 3,5-bis(methoxycarbonyl)phenyl group,
3-methoxycarbonyl-5-(trifluoromethyl)phenyl group,
3-carboxy-5-(trifluoromethyl)phenyl group, and 3,5-dicarboxyphenyl group
"A 3,5-di-substituted phenyl group wherein at least one of said substituents
is
trifluoromethyl group" is more preferred, a group selected from the following
Substituent Group 6 -4e is further preferred, and 3,5-
bis(trifluoromethyl)phenyl
group is most preferred.
[Substituent Group 8 -4e] 3,5-bis(trifluoromethyl)phenyl group,
3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl
group,
58
CA 02489091 2004-12-08
3-methoxy-5-(trifluoromethyl)phenyl group,
3-methoxycarbonyl-5-(trifluoromethyl)phenyl group, and
3-carboxy-5-(trifluoromethyl)phenyl group
Examples of the substituent in the definition of "a monocyclic or a fused
polycyclic heteroaryl group which may be substituted, provided that the
compound
wherein said heteroaryl group is ~l a fused polycyclic heteroaryl group
wherein the
ring which binds directly to -CONH- group is a benzene ring, ~ unsubstituted
thiazol-2-yl group, or ~3 unsubstituted benzothiazol-2-yl group is excluded"
in the
aforementioned definition of E include similar groups to the substituent
explained for
the definition "which may be substituted." The position of substituents
existing on
the heteroaryl group is not particularly limited, and when two or more
substituents
exist, they may be the same or different.
Examples of the "monocyclic heteroaryl group" in "a monocyclic or a fused
polycyclic heteroaryl group which may be substituted" in the aforementioned
definition
of E include similar groups to the "monocyclic heteroaryl group" in the
definition of the
aforementioned "heterocyclic group."
Examples of the "fused polycyclic heteroaryl group" in "a monocyclic or a
fused
polycyclic heteroaryl group which may be substituted" in the aforementioned
definition
of E include similar groups to the "fused polycyclic heteroaryl group" in the
definition
of the aforementioned "heterocyclic group."
As "a monocyclic or a fused polycyclic heteroaryl group which may be
substituted" in the aforementioned definition of E, ~l a fused polycyclic
heteroaryl
group wherein the ring which binds directly to -CONH- group in the general
formula (I) is a benzene ring, 2~ unsubstituted thiazol-2-yl group, and 3~
unsubstituted benzothiazol-2-yl group are excluded.
A 5 to 10-membered monocyclic or fused polycyclic heteroaryl group is
preferred as "a monocyclic or a fused polycyclic heteroaryl group" in "a
monocyclic or a
fused polycyclic heteroaryl group which may be substituted" in the
aforementioned
definition of E, and preferred examples of the group include thiazolyl group,
thienyl
group, pyrazolyl group, oxazolyl group, 1,3,4-thiadiazolyl group, pyridyl
group,
pyrimidinyl group, pyrazinyl group, and quinolyl group.
A 5-membered monocyclic heteroaryl group is more preferred as "a monocyclic
or a fused polycyclic heteroaryl group" in "a monocyclic or a fused polycyclic
heteroaryl
59
CA 02489091 2004-12-08
group which may be substituted" in the aforementioned definition of E.
Thiazolyl
group, thienyl group, pyrazolyl group, oxazolyl group, and 1,3,4-thiadiazolyl
group are
further preferred, and thiazolyl group is most preferred.
A substituted thiazolyl group is most preferred as said "a monocyclic or a
fused
polycyclic heteroaryl group which may be substituted," because unsubstituted
thiazol-2-yl group is excluded as "a monocyclic or a fused polycyclic
heteroaryl group
which may be substituted."
When "a monocyclic or a fused polycyclic heteroaryl group which may be
substituted" in the aforementioned definition of E is "a substituted thiazolyl
group," "a
mono-substituted thiazol-2-yl group" and "a di-substituted thiazol-2-yl group"
are
preferred, and "a di-substituted thiazol-2-yl group" is further preferred.
When "a monocyclic or a fused polycyclic heteroaryl group which may be
substituted" in the aforementioned definition of E is "a di-substituted
thiazol-2-yl
group," a group selected from the following Substituent Group b -5e is further
preferred, and 4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl
group is
most preferred.
[Substituent Group 8 -5e] 5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group,
5-bromo-4-(trifluoromethyl)thiazol-2-yl group,
5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-methylthiazol-2-yl group,
4,5-dimethylthiazol-2-yl group, 5-methyl-4-phenylthiazol-2-yl group,
5-(4-fluorophenyl)-4-methylthiazol-2-yl group,
4-methyl-5-[3-(trifluoromethyl)phenyl]thiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-ethylthiazol-2-yl group, 4-ethyl-5-phenylthiazol-2-
yl group,
4-isopropyl-5-phenylthiazol-2-yl group, 4-butyl-5-phenylthiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-(ethoxycarbonyl)thiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-yl group,
4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazol-2-yl group,
5-carboxymethyl-4-phenylthiazol-2-yl group, 4,5-diphenylthiazol-2-yl group,
4-benzyl-5-phenylthiazol-2-yl group, 5-phenyl-4-(trifluoromethyl)thiazol-2-yl
group,
5-acetyl-4-phenylthiazol-2-yl group, 5-benzoyl-4-phenylthiazol-2-yl group,
CA 02489091 2004-12-08
5-ethoxycarbonyl-4-phenylthiazol-2-yl group,
5-ethoxycarbonyl-4-(pentafluorophenyl)thiazol-2-yl group,
5-methylcarbamoyl-4-phenylthiazol-2-yl group, 5-ethylcarbamoyl-4-phenylthiazol-
2-yl
group, 5-isopropylcarbamoyl-4-phenylthiazol-2-yl group,
5-(2-phenylethyl)carbamoyl-4-phenylthiazol-2-yl group,
5-ethoxycarbonyl-4-(trifluoromethyl)thiazol-2-yl group,
5-carboxy-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group,
5-(ethoxycarbonyl)methyl-4-phenylthiazol-2-yl group, 5-carboxy-4-phenylthiazol-
2-yl
group, and 5-propylcarbamoyl-4-phenylthiazol-2-yl group.
When "a monocyclic or a fused polycyclic heteroaryl group which may be
substituted" in the aforementioned definition of E is "a mono-substituted
thiazol-2-yl
group," preferred examples of the group include groups represented by the
following
Substituent Group b -6e.
[Substituent Group b -6e] 4-[(1,1-dimethyl)ethyl]thiazol-2-yl group,
4-phenylthiazol-2-yl group, 4-[3,5-bis(trifluoromethyl)phenyl]thiazol-2-yl
group,
4-(2,4-dichlorophenyl)thiazol-2-yl group, 4-(3,4-dichlorophenyl)thiazol-2-yl
group,
4-[4-(trifluoromethyl)phenyl]thiazol-2-yl group, 4-(2,5-difluorophenyl)thiazol-
2-yl
group, 4-(4-methoxyghenyl)thiazol-2-yl group,
4-[3-(trifluoromethyl)phenyl]thiazol-2-yl group, and 4-
(pentafluorophenyl)thiazol-2-yl
group
Compounds other than "substituted benzoic acid derivatives represented by
the following general formula (X-1)" are preferred as the compound represented
by the
general formula (I).
~ ~ Rloo2
Rloo1 ~ (x - 1 )
i
1001
X
wherein Riooi represents the following general formula (X-2):
81003 81005
(X-2)
Rlooa NCH
2
or the following general formula (X-3):
61
CA 02489091 2004-12-08
OR~OO9
R~ooa R~oos
(X-3)
81004 ~ CH
2
OR~o~O
wherein each of Rloos~ Rioo4 and Rloos independently represents hydrogen atom,
an
alkyl group having from 1 to 6 carbons or an alkoxy group having from 1 to 6
carbons,
each of Rloos and Rloio independently represents hydrogen atom, an alkyl group
having
from 1 to 6 carbons, or an acyl group having from 2 to 11 carbons;
Riooz represents hydrogen atom, a lower alkyl group having from 1 to 6
carbons, which
may be substituted, an aryl group having from 6 to 12 carbons, which may be
substituted, a heteroaryl group having from 4 to 11 carbons, which may be
substituted,
an aralkyl group having from 7 to 14 carbons, which may be substituted, a
heteroarylalkyl group having from 5 to 13 carbons, which may be substituted,
or an
acyl group having from 2 to 11 carbons;
giooi represents carboxy group which may be esterified or amidated.
The compounds represented by the aforementioned general formula (I) may
form salts. Examples of pharmacologically acceptable salts include, when
acidic
groups exist, metal salts such as lithium salt, sodium salt, potassium salt,
magnesium
salt, calcium salts, or ammonium salts such as ammonium salt, methylammonium
salt,
dimethylammonium salt, trimethylammonium salt, dicyclohexylammonium salt, and
when basic groups exist, mineral acid salts such as hydrochloride, oxalate,
hydrosulfate, nitrate, phosphate, or organic acid salts such as methane
sulfonate,
benzene sulfonate, para-toluene sulfonate, acetate, propionate, tartrate,
fumarate,
maleate, malate, oxalate, succinate, citrate, benzoate, mandelate, cinnamate,
lactate.
Salts may sometimes be formed with amino acids such as glycine. As active
ingredients of the medicament of the present invention, pharmacologically
acceptable
salts may also be suitably used.
The compounds or salts thereof represented by the aforementioned general
formula (I) may exist as hydrates or solvates. As active ingredients of the
medicament of the present invention, any of the aforementioned substances may
be
used. Furthermore, the compounds represented by the aforementioned general
formula (I) may sometimes have one or more asymmetric carbons, and may exist
as
62
CA 02489091 2004-12-08
steric isomers such as optically active substance and diastereomer. As active
ingredients of the medicament of the present invention, pure forms of
stereoisomers,
arbitrary mixture of enantiomers or diastereomers, and racemates may be used.
Furthermore, when the compounds represented by the general formula (I) has,
for example, 2-hydroxypyridine form, the compounds may exist as 2-pyridone
form
which is a tautomer. As active ingredients of the medicament of the present
invention,
pure forms of tautomers or a mixture thereof may be used. When the compounds
represented by the general formula (I) have olefinic double bonds, the
configuration
may be in either E or Z, and as active ingredients of the medicament of the
present
invention, geometrical isomer in either of the configurations or a mixture
thereof may
be used.
Examples of the compounds included in the general formula (I) as active
ingredients of the medicaments of the present invention are shown below.
However,
the active ingredients of the medicaments of the present invention are not
limited to
the compound set out below.
The abbreviations used in the following tables have the following meanings.
Me: methyl group, Et: ethyl group.
63
CA 02489091 2004-12-08
A 'O O
\ NiE
Z H
Compound Number A.o E
z
CF3
Me O
\
/ CFg
OH
2 cF3
\
~ / ~ \
/ CF3
OH CFs
\
/ ~/
CF3
F
4 off cF3
/ ~ /
CF3
CI
~ cF3
Me"O \
/ CF3
CI
6 off cFs
\ \
/ ~ /
CF3
Br
64
CA 02489091 2004-12-08
OH CF3
\
/ ~/
CF3
I
OH CFs
\
~/
CF3
NOy
OH CF3
\
/ ~/
CF3
CN
1 ~ OH CF3
\
/ ~/
CF3
Me
1 1 OH CFg
\ \
/ I / CF3
Me Me
Me
1 2 OH CF3
/ CF3
O Me
1 3 OH CF3
\
/ CF3
HO
1 4 OH CF3
MeO,N~ Me / CF3
CA 02489091 2004-12-08
1 5 °H cF3
/
/ CFs
\ O'N Me
1 6 OH CF3
/ ~ /
CFg
\ CN
CN
°H CFg
\
/ ~ /
CFg
\ CN
COyMe
1 $ OH CF3
/
CF3
\ CN
COyH
1 9 °H cF3
/ ~ /
CFg
\
2 0 °" cF3
\ \
/
/ CFg
SiMeg
66
CA 02489091 2004-12-08
1 °" CF3
I \
/
/ CFs
H
2 2 °" CF3
\
/ I/
CFg
I
2 3 °H CF3
\
I/
CF3
2 4 °" CF3
\
/ ~ /
CFg
I
\
2 5 °" cF3
I \
/
/ CFs
CFg
2 6 °" cF3
\
/ I
/ CFs
C FyC F3
67
CA 02489091 2004-12-08
OH CF3
/ ~ /
CF3
N
8 O H CFs
/ ~ /
CFg
S \>
2 9 OH CF3
I
/ I/
CF3
S
3 0 °H CF3
/
/ CF3
N
S
Me
1 OH CF3
I
/ I /
CF3
N
N
3 2 OH CF3
I \
/ I/
CF3
N
68
CA 02489091 2004-12-08
3 3 off CF3
/ ~ /
CF3
OMe
3 4 off CF3
I
/ I /
CF3
Me
O
Me
3 5 °H cF3
/ I
/ CFs
COyMe
3 6 OH CF3
I
/ I/
CF3
COpH
3 7 off cF3
I ~ C F3
/ / / CF3
O N ~ I CF3
H
H OH CFg
I
/ I
/ CFs
CONMe2
3 9 OH CF3
I
/ (/
CF3
O N
69
CA 02489091 2004-12-08
4 0 off cF3
\
/ I/
CF3
O N / I
4 1 off CF3
I \
/ I
/ CF3
SOyNMe2
OH
4 2 CF3
\
I/ I\
/ CF3
O =S =O
N
4 3 °H cFs
I \
/ I/
CF3
NHZ
4 4 off CF3
I\ \
/ I/
CF3
NMe2
4 5 off CF3
I\ I\
CF3
/I /
HN \
O
4 6 OH CF3
I \
I/
H CF3
HN " N'
° I //
CA 02489091 2004-12-08
OH CF3
\
~/
H CF3
HN " N \
S I /
4 8 off CF3
\ \
/ I / CF3
N
N
NOy
4 9 off CF3
\
/ ~ /
N CF3
N
O =S -N ~
p H N
0 OH CF3
O I \ \
Me"N / I / CFg
H CI
5 1 OH CFs
\ \
CI I / I / CF3
5 2 OH CFg
\ ~\
/ OH / CF3
71
CA 02489091 2004-12-08
OH
3 CF3
\
Me /
I/
CF3
5 4 pH cFa
I \
HO / I / CF3
Br
OH
5 5 cF3
\
HO / I /
CF3
5 6 OH CF3
CI \
I \
/ I/
CF3
CI
5 7 HO OH CF3
I/ I\
/ CF3
OH
5 $ Me CF3
I/ I\
/ CFs
5 9 Me0 OH CF3
I/ I\
/ CFs
C 0 OH CF3
\ \
I / MeMe I / CFg
Me Me
Me
72
CA 02489091 2004-12-08
6 1 OH CF3
CI \
I \
/ CI I /
CF3
CI
6 2 Me OH CF3
Me
Me ~ \ ~ \
/ /
CF3
Me Me
Me
OH
6 3 cF3
\
/ \
F
/ CF3
OH
6 4 cl cF3
\
/ I \
/ CFs
OH
6 5 cF3
\
I \
Me0 / I /
CF3
6 6 OH CF3
I\ I\
/ OMe / CFg
6 7 OH CF3
\
/ CFs
NHSOyMe
H ~H CF3
I
I / / CF3
HN ,SO
O I \
73
CA 02489091 2004-12-08
6 9 OH CF3
/ I /
CF3
HN "Me
~O
OH CFg
I
/
/ CF3
SOyNHy
OH
7 1 cF3
/
/
/ CF3
7 2 °" cF3
I
/
I / / CF3
7 3 °" cF3
/
W
/ CF3
7 4 OH CFg
Br~
S
/ CF3
7 5 °H cF3
N
/ CF3
CI
OH
7 6 cF3
~N
/ CF3
74
CA 02489091 2004-12-08
7 7 off cF3
HN ~ ~ \
CF3
CI
8 OH CFg
HN ~ \
~ CF3
OH CFg
HN ~ ~ \
CF3
CI
8 ~ °H CF3
N
,N
~ CF3
OH CF3
CI CF3
8 2 o cFa
Me~o
i
CF3
CI
8 3 °" cFs
\
i
Br CFs
8 4 °H CF3
Me CF3
CA 02489091 2004-12-08
8 5 o ff -cF3-.
\
/ F
CI
OH CFs
8 6
\
/ ~ / Br
Br
8 7 off cF3
\ \
/ ~ /
CI F
OH CF3
\ \
/ ~ /
CI CI
8 9 0 ~F3
Me"O
/ CI
CI
OH CFg
\ \
/ ~ /
Br CI
9 1 off cF3
/ /
CI NOZ
OH CF3
\ \
/ ~/
CI Me
76
CA 02489091 2004-12-08
OH CF3
9 3
/ ~OMe
Br
OH CF3
\ \
/ ~ /
Br OMe
cJ OH CF3
\ \
/ ~/
CI OMe
9 6 ~H ~F3
\ \
I/ i/
CI SMe
9 7 ~H ~Fa
/ I/
Br N
OH CF3
\
/ /
Br N
O
9 9 ~" ~F3
/ /
NOy CI
1 O O OH CF3
\ \
/ ~ /
Me CI
77
CA 02489091 2004-12-08
1 0 1 OH CF3
\ \
/ I /
OMe CI
OH C Fg
\ \
/ I /
Me Me
1 0 3 OH CF3
\ \
/ ~ /
Me OMe
OH CFs
1 0 4
~Br
CI
1 0 5 °H s
\ \
/ I / oMe
CI
1 0 6 off cF'
\ ~ \
/ /
CI
O
OH CF3
\ \
/
CI Br
1 0 8 OH CF3
/ ~/
COZMe
CI
78
CA 02489091 2004-12-08
1 0 9 OH CF3
COyH
CI
1 1 0 ~H CF3
/ i
CI ° \ \
1 1 1 OH CFg
\
/ /
CI O \
CI' v _CI
1 1 2 ~H cFa
/ ~ /
CI
CF3
1 1 3 OH CF3
\ I\
/ /
CI OCHZCF3
1 1 4 OH CF3
\ I\
/ /
CI
Me0 I /
79
CA 02489091 2004-12-08
1 1 ~J O
/ I/
CI O \ Me
I / CI
Me
1 1 6 OH CF3
I\ I\
/ /
CI
1 1 7 OH CF3
I I
/ /
CI o
I / Me
1 1 8 off cF,
I\ I\
/ /
cl
/ cl
1 1 9 off cF3
N / I /
CI CI
CI
1 2 0 ~
Me"O I \
/ CI
I \
OH CI
1 2 1
\
I / / cl
CA 02489091 2004-12-08
1 2 2 off cl
I I
/ /
ci ci
1 2 3 off F
y
i / %~ F
Br
1 2 4 off cl
I r~cl
/
F
1 2 5 °H I
I %~cl
i
cl
OH CI
126
I ~ %~cl
Br
OH CI
1 2 7
I i ~cl
i
1 2 8 off cl
Br ~ I
/ cl
/
Br
CI
1 2 9 off
Iw
I /
cl
ci /
OH Ci
130
I / ~cl
NOy
81
CA 02489091 2004-12-08
CI
1 3 1 off
\
/ / cl
Me
CI
1 3 2 off
I / / cl
OMe
1 3 3 off NOZ
I \
/ I / N02
Br
1 3 4 off
Me MeMe
I
CI
Me Me
Me
1 3 5 off
Me MeMe
I
I
CI /
OMe
136
Me MeMe
Me' _O
I/ I/
CI OMe
1 3 7 off Me
\ \
I / I /
Me
Br
82
CA 02489091 2004-12-08
1 3 8 off
Me
\ Me Me
/ \
CI I / Me
Me
Me
1 3 9 o Me
~ Me Me
Me"O
\ \
I / I / Me
Me
CI Me
1 4 0 off
Me
\ Me Me
I/
I
Br / Me
Me
Me
1 4 1 off
( \
/
/
\
CI I /
O Me
1 4 2 OH OMe
I \ ~ \
/ /
Br OMe
1 4 3 off oMe
\ I ~
I / %~OMe
Br
1 4 4 off
COZMe
I \
/ I
/ COZMe
Br
83
CA 02489091 2004-12-08
1 4 5 °" Me MeMe
I\
/ '\
Me /
Me Me
Me
1 4 6 0"
Me
\ Me Me
/
NOz I / Me
Me
Me
1 4 7 °" Me
Me Me
I\
/ \
Me I / Me
Me
Me
1 4 H °" Me
Me Me
I\
/ \
OMe I / Me
Me
Me
1 4 9 °" Me
Me Me
I
/ \
Me I
OMe
1 5 0 °" coZH
1 w
/ I~
COyH
Br
1 5 1 O" Me Me
I
/ I /
CI Me
84
CA 02489091 2004-12-08
1 5 2 °H OEt
/ /
CI OEt
1 5 3 °H Me
\ \
/ ~ /
CI Me
1 5 4 °H cl
\ \
/ I /
Cl CN
1 5 5 OH SOyNEty
CI OMe
1 5 6 °H No2
\ \
/
cl cl
1 5 7 °H H
\ O N \
/ ~ /
CI
OMe
1 5 8 off OMe
/ /
CI OMe
1 5 9 °H o
HN~Me
/ \
CI ~ /
O Me
CA 02489091 2004-12-08
1 6 0 OH OMe
I I
/ /
CI Me
1 6 1 off o ~~' Me
\ \
1/ I/
CI o~Me
1 6 2 off Me
I \ O_ v _Me
CI I /
O~Me
'' ~M'e
1 6 3 off CONHy
I \ I
/ /
CI OMe
1 6 4 off Me
Me
\ ~Me
CI I /
O \
I/
1 6 5 off
S02Me
,\
I
CI
O Me
1 6 6 off MeMe
\ O
I 'Me
CI I /
Me
86
CA 02489091 2004-12-08
1 6 7 off
OMe
I \ \
/ I/
CI
1 6 8 off
cl
I
/
I
/
cl o =s ~ ~ Me
0
1 6 9 off
0
I \ o=s ~ ~ Me
/ \
cl I /
cl
1 7 0 off so2Me
I \
/
CI F
1 7 1 off
/
I\ \i
0
/
cl
/
OMe
1 7 2 off \
\ I /
I/
cl
I
/
Me
1 7 3 off /
I \ Me Me \
CI
i
OMe
87
CA 02489091 2004-12-08
1 7 4 off ~o~
JN
CI I /
NOy
1 7 5 off F
\ \
/ I /
CI N
N
1 7 6 off N°2
\
I / /
cl Me
1 7 7 off
Me
\ Me Me
/ \
CI I /
OH
OH Me
\ \
/ ~ /
CI OMe
1 7 9 off F
\ \
/ ~ /
CI F
1 8 0 off F
\ I \
/ %~ F
CI
1 8 1 off cl
I / %~cl
I/
88
CA 02489091 2004-12-08
1 8 2 off cl
Iw Iw
/ / cl
1 8 3 OH OMe
I
I/
I / OMe
1 8 4 off
Me
Me Me
N
I /
I
CI / Me
MeMe
1 8 5 off MeMe
I ~ ,N I Me
--~~S
Br
1 8 6 off
Me
Me
I ,N I Me
~,S Br
Br
1 8 7 OH N CF3
I ~ -~' Z
S Br
/
Br
1 8 8 off
Me
Me
I ,N I Me
C I ---~~S C N
1 8 9 off
Me
Me
I / ,N I Me
Br -~~S CN
89
CA 02489091 2004-12-08
1 9 0 °H N
I
S ~Me
Br
1 9 1 OH N Me
\ --~' ~C
/ S Me
Br
1 9 2 °H
I\ N \I
/ --~'
Br S Me
1 9 3 °H N Me
\ ~I
/ S I \
/ F
Br
1 9 4 °H N Me
\ / I
/ g \ CFg
/
Br
1 9 5 °H Me
Me
\ N
I Me
Et
Br
1 9 6 °H N Et
\ ~S I
/ ~\
Br /
OH Me
\ N Me
I ~S I
Br
1 9 8 °H N
'Me
\ -('
s
/ I
Br
CA 02489091 2004-12-08
1 9 9 OH Me
Me
\ N Me
/ 'I
S O
CI
Me Me
Me
200 0
MeMe
Me"O N Me
---~'I
\ 'S O
Me Me
CI Me
2 0 1 OH Me
Me
\ N Me
I O
S
Br ~
Me~Me
Me
202 ~" Me
Me
\ N Me
/ I
S COyEt
Br
2 0 3 OH Me
Me
\ N Me
/ -~'
S COyH
Br
2 0 4 ~H MeMe
N Me
I
I / ~S N
Br
2 05 MeMe
N Me
I
/ ~ N
Br
O
91
CA 02489091 2004-12-08
206 off
Me
Me
I N Me
/
Br
N
N
~Me
2 0 7 off MeMe
N Me
'I
I / ~S N
Br
2 0 8 off
I\ \I
N
i I
Br
209 off
I\ ~I
N
/ 'S I COZEt
Br
2 1 0 off
/
I\ N ~I
/ --~'
S COyH
Br
2 1 1 off
i
/ -~'N
Br S I \
/
2 1 2 off
N
/ --~S I V
Br I /
2 1 3 off N CF3
I \ -OS I
I \
8r /
92
CA 02489091 2004-12-08
2 1 4 off / I
\ N \
I / ~g I Me
Br
O
2 1 5 off / I
\ N \_
I ~~/
\S I O
Br
2 1 6 off
/
I\ N \I
/ ~r I
Br S COyEt
2 1 7 off
/
I\ N \I
/ ~ I
gr S COyH
2 1 8 off /
I \ N \
/ \S I
C I COyEt
2 1 9 off F
I \ F / F
/ I
N \ F
Br i I
S F
COZEt
2 2 0 off
/
I\ N \I
/ i I
Br S CONHMe
2 2 1 off
/
I\ N \I
/ -~. 1
Br S CONHEt
93
CA 02489091 2004-12-08
2 2 2 off / I
\ N \
I ~/ I H
/ S N~Me
Br O MIe
2 2 3 off / I
\ N \
/ ~/ I N
I\
Br O /
2 2 4 OH N~CF3
I / S C02Et
Br
2 2 5 off /
I\ N \I
/ ~ I
COyEt
I
2 2 6 off / I
\ N \
I / ~S I
COyEt
I
F
2 2 7 off / I
\ N \
I/ ~ I
COyEt
/ F
\I
F
94
CA 02489091 2004-12-08
228 off /
\ N \I
/ / v
S COZEt
I
CF3
2 2 9 off /
\ N \I
/ / I v
S COZEt
N
2 3 0 off /
\ N \I
I/ / I v
S COZEt
~ ~S
2 3 1 off cF3
\ I
I / N \ CF3
CI S
2 3 2 OH EtOyC
I IS
CI
2 3 3 OH N-NH _
I \ I f \ /
/
Br
2 3 4 off Et
N
\ ~~-Et
/ O
Br
CA 02489091 2004-12-08
2 3 5 off
/ N \
I
Br ~O
2 3 6 off \
\ ~ o
/ N \ o
jI I
Br
2 3 7 off N_N
\ ~ ~CF3
/ S
N_N
\ ~ / CF3
S
Br
2 3 9 off
~ \ ~N
/
cl
2 4 0 off \ cl
\ ~ ,N
CI
2 4 1 OH OMe
N~
\
/ ~N CI
CI
2 4 2 0" ~N
\ \ ~ /
/
cl
2 4 3 off \
\
N Br
CI
96
CA 02489091 2004-12-08
244 ~H N'
JlI
~N~
CI
2 4 5 QH N ~ Br
I / N~
Br
246 ~H / I
\ N
H
/ N
~Me
Br
2 4 7 off CF3
\
I/
O =S -NH CF3
i~
O
CF3
F3C
248 off
\ Me \ / Me0 pH
/ / \ H
CI F3C CF3 /
CI
2 4 9 / OH CF3
\~ \ I\
/ / CF3
2 5 0 OH CFg
\ ~ \
F ~ / CFs
2 5 1 off
Me ~ \ / ~ Me
/ / \ NH2
F3C CF3
CI
97
CA 02489091 2004-12-08
2 5 2 off CF3
I \ I \
/ /
CI O \
/
CN
2 5 3 off CF3
\ I \
/ /
cl O \
I /
OMe
2 5 4 off CF3
/ I /
CF3
2 5 5 off / CI
N \I
~r I
CI
CI
2 5 6 Me OH CF3
Me I \ ~ \
/ / CF3
2 5 7 Me off
CF3
Me I \
/ ~ \
/ CF3
Br
2 5 8 off
CF3
Me \
I \
~/
CF3
Br
2 5 9 cFs
/ OH
I I \
\ \
I / / CFa
Br
98
CA 02489091 2004-12-08
260 off / CI
I\ I
/ ,N I \ CI
CI
2 6 1 off / CF3
I\ I
N \
/
CI S
2 6 2 OH CF3
\ I\
\ I / / CFg
I/
2 6 3 off F /
\
N \I
I / / I F
GI S
2 6 4 off / OMe
I\ \I
N
/
CI S
2 6 5 off
/
\ I
I / ,,N I \ CFg
CI --~S
2 6 6 off
F
I \ F / F
/ (
N \ F
CI / I
S F
2 6 7 ~H Me
\ \
I / I /
CI ~ I \
99
Image
CA 02489091 2004-12-08
The compounds represented by the general formula (I) can be prepared, for
example, by a method described in the following reaction scheme.
Reaction Scheme
R~o~
~N _Elo~
Aio1\ H Atot\
O O ~2) O O A'O O
N,Eao1 ~ N,E
first process z R~oi second process Z R
amidation deprotection,
( 1 ) ~ 3 ) functional group ~ 4 ~
modification
wherein each of A, ring Z, and E has the same meaning as that defined in the
general
formula (I), Aloe represents a hydrogen atom or protecting groups of hydroxy
group
(preferably, an alkyl group such as methyl group and the like; an aralkyl
group such as
benzyl group and the like; an acetyl group, an alkoxyalkyl group such as
methoxymethyl group and the like; a substituted silyl group such as
trimethylsilyl
group or the like), each of R and Rlol represents a hydrogen atom, a Ci to Cs
alkyl
group or the like, Eloi represents E or precursor of E in the definition of
the general
formula (I), G represents a hydroxy group, halogen atoms (preferably, a
chlorine atom),
a hydrocarbon-oxy group (preferably, an aryl-oxy group which may be
substituted by
halogen atom), an acyl-oxy group, an imido-oxy group or the like.
(First Step)
The amide (3) can be prepared by dehydrocondensation of the carboxylic acid
derivative (1) and the amine (2). This reaction is carried out at a reaction
temperature of from 0°C to 180°C, without solvent or in an
aprotic solvent, in the
presence of an acid halogenating agent or a dehydrocondensing agent, and in
the
presence or absence of a base.
As the halogenating agent, examples include, for example, thionyl chloride,
thionyl bromide, sulfuryl chloride, phosphorus oxychloride, phosphorus
trichloride,
phosphorus pentachloride or the like. When Aloe is hydrogen atom, phosphorus
trichloride is preferable, and when Aloe is acetyl group or the like,
phosphorus
oxychloride is preferable. As the dehydrocondensing agent, examples include,
for
example, N,N'-dicyclohexylcarbodiimide,
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride,
101
CA 02489091 2004-12-08
diphenylphosphorylazide or the like. As the base, examples include inorganic
bases
such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate or the
like,
or organic bases such as pyridine, triethylamine, N,N'-diethylaniline or the
like. As
the aprotic solvent, examples include dichloromethane, dichloroethane,
chloroform,
tetrahydrofuran, 1,4-dioxane, benzene, toluene, monochlorobenzene,
o-dichlorobenzene, N,N'-dimethylformamide, N-methylpyrrolidone or the like,
when
the reaction is carried out in the presence of the acid halogenating agent,
particularly,
toluene, monochlorobenzene, o-dichlorobenzene are preferable.
A target compound can also be prepared, for example, by a method or similar
method described in Journal of Medicinal Chemistry, (USA), 1998, Vo1.41,
No.l6,
p.2939-2945, in which the acid chloride is prepared and isolated beforehand
from
carboxylic acid, then the result is made to react with an amine having Eloi,
When G is hydroxy group, the reaction condition described in Archiv der
Pharmazie, (Germany), 1998, Vo1.331, No.l, p.3-6 can be used as a preferred
reaction
condition.
Kinds of carboxylic acid derivative (1) and amine (2) are not particularly
limited, and new compounds synthesized by referring to well-known preparation
method described in the literature or commercially available reagents can be
used for
the aforementioned reaction.
(Second Step)
When the amide (3) has a protecting group and/or has a favorable substituent
for functional group modification, for example, an amino group and a protected
amino
group or its precursor; a carboxy group and a protected carboxy group or its
precursor;
a hydroxy group and a protected hydroxy group or its precursor, the final
target
compound (4) can be prepared by a reaction for deprotection and/or functional
group
modification in this step. Various well-known methods can be used for the
reaction.
For the reaction of deprotection and functional group modification, for
example,
methods described in "Protective Groups in Organic Syntheses", (USA), Theodra
W.
Green, Peter G.M. Wuts, Eds., Third edition, Apr. in 1999, John Wiley & Sons,
and
"Handbook of Reagents for Organic Synthesis", (USA), 4 Volumes, Jun. in 1999,
John
Wiley & Sons can be used, and for the reaction of functional group
modification, for
example, methods described in "Palladium Reagents in Organic Syntheses",
(USA),
102
CA 02489091 2004-12-08
Richard F. Heck, 1985, Academic Pxess, and "Palladium Reagents and Catalysts:
Innovations in Organic Synthesis", (USA), J. Tsuji, 1999, John Wiley & Sons,
or the
like can be used.
The compounds represented by the general formula (I) prepared by the
aforementioned methods can be isolated and purified by methods widely known by
those skilled in the art, fox example, extraction, precipitation, fractional
chromatography, fractional crystallization, suspension and washing, and
recrystallization. Furthermore, each of the pharmaceutically acceptable salt
of the
compound of the present invention, the hydrate thereof and the solvate thereof
can be
prepared by methods widely known by those skilled in the art.
In the examples of the specification, preparation methods of typical
compounds included in the general formula (I) are explained in details.
Therefore,
those skilled in the art can prepare any compound fall within the general
formula (I)
by referring to the explanations of the aforementioned general preparation
methods
and those of specific preparation methods of the examples, by choosing
appropriate
reaction raw materials, reaction reagents, and reaction conditions, and by
adding
appropriate modification and alteration of these methods, if necessary.
The compounds represented by the general formula (I) are useful as active
ingredients of pharmaceutical compositions having inhibitory action against NF-
rc B
activation. Based on the inhibitory against NF- ~c B activation, the
aforementioned
medicament can inhibit a gene expression of one or more substances selected
from a
group consisting of tumor necrosis factor (TNF), interleukin-1, interleukin-2,
interleukin-6, interleukin-8, granulocyte colony-stimulating factor,
interferon a , cell
adhesion factor ICAM-1, VCAM-1, and ELAM-1, nitricoxide synthetase, major
histocompatibility antigen family class I, major histocompatibility antigen
family class
II, a 2-microglobulin, immunoglobulin light chain, serum amyloid A,
angiotensinogen,
complement B, complement C4, c-myc, transcript derived from HIV gene,
transcript
derived from HTLV-1 gene, transcript derived from simian virus 40 gene,
transcript
derived from cytomegalovirus gene, and transcript derived from adenovirus
gene.
Therefore, the medicament of the present invention is useful for preventive
and/or
therapeutic treatment of diseases caused by NF- ~c B activation and
inflammatory
cytokine overproduction.
More specifically, the medicament of the pxesent invention may be used for
103
CA 02489091 2004-12-08
preventive and/or therapeutic treatment of the following diseases wherein NF-
rc B
activation and/or inflammatory cytokine is believed to be involved, for
example,
autoimmune diseases such as chronic rheumatism, osteoarthritis, systematic
lupus
erythematosus, systematic scleroderma, polymyositis, Sjoegren's syndrome,
vasculitis
syndrome, antiphospholipid syndrome, Still's disease, Behcet's disease,
periarteritis
nodosa, ulcerative colitis, Crohn's disease, active chronic hepatitis,
glomerulonephritis,
and chronic nephritis, chronic pancreatitis, gout, atherosclerosis, multiple
sclerosis,
arteriosclerosis, endothelial hypertrophy, psoriasis, psoriatic arthritis,
contact
dermatitis, atopic dermatitis, pruritus, allergic disease such as pollinosis,
asthma,
bronchitis, interstitial pneumonia, lung disease involving granuloma, chronic
obstructive lung disease, chronic pulmonary thromboembolism, inflammatory
colitis,
insulin resistance, obesity, diabetes and its complications (nephropathy,
retinopathy,
neurosis, hyperinsulinemia, arteriosclerosis, hypertention, peripheral vessel
obstruction, etc.) diseases involving abnormal vascular proliferation such as
hyperlipemia, retinopathy, and pneumonia, Alzheimer's disease,
encephalomyelitis,
epilepsy, acute hepatitis, chronic hepatitis, drug induced toxic hepatopathy,
alcoholic
hepatitis, viral hepatitis, icterus , cirrhosis, hepatic insufficiency, atrial
myxoma,
Caslemann's syndrome, mesangial nephritis, kidney cancer, lung cancer, liver
cancer,
breast cancer, uterine cancer, pancreatic cancer, other solid cancer, sarcoma,
osteosarcoma, metastatic invasion of cancer, canceration of inflammatory
focus,
cancerous cachexia, metastasis of cancer, leukemia such as acute myeloblastic
leukemia, multiple myeloma, Lennert's lymphoma, malignant lymphoma,
development
of carcinostatic resistance of cancer, canceration of foci such as viral
hepatitis and
cirrhosis, canceration from polyp of colon, brain tumor, nervous tumor,
sarcoidosis,
endotoxic shock, sepsis, cytomegaloviral pneumonia, cytomegaloviral
retinopathy,
adenoviral cold, adenoviral pool fever, adenoviral ophthalmia, conjunctivitis,
AIDS,
uveitis, periodontal disease, diseases or complications provoked by infections
of other
bacteria, viruses, and mycetes, complications after surgery such as
generalized
inflammatory symptoms, restenosis after percutaneous tubal coronary artery
plastic
surgery, reperfusion disorders after vascular occulusion opening such as
ischemia
reperfusion disorders, organ transplantation rejection and reperfusion
disorders of
heart, liver, kidney and the like, pruritus, alopecia, anorexia, malaise,
chronic fatigue
syndrome and the like. Furthermore, inflammatory cytokine and NF- r~ B are
104
CA 02489091 2004-12-08
involved in differentiation and activation of osteoclast, and consequently,
the
medicament of the present invention is also useful for preventive and/or
therapeutic
treatment of metabolic bone diseases or the like such as osteoporosis and
osteocarcinomic pain or the like. The medicament may also be used for
prevention of
deterioration of an organ during organ conservation before transplantation.
Compound No. 4 of the present invention exhibited a renal protective action by
an intraperitoneal administration of less than 15 mg/kg in a rat Thy-1
nephritis model,
and significantly inhibited hepatopathy as well as lowered endotoxic levels
and TNF a
concentration in blood by an intraperitoneal administration of 10 mg/kg in rat
intestinal ischemic reperfusion-caused hepatopathy model. Therefore, it is
suggested
by the animal experiments that the compound is useful for preventive and/or
therapeutic treatment of an immunologic disease, an organ damage directly
and/or
indirectly caused by ischemic reperfusion, and an organ damage caused by
endotoxin
and/or TNF a .
The compound of the present invention (Compound No. 4) significantly also
inhibited the onset of myocarditis by an intraperitoneal administration at 10
mg/kg in
rat myocarditis model immunized with pig heart-derived myoglobin. Therefore,
it is
suggested by the animal experiments that the compound is useful for preventive
and/or therapeutic treatment of myocarditis and/or myositis caused by immune
disorders such as autoimmune disease or the like, as well as myocarditis
and/or
myositis caused by certain causes such as infection caused by bacteria or
viruses.
Moreover, the compounds of the present invention inhibited cell proliferation
of coronary artery vascular smooth muscle cells under proliferative
stimulation, and
the compound of Compound No. 4 significantly inhibited proliferation of
vascular
endothelial cells and vascular smooth muscle cells by an intraperitoneal
administration at 10 mg/kg in a mouse artery abrasion restenosis model.
Therefore,
it is suggested that the compounds are useful for prevention of restenosis
after PTCA
or after placement of a stent, and useful for preventive and/or therapeutic
treatment of
arteriosclerosis.
Furthermore, in experiments of inhibition against production of Interleukin-6
(IL-6), Interleukin-8 (IL-8), and PGE2 by using rheumatic patient-derived
synovial
fibroblasts under TNF a stimulation, Compound Nos. 83, 88, 90, and 135,
particularly
Compound No. 83 strongly inhibited the production of IL-6, IL-8, and PGE2
under TNF
105
CA 02489091 2004-12-08
a stimulation. Therefore, it is suggested that the compounds of the present
invention, particularly, the compounds of the general formula (I) wherein E is
a
2,5-di-substituted phenyl group, more preferably, a 2,5-di-substituted phenyl
group
wherein at least one of said substituents is trifluorophenyl group, and most
preferably,
2,5-bis(trifluoromethyl)phenyl group, are useful for preventive and/or
therapeutic
treatment of diseases in which inflammatory mediators, particularly, IL-6
and/or IL-8
and/or PGE2 participate.
Although it is not intended to be bound by any specific theory, the substances
selected from the group consisting of a compound represented by the general
formula
(I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and
a solvate
thereof have inhibitory activity against IKK- /3 or MEKK-1, and they are
useful as an
active ingredient of a medicament having inhibitory activity against IKK- a or
MEKK-1. Furthermore, since the aforementioned substances have inhibitory
activity
against kinases structurally similar to IKK- (3 or MEKK-1, they are also
useful as an
active ingredient of a medicament having inhibitory activity against kinases
structurally similar to IKK- ~3 or MEKK-1. When IKK- a or MEKK-1 is herein
referred to, those included are naturally-derived IKK- /3 or MEKK-1, as well
as
proteins that are amino acid-mutant generated by a technique such as gene
recombination and have substantially the same biological functions as those of
naturally-derived IKK- a or MEKK-1. Moreover, examples of the kinases
structurally similar to IKK- /3 or MEKK-1 include kinases which have similar
ligand
binding sites to those of IKK- a or MEKK-1.
Therefore, the medicament of the present invention induces an inhibition of an
expression of genes of one or more substances selected from a group consisting
of
tumor necrosis factor (TNF), interleukin-1, interleukin-2, interleukin-6,
interleukin-8,
granulocyte colony-stimulating factor, interferon a , cell adhesion factor
ICAM-1,
VCAM-1, and ELAM-1, nitricoxide synthetase, major histocompatibility antigen
family
class I, major histocompatibility antigen family class II, (3 2-microglobulin,
immunoglobulin light chain, serum amyloid A, angiotensinogen, complement B,
complement C4, c-myc, transcript derived from HIV gene, transcript derived
from
HTLV-1 gene, transcript derived from simian virus 40 gene, transcript derived
from
cytomegalovirus gene, and transcript derived from adenovirus gene by
inhibiting IKK-
a and/or MEKK-1 or kinases structurally similar thereto. The medicament of the
106
CA 02489091 2004-12-08
present invention thus can be used for a purpose of preventive and/or
therapeutic
treatment of diseases caused by NF- ~ B activation and inflammatory cytokine
overproduction as a medicament for an inhibition of IKK- a and/or MEKK-1 or
kinases
structurally similar thereto.
As the active ingredient of the medicament on the present invention, one or
more kinds of substances selected from the group consisting of the compound
represented by the general formula (I) and a pharmacologically acceptable salt
thereof,
and a hydrate thereof and a solvate thereof may be used. The aforementioned
substance, per se, may be administered as the medicament of the present
invention,
however, preferably, the medicament of the present invention is provided in
the form of
a pharmaceutical composition comprising the aforementioned substance which is
an
active ingredient together with one or more pharmacologically acceptable
pharmaceutical additives. In the aforementioned pharmaceutical compositions, a
ratio of the active ingredient to the pharmaceutical additives is 1 weight %
to 90
weight %.
The pharmaceutical compositions of the present invention may be
administered as pharmaceutical compositions for oral administration, for
example,
granules, subtilized granules, powders, hard capsules, soft capsules, syrup,
emulsion,
suspension, or solution, or may be administered as pharmaceutical compositions
for
parenteral administration, for example, injections for intravenous
administration,
intramuscular administration, or subcutaneous administration, drip infusions,
suppositories, percutaneous absorbent, transmucosal absorption preparations,
nasal
drops, ear drops, instillation, and inhalants. Preparations made as
pharmaceutical
compositions in a form of powder may be dissolved when necessary and used as
injections or drip infusions.
For preparation of pharmaceutical compositions, solid or liquid
pharmaceutical additives may be used. Pharmaceutical additives may either be
organic or inorganic. When an oral solid preparation is prepared, an excipient
is
added to the active ingredient, and further binders, disintegrator, lubricant,
colorant,
corrigent are added, if necessary, to manufacture preparations in the forms of
tablets,
coating tablets, granules, powders, capsules and the like by ordinary
procedures.
Examples of the excipient include lactose, sucrose, saccharose, glucose, corn
starch,
starch, talc, sorbit, crystal cellulose, dextrin, kaolin, calcium carbonate,
and silicon
107
CA 02489091 2004-12-08
dioxide. Examples of the binder include, for example, polyvinyl alcohol,
polyvinyl
ether, ethyl cellulose, methyl cellulose, gum Arabic, tragacanth, gelatine,
shellac,
hydroxypropyl cellulose, hydroxypropyl methyl cellulose, calcium citrate,
dextrin, and
pectin. Examples of the lubricant include, for example, magnesium stearate,
talc,
polyethylene glycol, silica, and hydrogenated vegetable oil. As the coloring
agent, any
material can be used which are approved to be added to ordinary
pharmaceuticals. As
the corrigent, cocoa powder, menthol, aromatic acid, peppermint oil, d-
borneol,
cinnamon powder and the like can be used. These tables and granules may be
applied
with sugarcoating, gelatin coating, or an appropriate coating, if necessary.
Preservatives, antioxidant and the like may be added, if required.
For liquid preparations for oral administration such as emulsions, syrups,
suspensions, and solutions, ordinary used inactive diluents, for example,
water or
vegetable oil may be used. For these preparations, besides inactive diluents,
adjuvants such as wetting agents, suspending aids, sweating agents, flavoring
agents,
coloring agents or preservatives may be blended. After a liquid preparation is
manufactured, the preparation may be filled in capsules made of a absorbable
substance such as gelatin. Examples of solvents or suspending agents used for
the
preparations of parenteral administration such as injections or suppositories
include,
for example, water, propylene glycol, polyethylene glycol, benzyl alcohol,
ethyl oleate,
and lecithin. Examples of base materials used for preparation of suppositories
include, for example, cacao butter, emulsified cacao butter, lauric fat, and
witepsol.
Methods for preparation of the aforementioned preparations are not limited,
and any
method ordinarily used in the art may be used.
When the composition are prepared in the form of injections, carriers such as,
for example, diluents including water, ethanol, macrogol, propylene glycol,
citric acid,
acetic acid, phosphoric acid, lactic acid, sodium lactate, sulfuric acid and
sodium
hydroxide, pH modifiers and buffer solutions including sodium citrate, sodium
acetate
and sodium phosphate, stabilizers such as sodium pyrosulfite,
ethylenediaminetetraacetic acid, thioglycolic acid and thiolactate may be
used. For
the preparation, a sufficient amount of a salt, glucose, mannitol or glycerin
may be
blended in the preparation to manufacture an isotonic solution, and an
ordinary
solubilizer, a soothing agent, or a topical anesthetic may be used.
When the preparation in the form of an ointment such as a paste, a cream, and
108
CA 02489091 2004-12-08
a gel is manufactured, an ordinarily used base material, a stabilizer, a
wetting agent,
and a preservative may be blended, if necessary, and may be prepared by mixing
the
components by a common method. As the base material, for example, white
petrolatum, polyethylene, paraffin, glycerin, cellulose derivatives,
polyethylene glycol,
silicon, and bentonite may be used. As the preservative, paraoxy methyl
benzoate,
paraoxy ethyl benzoate, paraoxy propyl benzoate and the like may be used. When
the
preparation in the form of a patch is manufactured, the aforementioned
ointment,
cream gel, or paste and the like may be applied by a common method to an
ordinary
support. As the support, fabric made of cotton, span rayon, and synthetic
fibersor or
nonwoven fabric, and a film or a foam sheet such as made of soft vinyl
chloride,
polyethylene, and polyurethane and the like may be preferably used.
A dose of the medicament of the present invention is not particularly limited.
For oral administration, a dose may generally be 0.01 to 5,000 mg per day for
an adult
as the weight of the compound of the present invention. It is preferred to
increase or
decrease the above dose appropriately depending on the age, pathological
conditions,
and symptoms of a patient. The above dose may be administered once a day or 2
to 3
times a day as divided portions with appropriate intervals, or intermittent
administration for every several days may be applied. When the medicament is
used
as an injection, the dose may be 0.001 to 100 mg per day for an adult as the
weight of
the compound of the present invention.
Examples
The present invention will be explained more specifically with reference to
the
following examples. However the scope of the present invention is not limited
to the
following examples. The compound number in the following examples correspond
to
those in the table shown above. And the commercially available compounds,
which
were purchased and used for the examinations, are contained in these examples.
As
for such compounds, the suppliers of the reagents and the catalog code numbers
are
shown.
Example 1: Preparation of the compound of Compound No. 1.
3,5-Bis(trifluoromethyl)aniline(500mg, 2.2mmo1) and pyridine(0.5mL) were
added to a solution of 0-acetylsalicyloyl chloride(345mg, l.7mmo1) in
benzene(lOmL)
under argon atmosphere, and the mixture was stirred at room temperature for 1
hour.
109
CA 02489091 2004-12-08
The reaction mixture was poured into 2N hydrochloric acid and extracted with
ethyl
acetate. After the ethyl acetate layer was washed successively with water and
brine,
dried over anhydrous sodium sulfate, the residue obtained by evaporation of
the
solvent under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=3:1) to give the title compound(570mg,
84.2°/) as a white
solid.
mp 124-125°C.
1H-NMR(DMSO-ds): 8 2.36(3H, s), 7.19(1H, dd, J=8.0, l.2Hz), 7.39(1H, td,
J=7.6,
l.2Hz), 7.57(1H, ddd, J=8.0, 7.6, l.6Hz), 7.65(1H, s), 7.83(1H, dd, J=8.0,
l.6Hz),
8.11(2H, s), 8.31(1H, s).
Example 2: Preparation of the compound of Compound No. 2.
2N Aqueous sodium hydroxide(0.5mL, lmmol) was added to a solution of
2-acetoxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide(Compound No. 1; 100mg,
0.25mmo1) in ethanol(5mL), and the mixture was stirred at room temperature for
1
hour. The reaction mixture was poured into 2N hydrochloric acid and extracted
with
ethyl acetate. After the ethyl acetate layer was washed successively with
water and
brine, dried over anhydrous sodium sulfate, the residue obtained by
evaporation of the
solvent under reduced pressure was recrystallized from n-hexane/ethyl acetate
to give
the title compound(40mg, 45.1%) as a white solid.
mp 179-180°C.
1H-NMR(DMSO-ds): 8 6.96-7.02(2H, m), 7.45(1H, ddd, J=8.0, 7.2, l.6Hz),
7.81(1H, s),
7.87(1H, dd, J=8.0, l.6Hz), 8.46(2H, s), 10.80(1H, s), 11.26(1H, s).
Example 3: Preparation of the compound of Compound No. 3.
A mixture of 5-fluorosalicylic acid(156mg, lmmol),
3,5-bis(trifluoromethyl)aniline(229mg, lmmol), phosphorus trichloride(44 ~c L,
0.5mmol) and monochlorobenzene(5mL) was refluxed for 3 hours under argon
atmosphere. After the reaction mixture was cooled to room temperature, it was
diluted with ethyl acetate(50mL). After the ethyl acetate layer was washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was purified by
column
chromatography on silica gel(n-hexane:ethyl acetate=6:1) to give the title
compound(215mg, 58.7%) as a white solid.
1H-NMR(DMSO-ds): b 7.04(1H, ddd, J=9.0, 4.5, l.2Hz), 7.30-7.37(1H, m),
7.66(1H, ddd,
110
CA 02489091 2004-12-08
J=9.0, 3.3, l.2Hz), 7.84(1H, s), 8.46(2H, s), 10.85(IH, s), I1.21(1H, brs).
When the method described in Example 3 is referred in the following examples,
phosphorus trichloride was used as the acid halogenating agent. As the
reaction
solvent, solvents such as monochlorobenzene, toluene or the like were used.
Example 4: Preparation of the compound of Compound No. 4.
Using 5-chlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 85.5%.
IH-NMR(DMSO-ds): b 7.05(1H, d, J=8.7Hz), 7.49(1H, dd, J=8.7, 2.7Hz), 7.85(1H,
s),
7.87(1H, d, J=2.7Hz), 8.45(2H, s), 10.85(1H, s), 11.39(1H, s).
Example 5: Preparation of the compound of Compound No. 5.
Acetyl chloride(234mg, 3.3mmol)was added to a solution of
N-[3,5-bis(trifluoromethylphenyl)]-5-chloro-2-hydroxybenzamide(Compound No. 4;
1.51g, 3mmo1) and pyridine(285mg, 3.6mmo1) in tetrahydrofuran(6mL) under ice
cooling, and the mixture was stirred at room temperature for 1 hour. 2N
Hydrochloric
acid was added to the residue obtained by evaporation of the solvent under
reduced
pressure and the mixture was extracted with ethyl acetate. After the ethyl
acetate
layer was washed successively with water and brine, dried over anhydrous
magnesium
sulfate, the residue obtained by evaporation of the solvent under reduced
pressure was
recrystallized from n-hexane/ethyl acetate to give the title compound(1.06g,
83.0%) as
a white solid.
1H-NMR(DMSO-ds): 8 2.22(3H, s), 7.35(1H, d, J=9.OHz), 7.71(1H, dd, J=8.7,
2.7Hz),
7.85(1H, s), 7.88(1H, d, J=2.7Hz), 8.37(2H, s), 11.05(1H, brs).
When the method described in Example 5 is referred in the following examples,
organic bases such as pyridine, triethylamine or the like were used as the
base. As
the reaction solvent, solvents such as dichloromethane, tetrahydrofuran,
benzene or
the like were used.
Example 6: Preparation of the compound of Compound No. 6.
Using 5-bromosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 88.5%.
1H-NMR(DMSO-ds): 8 6.98(1H, d, J=8.8Hz), 7.59(1H, dd, J=8.8, 2.8Hz), 7.83(1H,
s),
7.98(1H, d, J=2.8Hz), 8.43(2H, s), 10.82(1H, s), 11.37(1H, s).
111
CA 02489091 2004-12-08
This compound was obtained also by the following preparation method.
Iron powder(30mg, 0.54mmo1) and bromine(0.02mL, 0.39mmo1) were added to
a solution of 2-acetoxy-N-[3,5-bis(trifluoromethyl)]benzamide(Compound No. 1;
100mg,
0.25mmo1) in carbon tetrachloride(8mL), and the mixture was stirred at
50°C for 4
hours. After the reaction mixture was cooled to room temperature, it was
poured into
aqueous NaHSOa and extracted with ethyl acetate. The ethyl acetate layer was
washed with water and brine, and dried over anhydrous sodium sulfate. The
residue
obtained by evaporation of the solvent under reduced pressure was purified by
column
chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title
compound(600mg, 54.9%) as a white solid.
Example 7: Preparation of the compound of Compound No. 7.
Using 5-iodosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 62.2%.
1H-NMR(DMSO-ds): 8 6.86(1H, d, J=8.4Hz), 7.74(1H, dd, J=8.7, 2.4Hz), 7.84(1H,
s),
8.13(1H, d, J=2.lHz), 8.84(2H, s), 10.82(1H, s), 11.41(1H, s).
Example 8: Preparation of the compound of Compound No. 8.
Using 5-nitrosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 57.2%.
1H-NMR(DMSO-ds): b 7.18(1H, d, J=9.OHz), 7.86(1H, s), 8.31(1H, dd, J=9.0,
3.OHz),
8.45(2H, s), 8.70(1H, d, J=3.OHz), 11.12(1H, s).
Example 9: Preparation of the compound of Compound No. 9.
(1) 2-Benzyloxy-5-formylbenzoic acid benzyl ester.
A mixture of 5-formylsalicylic acid(4.98g, 30mmol), benzyl bromide(15.39g,
90mmol), potassium carbonate(16.59g, 120mmo1), and methyl ethyl ketone(350mL)
was refluxed for 8 hours. After cooling, the solvent was evaporated under
reduced
pressure. 2N Hydrochloric acid was added to the residue, and the mixture was
extracted with ethyl acetate. The layer was washed with water and brine, and
dried
over anhydrous magnesium sulfate. The residue obtained by evaporation of the
solvent under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=3:1), suspended and washed with isopropyl ether
under
heating at reflux to give the title compound(5.98g, 57.5°/) as a white
solid.
112
CA 02489091 2004-12-08
1H-NMR(CDCIs): 8 5.27(2H, s), 5.37(2H, s), 7.15(1H, d, J=9.OHz), 7.26-
7.46(lOH, m),
7.99(1H, dd, J=9.0, 2.4Hz), 8.36(1H, d, J=2.4Hz), 9.91(1H, s).
(2) 2-Benzyloxy-5-cyanobenzoic acid benzyl ester.
A mixture of 2-benzyloxy-5-formylbenzoic acid benzyl ester(693mg, 2mmo1),
hydroxylamine hydrochloride(167mg, 2.4mmo1), and N-methylpyrrolidone(3mL) was
stirred at 115°C for 4 hours. After the reaction mixture was cooled, 2N
hydrochloric
acid(5mL) and water(30mL) were added and the mixture was extracted with ethyl
acetate. The organic layer was washed with 2N aqueous sodium hydroxide, water,
and brine, and dried over anhydrous magnesium sulfate. The residue obtained by
evaporation of the solvent under reduced pressure was suspended and washed
with
isopropyl ether under heating at reflux to give the title compound(527mg,
76.7%) as a
white solid.
1H-NMR(CDCIs): b 5.23(2H, s), 5.35(2H, s), 7.08(1H, d, J=8.7Hz), 7.33-7,
43(lOH, m),
7.70(1H, dd, J=8.7, 2.4Hz), 8.13(1H, d, J=2.4Hz).
(3) 5-Cyanosalicylic acid.
Ethanol(lOmL) and tetrahydrofuran(lOmL) were added to
2-benzyloxy-5-cyanobenzoic acid benzyl ester(446mg, l.3mmo1) and 5% palladium
on
carbon(45mg), and the mixture was hydrogenated at room temperature for 2
hours.
After the insoluble matter was filtered off, the solvent was evaporated under
reduced
pressure to give the title compound(212mg, 100.0%) as a white solid.
1H-NMR(DMSO-ds): b 7.02(1H, d, J=8.7Hz), 7.82(1H, dd, J=8.7, 2.4Hz), 8.12(1H,
d,
J=2.lHz).
(4) N-[3,5-Bis(trifluoromethyl)phenyl]-5-cyano-2-hydroxybenzamide(Compound No.
9).
Using 5-cyanosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 16.6%.
1H-NMR(DMSO-ds): 8 7.15(1H, d, J=8.7Hz), 7.85(1H, s), 7.86(1H, dd, J=8.7,
2.lHz),
8.22(1H, d, J=2.4Hz), 8.43(2H, s), 10.93(1H, s), 12.00(1H, brs).
Example 10: Preparation of the compound of Compound No. 10.
Using 5-methylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 54.9%.
1H-NMR(DMSO-ds): b 6.92(1H, d, J=8.7Hz), 7.28(1H, dd, J=8.7, l.BHz), 7.71(1H,
d,
113
CA 02489091 2004-12-08
J=l.BHz), 7.82(1H, s), 8.47(2H, s), 10.80(1H, s), 11.14(1H, s).
Example 11: Preparation of the compound of Compound No. 11.
(1) 5-[(1,1-Dimethyl)ethyl]salicylic acid.
Sulfamic acid(1.76g, 18.1mmol) and sodium dihydrogenphosphate(7.33g,
47mmo1) were added to a solution of
5-[(1,1-dimethyl)ethyl]-2-hydroxybenzaldehyde(2.15g, l2.lmmol) in
1,4-dioxane(100mL) and water(40mL). A solution of sodium chlorite(1.76g,
15.5mmo1)
in water(lOmL) was added to the mixture under ice cooling, and it was stirred
for 1
hour. Then, sodium sulfite(1.80g, 14.3mmol) was added to the mixture, and it
was
stirred for 30 minutes. Concentrated hydrochloric acid was added to the
reaction
mixture, and pH was adjusted to 1. The residue obtained by evaporation of
1,4-dioxane under reduced pressure was extracted with ethyl acetate. The
organic
layer was washed with water and brine, and dried over anhydrous magnesium
sulfate.
The residue obtained by evaporation of the solvent under reduced pressure was
washed with n-hexane under suspension to give the title compound(1.81g, 77.4%)
as a
white powder.
1H-NMR(DMSO-ds): b 1.26(9H, s), 6.90(1H, d, J=9.OHz), 7.58(1H, dd, J=8.7,
2.4Hz),
7.75(1H, d, J=2.4Hz), 11.07(1H, brs).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-5-[(1,1-dimethyl)ethyl]-2-
hydroxybenzamide
(Compound No. 11).
Using 5-[(1,1-dimethyl)ethyl]salicylic acid and 3,5-
bis(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 53.8%.
1H-NMR(DMSO-ds): b 1.30(9H, s), 6.96(1H, d, J=8.7Hz), 7.50(1H, dd, J=8.7,
2.4Hz),
7.82(1H, d, J=2.4Hz), 7.83(1H, s), 8.46(2H, s), 10.80(1H, s)11.12(1H, s).
Example 12: Preparation of the compound of Compound No. 12.
(1) 5-Acetyl-2-benzyloxybenzoic acid methyl ester.
A mixture of 5-acetylsalicylic acid methyl ester(13.59g, 70mmol), benzyl
bromide(17.96g, 105mmo1), potassium carbonate(19.35g, 140mmo1) and methyl
ethyl
ketone(350mL) was refluxed for 8 hours. After cooling, the solvent was
evaporated
under reduced pressure. 2N Hydrochloric acid was added to the residue, and it
was
extracted with ethyl acetate. After the ethyl acetate layer was washed with
water
and brine, dried over anhydrous magnesium sulfate and concentrated, the
residue was
114
CA 02489091 2004-12-08
recrystallized from isopropyl ether to give the title compound(14.20g, 71.4%)
as a white
solid.
1H-NMR(CDCIs): b 2.58(3H, s), 3.93(3H, s), 5.27(2H, s), 7.07(1H, d, J=8.7Hz),
7.26-7.43(3H, m), 7.47-7.50(2H, m), 8.07(1H, dd, J=8.7, 2.4Hz), 8.44(1H, d,
J=2.4Hz).
(2) 5-Acetyl-2-benzyloxybenzoic acid.
2N Sodium hydroxide( llmL) was added to a solution of
5-acetyl-2-benzyloxybenzoic acid methyl ester(5.69g, 20mmo1) in a mixed
solvent of
methanol/tetrahydrofuran(20mL+20mL), and the mixture was stirred for 8 hours.
2N
Hydrochloric acid was added to the residue obtained by evaporation of the
solvent
under reduced pressure and the mixture was extracted with dichloromethane.
After
the dichloromethane layer was washed successively with water and brine, dried
over
anhydrous magnesium sulfate, the residue obtained by evaporation of the
solvent
under reduced pressure was washed with isopropyl ether to give the title
compound(4.92g, 91.0%) as a white solid.
1H-NMR(DMSO-ds): b 2.55(3H, s), 5.32(2H, s), 7.30-7.43(4H, m), 7.49-7.52(2H,
m),
8.09(1H, dd, J=9.0, 2.7Hz), 8.22(1H, d, J=2.4Hz).
(3) 5-Acetyl-2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide.
Phosphorus oxychloride(1.85mL, 19.8mmo1) was added to a solution of
5-acetyl-2-benzyloxybenzoic acid(4.87g, l8mmol), 3,5-
bis(trifluoromethyl)aniline(4.54g,
19.8mmo1) and pyridine(5.70g, 72mmo1) in a mixed solvent of
tetrahydrofuran/dichloromethane(72mL+36mL) under ice cooling, and the mixture
was stirred at room temperature for 12 hours. 1N Hydrochloric acid(100mL) was
added to the residue obtained by evaporation of the solvent under reduced
pressure
and the mixture was extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous magnesium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(n-hexane:ethyl acetate=3:12:1) to give
the
title compound(5.47g, 63.1%) as a slightly yellowish green crystal.
1H-NMR(DMSO-ds): b 2.57(3H, s), 7.11(1H, d, J=8.7Hz), 7.86(1H, s), 8.05(1H,
dd,
J=8.4, 2.lHz), 8.44(1H, d, J=2.lHz), 8.47(2H, s), 10.96(1H, s), 11.97(1H,
brs).
When the preparation method described in Example 12(3) is referred in the
following examples, phosphorus oxychloride was used as the acid halogenating
agent.
Pyridine was used as the base. As the reaction solvent, solvents such as
115
CA 02489091 2004-12-08
dichloromethane, tetrahydrofuran or the like were used alone or as a mixture.
(4) 5-Acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide(Compound
No.
12).
Ethanol(6mL) and tetrahydrofuran(72mL) were added to
5-acetyl-2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide(602mg,
1.25mmo1)
and 5% palladium on carbon(60mg), and the mixture was stirrred at room
temperature
for 30 minutes under hydrogen atmosphere. After the insoluble matter was
filtered
off, the residue obtained by evaporation of the solvent under reduced pressure
was
recrystallized from n-hexane/ethyl acetate to give the title compound(230mg,
47.0%) as
a white solid.
1H-NMR(DMSO-ds): b 2.59(3H, s), 5.35(2H, s), 7.32-7.36(3H, m), 7.43(1H, d,
J=8.7Hz),
7.52-7.55(2H, m), 7.82(1H, s), 8.16(1H, dd, J=8.7, 2.4Hz), 8.25(1H, d,
J=2.4Hz),
8.31(2H, s), 10.89(1H, s).
Example 13: Preparation of the compound of Compound No. 13.
Sodium borohydride(23.6mg, 0.62mmol) was added to a suspension of
5-acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide(Compound No.
12;
50.5mg, 0.13mmol) in ethanol(2mL), and the mixture was stirred at room
temperature
for 12 hours. The reaction mixture was poured into diluted hydrochloric acid
and
extracted with ethyl acetate. After the ethyl acetate layer was washed with
water
and brine, dried over anhydrous sodium sulfate, the residue obtained by
evaporation of
the solvent under reduced pressure was washed with isopropyl ether/n-hexane
under
suspension to give the title compound(39.7mg, 78.3%) as a white powder.
1H-NMR(DMSO-ds): b 1.34(3H, d, J=6.3Hz), 4.71(1H, q, J=6.3Hz), 5.18(1H, brs),
6.97(1H, d, J=8.4Hz), 7.44(1H, dd, J=8.4, 2.lHz), 7.84(1H, s), 7.86(1H, d,
J=2.lHz),
8.48(2H, s), 10.85(1H, s), 11.32(1H, s).
Example 14: Preparation of the compound of Compound No. 14.
Pyridine(45 ~ L, 0.56mmo1) and O-methylhydroxylamine hydrochloride(25.8mg,
0.31mmol) were added to a solution of 5-acetyl-N-[3,5-
bis(trifluoromethyl)phenyl]-
2-hydroxybenzamide(Compound No. 12; 100.Omg, 0.26mmol) in ethanol(3mL), and
the
mixture was refluxed for 1 hour. After the reaction mixture was cooled to room
temperature, it was poured into diluted hydrochloric acid and extracted with
ethyl
acetate. After the ethyl acetate layer was washed with water and brine, dried
over
anhydrous sodium sulfate, the residue obtained by evaporation of the solvent
under
116
CA 02489091 2004-12-08
reduced pressure was purified by column chromatography on silica gel(n-
hexane:ethyl
acetate=4:1) to give the title compound(102.1mg, 95.3%) as a white crystal.
1H-NMR(DMSO-ds): b 2.19(3H, s), 3.91(3H, s), 7.05(1H, d, J=8.7Hz),7.77(1H, dd,
J=8.7, 2.4Hz), 7.85(1H, s), 8.09(1H, d, J=2.4Hz), 8.47(2H, s), 10.87(1H, s),
11.48(1H, s).
Example 15: Preparation of the compound of Compound No. 15.
Using 5-acetyl-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide
(Compound No. 12) and O-benzylhydroxylamine hydrochloride as the raw
materials,
the same operation as the Example 14 gave the title compound.
Yield: 79.9%.
1H-NMR(DMSO-ds): b 2.24(3H, s), 5.20(2H, s), 7.04(1H, d, J=8.7Hz), 7.29-
7.47(5H, m),
7.76(1H, dd, J=8.7, 2.4Hz), 7.85(1H, s), 8.07(1H, d, J=2.lHz), 8.46(2H, s),
10.87(1H, s),
11.47(1H, s).
Example 16: Preparation of the compound of Compound No. 16.
(1) 5-(2,2-Dicyanoethen-1-yl)-2-hydroxybenzoic acid.
5-Formylsalicylic acid (332mg, 2mmo1) was added to a solution of
malononitrile(132mg, 2mmo1) in ethanol(6mL). Benzylamine(O.lmL) was added
under ice cooling and the mixture was stirred at room temperature for 2 hours.
The
separated yellow crystal was filtered and recrystallized from ethanol to give
the title
compound(139.9mg, 32.7%) as a light yellow solid.
1H-NMR(DMSO-ds): b 7.12(1H, d, J=8.7Hz), 8.09(1H, dd, J=8.7, 2.4Hz), 8.41(1H,
s),
8.50( 1H, d, J=2.4Hz).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-5-(2,2-dicyanoethen-1-yl)-2-
hydroxybenzamide
(Compound No. 16).
Using 5-(2,2-dicyanoethen-1- yl)-2-hydroxybenzoic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 9.1°/.
1H-NMR(DMSO-ds): b 7.13(1H, d, J=9.OHz), 7.83(1H, s), 8.04(1H, dd, J=9.0,
2.4Hz),
8.36(1H, s), 8.38(1H, d, J=2.4Hz), 8.43(2H, s), 11.43(1H, s).
Example 17: Preparation of the compound of Compound No. 17.
(1) 5-[(2-Cyano-2-methoxycarbonyl)ethen-1-yl]-2-hydroxybenzoic acid.
A mixture of 5-formylsalicylic acid(332mg, 2mmo1), Cyanoacetic acid methyl
ester(198mg, 2mmo1), acetic acid(6mL) and triethylamine(0.2m1) was refluxed
for 5
11?
CA 02489091 2004-12-08
hours. After the reaction mixture was cooled to room temperature, it was
poured into
water, and the separated crystal was filtered and recrystallized from n-hexane
to give
the title compound(327.7mg, 66.3%) as a light yellow solid.
1H-NMR(DMSO-ds): 8 3.85(3H, s), 7.15(1H, d, J=8.7Hz), 8.20(1H, dd, J=8.7,
2.4Hz),
8.37(1H, s), 8.66(1H, d, J=2.4Hz).
(2) 3-({N-[3,5-Bis(trifluoromethyl)phenyl]carbamoyl}-4-hydroxyphenyl)-2-
cyanoacrylic
acid methyl ester(Compound No. 17).
Using 5-[(2-cyano-2-methoxycarbonyl)ethen-1-yl]-2-hydroxybenzoic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 66.3%.
1H-NMR(DMSO-ds): 8 3.85(3H, s), 7.19(1H, d, J=9.OHz), 7.85(1H, s), 8.20(1H,
dd,
J=8.7, 2.lHz), 8.33(1H, s), 8.45(2H, s), 8.50(1H, d, J=2.lHz), 11.00(1H, s),
11.03(1H, s).
Example 18: Preparation of the compound of Compound No. 18.
2N Sodium hydroxide(O.llml, 0.22mmol) was added to a solution of
3-({N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-hydroxyphenyl)-2-
cyanoacrylic
acid methyl ester(Compound No. 17; 50mg, 0.11mmo1) in ethanol(5mL), and the
mixture was stirred at room temperature for 3 hours. The reaction mixture was
poured into diluted hydrochloric acid and extracted with ethyl acetate. After
the
organic layer was washed with brine, dried over anhydrous magnesium sulfate,
the
residue obtained by evaporation of the solvent under reduced pressure was
recrystallized from ethyl acetate to give the title compound(13.5mg, 30.4%) as
a light
yellow solid.
1H-NMR(DMSO-ds): b 7.12(1H, d, J=8.4Hz), 7.84(1H, s), 7.94(1H, dd, J=8.4,
2.lHz),
8.38(1H, d, J=2.lHz), 8.45(2H, s), 9.87(1H, s), 11.41(1H, s).
Example 19: Preparation of the compound of Compound No. 19.
A mixture of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide
(Compound No. 7; 475mg, lmmol), styrene(130mg, 1.25mmo1), palladium
acetate(4.5mg, 0.02mmol), tris(ortho-tolyl)phosphine(12.2mg, 0.04mmo1),
diisopropylamine(388mg, 3mmo1) and N,N-dimethylformamide(2mL) was refluxed for
8 hours. After the reaction mixture was cooled to room temperature, water was
added
and the mixture was extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous magnesium
sulfate,
118
CA 02489091 2004-12-08
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(n-hexane:isopropyl ether=2:1-->1:1) to
give the
title compound(173mg, 38.3%) as a pale yellow solid.
1H-NMR(DMSO-ds): 8 7.04(1H, d, J=8.4Hz), 7.20-7.29(3H, m), 7.38(2H, t,
J=7.5Hz),
7.59(2H, d, J=7.5Hz), 7.72(1H, dd, J=8.4, 2.lHz), 7.86(1H, s), 8.07(1H, d,
J=2.lHz),
8.49(2H, s), 10.89(1H, s), 11.33(1H, brs).
Example 20: Preparation of the compound of Compound No. 20.
Tetrakis(triphenylphosphine)palladium(23mg, 0.02mmo1) and cuprous
iodide(4mg, 0.02mmo1) were added to a solution of
N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide(Compound No. 7;
950mg, 2mmo1), trimethylsilylacetylene(246mg, 2.5mmo1) and triethylamine(2mL)
in
N,N-dimethylformamide(4mL) under argon atmosphere, and the mixture was stirred
at 40°C for 2 hours. After the reaction mixture was cooled to room
temperature, it
was poured into ethyl acetate(100mL) and 1N citric acid(100mL), stirred, and
filtered
through celite. After the ethyl acetate layer was washed successively with
water and
brine, dried over anhydrous magnesium sulfate, the residue obtained by
evaporation of
the solvent under reduced pressure was purified by column chromatography on
silica
gel(n-hexane:ethyl acetate=19:1) and crystallized by n-hexane to give the
title
compound(286mg, 32.1%) as a white crystal.
1H-NMR(DMSO-ds): b 0.23(9H, s), 7.00(1H, d, J=8.7Hz), 7.54(1H, dd, J=8.7,
2.4Hz),
7.85(1H, s), 7.98(1H, d, J=2.lHz), 8.46(2H, s), 10.86(1H, s), 11.69(1H, s).
Example 21: Preparation of the compound of Compound No. 21.
2N Sodium hydroxide(1mL) was added to a solution of
N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-
[(trimethylsilyl)ethynyl]benzamide
(Compound No. 20; 233mg, 0.5mmo1) in methanol(1mL), and the mixture was
stirred
at room temperature for 1 hour. The reaction mixture was poured into 2N
hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous magnesium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
recrystallized from ethanol/water to give the title compound(67mg, 35.9%) as a
light
gray crystal.
1H-NMR(DMSO-ds): 8 4.11(1H, s), 7.02(1H, d, J=8.4Hz), 7.55(1H, dd, J=8.4,
2.lHz),
7.85(1H, s), 7.98(1H, d, J=2.lHz), 8.46(2H, s), 8.46(2H, s), 10.86(1H, s),
11.62(1H, s).
119
CA 02489091 2004-12-08
Example 22: Preparation of the compound of Compound No. 22.
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide
(Compound No. 7) and phenylacetylene as the raw materials, the same operation
as
the Example 20 gave the title compound.
Yield: 40.8%.
1H-NMR(DMSO-ds): b 7.06(1H, d, J=8.4Hz), 7.42-7.46(3H, m), 7.53-7.57(2H, m),
7.64(1H, dd, J=8.7, 2.lHz), 7.86(1H, s), 8.06(1H, d, J=2.lHz), 8.48(2H, s),
10.94(1H, s),
11.64(1H, brs).
Example 23: Preparation of the compound of Compound No. 23.
Tetrakis(triphenylphosphine)palladium(l6mg, 0.0014mmo1) was added to a
solution of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-
iodobenzamide(Compound
No. 7; 200mg, 0.42mmol) in 1,2-dimethoxyethane(3mL) under argon atmosphere,
and
the mixture was stirred at room temperature for 5 minutes. Then
dihydroxyphenylborane(57mg, 0.47mmo1) and lmol/L aqueous sodium
carbonate(l.3mL) were added and the mixture was refluxed for 2 hours. After
the
reaction mixture was cooled to room temperature, it was poured into diluted
hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous sodium sulfate,
the
residue obtained by evaporation of the solvent under reduced pressure was
purified by
column chromatography on silica gel(n-hexane:ethyl acetate=6:1-~3:1) to give
the title
compound(109mg, 61.1%) as a white crystal.
1H-NMR(DMSO-ds): b 7.12(1H, d, J=8.7Hz), 7.33-7.38(1H, m), 7.48(2H, t,
J=7.5Hz),
7.67-7.70(2H, m), 7.79(1H, dd, J=8.4, 2.4Hz), 7.87(1H, s), 8.17(1H, d,
J=2.4Hz),
8.49(2H, s), 10.92(1H, s), 11.41(1H, s).
Example 24: Preparation of the compound of Compound No. 24.
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-(phenylethynyl)-
benzamide(Compound No. 22) as the raw material, the same operation as the
Example
12(4) gave the title compound.
Yield: 86.2%.
1H-NMR(DMSO-ds): 8 2.88(4H, s), 6.93(1H, d, J=S.lHz), 7.15-7.34(6H, m),
7.76(1H, d,
J=2.4Hz), 7.84(1H, s), 8.47(2H, s), 10.79(1H, s), 11.15(1H, s).
Example 25: Preparation of the compound of Compound No. 25.
Using 2-hydroxy-5-(trifluoromethyl)benzoic acid and
120
CA 02489091 2004-12-08
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 44.7%.
1H-NMR(CDCIs): 8 7.17(1H, d, J=9.OHz) 7.72-7.75(2H, m), 7.86(1H, s), 8.17(2H,
s),
8.35(1H, s) 11.88(1H, s).
[2-Hydroxy-5-(trifluoromethyl)benzoic acid: Refer to "Chemical and
Pharmaceutical
Bulletin", 1996, Vo1.44, No.4, p.734-745.]
Example 26: Preparation of the compound of Compound No. 26.
Using 2-hydroxy-5-(pentafluoroethyl)benzoic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 65.7%.
1H-NMR(CDCIs): b 7.19(1H, d, J=9.OHz) 7.70(1H, dd, J=8.7, 2.lHz), 7.81(1H, d,
J=2.lHz), 8.17(2H, s), 8.37(1H, s), 11.92(1H, s).
[2-Hydroxy-5-(pentafluoroethyl)benzoic acid: Refer to "Chemical and
Pharmaceutical
Bulletin", 1996, Vo1.44, No.4, p.734-745.]
Example 27: Preparation of the compound of Compound No. 27.
Using 2-hydroxy-5-(pyrrol-1-yl)benzoic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 57.8%.
1H-NMR(DMSO-ds): b 6.27(2H, dd, J=2.4, l.BHz), 7.10(1H, d, J=9.OHz), 7.29(2H,
dd,
J=2.4, l.BHz), 7.66(1H, dd, J=9.0, 2.7Hz), 7.86(1H, s), 7.98(1H, d, J=2.4Hz),
8.47(2H, s),
10.89(1H, s), 11.24(1H, s).
Example 28: Preparation of the compound of Compound No. 28.
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide
(Compound No. 7) and 2-thiopheneboronic acid as the raw materials, the same
operation as the Example 23 gave the title compound.
Yield: 44.4%.
1H-NMR(DMSO-ds): 8 7.08(1H, d, J=8.4Hz), 7.14(1H, dd, J=5.4, 3.6Hz), 7.45(1H,
dd,
J=3.6, l.2Hz), 7.51(1H, dd, J=5.1, 0.9Hz), 7.75(1H, dd, J=8.4, 2.4Hz),
7.59(1H, s),
8.08(1H, d, J=2.4Hz), 8.48(2H, s), 10.91(1H, s), 11.38(1H, s).
Example 29: Preparation of the compound of Compound No. 29.
121
CA 02489091 2004-12-08
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide
(Compound No. 7) and 3-thiopheneboronic acid as the raw materials, the same
operation as the Example 23 gave the title compound.
Yield: 38.7%.
1H-NMR(DMSO-ds): 8 7.06(1H, d, J=8.7Hz), 7.57(1H, dd, J=4.8, l.SHz), 7.66(1H,
dd,
J=4.8, 3.OHz), 7.81-7.84(2H, m), 7.86(1H, s), 8.18(1H, d, J=2.lHz), 8.49(2H,
s),
10.90(1H, s), 11.33(1H, s).
Example 30: Preparation of the compound of Compound No. 30.
(1) 2-Benzyloxy-5-(2-bromoacetyl)-N-[3,5-bis(trifluoromethyl)phenyl]benzamide.
Phenyltrimethylammonium tribromide(3.75g, lOmmol) was added to a
solution of 5-acetyl-2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]benzamide
(compound of Example 12(3); 4.81g, lOmmol) in tetrahydrofuran(30m1), and the
mixture was stirred at room temperature for 12 hours. The reaction mixture was
poured into water and extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with aqueous sodium hydrogen sulfite, water and brine,
dried
over anhydrous magnesium sulfate, the residue obtained by evaporation of the
solvent
under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=4:1), and recrystallized from ethyl acetate/n-
hexane to give
the title compound(2.39g, 42.7%) as a white solid.
1H-NMR(DMSO-ds): b 4.91(2H, s), 5.36(2H, s), 7.32-7.35(3H, m), 7.47(1H, d,
J=9.OHz),
7.52-7.56(2H, m), 7.82(1H, s), 8.21(1H, dd, J=8.7, 2.4Hz), 8.29(1H, d,
J=2.4Hz),
8.31(2H, s), 10.91(1H, s).
(2) 2-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(2-methylthiazol-4-
yl)benzamide.
A mixture of 2-benzyloxy-5-(2-bromoacetyl)-N-[3,5-bis(trifluoromethyl)
phenyl]benzamide(280mg, 0.5mmo1), thioacetamide(4lmg, 0.55mmo1), sodium
hydrogen carbonate(50mg, 0.6mmo1) and ethanol(l5mL) was refluxed for 1 hour.
After the reaction mixture was cooled to room temperature, it was poured into
water
and extracted with ethyl acetate. After the ethyl acetate layer was washed
successively with water and brine, dried over anhydrous magnesium sulfate, the
residue obtained by evaporation of the solvent under reduced pressure was
purified by
column chromatography on silica gel(hexane:ethyl acetate=4:1) to give the
title
compound(181mg, 67.5%) as a white solid.
1H-NMR(DMSO-ds): b 2.72(3H, s), 5.29(2H, s), 7.33-7.36(3H, m), 7.40(1H, d,
J=9.OHz),
122
CA 02489091 2004-12-08
7.54-7.57(2H, m), 7.81(1H, s), 7.94(1H, s), 8.12(1H, dd, J=8.7, 2.lHz),
8.27(1H, d,
J=2.lHz), 8.31(2H, s), 10.86(1H, s).
(3) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(2-methylthiazol-4-
yl)benzamide
(Compound No. 30).
Ethanol(lOml) was added to 2-benzyloxy-N-[3,5-bis(trifluoromethyl)-
phenyl]-5-(2-methylthiazol-4-yl)benzamide(160mg, 0.3mmo1) and 10% palladium on
carbon(240mg), and the mixture was stirred for 3.5 hours under hydrogen
atmosphere.
The reaction mixture was filtered and the solvent was evaporated under reduced
pressure to give the title compound(103.4mg, 79.2%) as a white solid.
1H-NMR(DMSO-ds): b 2.72(3H, s), 7.08(1H, d, J=8.7Hz), 7.83(1H, s), 7.85(1H,
s),
8.01(1H, dd, J=8.7, 2.4Hz), 8.42(1H, d, J=2.lHz), 8.50(2H, s), 10.96(1H, s),
11.40(1H,
s).
Example 31: Preparation of the compound of Compound No. 31.
A mixture of 2-benzyloxy-5-(2-bromoacetyl)-N-[3,5-bis(trifluoromethyl)-
phenyl]benzamide (compound of Example 12(3); 280mg, 0.5mmo1),
2-aminopyridine(51.8mg, 0.55mmo1), sodium hydrogen carbonate(50mg, 0.6mmo1)
and
ethanol(lOmL) was refluxed for 2 hours. After the reaction mixture was cooled
to
room temperature, it was poured into aqueous sodium hydrogen carbonate and
extracted with ethyl acetate. After the ethyl acetate layer was washed
successively
with water and brine, dried over anhydrous magnesium sulfate, the residue
obtained
by evaporation of the solvent under reduced pressure was purified by column
chromatography on silica gel(hexane:ethyl acetate=1:2) to give a white
solid(130.3mg,
45.9%). Then, a mixture of this solid(108mg, 0.19mmol), 10% palladium on
carbon(llmg), ethanol(8mL) and ethyl acetate(8mL) was stirred for 7 hours
under
hydrogen atmosphere. The reaction mixture was filtered and the residue
obtained by
evaporation of the solvent under reduced pressur was purified by column
chromatography on silica gel(n-hexane:ethyl acetate=1:3) to give the title
compound(18.3mg, 20.2%) as a white solid.
1H-NMR(DMSO-ds): b 6.90(1H, dt, J=6.6, 0.9Hz), 7.10(1H, d, J=8.7Hz), 7.25(1H,
m),
7.57(1H, d, J=9.OHz), 7.86(1H, s), 8.04(1H, dd, J=8.7, 2.lHz), 8.35(1H, s),
8.48-8.56(4H,
m), 11.00(1H, s), 11.41(1H, s).
Example 32: Preparation of the compound of Compound No. 32.
(1) N-[3,5-Bis(trifluoromethyl)phenyl]-5-iodo-2-methoxymethoxybenzamide.
123
CA 02489091 2004-12-08
A mixture of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-iodobenzamide
(Compound No. 7; 4.75g, lOmmol), chloromethyl methyl ether(1.14m1, l5mmol),
potassium carbonate(2.76g, 20mmol) and acetone(50mL) was refluxed for 8 hours.
After the reaction mixture was cooled to room temperature, it was poured into
diluted
hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous magnesium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(hexane:ethyl acetate=3:1) and
recrystallized
from n-hexane/ethyl acetate to give the title compound(3.96g, 76.3%) as a
white solid.
1H-NMR(DMSO-ds): 8 3.38(3H, s), 5.28(2H, s), 7.12(1H, d, J=9.OHz), 7.81(1H,
s),
7.82(1H, dd, J=8.7, 2.4Hz), 7.88(1H, d, J=2.4Hz), 8.40(2H, s), 10.87(1H, s).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxymethoxy-5-(pyridin-2-
yl)benzamide.
Tri-n-butyl(2-pyridyl)tin (0.13m1, 0.41mmol) and dichlorobis-
(triphenylphosphine)palladium(32.1mg, 0.05mmo1) were added to a solution of
N-[3,5-bis(trifluoromethyl)phenyl]-5-iodo-2-methoxymethoxybenzamide(0.20g,
0.39mmo1) in N,N-dimethylformamide(8m1), and the mixture was stirred at
100°C for
1.5 hours. After the reaction mixture was cooled to room temperature, it was
poured
into water and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was purified by
column
chromatography on silica gel(n-hexane:ethyl acetate=2:1-~1:1) to give the
title
compound(37.9mg, 20.8%) as a white powder.
1H-NMR(CDCIs): 8 3.64(3H, s), 5.53(2H, s), 7.23-7.28(1H, m),7.36(1H, d,
J=8.7Hz),
7.65(1H, s), 7.77-7.84(2H, m), 8.20(2H, s), 8.31(1H, dd, J=8.7, 2.4Hz), 8.68-
8.70(1H, m),
8.83(1H, d, J=2.4Hz), 10.12(1H, s).
(3) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(pyridin-2-yl)benzamide
(Compound No. 32).
Methanol(3m1) and concentrated hydrochloric acid(0.5m1) were added to
N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxymethoxy-5-(pyridin-2-
yl)benzamide(37.9
mg, 0.08mmol), and the mixture was refluxed for 2 hours. After the reaction
mixture
was cooled to room temperature, it was poured into saturated aqueous sodium
hydrogen carbonate and extracted with ethyl acetate. After the ethyl acetate
layer
was washed successively with water and brine, dried over anhydrous sodium
sulfate,
124
CA 02489091 2004-12-08
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the
title
compound(16.2mg, 47.2%) as a white powder.
1H-NMR(DMSO-ds): b 7.13(1H, d, J=8.4Hz), 7.33(1H, ddd, J=7.5, 6.3, l.2Hz),
7.86-7.91(2H, m), 7.97(1H, d, J=7.8Hz), 8.20(1H, dd, J=8.7, 2.lHz), 8.50(2H,
s),
8.59(1H, d, J=2.4Hz), 8.64-8.66(1H, m), 10.97(1H, s), 11.53(1H, s).
Example 33: Preparation of the compound of Compound No. 33.
Using 5-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 56.8%.
1H-NMR(DMSO-ds): 8 3.77(3H, s), 6.97(1H, d, J=9.OHz), 7.10(1H, dd, J=9.0,
3.OHz),
7.43(1H, d, J=3.OHz), 7.84(1H, s), 8.47(2H, s), 10.84(1H, s), 10.91(1H, s).
Example 34: Preparation of the compound of Compound No. 34.
(1) 5-Acetyl-2-methoxybenzoic acid methyl ester.
Methyl iodide(2.5mL, 40.1mmo1) was added to a mixture of 5-acetylsalicylic
acid methyl ester(S.OOg, 25.7mmo1), sodium carbonate(7.lOg, 51.4mmo1) and
N,N-dimethylformamide(25mL) under ice cooling, and the mixture was stirred at
room
temperature for 3 hours. The reaction mixture was poured into water,
neutralized by
hydrochloric acid, and extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous sodium sulfate,
the
residue obtained by evaporation of the solvent under reduced pressure was
washed
under suspension(isopropyl ether/n-hexane) to give the title compound(5.17g,
96.5%)
as a white crystal.
1H-NMR(CDCIa): b 2.59(3H, s), 3.92(3H, s), 3.99(3H, s), 7.04(1H, d, J=8.7Hz),
8.12(1H,
dd, J=8.7, 2.4Hz), 8.41(1H, d, J=2.4Hz).
(2) 5-Isobutyryl-2-methoxybenzoic acid methyl ester.
Methyl iodide(0.5mL, 8.03mmo1) was added to a mixture of
5-acetyl-2-methoxybenzoic acid methyl ester(0.50g, 2.40mmol), potassium
tert-butoxide(0.81g, 7.22mmol) and tetrahydrofuran(lOmL), and the mixture was
stirred at room temperature for 1 hour. The reaction mixture was poured into
water,
neutralized by hydrochloric acid, and extracted with ethyl acetate. After the
ethyl
acetate layer was washed successively with water and brine, dried over
anhydrous
sodium sulfate, the residue obtained by evaporation of the solvent under
reduced
125
CA 02489091 2004-12-08
pressure was purified by column chromatography on silica gel(n-hexane:ethyl
acetate=3:12:1) to give the title compound(143.1mg, 25.2%) as a light yellow
oil.
1H-NMR(CDCIs): 8 1.22(6H, d, J=6.9Hz), 3.52(1H, m), 3.92(3H, s), 3.98(3H, s),
7.05(1H, d, J=8.7Hz), 8.13(1H, dd, J=8.7, 2.4Hz), 8.42(1H, d, J=2.4Hz).
(3) 5-Isobutyryl-2-methoxybenzoic acid.
2N Aqueous sodium hydroxide(1mL) was added to a solution of
5-isobutyryl-2-methoxybenzoic acid methyl ester(143.1mg, 0.60mmo1) in
methanol(5mL), and the mixture was refluxed for 1 hour. After the reaction
mixture
was cooled to room temperature, it was poured into 2N hydrochloric acid and
extracted
with ethyl acetate. After the ethyl acetate layer was washed successively with
water
and brine, dried over anhydrous sodium sulfate, the solvent was evaporated
under
reduced pressure to give the title compound(134mg, quantitative) as a white
crystal.
1H-NMR(CDCIa): 8 1.22(6H, d, J=6.9Hz), 3.59(1H, m), 4.15(3H, s), 7.16(1H, d,
J=8.7Hz), 8.24(1H, dd, J=8.7, 2.4Hz), 8.73(1H, d, J=2.lHz).
(4) 5-Isobutyryl-N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxybenzamide.
Using 5-isobutyryl-2-methoxybenzoic acid and 3,5-bis(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 61.4%.
1H-NMR(CDCIs): 8 1.23(6H, d, J=6.9Hz), 3.64(1H, m), 4.20(3H, s), 7.18(1H, d,
J=8.7Hz), 7.65(1H, s), 8.19(2H, s), 8.22(1H, dd, J=8.7, 2.lHz), 8.88(1H, d,
J=2.lHz),
9.98(1H, s).
(5) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-
isobutyrylbenzamide(Compound
No. 34).
A mixture of 5-isobutyryl-N-[3,5-bis(trifluoromethyl)phenyl]-2-
methoxybenzamide(143.4mg, 0.33mmo1), 2,4,6-collidine(3ml) and lithium
iodide(53.1mg, 0.40mmo1) was refluxed for 1 hour. After the reaction mixture
was
cooled to room temperature, it was poured into 2N hydrochloric acid and
extracted
with ethyl acetate. After the ethyl acetate layer was washed with brine, dried
over
anhydrous sodium sulfate, the residue obtained by evaporation of the solvent
under
reduced pressure was purified by column chromatography on silica gel(n-
hexane:ethyl
acetate=3:1) and crystallized by ethyl acetate/isopropyl ether to give the
title
compound(90.3mg, 65.3%) as a white crystal.
1H-NMR(DMSO-ds): 8 1.12(6H, d, J=6.9Hz), 3.66(1H, m), 7.12(1H, d, J=8.4Hz),
126
CA 02489091 2004-12-08
7.85(1H, s), 8.07(1H, dd, J=8.4, 2.4Hz), 8.45(1H, d, J=2.4Hz), 8.47(2H, s),
10.93(1H, s),
11.95(1H, brs).
Example 35: Preparation of the compound of Compound No. 35.
Using 4-hydroxyisophthalic acid 1-methyl ester and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 91.5%.
1H-NMR(DMSO-ds): b 3.85(3H, s), 7.12(1H, d, J=8.4Hz), 7.86(1H, s), 8.02(1H,
dd,
J=8.7, 2.4Hz), 8.46-8.47(3H, m), 10.96(1H, s), 12.03(1H, brs).
[4-Hydroxyisophthalic acid 1-methyl ester: Refer to "Journal of the Chemical
Society",
(England), 1956, p.3099-3107.]
Example 36: Preparation of the compound of Compound No. 36.
2N Aqueous sodium hydroxide(l4mL) was added to a suspension of
N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxyisophthalamic acid methyl
ester(Comound No. 35; 2.85g, 7mmo1) in a mixed solvent of
methanol/tetrahydrofuran(l4mL+l4mL), and the mixture was refluxed for 2 hours.
After the reaction mixture was cooled to room temperature, 2N hydrochloric
acid(20m1)
was added and the separated solid was filtered, washed with water, dried to
give the
title compound(2.68g, 97.4%) as a white crystal.
1H-NMR(DMSO-ds): b 7.10(1H, d, J=8.7Hz), 7.82(1H, s), 7.86(1H, s), 8.01(1H,
dd,
J=8.7, 2.4Hz), 8.47(2H, s), 8.48(1H, d, J=2.4Hz), 10.97(1H, s), 11.98(1H,
brs).
When the method described in Example 36 is referred in the following
examples, inorganic bases such as sodium hydroxide, potassium carbonate or the
like
were used as the base. As the reaction solvent, solvents such as water,
methanol,
ethanol, tetrahydrofuran or the like were used alone or as a mixture.
Example 37: Preparation of the compound of Compound No. 37.
Using 4-hydroxyisophthalic acid(182mg, lmmol), 3,5-bis(trifluoromethyl)-
aniline(687mg, 3mmo1), phosphorus trichloride(87 a L; lmmol) and
toluene(lOmL), the
same operation as the Example 3 gave the title compound(151mg, 25.0%) as a
white
crystal.
1H-NMR(DMSO-ds): & 7.18(1H, d, J=8.7Hz), 7.82(1H, s), 7.86(1H, s), 8.11(1H,
dd,
J=8.7, 2.4Hz), 8.50(2H, s), 8.54(2H, s), 8.56(1H, d, J=2.4Hz), 10.79(1H, s),
10.99(1H, s),
11.84(1H, brs).
127
CA 02489091 2004-12-08
Example 38: Preparation of the compound of Compound No. 38.
(1) 4-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid methyl
ester.
A solution of N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxyisophthalamic acid
methyl ester(Compound No. 35; 8.15g, 20mmo1) in N,N-dimethylformamide(100mL)
was added to a suspension of sodium hydride(60%; 1.04g, 26mmo1) in
N,N-dimethylformamide(100mL) under ice cooling, and the mixture was stirred at
room temperature for 1 hour. A solution of benzyl bromide(4.45g, 26mmo1) in
N,N-dimethylformamide(lOmL) was added and the mixture was stirred at
60°C for 3
hours. After the reaction mixture was cooled to room temperature, it was
poured into
ice and water, and extracted with ethyl acetate. After the ethyl acetate layer
was
washed successively with water and brine, dried over anhydrous magnesium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
recrystallized from ethyl acetate/n-hexane to give the title compound(5.38g,
54.1%) as
a white solid.
1H-NMR(DMSO-ds): b 3.87(3H, s), 5.33(2H, s), 7.33-7.36(3H, m), 7.46(1H, d,
J=8.7Hz),
7.53-7.56(2H, m), 7.82(1H, s), 8.15(1H, dd, J=8.7, 2.lHz), 8.25(1H, d,
J=2.lHz)8.28(2H,
s), 10.87(1H, s).
(2) 4-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid.
Using 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid
methyl ester as the raw material, the same operation as the Example 36 gave
the title
compound.
Yield: 79.7%.
1H-NMR(DMSO-ds): b 5.32(2H, s), 7.32-7.34(3H, m), 7.43(1H, d, J=8.7Hz),
7.52-7.56(2H, m), 7.81(1H, s), 8.12(1H, dd, J=8.7, 2.lHz), 8.22(1H, d,
J=2.lHz),
8.28(2H, s), 10.85(1H, s), 13.81(1H, brs).
(3) 4-Benzyloxy-N3-[3,5-bis(trifluoromethyl)phenyl]-N1,N1-
dimethylisophthalamide.
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (hereinafter
abbreviated as WSC ~ HC1; 95mg, 0.50mmo1) was added to a solution of
4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic acid(242mg,
0.50mmo1),
dimethylamine hydrochloride(4lmg, 0.50mmo1) and triethylamine(5lmg, 0.50mmol)
in
tetrahydrofuran(5mL) under ice cooling, and the mixture was stirred at room
temperature for 3 hours. The reaction mixture was poured into water and
extracted
with ethyl acetate. After the ethyl acetate layer was washed successively with
128
CA 02489091 2004-12-08
diluted hydrochloric acid, water and brine, dried over anhydrous magnesium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(hexane:ethyl acetate=1:4) to give the
title
compound(165mg, 64.9%) as a white solid.
1H-NMR(DMSO-ds): b 2.99(6H, s)5.29(2H, s), 7.32-7.38(4H, m), 7.52-7.56(2H, m),
7.64(1H, dd, J=8.7, 2.lHz), 7.73(1H, d, J=2.lHz), 7.80(1H, s), 8.28(2H, s),
10.83(1H, s).
When the method described in Example 38(3) is referred in the following
examples, organic bases such as pyridine, triethylamine or the like were used
as the
base. As the reaction solvent, solvents such as dichloromethane,
tetrahydrofuran or
the like were used alone or as a mixture.
(4) N3-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-N1,N1-dimethylisophthalamide
(Compound No. 38).
A mixture of 4-benzyloxy-N3-[3,5-bis(trifluoromethyl)phenyl]-N1,N1-dimethyl-
isophthalamide(141mg, 0.28mmo1), 5% palladium on carbon(l4mg), ethanol(5m1)
and
ethyl acetate(5m1) was stirred at room temperature for 1 hour under hydrogen
atmosphere. The reaction mixture was filtered and the filtrate was evaporated
under
reduced pressure to give the title compound(106mg, 91.2%) as a white solid.
1H-NMR(DMSO-ds): b 2.98(6H, s), 7.02(1H, d, J=8.7Hz), 7.52(1H, dd, J=8.7,
2.lHz),
7.84(1H, s), 7.95(1H, d, J=2.lHz), 8.46(2H, s), 11.10(1H, brs), 11.63(1H,
brs).
Example 39: Preparation of the compound of Compound No. 39.
(1) 2-Benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(piperidine-1-carbonyl)-
benzamide.
Using 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic
acid(compound of Example 38(2)) and piperidine as the raw materials, the same
operation as the Example 38(3) gave the title compound.
Yield: 56.4%.
IH-NMR(CDCIs): b 1.53-1.70(6H, m), 3.44(2H, brs), 3.70(2H, brs), 5.26(2H, s),
7.24(1H,
d, J=8.7Hz), 7.26(1H, s), 7.52-7.58(5H, m), 7.66(2H, s), 7.74(1H, dd, J=8.7,
2.4Hz),
8.37(1H, d, J=2.lHz), 10.27(1H, s).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(piperidine-1-
carbonyl)benzamide
(Compound No. 39).
Using 2-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]-5-(piperidine-1-
carbonyl)benzamide as the raw material, the same operation as the Example
38(4)
129
CA 02489091 2004-12-08
gave the title compound.
Yield: 96.3%, white solid.
1H-NMR(DMSO-ds): 8 1.51(4H, brs), 1.60-1.65(2H, m), 3.47(4H, brs), 7.04(1H, d,
J=8.4Hz), 7.48(1H, dd, J=8.4, 2.lHz), 7.85(1H, s), 7.92(1H, d, J=2.lHz),
8.46(2H, s),
10.99(1H, s), 11.64(1H, brs).
Example 40: Preparation of the compound of Compound No. 40.
(1) 2-Benzyloxy-5-(4-benzylpiperidine-1-carbonyl)-N-[3,5-
bis(trifluoromethyl)phenyl]-
benzamide.
Using 4-benzyloxy-N-[3,5-bis(trifluoromethyl)phenyl]isophthalamic
acid(compound of Example 38(2)) and 4-benzylpiperidine as the raw materials,
the
same operation as the Example 38(3) gave the title compound.
Yield: 76.7%.
1H-NMR(CDaOD): 8 1.18-1.38(2H, m), 1.67(1H, brs), 1.74(1H, brs), 1.84-1.93(1H,
m),
2.60(2H, d, J=7.2Hz), 2.83(1H, brs), 3.10(1H, brs), 3.78(1H, brs), 4.59(1H,
brs), 5.34(2H,
s), 7.15-7.18(3H, m), 7.24-7.28(2H, m), 7.40-7.46(4H, m), 7.57-7.63(3H, m),
7.65(1H, dd,
J=8.7, 2.4Hz), 7.96(2H, s), 8.05(1H, d, J=2.lHz).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(4-benzylpiperidine-1-
carbonyl)-
benzamide(Compound No. 40).
Using 2-benzyloxy-5-(4-benzylpiperidine-1-carbonyl)-N-[3,5-bis-
(trifluoromethyl)phenyl]-benzamide as the raw material, the same operation as
the
Example 38(4) gave the title compound.
Yield: 54.3%, white solid.
1H-NMR(DMSO-ds): 8 1.08-1.22(2H, m), 1.59-1.62(2H, m), 1.77-1.80(1H, m),
2.50-2.55(2H, m), 2.87(2H, brs), 3.75(1H, br), 4.39(1H, br), 7.06(1H, d,
J=8.4Hz),
7.17-7.20(3H, m), 7.28(2H, t, J=7.2Hz), 7.49(1H, dd, J=8.4, 2.lHz), 7.84(1H,
s), 7.93(1H,
d, J=2.lHz), 8.47(2H, s), 10.89(1H, s), 11.65(1H, s).
Example 41: Preparation of the compound of Compound No. 41.
(1) 2-Methoxy-5-sulfamoylbenzoic acid.
2N Aqueous sodium hydroxide(30mL, 60mmo1) was added to a solution of
methyl 2-methoxy-5-sulfamoylbenzoate(4.91g, 20mmo1) in methanol(30mL), and the
mixture was stirred at room temperature for 1 hour. The reaction mixture was
poured into 2N hydrochloric acid, and the separated solid was filtered to give
the title
compound(4.55g, 98.3%) as a white solid.
130
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): 8 3.89(3H, s), 7.30(1H, d, J=8.7Hz), 7.32(2H, s), 7.92(1H,
dd,
J=8.7, 2.7Hz), 8.09(1H, d, J=2.7Hz), 13.03(1H, br).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxy-5-sufamoylbenzamide.
Using 2-methoxy-5-sulfamoylbenzoic acid and 3,5-bis(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 12(3) gave the title
compound.
Yield: 24.2%.
1H-NMR(DMSO-ds): b 3.97(3H, s), 7.38(2H, s), 7.39(1H, d, J=8.7Hz), 7.85(1H,
s),
7.96(1H, dd, J=8.7, 2.4Hz), 8.06(1H, d, J=2.4Hz), 8.43(2H, s), 10.87(1H, s).
(3) N-[3,5-Bis(trifluoromethyl)phenyl]-5-dimethylsufamoyl-2-methoxybenzamide.
A suspension of N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5
sufamoylbenzamide(442mg, l.Ommo1), methyl iodide(710mg, 5.Ommo1), sodium
carbonate(415mg, 3.Ommo1) and acetonitrile(lOmL) was refluxed for 3 hours.
After
the reaction mixture was cooled to room temperature, it was poured into water
and
extracted with ethyl acetate. After the ethyl acetate layer was washed
successively
with water and brine, dried over anhydrous magnesium sulfate, the residue
obtained
by evaporation of the solvent under reduced pressure was recrystallized from
n-hexane/ethyl acetate to give the title compound(207mg, 44.1%) as a white
solid.
1H-NMR(DMSO-ds): b 2.62(6H, s), 3.99(3H, s), 7.45(1H, d, J=9.OHz), 7.85(1H,
s),
7.91(1H, dd, J=8.7, 2.4Hz), 7.95(1H, d, J=2.4Hz)8.43(2H, s), 10.90(1H, s).
(4) N-[3,5-Bis(trifluoromethyl)phenyl]-5-dimethylsufamoyl-2-hydroxybenzamide
(Compound No. 41).
Using N-[3,5-bis(trifluoromethyl)phenyl]-5-dimethylsufamoyl-2-
methoxybenzamide as the raw material, the same operation as the Example 34(5)
gave
the title compound.
Yield: 45.5%.
1H-NMR(DMSO-ds):d 2.61(6H, s), 7.20(1H, d, J=8.7Hz), 7.77(1H, dd, J=8.7,
2.lHz),
7.86(1H, s), 8.14(1H, d, J=2.lHz)8.45(2H, s), 11.16(1H, s), 12.15(1H, br).
Example 42: Preparation of the compound of Compound No. 42.
(1) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxy-5-(pyrrole-1-
sulfonyl)benzamide.
A mixture of N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5-sulfamoyl-
benzamide(compound of Example 41(2); 442mg, lmmol),
2,5-dimethoxytetrahydrofuran(159mg, l.2mmo1) and acetic acid(5mL) was refluxed
for
131
CA 02489091 2004-12-08
2 hours. After the reaction mixture was cooled to room temperature, it was
poured
into water and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water, saturated aqueous sodium hydrogen carbonate and
brine,
dried over anhydrous magnesium sulfate, the residue obtained by evaporation of
the
solvent under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=3:2) to give the title compound(436.5mg, 88.6%) as
a white
solid.
1H-NMR(DMSO-ds): 8 3.96(3H, s), 6.36(2H, dd, J=2.4, 2.lHz), 7.37(2H, dd,
J=2.4,
2.lHz), 7.42(1H, d, J=9.OHz), 7.85(1H, s), 8.80(1H, dd, J=9.0, 2.4Hz)8.18(1H,
d,
J=2.7Hz), 8.38(2H, s), 10.92(1H, s).
(2) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-(pyrrole-1-
sulfonyl)benzamide
(Compound No. 42).
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5-(pyrrole-
1-sulfonyl)benzamide as the raw material, the same operation as the Example
34(5)
gave the title compound.
Yield: 79.4%.
1H-NMR(DMSO-ds) b 6.36(2H, dd, J=2.4, 2.lHz), 7.18(1H, d, J=9.OHz), 7.34(2H,
dd,
J=2.4, 2.lHz), 7.86(1H, s), 7.99(1H, dd, J=9.0, 2.7Hz)8.31(1H, d, J=2.7Hz),
8.42(2H, s),
10.98(1H, s).
Example 43: Preparation of the compound of Compound No. 43.
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide
(Compound No. 8) as the raw material, the same operation as the Example 38(4)
gave
the title compound.
Yield: 98.0%.
1H-NMR(DMSO-ds): b 4.79(2H, brs), 6.76(1H, d, J=2.lHz), 6.76(1H, s), 7.09(1H,
dd,
J=2.1, l.2Hz), 7.80(1H, s), 8.45(2H, s), 10.30(1H, br), 10.84(1H, s).
Example 44: Preparation of the compound of Compound No. 44.
Using 5-dimethylaminosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 28.8%.
1H-NMR(DMSO-ds): b 2.85(6H, s), 6.92(1H, d, J=9.OHz), 7.01(1H, dd, J=8.7,
3.OHz),
7.22(1H, d, J=3.OHz), 7.84(1H, s), 8.47(2H, s), 10.62(1H, s), 10.83(1H, s).
Example 45: Preparation of the compound of Compound No. 45.
132
CA 02489091 2004-12-08
Benzoyl chloride(155mg, l.lmmol) was added to a mixture of
5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide(Compound No. 43;
364mg, lmmol), pyridine(95mg, l.2mmol) and tetrahydrofuran(lOmL) under ice
cooling, and the mixture was stirred for 1 hour. The reaction mixture was
poured into
water and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water and brine, dried over anhydrous magnesium sulfate, the
residue obtained by evaporation of the solvent under reduced pressure was
purified by
column chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the
title
compound(121mg, 25.7%) as a white solid.
1H-NMR(DMSO-ds): b 7.04(1H, d, J=8.7Hz), 7.51-7.62(3H, m), 7.81(1H, dd, J=8.7,
2.4Hz), 7.83(1H, s), 7.98(2H, d, J=7.2Hz), 8.22(1H, d, J=2.4Hz), 8.49(2H, s),
10.27(1H,
s), 10.89(1H, s), 11.07(1H, s).
Example 46: Preparation of the compound of Compound No. 46.
4-Dimethylaminopyridine(3mg) and phenylisocyanate(30 ~ L, 0.28mmo1) were
added to a solution of 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-
hydroxybenzamide(Compound No. 43; 100.2mg, 0.28mmol) in acetonitrile(4m1), and
the mixture was stirred at 60°C for 5 minutes. After the reaction
mixture was cooled
to room temperature, the residue obtained by evaporation of the solvent under
reduced
pressure was purified by column chromatography on silica gel(n-hexane:ethyl
acetate=1:1) to give the title compound(54.8mg, 41.2%) as a light brown solid.
1H-NMR(DMSO-ds): b 6.93-6.98(1H, m), 6.97(1H, d, J=9.3Hz),7.27(2H, t,
J=7.8Hz),
7.34-7.46(2H, m), 7.50(1H, dd, J=9.0, 2.4Hz), 7.83(1H, s), 7.88(1H, s),
8.47(2H, s),
8.56(1H, s), 8.63(1H, s), 10.87(1H, s), 10.89(1H, s).
Example 47: Preparation of the compound of Compound No. 47.
Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide
(Compound No. 43) and phenylisothiocyanate as the raw materials, the same
operation
as the Example 46 gave the title compound.
Yield: 66.3%.
1H-NMR(DMSO-ds): b 7.00(1H, d, J=8.4Hz), 7.13(1H, tt, J=7.5, l.2Hz),7.34(2H,
t,
J=7.8Hz), 7.45-7.51(3H, m), 7.84(1H, s), 7.87(1H, d, J=2.7Hz), 8.47(2H, s),
9.65(1H, s),
9.74(1H, s), 10.84(1H, s), 11.32(1H, s).
Example 48: Preparation of the compound of Compound No. 48.
Using 5-[(4-nitrophenyl)diazenyl]salicylic acid and
133
CA 02489091 2004-12-08
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 11.3%.
1H-NMR(DMSO-ds): b 7.23(1H, d, J=9.OHz), 7.87(1H, s),8.06(2H, d, J=9.OHz),
8.10(1H,
dd, J=9.0, 2.4Hz), 8.44(2H, d, J=9.OHz), 8.50(2H, s), 8.53(1H, d, J=2.4Hz),
11.13(1H, s),
12.14(1H, br).
Example 49: Preparation of the compound of Compound No. 49.
Using 5-({[(4-pyridin-2-yl)sulfamoyl]phenyl}diazenyl)salicylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 7.9%.
1H-NMR(DMSO-ds): b 6.87(1H, t, J=6.OHz), 7.22(1H, d, J=8.7Hz), 7.21-7.23(1H,
m),
7.77(1H, t, J=8.4Hz), 7.87(1H, s), 7.95-7.98(3H, m), 8.03-8.07(4H, m),
8.47(1H, d,
J=2.4Hz), 8.49(2H, s), 11.14(1H, s), 12.03(1H, br).
Example 50: Preparation of the compound of Compound No. 50.
(1) 4-Acetylamino-5-chloro-2-methoxybenzoic acid.
Using 4-acetylamino-5-chloro-2-methoxybenzoic acid methyl ester as the raw
material, the same operation as the Example 36 gave the title compound.
Yield: 88.0%.
1H-NMR(DMSO-ds): b 2.16(3H, s), 3.78(3H, s), 7.72(1H, s), 7.77(1H, s),
9.57(1H, s),
12.74(1H, s).
(2) 4-Acetylamino-N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-
methoxybenzamide.
Using 4-acetylamino-5-chloro-2-methoxybenzoic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 12(3) gave the title compound.
Yield: 23.8%.
1H-NMR(DMSO-ds): b 2.17(3H, s), 3.89(3H, s), 7.77-7.82(3H, m), 8.45-8.49(2H,
m),
9.66(1H, s), 10.68(1H, s).
(3) 4-Acetylamino-N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-
hydoxybenzamide
(Compound No. 50).
Using 4-acetylamino-N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-
methoxybenzamide as the raw material, the same operation as the Example 34(5)
gave
the title compound.
134
CA 02489091 2004-12-08
Yield: 72.8%.
1H-NMR(DMSO-ds): b 2.17(3H, s), 7.75(1H, s), 7.82(1H, s), 7.95(1H, s),
8.44(2H, s),
9.45(1H, s), 11.16(1H, brs), 11.63(1H, brs).
Example 51: Preparation of the compound of Compound No. 51.
Using 4-chlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 55.8%.
1H-NMR(DMSO-ds): 8 7.05-7.08(2H, m), 7.84-7.87(2H, m), 8.45(2H, s), 10.84(1H,
s)11.64(1H, brs).
Example 52: Preparation of the compound of Compound No. 52.
Using 6-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 86.9%.
1H-NMR(DMSO-ds): 6 6.36(2H,d,J=8.4Hz), 7.13(lH,t,J=8.4Hz),7.79(1H, s),8.38(2H,
s),11.40(2H,brs),11.96(1H, brs).
Example 53: Preparation of the compound of Compound No. 53.
Using 4-methylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 42.9%.
1H-NMR(DMSO-ds): b 2.32(3H, s)6.82(1H, d, J=6.6Hz)6.84(1H, s)7.83(1H,
s)7.84(1H,
d, J=8.5Hz)8.47(2H, s)10.76(1H, s)11.44(1H, s).
Example 54: Preparation of the compound of Compound No. 54.
Using 5-bromo-4-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 82.4%.
1H-NMR(CDCIs): b 5.89(1H, s)6.70(1H, s)7.69(2H, s)7.95(1H, s)8.12(2H,
s)11.62(1H,
s).
Example 55: Preparation of the compound of Compound No. 55.
Using 4-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 29.9°/ .
1H-NMR(DMSO-ds): 8 6.37(1H, d, J=2.5Hz), 6.42(1H, dd, J=8.8, 2.5Hz), 7.81(1H,
s),
7.86(1H, d, J=8.5Hz), 8.44(2H, s), 10.31(1H, s), 10.60(1H, s), 11.77(1H, s).
135
CA 02489091 2004-12-08
Example 56: Preparation of the compound of Compound No. 56.
Using 3,5-dichlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 44.8°/ .
1H-NMR(DMSO-ds): 8 7.85(1H, d, J=2.5Hz), 7.91(1H, s), 8.01(1H, d, J=2.5Hz),
8.42(2H, s), 11.10(1H, s).
Example 57: Preparation of the compound of Compound No. 57.
Using 3-hydroxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 22.7%.
zH-NMR(DMSO-ds): b 6.81(1H, t, J=8.OHz), 7.01(lH, dd, J=8.0, l.SHz), 7.35(1H,
dd,
J=8.0, l.SHz), 7.84(1H, s), 8.46(2H, s), 9.56(1H, s), 10.79(1H, s), 10.90(1H,
brs).
Example 58: Preparation of the compound of Compound No. 58.
Using 3-methylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 54.9%.
1H-NMR(DMSO-ds): b 2.22(3H, s), 6.94(1H, t, J=7.4Hz), 7.42(1H, d, J=7.4Hz),
7.84-7.85(2H, m), 8.47(2H, s), 10.87(1H, s), 11.87(1H, s).
Example 59: Preparation of the compound of Compound No. 59.
Using 3-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 34.6%.
1H-NMR(DMSO-ds): b 3.85(3H, s), 6.94(1H, t, J=8.OHz), 7.20(1H, dd, J=8.0,
l.4Hz),
7.44(1H, dd, J=8.0, l.4Hz), 7.84(1H, s), 8.45(2H, s), 10.82(1H, s), 10.94(1H,
brs).
Example 60: Preparation of the compound of Compound No. 60.
Using 5-[(1,1,3,3-tetramethyl)butyl]salicylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 64.2%.
1H-NMR(DMSO-ds): b 0.70(9H, s), 1.35(6H, s), 1.72(2H, s), 6.95(1H, d,
J=8.4Hz),
7.50(1H, dd, J=8.0, 2.lHz), 7.83(1H, s), 7.84(1H, d, J=2.lHz), 8.46(1H, s),
10.77(1H, s),
11.20(1H, s).
Example 61: Preparation of the compound of Compound No. 61.
136
CA 02489091 2004-12-08
Using 3,5,6-trichlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 26.2%.
1H-NMR(DMSO-ds): b 7.88(1H, s), 7.93(1H, s), 8.33(2H, s), 10.88(1H, s),
11.36(1H, s).
Example 62: Preparation of the compound of Compound No. 62.
Using 3,5-bis[(1,1-dimethyl)ethyl]salicylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 65.0%.
1H-NMR(DMSO-ds): b 1.34(9H, s), 1.40(9H, s), 7.49(1H, d, J=2.2Hz), 7.82(1H, d,
J=2.2Hz), 7.91(1H, s), 8.40(2H, s), 10.82(1H, s), 12.44(1H, s).
Example 63: Preparation of the compound of Compound No. 63.
Using 6-fluorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 35.9%.
1H-NMR(DMSO-ds): b 6.73-6.82(2H, m), 7.32(1H, ddd, J=1.4, 8.5, 15.3Hz),
7.83(1H, s),
8.39(2H, s), 10.50(1H, d, J=l.4Hz), 11.11(1H, s).
Example 64: Preparation of the compound of Compound No. 64.
Using 3-chlorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 61.3%.
1H-NMR(DMSO-ds): 8 7.05(1H, dd, J=7.6, 8.OHz), 7.69(1H, dd, J=1.4, 13.3Hz),
7.90(1H, s), 7.93(1H, dd, J=1.4, 8.OHz), 8.44(2H, s), 11.01(1H, s), 11.92(1H,
br.s).
Example 65: Preparation of the compound of Compound No. 65.
Using 4-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 14.2%.
1H-NMR(DMSO-ds): 8 3.81(3H, s), 6.54(1H, d, J=2.5Hz), 6.61(1H, dd, J=2.5,
8.8Hz),
7.83(1H, s), 7.95(1H, d, J=8.8Hz), 8.45(2H, s), 10.69(1H, s), 11.89(1H, s).
Example 66: Preparation of the compound of Compound No. 66.
Using 6-methoxysalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 63.1%.
137
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): b 3.24(3H, s), 6.03(1H, d, J=8.OHz), 6.05(1H, d, J=8.5Hz),
6.71(1H, dd, J=8.2, 8.5Hz), 7.25(1H, s), 7.88(2H, s), 9.67(1H, s), 10.31(1H,
s)
Example 67: Preparation of the compound of Compound No. 67.
Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide
(Compound No. 43) and methanesulfonyl chloride as the raw materials, the same
operation as the Example 45 gave the title compound.
Yield: 22.6%.
1H-NMR(DMSO-ds): b 2.93(3H, s), 7.02(1H, d, J=8.4Hz), 7.31(1H, dd, J=8.4,
2.7Hz),
7.68(1H, d, J=2.7Hz), 7.83(1H, s), 8.46(2H, s), 9.48(1H, s), 10.85(1H, s),
11.15(1H, s).
Example 68: Preparation of the compound of Compound No. 68.
Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide
(Compound No. 43) and benzenesulfonyl chloride as the raw materials, the same
operation as the Example 45 gave the title compound.
Yield: 45.3%.
1H-NMR(DMSO-ds): 8 6.89(1H, d, J=8.7Hz), 7.10(1H, dd, J=8.7, 2.7Hz), 7.51-
7.64(4H,
m), 7.68-7.71(2H, m), 7.81(1H, s), 8.42(2H, s), 10.03(1H, s), 10.87(1H, s),
11.13(1H,
brs).
Example 69: Preparation of the compound of Compound No. 69.
Using 5-amino-N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxybenzamide
(Compound No. 43) and acetyl chloride as the raw materials, the same operation
as the
Example 45 gave the title compound.
Yield: 44.8%.
1H-NMR(DMSO-ds): 8 2.02(3H, s), 6.97(1H, d, J=8.7Hz), 7.61(1H, dd, J=8.7,
2.7Hz),
7.82(1H, s), 7.99(1H, d, J=2.7Hz), 8.46(2H, s), 9.90(1H, s), 10.85(1H, s),
10.94(1H, s).
Example 70: Preparation of the compound of Compound No. 70.
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-5-sulfamoylbenzamide
(compound of Example 41(2)) as the raw material, the same operation as the
Example
34(5) gave the title compound.
Yield: 59.9%.
1H-NMR(DMSO-ds): b 7.17(1H, d, J=8.7Hz), 7.31(2H, s), 7.85(1H, s), 7.86(1H,
dd,
J=8.4, 2.4Hz), 8.26(1H, d, J=2.7Hz), 8.47(2H, s), 10.95(1H, s), 11.90(1H, s).
Example 71: Preparation of the compound of Compound No. 71.
Using 1-hydroxynaphthalene-2-carboxylic acid and
138
CA 02489091 2004-12-08
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 65.5%.
1H-NMR(DMSO-ds): 8 7.51(1H, d, J=9.OHz), 7.60(1H, td, J=7.8, 0.9Hz), 7.70(1H,
td,
J=7.8, 0.9Hz), 7.89(1H, s), 7.93(1H, d, J=8.4Hz), 8.09(1H, d, J=9.OHz),
8.33(1H, d,
J=8.7Hz), 8.51(2H, s), 10.92(1H, s), 13.36(1H, s).
Example 72: Preparation of the compound of Compound No. 72.
Using 3-hydroxynaphthalene-2-carboxylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 46.9%.
1H-NMR(DMSO-ds): 8 7.36-7.41(2H, m), 7.50-7.55(1H, m), 7.79(1H, d, J=8.2Hz),
7.85(1H, d, J=0.6Hz), 7.96(1H, d, J=S.OHz), 8.51(2H, s), 10.98(1H, s),
11.05(1H, s).
Example 73: Preparation of the compound of Compound No. 73.
Using 2-hydroxynaphthalene-1-carboxylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 30.2%.
1H-NMR(DMSO-ds): b 7.27(1H, d, J=8.8Hz), 7.32-7.38(1H, m), 7.45-7.50(1H, m),
7.72(1H, d, J=8.5Hz), 7.82-7.93(3H, m), 8.50(1H, s), 10.28(1H, s), 11.07(1H,
brs).
Example 74: Preparation of the compound of Compound No. 74.
(1) 4-Bromo-3-hydroxythiophene-2-carboxylic acid.
A solution of 4-bromothiophene-2-carboxylic acid methyl ester(500mg,
2.lmmol), sodium hydroxide(261mg, 6.3mmol) in a mixed solvent of
methanol/water(2.5mL+2.5mL) was refluxed for 2 hours. After the reaction
mixture
was cooled to room temperature, 2N hydrochloric acid was added to adjust pH to
1, and
it was diluted with ethyl acetate. The ethyl acetate layer was washed
successively
with water and brine, and dried over anhydrous sodium sulfate. The solvent was
evaporated under reduced pressure to give the title compound(326mg, 69.4%) as
a red
brown powder.
1H-NMR(CDCla): b 4.05(1H, brs), 7.40(1H, s).
(2) 4-Bromo-3-hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]thiophene-2-
carboxamide
(Compound No. 74).
139
CA 02489091 2004-12-08
Using 4-bromo-3-hydroxythiophene-2-carboxylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 82.4°/.
1H-NMR(CDCIa): 8 7.42(1H, s), 7.67(1H, brs), 7.78(1H, brs), 8.11(2H, s),
9.91(1H, brs).
Example 75: Preparation of the compound of Compound No. 75.
Phosphorus oxychloride(0.112m1, l.2mmol) was added to a solution of
5-chloro-2-hydroxynicotinic acid(174mg, lmmol),
3,5-bis(trifluoromethyl)aniline(275mg, l.2mmo1), pyridine(316mg, 4mmo1) in
tetrahydrofuran/dichloromethane(20mL+lOmL), and the mixture was stirred at
room
temperature for 2 hours. The reaction mixture was poured into ethyl
acetate(100mL)
and 0.2N hydrochloric acid(100mL), filtered through celite after stirring for
30
minutes, and the water layer was extracted with ethyl acetate. After the
combined
ethyl acetate layer was washed successively with water and brine, dried over
anhydrous magnesium sulfate, the residue obtained by evaporation of the
solvent
under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=2:1-X1:1), washed with ethanol under suspension to
give
the title compound(183mg, 47.6%) as a white crystal.
mp >270°C.
1H-NMR(DMSO-ds): b 7.83(1H, s), 8.15(1H, d, J=3.3Hz), 8.36(1H, d, J=3.OHz),
8.40(2H, s), 12.43(1H, s).
When the preparation method described in Example 75 is referred in the
following examples, phosphorus oxychloride was used as the condensating
agent(acid
halogenating agent). Pyridine was used as the base. As the reaction solvent,
solvents such as dichloromethane, tetrahydrofuran or the like were used alone
or as a
mixture.
Example 76: Preparation of the compound of Compound No. 76.
Using 3-hydroxypyridine-2-carboxylic acid and 3,5-bis(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 75 gave the title
compound.
Yield: 45.0%.
1H-NMR(CDCls): b 7.40(1H, dd, J=8.4, l.BHz), 7.46(1H, dd, J=8.4, 4.2Hz),
7.68(1H, s),
8.16(1H, dd, J=4.2, l.2Hz), 8.25(2H, s), 10.24(1H, s), 11.42(1H, s).
Example 77: Preparation of the compound of Compound No. 77.
140
CA 02489091 2004-12-08
A solution of 6-chloro-oxindole(184mg, I.lmmol) in tetrahydrofuran(5ml) and
triethylamine(0.3mL) were added to a solution of
3,5-bis(trifluoromethyl)phenylisocyanate(255mg, l.Ommol) in
tetrahydrofuran(5mL)
under argon atmosphere, and the mixture was stirred at room temperature for 4
hours.
The reaction mixture was poured into diluted hydrochloric acid and extracted
with
ethyl acetate. The ethyl acetate layer was washed successively with water and
brine,
and dried over anhydrous magnesium sulfate. The residue obtained by
evaporation of
the solvent under reduced pressure was purified by column chromatography on
silica
gel(n-hexane:ethyl acetate=4:1) to give the title compound(172.2mg, 40.7%) as
a pink
solid.
1H-NMR(DMSO-ds): b 3.97(2H, s), 7.29(1H, dd, J=8.1, 2.lHz), 7.41(1H, d,
J=8.lHz),
7.88(1H, s), 8.04(1H, d, J=2.lHz), 8.38(2H, s), 10.93(1H, s).
Example 78: Preparation of the compound of Compound No. 78.
Using 3,5-bis(trifluoromethyl)phenylisocyanate and oxindole as the raw
materials, the same operation as the Example 77 gave the title compound.
Yield: 44.8°/ .
1H-NMR(DMSO-ds): 8 3.98(2H, s), 7.22(1H, td, J=7.8, I.2Hz), 7.33-7.40(2H, m),
7.87(1H, s), 8.02(1H, d, J=7.8Hz), 8.38(2H, s), I1.00(1H, s).
Example 79: Preparation of the compound of Compound No. 79.
Using 3,5-bis(trifluoromethyl)phenylisocyanate and 5-chlorooxindole as the
raw materials, the same operation as the Example 77 gave the title compound.
Yield: 31.1%.
1H-NMR(DMSO-ds): 8 3.99(2H, s), 7.41(1H, dd, J=8.7, 2.4Hz), 7.47(1H, d,
J=2.lHz),
7.87(1H, s), 8.01(1H, d, J=8.4Hz), 8.38(2H, s), 10.93(1H, s).
Example 80: Preparation of the compound of Compound No. 80.
Using 3-hydroxyquinoxaline-2-carboxylic acid and
3,5-bis(trifluoromethyl)aniline as the raw materials, the same operation as
the
Example 3 gave the title compound.
Yield: 2.7%.
iH-NMR(DMSO-ds): 8 7.40-7.45(2H, m), 7.69(1H, td, J=8.4, l.SHz), 7.90-7.93(2H,
m),
8.41(2H, s), I1.64(1H, s), I3.02(1H, s).
Example 81: Preparation of the compound of Compound No. 81.
Using 5-chlorosalicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw
141
CA 02489091 2004-12-08
materials, the same operation as the Example 3 gave the title compound.
Yield: 3.6°/ .
1H-NMR(CDCIa): 8 7.03(1H, d, J=8.7Hz), 7.43-7.48(2H, m), 6.61(1H, d, J=8.lHz),
7.85(1H, d, J=8.4Hz), 8.36(1H, brs), 8.60(1H, s), 11.31(1H, s).
Example 82: Preparation of the compound of Compound No. 82.
Using N-[2,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide
(Compound No. 81) and acetyl chloride as the raw materials, the same operation
as the
Example 5 gave the title compound.
Yield: 6.6%.
1H-NMR(CDCIa): & 2.35(3H, s), 7.17(1H, d, J=8.7Hz),7.54(1H, dd, J=8.7, 2.4Hz),
7.55(1H, d, J=8.lHz), 7.80(1H, d, J=8.lHz), 7.95(1H, d, J=2.4Hz), 8.60(1H, s),
8.73(1H,
s).
Example 83: Preparation of the compound of Compound No. 83.
Using 5-bromosalicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 24.0%.
1H-NMR(DMSO-ds): 8 7.03(1H, d, J=8.7Hz), 7.65(1H, dd, J=8.7, 2.7Hz), 7.76(1H,
d,
J=8.4Hz), 8.03(1H, d, J=8.lHz)8.11(1H, d, J=2.7Hz), 8.74(1H, s), 11.02(1H, s),
12.34(1H, s).
Example 84: Preparation of the compound of Compound No. 84.
Using 5-methylsalicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 1.5 %.
1H-NMR(CDCIs): 6 2.36(3H, s), 6.97(1H, d, J=8.4Hz), 7.23(1H, s), 7.32(1H, dd,
J=8.4,
l.5Hz), 7.57(1H, d, J=8.4Hz), 7.83(1H, d, J=8.4Hz), 8.46(1H, s), 8.69(1H, s),
11.19(1H,
s).
Example 85: Preparation of the compound of Compound No. 85.
Using 5-chlorosalicylic acid and 3-fluoro-5-(trifluoromethyl)aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 62.0%.
1H-NMR(DMSO-ds): 8 7.04(1H, d, J=8.7Hz), 7.42(1H, d, J=8.4Hz), 7.48(1H, dd,
J=9.0,
3.OHz), 7.85(1H, d, J=2.4Hz), 7.94(1H, dd, J=11.4, 2.lHz), 7.99(1H, s),
10.73(1H, s),
11.46(1H, s).
142
CA 02489091 2004-12-08
Example 86: Preparation of the compound of Compound No. 86.
Using 5-bromosalicylic acid and 3-bromo-5-(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 73.3%.
1H-NMR(DMSO-ds): b 6.99(1H, d, J=9.OHz), 7.60(1H, dd, J=9.0, 2.4Hz), 7.72(1H,
s),
7.97(1H, d, J=2.7Hz), 8.I6(1H, s), 8.28(1H, s), 10.69(1H, s), 11.45(1H, s).
Example 87: Preparation of the compound of Compound No. 87.
Using 5-chlorosalicylic acid and 2-fluoro-5-(trifluoromethyl)aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 77.9%.
1H-NMR(DMSO-ds): b 7.07(1H, d, J=9.OHz), 7.52(1H, dd, J=9.0, 2.7Hz), 7.58-
7.61(2H,
m), 7.95(1H, d, J=2.7Hz), 8.71(1H, d, J=7.5Hz), 10.90(1H, s), 12.23(1H, s).
Example 88: Preparation of the compound of Compound No. 88.
Using 5-chlorosalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 49.1%.
1H-NMR(DMSO-ds): 8 7.09(1H, d, J=9.OHz), 7.53(1H, dd, J=9.0, 3.OHz), 7.55(1H,
dd,
J=8.4, 2.7Hz), 7.83(1H, d, J=8.4Hz), 7.98(1H, d, J=3.OHz), 8.88(1H, d,
J=2.7Hz),
11.14(1H, s), 12.39(1H, s).
Example 89: Preparation of the compound of Compound No. 89.
Using 5-chloro-N-[2-chloro-5-(trifluoromethyl)phenyl]-2-hydroxybenzamide
(Compound No. 88) and acetyl chloride as the raw materials, the same operation
as the
Example 5 gave the title compound.
Yield: 34.0%.
IH-NMR(CDCIs): b 2.39(3H, s), 7.16(1H, d, J=8.7Hz),7.37(1H, ddd, J=8.7, 2.4,
0.6Hz),
7.51-7.56(2H, m), 7.97(1H, d, J=3.OHz), 8.85(1H, s), 8.94(1H, d, J=l.BHz).
Example 90: Preparation of the compound of Compound No. 90.
Using 5-bromosalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 34.2%.
1H-NMR(DMSO-ds): 8 7.04(1H, d, J=8.7Hz), 7.56(1H, ddd, J=8.1, 2.4, l.2Hz),
7.64(1H,
dd, J=8.7, 2.7Hz), 7.83(1H, dd, J=8.1, l.2Hz), 8.11(1H, d, J=2.7Hz), 8.87(1H,
d,
J=2.4Hz), 11.12(IH, s), 12.42(IH, s).
143
CA 02489091 2004-12-08
Example 91: Preparation of the compound of Compound No. 91.
Using 5-chlorosalicylic acid and 2-nitro-5-(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 8.1%.
1H-NMR(DMSO-ds): b 7.08(1H, d, J=9.OHz), 7.53(1H, dd, J=8.7, 2.7Hz), 7.73(1H,
dd,
J=8.4, l.8Hz), 7.95(1H, d, J=3.OHz), 8.36(1H, d, J=8.7Hz), 9.01(1H, d,
J=l.BHz),
12.04(1H, s), 12.20(1H, s).
Example 93: Preparation of the compound of Compound No. 93.
Using 5-chlorosalicylic acid and 2-methyl-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 73.3%.
iH-NMR(DMSO-ds): b 2.39(3H, s), 7.07(1H, d, J=8.7Hz), 7.44-7.54(3H, m),
7.99(1H, d,
J=3.OHz), 8.43(1H, s), 10.52(1H, s), 12.17(1H, brs).
Example 93: Preparation of the compound of Compound No. 93.
Using 5-bromosalicylic acid and 3-methoxy-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 58.8%.
IH-NMR(DMSO-ds): b 3.85(3H, s), 6.98(1H, d, J=8.7Hz), 7.03(1H, s), 7.57-
7.61(2H, m),
7.77(1H, s), 8.00(1H, d, J=2.4Hz), 10.57(1H, s), 11.56(1H, s).
Example 94: Preparation of the compound of Compound No. 94.
Using 5-bromosalicylic acid and 2-methoxy-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 71.3%.
1H-NMR(DMSO-ds): b 3.99(3H, s), 7.03(1H, d, J=9.OHz), 7.30(1H, d, J=8.7Hz),
7.47-7.51(1H, m), 7.61(1H, dd, J=9.0, 2.4Hz), 8.10(1H, d, J=2.4Hz), 8.82(1H,
d,
J=2.lHz)11.03(1H, s), 12.I9(IH, s).
Example 95: Preparation of the compound of Compound No. 95.
Using 5-chlorosalicylic acid and 2-methoxy-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 83.4%.
1H-NMR(DMSO-ds): 8 4.00(3H, s), 7.08(1H, d, J=9.OHz), 7.30(1H, d, J=8.7Hz),
7.47-7.52(2H, m), 7.97(1H, d, J=2.7Hz), 8.83(1H, d, J=2.4Hz), 11.05(1H, s),
12.17(1H,
s).
144
CA 02489091 2004-12-08
Example 96: Preparation of the compound of Compound No. 96.
Using 5-chlorosalicylic acid and 2-methylsulfanyl-5-(trifluoromethyl)aniline
as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 79.2%.
1H-NMR(DMSO-ds): b 2.57(3H, s), 7.07(1H, d, J=8.7Hz), 7.52(1H, dd, J=8.7,
2.4Hz),
7.55(1H, dd, J=8.4, l.SHz), 7.63(1H, d, J=8.lHz), 8.00(1H, d, J=2.4Hz),
8.48(1H, d,
J=l.SHz), 10.79(1H, s), 12.26(1H, s).
Example 97: Preparation of the compound of Compound No. 97.
Using 5-bromosalicylic acid and 2-(1-pyrrolidinyl)-5-(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 44.5%.
1H-NMR(DMSO-ds): b 1.86-1.91(4H, m), 3.20-3.26(4H, m), 6.99(1H, d, J=8.7Hz),
7.07(1H, d, J=8.7Hz), 7.43(1H, dd, J=8.7, 2.lHz), 7.62(1H, dd, J=8.7, 2.4Hz),
7.94(1H, d,
J=2.lHz), 8.17(1H, d, J=2.4Hz), 10.54(1H, s), 12.21(1H, s).
Example 98: Preparation of the compound of Compound No. 98.
Using 5-bromosalicylic acid and 2-morpholino-5-(trifluoromethyl)aniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 65.9%.
1H-NMR(DMSO-ds): b 2.90(4H, dd, J=4.5, 4.2Hz), 3.84(4H, dd, J=4.8, 4.2Hz),
7.09(1H,
d, J=8.4Hz), 7.48(2H, s), 7.61(1H, dd, J=8.4, 2.7Hz), 8.13(1H, d, J=2.7Hz),
8.90(1H, s),
11.21(1H, s), 12.04(1H, s).
Example 99: Preparation of the compound of Compound No. 99.
Using 5-nitrosalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 31.1%.
1H-NMR(DMSO-ds): 8 6.98(1H, d, J=9.3Hz), 7.52(1H, dd, J=8.4, 2.lHz), 7.81(1H,
d,
J=8.4Hz), 8.21(1H, dd, J=9.0, 3.3Hz), 8.82(1H, d, J=3.OHz), 8.93(1H, d,
J=2.4Hz),
12.18(1H, s).
Example 100: Preparation of the compound of Compound No. 100.
Using 5-methylsalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 15.8%.
1H-NMR(CDCIa): 8 2.36(3H, s), 6.95(1H, d, J=8.lHz), 7.26-7.31(2H, m), 7.37(1H,
dd,
145
CA 02489091 2004-12-08
J=8.4, l.BHz), 7.56(1H, d, J=8.4Hz), 8.65(1H, brs), 8.80(1H, d, J=l.BHz),
11.33(1H,
brs).
Example 101: Preparation of the compound of Compound No. 101.
Using 5-methoxysalicylic acid and 2-chloro-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 56.4%.
1H-NMR(DMSO-ds): 8 3.77(3H, s), 6.91(1H, d, J=9.OHz), 7.07(1H, dd, J=8.7,
3.OHz),
7.20(1H, t, J=l.BHz), 7.52-7.54(3H, m), 10.33(1H, s), 11.44(1H, s).
Example 102: Preparation of the compound of Compound No. 102.
Using 5-methylsalicylic acid and 2-methyl-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 14.2%, white solid.
1H-NMR(DMSO-ds): b 2.29(3H, s), 2.38(3H, s), 6.94(1H, d, J=8.4Hz), 7.27(1H,
ddd,
J=8.4, 2.4, 0.6Hz), 7.44(1H, dd, J=8.1, l.SHz), 7.52(1H, d, J=7.8Hz), 7.84(1H,
d,
J=2.4Hz), 8.46(1H, d, J=l.SHz), 10.55(1H, s), 11.72(1H, s).
Example 103: Preparation of the compound of Compound No. 103.
Using 5-methylsalicylic acid and 2-methoxy-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 77.9%.
1H-NMR(CDCIs): 8 2.35(3H, s), 4.02(3H, s), 6.93(1H, d, J=9.OHz), 6.98(1H, d,
J=8.4Hz),
7.25-7.28(2H, m), 7.36(1H, ddd, J=8.4, 2.1, 0.9Hz), 8.65(1H, brs), 8.73(1H, d,
J=2.lHz),
11.69(1H, s).
Example 104: Preparation of the compound of Compound No. 104.
Using 5-chlorosalicylic acid and 3-bromo-5-(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 37.1%.
1H-NMR(DMSO-ds): b 7.03(1H, d, J=9.3Hz), 7.48(1H, dd, J=8.7, 2.4Hz), 7.72(1H,
s),
7.84(1H, d, J=2.7Hz), 8.16(1H, s), 8.28(1H, s), 10.69(1H, s), 11.42(1H, s).
Example 105: Preparation of the compound of Compound No. 105.
Using 5-chlorosalicylic acid and 3-methoxy-5-(trifluoromethyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 68.0%.
1H-NMR(DMSO-ds): 8 3.85(3H, s), 7.02(1H, s), 7.03(1H, d, J=8.7Hz), 7.48(1H,
dd,
146
CA 02489091 2004-12-08
J=8.7, 2.7Hz), 7.61(1H, s), 7.77(1H, s), 7.88(1H, d, J=2.7Hz), 10.57(1H, s),
11.53(1H, s).
Example 106: Preparation of the compound of Compound No. 106.
Using 5-chlorosalicylic acid and 2-morpholino-5-(trifluoromethyl)aniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 64.8%.
1H-NMR(DMSO-ds): 8 2.90(4H, m), 3.84(4H, m), 7.15(1H, d, J=9.OHz), 7.48(2H,
s),
7.50(1H, dd, J=9.0, 2.7Hz), 8.00(1H, d, J=2.7Hz), 8.91(1H, s), 11.24(1H, s),
12.05(1H,
s).
Example 107: Preparation of the compound of Compound No. 107.
Using 5-chlorosalicylic acid and 2-bromo-5-(trifluoromethyl)aniline as the raw
material, the same operation as the Example 3 gave the title compound.
Yield: 59.2%.
1H-NMR(DMSO-ds): b 7.10(1H, d, J=8.7Hz), 7.48(1H, dd, J=8.4, 2.lHz), 7.53(1H,
dd,
J=8.7, 3.OHz), 7.97-7.99(2H, m), 8.81(1H, d, J=2.lHz), 11.03(1H, s), 12.38(1H,
s).
Example 108: Preparation of the compound of Compound No. 108.
Using 5-chlorosalicylic acid and 3-amino-5-(trifluoromethyl)benzoic acid
methyl ester as the raw materials, the same operation as the Example 3 gave
the title
compound.
Yield: 67.0%.
1H-NMR(DMSO-ds): b 3.91(3H, s), 7.02(1H, d, J=9.3Hz), 7.43(1H, dd, J=9.0,
2.4Hz),
7.57(1H, d, J=2.4Hz), 8.13(1H, s), 8.23(1H, s), 8.29(1H, s), 8.36(1H, s),
11.52(1H, s).
Example 109: Preparation of the compound of Compound No. 109.
2N Aqueous sodium hydroxide(0.6mL) was added to a suspension of
5-chloro-2-hydroxy-N-[3-methoxycarbonyl-5-(trifluoromethyl)phenyl]benzamide
(Compound No. 108; 105mg, 0.281mmol) in methanol(2.5mL), and the mixture was
stirred at room temperature for 3 hours. Water was added to the reaction
mixture
and it was washed with ethyl acetate. After the water layer was acidified by
addition
of diluted hydrochloric acid, it was extracted with ethyl acetate. After the
ethyl
acetate layer was washed successively with water and brine, dried over
anhydrous
sodium sulfate, the residue obtained by evaporation of the solvent under
reduced
pressure was crystallized by isopropyl ether to give the title compound(100mg,
99.0%)
as a white solid.
iH-NMR(DMSO-ds): b 7.04(1H, d, J=9.OHz), 7.49(1H, dd, J=8.7, 2.7Hz), 7.91(1H,
d,
147
CA 02489091 2004-12-08
J=2.7Hz), 7.93(1H, s), 8.43(1H, s), 8.59(1H, s), 10.78(1H, s), 11.48(1H, s).
Example 110: Preparation of the compound of Compound No. 110.
Using 5-chlorosalicylic acid and 2-(2-naphthyloxy)-5-(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 89.6%.
1H-NMR(CDCls): 8 6.94(1H, d, J=9.6Hz), 6.98(1H, d, J=9.2Hz), 7.25-7.41(4H, m),
7.48-7.57(3H, m), 7.81(1H, d, J=6.9Hz), 7.88(1H, d, J=6.9Hz), 7.95(1H, d,
J=8.9Hz),
8.72(1H, s), 8.83(1H, d, J=2.OHz), 11.70(1H, s).
Example 111: Preparation of the compound of Compound No. 111.
Using 5-chlorosalicylic acid and 2-(2,4-dichlorophenoxy)-5-
(trifluoromethyl)aniline as the raw materials, the same operation as the
Example 3
gave the title compound.
Yield: 4.7%.
1H-NMR(CDCIa): 8 6.78(1H, d, J=8.9Hz), 7.02(1H, d, J=8.6Hz), 7.16(1H, d,
J=8.6Hz),
7.33-7.38(3H, m), 7.42(1H, dd, J=8.6, 2.6Hz), 7.49(1H, d, J=2.6Hz)7.58(1H, d,
J=2.3Hz),
8.66(1H, brs, ), 8.82(1H, d, J=2.OHz), 11.65(1H, s).
Example 112: Preparation of the compound of Compound No. 112.
Using 5-chlorosalicylic acid and 2-[(4-trifluoromethyl)piperidino]-5-
(trifluoromethyl)aniline as the raw materials, the same operation as the
Example 3
gave the title compound.
Yield: 60.5%.
1H-NMR(CDCIs): b 1.85-2.05(2H, m), 2.15(2H, d, J=10.9Hz), 2.28(1H, m),
2.82(2H, t,
J=1l.OHz), 3.16(2H, d, J=12.2Hz), 7.02(1H, d, J=8.9Hz), 7.31(1H, d, J=8.3Hz),
7.42(2H,
m), 7.50(1H, d, J=2.6Hz), 8.75(1H, s), 9.60(1H, s), 11.94(1H, s)
Example 113: Preparation of the compound of Compound No. 113.
Using 5-chlorosalicylic acid and 2-(2,2,2-trifluoroethoxy)-5-
(trifluoromethyl)aniline as the raw materials, the same operation as the
Example 3
gave the title compound.
Yield: 94.5%.
1H-NMR(CDCIa): b 4.58(2H, q, J=7.9Hz), 6.99-7.05(2H, m), 7.41-7.50(3H, m),
8.63(1H,
brs), 8.79(1H, d, J=2.OHz), 11.59(1H, s).
Example 114: Preparation of the compound of Compound No. 114.
Using 5-chlorosalicylic acid and 2-(2-methoxyphenoxy)-5-
148
CA 02489091 2004-12-08
(trifluoromethyl)aniline as the raw materials, the same operation as the
Example 3
gave the title compound.
Yield: 80.6%.
1H-NMR(DMSO-ds): b 3.74(3H, s), 6.70(1H, d, J=8.4Hz), 7.02(1H, d, J=8.7Hz),
7.07(1H, dd, J=1.5, ?.BHz), 7.24-7.39(4H, m), 7.49(1H, dd, J=3.0, 8.7Hz),
8.00(1H, d,
J=3.OHz), 8.92(1H, d, J=2.lHz), 11.36(1H, s), 12.18(1H, s).
Example 115: Preparation of the compound of Compound No. 115.
Using 5-chlorosalicylic acid and 2-(4-chloro-3,5-dimethylphenoxy)-5-
(trifluoromethyl)aniline as the raw materials, the same operation as the
Example 3
gave the title compound.
Yield: 91.5%.
1H-NMR(DMSO-ds): 8 2.34(6H, s), 7.03(1H, d, J=8.8Hz), 7.05(1H, d, J=8.lHz),
7.11(2H, s), 7.43-7.47(1H, m), 7.48(1H, dd, J=2.9, 8.8Hz), 7.97(1H, d,
J=2.6Hz), 8.94(1H,
d, J=2.2Hz), 11.25(1H, s), 12.12(1H, s).
Example 116: Preparation of the compound of Compound No. 116.
Using 5-chlorosalicylic acid and 2-piperidino-5-(trifluoromethyl)aniline as
the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 73.7%.
1H-NMR(CDCIs): b 1.68-1.72(2H, m), 1.80-1.88(4H, m), 2.89(4H, t, J=5.2Hz),
7.01(1H,
d, J=8.7Hz), 7.31(1H, d, J=8.4Hz), 7.39-7.43(2H, m), 7.55(1H, d, J=2.4Hz),
8.73(1H, d,
J=l.BHz), 9.71(1H, s), 12.05(1H, s)
Example 117: Preparation of the compound of Compound No. 117.
Using 5-chlorosalicylic acid and 2-(4-methylphenoxy)-5-(trifluoromethyl)-
aniline as the raw materials, the same operation as the Example 3 gave the
title
compound.
Yield: 67.3%.
1H-NMR(DMSO-ds): b 2.33(3H, s), 6.93(1H, d, J=8.8Hz), 7.03(1H, dd, J=0.5,
8.8Hz),
7.12(2H, d, J=8.2Hz), 7.29(2H, d, J=8.5Hz), 7.43(1H, dd, J=2.0, 8.6Hz),
7.48(1H, ddd,
J=0.8, 2.7, 8.8Hz), 7.98(1H, dd, J=0.8, 2.7Hz), 8.94(1H, d, J=2.2Hz),
11.29(1H, s),
12.15(1H, s).
Example 118: Preparation of the compound of Compound No. 118.
Using 5-chlorosalicylic acid and 2-(4-chlorophenoxy)-5-(trifluoromethyl)-
aniline as the raw materials, the same operation as the Example 3 gave the
title
149
CA 02489091 2004-12-08
compound.
Yield: 74.5%.
1H-NMR(DMSO-ds): B 7.01(1H, d, J=8.8Hz), 7.06(1H, d, J=8.5Hz), 7.22(1H, d,
J=8.5Hz), 7.43-7.48(2H, m), 7.50(2H, d, J=8.2Hz), 7.94(1H, dd, J=0.5, 2.7Hz),
8.92(1H,
d, J=2.2Hz), 11.20(1H, s), 12.10(1H, s).
Example 119: Preparation of the compound of Compound No. 119.
Using 5-chloro-2-hydroxynicotinic acid and 2-chloro-5-(trifluoromethyl)aniline
as the raw materials, the same operation as the Example 75 gave the title
compound.
Yield: 42.9%.
1H-NMR(DMSO-ds): 8 7.52(1H, dd, J=8.4, 2.lHz), 7.81(1H, d, J=8.4Hz), 8.16(1H,
s),
8.39(1H, d, J=2.7Hz), 8.96(1H, d, J=2.lHz), 12.76(1H, s), 13.23(1H, s).
Example 120: Preparation of the compound of Compound No. 120.
Using O-acetylsalicyloyl chloride and 3,5-dichloroaniline as the raw
materials,
the same operation as the Example 1 gave the title compound.
Yield: 73.5%.
mp 167-168°C.
1H-NMR(CDCIs): b 2.35(3H, s), 7.14-7.18(2H, m), 7.35-7.40(1H, m), 7.52-
7.57(3H,
m), 7.81(1H, dd, J=7.8, l.BHz), 8.05(1H, brs).
Example 121: Preparation of the compound of Compound No. 121.
Using 2-acetoxy-N-(3,5-dichlorophenyl)benzamide(Compound No. 121) as the
raw material, the same operation as the Example 2 gave the title compound.
Yield: 60.3%.
mp 218-219°C.
1H-NMR(DMSO-ds): 8 6.95-7.02(2H, m), 7.35-7.36(1H, m), 7.42-7.47(1H, m),
7.83-7.87(3H, m), 10.54(1H, s), 11.35(1H, s).
Example 122: Preparation of the compound of Compound No. 122.
Using 5-chlorosalicylic acid and 2,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 10.8%.
1H-NMR(DMSO-ds): b 7.08(1H, d, J=9.OHz), 7.24-7.28(1H, m), 7.50-7.54(1H, m),
7.61(1H, dd, J=9.0, 3.OHz), 7.97(1H, d, J=2.7Hz), 8.58(1H, d, J=2.4Hz),
11.02(1H, s),
12.35(1H, brs).
Example 123: Preparation of the compound of Compound No. 123.
150
CA 02489091 2004-12-08
Using 5-bromosalicylic acid and 3,5-difluoroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 36.3%.
mp 259-261°C.
1H-NMR(DMSO-ds): b 6.96-7.04(2H, m), 7.45-7.54(2H, m), 7.58(1H, dd, J=8.7,
2.7Hz),
7.94(1H, d, J=2.7Hz), 10.60(1H, s) 11.48(1H, s).
Example 124: Preparation of the compound of Compound No. 124.
Using 5-fluorosalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 33.3%.
mp 258-260°C.
1H-NMR(DMSO-ds): 8 7.00-7.05(1H, m), 7.28-7.37(2H, m), 7.63(1H, dd, J=9.3,
3.3Hz),
7.84(2H, d, J=2.lHz), 10.56(1H, s), 11.23(1H, s).
Example 125: Preparation of the compound of Compound No. 125.
Using 5-chlorosalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 41.2%.
1H-NMR(DMSO-ds): 8 7.03(1H, d, J=9.OHz), 7.36-7.37(1H, m), 7.48(1H, dd, J=8.7,
2.7Hz), 7.83-7.84(3H, m), 10.56(1H, s), 11.44(1H, s).
Example 126: Preparation of the compound of Compound No. 126.
Using 5-bromosalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 61.6%.
mp 243-244°C.
1H-NMR(DMSO-ds): 8 6.98(1H, d, J=8.7Hz), 7.36-7.37(1H, m), 7.59(1H, dd, J=9.0,
2.4Hz), 7.83(2H, d, J=l.BHz), 7.95(1H, d, J=2.4Hz), 10.56(1H, s), 11.46(1H,
s).
Example 127: Preparation of the compound of Compound No. 127.
Using 5-iodosalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 65.4°/ .
mp 244-245°C.
1H-NMR(DMSO-ds): b 6.84(1H, d, J=9.OHz), 7.35-7.37(1H, m), 7.72(1H, dd, J=9.0,
2.lHz), 7.83(2H, d, J=l.BHz), 8.09(1H, d, J=2.lHz), 10.55(1H, s), 11.45(1H,
s).
151
CA 02489091 2004-12-08
Example 128: Preparation of the compound of Compound No. 128.
Using 3,5-dibromosalicylic acid and 3,5-dichloroaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 44.2%.
mp 181-182°C.
1H-NMR(DMSO-ds): b 7.42-7.43(1H, m), 7.80(2H, d, J=l.8Hz), 8.03(1H, d,
J=2.lHz),
8.17(1H, d, J=2.lHz), 10.82(1H, s).
Example 129: Preparation of the compound of Compound No. 129.
Using 4-chlorosalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 57.2%.
mp 255-256°C.
1H-NMR(DMSO-ds): b 7.03-7.06(2H, m), 7.34-7.36(1H, m), 7.82-7.85(3H,m),
10.51(1H,
s), 11.70(1H, brs).
Example 130: Preparation of the compound of Compound No. 130.
Using 5-nitrosalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 83.1%.
mp 232-233°C.
1H-NMR(DMSO-ds): b 7.16(1H, d, J=9.6Hz), 7.37-7.39(1H, m), 7.84(1H, d,
J=2.lHz),
8.29(1H, dd, J=9.0, 3.OHz), 8.65(1H, d, J=3.OHz), 10.83(1H, s).
Example 131: Preparation of the compound of Compound No. 131.
Using 5-methylsalicylic acid and 3,5-dichloroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 71.0%.
mp 216-217°C.
1H-NMR(DMSO-ds): 8 2.28(3H, s), 6.90(1H, d, J=8.4Hz), 7.26(1H, dd, J=8.7,
l.8Hz),
7.34-7.36(1H, m), 7.67(1H, d, J=l.SHz), 7.85(2H, d, J=l.8Hz), 10.52(1H, s),
11.15(1H,
s).
Example 132: Preparation of the compound of Compound No. 132.
Using 5-methoxysalicylic acid and 3,5-dichloroaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 29.8%.
152
CA 02489091 2004-12-08
mp 230-232°C.
1H-NMR(DMSO-ds): 8 3.76(3H, s), 6.95(1H, d, J=8.7Hz), 7.08(1H, dd, J=9.0,
3.OHz),
7.35-7.36(1H, m), 7.40(1H, d, J=3.OHz), 7.85(2H, d, J=l.SHz), 10.55(1H, s),
10.95(1H,
s).
Example 133: Preparation of the compound of Compound No. 133.
Using 5-bromosalicylic acid and 3,5-dinitroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 32.2%.
mp 258-260°C.
1H-NMR(DMSO-ds): b 6.98-7.02(1H, m), 7.59-7.63(1H, m), 7.96-7.97(1H, m),
8.56-8.58(1H, m), 9.03-9.05(2H, m), 11.04(1H, s), 11.39(1H, brs).
Example 134: Preparation of the compound of Compound No. 134.
Using 5-chlorosalicylic acid and 2,5-bis[(1,1-dimethyl)ethyl]aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 75.7%.
1H-NMR(DMSO-ds): 8 1.27(9H, s), 1.33(9H, s), 7.04(1H, d, J=9.OHz), 7.26(1H,
dd,
J=8.4, 2.lHz), 7.35-7.38(2H, m), 7.49(1H, dd, J=8.7, 2.7Hz), 8.07(1H, d,
J=2.4Hz),
10.22(1H, s), 12.38(1H, brs).
Example 135: Preparation of the compound of Compound No. 135.
Using 5-chlorosalicylic acid and 5-[(1,1-dimethyl)ethyl]-2-methoxyaniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 89.5%.
1H-NMR(DMSO-ds): 8 1.28(9H, s), 3.33(3H, s), 7.01(1H, d, J=8.7Hz), 7.05(1H, d,
J=9.OHz), 7.11(1H, dd, J=8.7, 2.4Hz), 7.47(1H, dd, J=9.0, 3.OHz), 7.99(1H, d,
J=3.OHz),
8.49(1H, d, J=2.4Hz), 10.78(1H, s), 12.03(1H, s).
Example 136: Preparation of the compound of Compound No. 136.
Using 5-chloro-N-{5-[(1,1-dimethyl)ethyl]-2-methoxyphenyl}-2-
hydroxybenzamide(Compound No. 135) and acetyl chloride as the raw materials,
the
same operation as the Example 5 gave the title compound.
Yield: 87.5%.
1H-NMR(CDCIs): b 1.35(9H, s), 2.37(3H, s), 3.91(3H, s), 6.86(1H, d,
J=8.7Hz),7.12(1H,
dd, J=8.7, 2.4Hz), 7.13(1H, d, J=9.OHz), 7.47(1H, dd, J=9.0, 2.4Hz), 8.02(1H,
d,
J=2.7Hz), 8.66(1H, d, J=2.4Hz), 8.93(1H, s).
153
CA 02489091 2004-12-08
Example 137: Preparation of the compound of Compound No. 137.
Using 5-bromosalicylic acid and 3,5-dimethylaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 58.1%.
mp 188-190°C.
1H-NMR(DMSO-ds): 8 2.28(6H, s), 6.80(1H, s), 6.96(1H, d, J=8.7Hz), 7.33(2H,
s),
7.58(1H, dd, J=9.0, 2.4Hz), 8.10(1H, d, J=2.4Hz), 10.29(1H, s), 11.93(1H,
brs).
Example 138: Preparation of the compound of Compound No. 138.
Using 5-chlorosalicylic acid and 3,5-bis[(l,l-dimethyl)ethyl]aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 34.1%.
1H-NMR(CDCIs): 8 1.26(18H, s), 6.99(1H, d, J=8.7Hz), 7.29(1H, t, J=l.BHz),
7.39(1,
dd, J=9.0, 2.4Hz), 7.41(2H, d, J=l.SHz), 7.51(1H, d, J=2.lHz), 7.81(1H, brs),
12.01(1H,
s).
Example 139: Preparation of the compound of Compound No. 139.
Using N-{3,5-bis[(1,1-dimethyl)ethyl]phenyl}-5-chloro-2-hydroxybenzamide
(Compound No. 138) and acetyl chloride as the raw materials, the same
operation as
the Example 5 gave the title compound.
Yield: 66.1%.
1H-NMR(CDCIa): 8 1.34(18H, s), 2.36(3H, s), 7.12(1H, d, J=8.4Hz),7.25(1H, d,
J=l.SHz), 7.44(2H, d, J=l.2Hz), 7.47(1H, dd, J=8.7, 2.7Hz), 7.87(1H, d,
J=2.4Hz),
7.98(1H, s).
Example 140: Preparation of the compound of Compound No. 140.
Using 5-bromosalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 45.2%.
1H-NMR(DMSO-ds): 8 1.30(18H, s), 6.95(1H, d, J=8.7Hz), 7.20(1H, t, J=l.SHz),
7.56(2H, d, J=l.SHz), 7.58(1H, dd, J=8.7, 2.4Hz), 8.12(1H, d, J=2.7Hz),
10.39(1H, s),
11.98(1H, s).
Example 141: Preparation of the compound of Compound No. 141.
Using 5-chlorosalicylic acid and 3-amino-4-methoxybiphenyl as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 37.0%.
154
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): 8 3.95(3H, s), 7.08(1H, d, J=8.7Hz), 7.20(1H, d, J=8.4Hz),
7.34(1H, t, J=7.2Hz), 7.40-7.50(4H, m), 7.62(1H, d, J=8.7Hz), 8.00(1H, d,
J=3.OHz),
8.77(1H, d, J=2.lHz), 10.92(1H, s), 12.09(1H, s).
Example 142: Preparation of the compound of Compound No. 142.
Using 5-bromosalicylic acid and 2,5-dimethoxyaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 39.7%.
1H-NMR(DMSO-ds): b 3.72(3H, s), 3.84(3H, s), 6.66(1H, ddd, J=9.0, 3.0, 0.6Hz),
6.99-7.03(2H, m), 7.58(1H, ddd, J=9.0, 2.7, 0.6Hz), 8.10(1H, dd, J=2.4,
0.6Hz), 8.12(1H,
d, J=3.OHz), 10.87(1H, s), 12.08(1H, s).
Example 143: Preparation of the compound of Compound No. 143.
Using 5-bromosalicylic acid and 3,5-dimethoxyaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 40.3%.
mp 207-209°C.
1H-NMR(DMSO-ds): b 3.75(6H, s), 6.30-6.32(1H, m), 6.94-6.97(3H, m), 7.57(1H,
dd,
J=8.7, 2.4Hz), 8.04(1H, d, J=2.4Hz), 10.32(1H, s), 11.78(1H, s).
Example 144: Preparation of the compound of Compound No. 144.
Using 5-bromosalicylic acid and 5-aminoisophthalic acid dimethyl ester as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 74.1%.
mp 254-256°C.
1H-NMR(DMSO-ds): b 3.92(6H, s), 6.97(1H, d, J=9.OHz), 7.60(1H, dd, J=9.0,
2.4Hz),
8.06(1H, d, J=2.4Hz), 8.24-8.25(1H, m), 8.62(2H, m), 10.71(1H, s), 11.57(1H,
s).
Example 145: Preparation of the compound of Compound No. 145.
Using 5-methylsalicylic acid and 2,5-bis[(1,1-dimethyl)ethyl]aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 61.1%.
1H-NMR(DMSO-ds): 8 1.27(9H, s), 1.33(9H, s), 2.28(3H, s), 6.89(1H, d,
J=8.lHz),
7.24(1H, d, J=2.lHz), 7.27(1H, d, J=2.lHz), 7.32(1H, d, J=2.4Hz), 7.37(1H, d,
J=8.4Hz),
7.88(1H, d, J=l.SHz), 10.15(1H, s), 11.98(1H, brs).
Example 146: Preparation of the compound of Compound No. 146.
Using 5-nitrosalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the raw
155
CA 02489091 2004-12-08
materials, the same operation as the Example 3 gave the title compound.
Yield: 46.7%.
1H-NMR(CDCIa): b 1.37(18H, s), 7.13(1H, d, J=9.3Hz), 7.32(1H, t, J=l.BHz),
7.46(2H,
d, J=l.BHz), 8.07(1H, s), 8.33(1H, dd, J=9.3, 2.lHz), 8.59(1H, d, J=2.4Hz),
13.14(1H, s).
Example 147: Preparation of the compound of Compound No. 147.
Using 5-methylsalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the
raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 16.3%.
1H-NMR(CDCIa): b 1.35(18H, s), 2.35(3H, s), 6.94(1H, d, H=8.4Hz), 7.23-
7.28(2H, m),
7.31(1H, s), 7.42(1H, d, J=l.BHz), 7.88(1H, s), 11.86(1H, s).
Example 148: Preparation of the compound of Compound No. 148.
Using 5-methoxysalicylic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 12.7%.
1H-NMR(DMSO-ds): 8 1.30(18H, s), 3.77(3H, s), 6.91(1H, d, J=9.OHz), 7.07(1H,
dd,
J=8.7, 3.OHz), 7.19-7.20(1H, m), 7.52-7.54(3H, m), 10.33(1H, s), 11.44(1H, s).
Example 149: Preparation of the compound of Compound No. 149.
Using 5-methylsalicylic acid and 5-[(1,1-dimethyl)ethyl]-2-methoxyaniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 84.7%.
1H-NMR(CDCIa): b 1.35(9H, s), 2.34(3H, s), 3.93(3H, s), 6.86(1H, d, J=8.7Hz),
6.93(1H,
d, J=8.4Hz), 7.12(1H, dd, J=8.7, 2.4Hz), 7.24(1H, dd, J=8.4, l.BHz), 7.27(1H,
brs),
8.48(1H, d, J=2.4Hz), 8.61(1H, brs), 11.95(1H, s).
Example 150: Preparation of the compound of Compound No. 150.
Using 5-bromo-2-hydroxy-N-[3,5-bis(methoxycarbonyl)phenyl]benzamide
(Compound No. 144) as the raw material, the same operation as the Example 109
gave
the title compound.
Yield: 89.0%.
1H-NMR(DMSO-ds): b 6.98(1H, d, J=8.7Hz), 7.60(1H, dd, J=8.7, 2.4Hz), 7.24(1H,
dd,
J=8.7, 2.7Hz), 8.08(1H, d, J=2.7Hz), 8.24(1H, t, J=l.SHz), 8.57(2H, d,
J=l.2Hz),
10.67(1H, s), 11.64(1H, s).
Example 151: Preparation of the compound of Compound No. 151.
Using 5-chlorosalicylic acid and 2-methyl-5-[(1-methyl)ethyl]aniline as the
156
CA 02489091 2004-12-08
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 19.1%.
1H-NMR(CDCIs): b 1.26(6H, d, J=6.9Hz), 2.30(3H, s), 2.87-2.96(1H, m), 7.00(1H,
d,
J=8.7Hz), 7.08(1H, dd, J=7.8, l.BHz), 7.20(1H, d, J=7.8Hz), 7.40(1H, dd,
J=8.7, 2.4Hz),
7.49(1H, d, J=2.7Hz), 7.50(1H, s), 7.71(1H, s), 11.99(1H, s).
Example 152: Preparation of the compound of Compound No. 152.
Using 5-chlorosalicylic acid and 2,5-diethoxyaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 59.2%.
1H-NMR(DMSO-ds): b 1.32(3H, t, J=6.9Hz), 1.41(3H, t, J=6.9Hz), 3.97(2H, q,
J=6.9Hz),
4.06(2H, q, J=6.9Hz), 6.61(1H, dd, J=9.0, 3.OHz), 6.98(1H, d, J=8.7Hz),
7.10(1H, d,
J=8.7Hz), 7.48(1H, dd, J=8.7, 2.7Hz), 7.97(1H, d, J=2.7Hz), 8.16(1H, d,
J=3.OHz),
10.96(1H, s), 11.91(1H, s).
Example 153: Preparation of the compound of Compound No. 153.
Using 5-chlorosalicylic acid and 2,5-dimethylaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 90.5°/.
1H-NMR(CDCIs): b 2.28(3H, s), 2.35(3H, s), 6.99(1H, d, J=8.8Hz), 7.02(1H,
brs),
7.15(1H, d, J=7.7Hz), 7.40(1H, dd, J=8.8, 2.5Hz), 7.45(1H, brs), 7.49(1H, d,
J=2.5Hz)7.70(1H, br), 11.96(1H, brs).
Example 154: Preparation of the compound of Compound No. 154.
Using 5-chlorosalicylic acid and 5-chloro-2-cyanoaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 90.0%.
1H-NMR(DMSO-ds): 8 7.09(1H, d, J=9.OHz), 7.53(1H, dd, J=8.7, 3.OHz), 7.82(1H,
dd,
J=8.7, 2.4Hz), 7.95(1H, d, J=3.OHz), 8.07(1H, d, J=2.4Hz), 8.36(1H, d,
J=9.OHz),
11.11(1H, s), 12.36(1H, s).
Example 155: Preparation of the compound of Compound No. 155.
Using 5-chlorosalicylic acid and 5-(N,N-diethylsulfamoyl)-2-methoxyaniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 44.8%.
1H-NMR(CDCls): b 1.17(6H, t, J=7.3Hz), 3.29(4H, q, J=7.3Hz), 4.05(3H, s),
7.00(2H,
dd, J=2.3, 8.9Hz), 7.41(1H, dd, J=2.3, 8.9Hz), 7.48(1H, d, J=2.6Hz), 7.65(1H,
dd, J=2.3,
157
CA 02489091 2004-12-08
8.6Hz), 8.56(1H, br.s), 8.84(1H, d, J=2.3Hz), 11.82(1H, s).
Example 156: Preparation of the compound of Compound No. 156.
Using 5-chlorosalicylic acid and 2-chloro-5-nitroaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 73.3°/.
1H-NMR(CDaOD): b 6.98(1H, d, J=8.6Hz), 7.43(1H, dd, J=2.6, 8.6Hz), 7.74(1H, d,
J=8.9Hz), 7.99(1H, dd, J=3.0, 8.9Hz), 8.08(1H, d, J=2.6Hz), 9.51(1H, d,
J=2.6Hz)
Example 157: Preparation of the compound of Compound No. 157.
Using 5-chlorosalicylic acid and 5-(N-phenylcarbamoyl)-2-methoxyaniline as
the raw material, the same operation as the Example 3 gave the title compound.
Yield: 40.3%.
1H-NMR(DMSO-ds): b 3.99(3H, s), 7.09(2H, dd, J=6.6, 6.9Hz), 7.24(1H, d,
J=8.6Hz),
7.35(2H, dd, 6.9, 7.3Hz), 7.49(1H, d, J=2.3, 8.9Hz), 7.77(3H, d, J=8.6Hz),
8.00(1H, s),
8.97(1H, s), 10.17(1H, s), 10.91(1H, s), 12.11(1H, s).
Example 158: Preparation of the compound of Compound No. 158.
Using 5-chlorosalicylic acid and 2,5-dimethoxyaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 73.9%.
1H-NMR(CDCIa): 8 3.82(3H, s), 3.93(3H, s), 6.66(1H, dd, J=3.0, 8.9Hz),
6.86(1H, d,
J=8.9Hz), 6.98(1H, d, J=8.9Hz), ?.39(1H, dd, J=2.6, 8.9Hz), 7.47(1H, d,
J=2.6Hz),
8.08(1H, d, J=3.OHz), 8.60(1H, br.s), 12.03(1H, s).
Example 159: Preparation of the compound of Compound No. 159.
Using 5-chlorosalicylic acid and 5-acetylamino-2-methoxyaniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 16.9%.
1H-NMR(DMSO-ds): b 2.01(3H, s), 3.85(3H, s), 7.03(2H, t, J=9.6Hz), 7.49(2H,
dd,
J=8.9, 9.2Hz), 7.96(1H, s), 8.51(1H, s), 9.87(1H, s), 10.82(1H, s), 12.03(1H,
d, J=4.OHz).
Example 160: Preparation of the compound of Compound No. 160.
Using 5-chlorosalicylic acid and 5-methoxy-2-methylaniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 100%.
1H-NMR(CDCIs): b 2.29(3H, s), 3.82(3H, s), 6.75(1H, dd, J=2.6, 8.2Hz),
7.00(1H, d,
J=8.9Hz), 7.16(1H, d, J=8.6Hz), 7.38(1H, d, 2.3Hz), 7.41(1H, dd, J=2.3,
8.9Hz), 7.48(1H,
158
CA 02489091 2004-12-08
d, J=2.3Hz), 7.70(1H, br.s), 11.92(1H, s).
Example 161: Preparation of the compound of Compound No. 161.
Using 5-chlorosalicylic acid and 2,5-dibutoxyaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 73.9%.
1H-NMR(CDCIs): b 0.98(3H, t, J=7.2Hz), 1.05(3H, t, J=7.2Hz), 1.44-1.65(4H, m),
1.72-1.79(2H, m), 1.81-1.91(2H, m), 3.97(2H, t, J=6.3Hz), 4.07(2H, t,
J=6.3Hz), 6.64(1H,
dd, J=9.0, 3.OHz), 6.85(IH, d, J=9.3Hz), 6.99(1H, d, J=9.OHz), 7.39(1H, dd,
J=8.7,
2.4Hz), 7.44(1H, d, J=2.7Hz), 8.08(1H, d, J=3.OHz), 8.76(1H, s), 12.08(1H, s).
Example 162: Preparation of the compound of Compound No. 162.
Using 5-chlorosalicylic acid and 2,5-diisopentyloxyaniline as the raw
materials,
the same operation as the Example 3 gave the title compound.
Yield: 59.7%.
1H-NMR(CDCIa): b 0.97(6H, d, J=6.6Hz), 1.03(6H, d, 6.6Hz), 1.64-1.98(6H, m),
3.99(2H, t, J=6.6Hz), 4.09(2H, t, J=6.3Hz), 6.63(1H, dd, J=8.7, 3.OHz),
6.85(1H, d,
J=8.7Hz), 6.98(1H, d, J=8.7Hz), 7.38(1H, dd, J=9.0, 2.4Hz), 7.43(IH, d,
J=2.?Hz),
8.09(1H, d, J=3.OHz), 8.75(1H, s), 12.08(1H, s).
Example 163; Preparation of the compound of Compound No. 163.
Using 5-chlorosalicylic acid and 5-carbamoyl-2-methoxyaniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 31.2%.
1H-NMR(CDsOD): 8 4.86(3H, s), 6.93(1H, d, J=7.6Hz), 7.18(1H, d, J=8.6Hz),
7.35(1H,
dd, J=3.0, 7.6Hz), 7.47(1H, dd, J=2.0, 8.6Hz), 8.00(IH, d, J=3.OHz), 8.80(1H,
d,
J=2.OHz).
Example 164: Preparation of the compound of Compound No. 164.
Using 5-chlorosalicylic acid and 5-((1,1-dimethyl)propyl]-2-phenoxyaniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 65.2%.
1H-NMR(CDCIs): 8 0.69(3H, t, J=7.6Hz), 1.29(6H, s), 1.64(2H, q, J=7.6Hz),
6.9I(1H,
dd, J=1.7, 7.6Hz), 6.96(1H, d, J=8.9Hz), 7.03(2H, d, J=8.9Hz), 7.10(1H, dt,
J=1.7,
7.6Hz), 7.16(1H, dt, J=1.7, 7.6Hz), 7.31-7.40(4H, m), 8.42(1H, dd, J=2.0,
7.9Hz),
8.53(1H, br.s)11.94(IH, s).
Example 165: Preparation of the compound of Compound No. 165.
159
CA 02489091 2004-12-08
Using 5-chlorosalicylic acid and 2-hexyloxy-5-(methylsulfonyl)aniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 33.0%.
1H-NMR(CDCIs): b 0.92(3H, t, J=6.9Hz), 1.40-1.59(6H, m), 1.90-2.01(2H, m),
3.09(3H,
s), 4.22(2H, t, J=6.3Hz), 7.01(1H, d, J=8.9Hz), 7.06(1H, d, J=8.6Hz), 7.40-
7.43(2H, m),
7.73(1H, dd, J=8.6, 2.3Hz), 8.74(1H, brs), 8.99(1H, d, J=2.3Hz), 11.76(1H, s).
Example 166: Preparation of the compound of Compound No. 163.
Using 5-chlorosalicylic acid and 3'-amino-2,2,4'-trimethylpropiophenone as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 44.8%.
1H-NMR(CDCIs): b 1.38(9H, s), 2.38(3H, s), 7.01(1H, d, J=8.9Hz), 7.31(1H, d,
J=7.9Hz),
7.42(1H, dd, J=8.9, 2.6Hz), 7.53(1H, d, J=2.6Hz), 7.57(1H, dd, J=7.9, 2.OHz),
7.83(1H,
brs), 8.11(1H, d, J=2.OHz), 11.82(1H, s).
Example 167: Preparation of the compound of Compound No. 167.
Using 5-chlorosalicylic acid and 5-methoxy-2-(1-pyrrolyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 53.4 % .
1H-NMR(CDCIa): b 2.46(3H, s), 6.51-6.52(2H, m), 6.82-6.85(3H, m), 6.93(1H, d,
J=8.9Hz), 7.06(1H, d, J=7.9Hz), 7.30(1H, d, J=7.9Hz), 7.32(1H, dd, J=2.3,
8.9Hz),
7.61(1H, s), 8.29(1H, s), 11.86(1H, br.s).
Example 168: Preparation of the compound of Compound No. 168.
Using 5-chlorosalicylic acid and 5-chloro-2-tosylaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 8.0%.
1H-NMR(CDCIa): 8 2.38(3H, s), 7.02(1H, d, J=8.9Hz), 7.25-7.31(3H, m), 7.46(1H,
dd,
J=2.6, 8.9Hz), 7.68(2H, d, J=8.6Hz), 7.74(1H, d, J=2.3Hz), 7.96(1H, d,
J=8.6Hz),
8.56(1H, d, J=2.OHz), 10.75(1H, s), 11.70(1H, s).
Example 169: Preparation of the compound of Compound No. 169.
Using 5-chlorosalicylic acid and 2-chloro-5-tosylaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 43.5%.
1H-NMR(CDCIa): b 2.38(3H, s), 7.02(1H, d, J=8.9Hz), 7.27(1H, d, J=7.9Hz),
7.29(1H,
dd, J=2.0, 6.6Hz), 7.46(1H, dd, J=2.3, 8.9Hz), 7.68(2H, d, J=8.6Hz), 7.73(2H,
d,
160
CA 02489091 2004-12-08
J=2.3Hz), 7.97(1H, d, J=8.6Hz), 8.56(1H, d, J=2.OHz), 10.73(1H, s), 11.71(1H,
s).
Example 170: Preparation of the compound of Compound No. 170.
Using 5-chlorosalicylic acid and 2-fluoro-5-(methylsulfonyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 28.8%.
1H-NMR(CDCIs): 8 3.12(3H, s), 7.03(1H, d, J=8.9Hz), 7.38(1H, dd, J=8.6,
10.2Hz),
7.45(1H, dd, J=2.3, 8.9Hz), 7.53(1H, d, J=2.3Hz), 7.80(1H, ddd, J=2.3, 4.6,
8.6Hz),
8.25(1H, s), 8.98(1H, dd, J=2.3, 7.7Hz), 11.33(1H, br.s).
Example 171: Preparation of the compound of Compound No. 171.
Using 5-chlorosalicylic acid and 2-methoxy-5-phenoxyaniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 77.0%.
1H-NMR(CDCIa): 8 3.98(3H, s), 6.80(1H, d, J=8.8Hz), 6.90(1H, d, J=8.8Hz),
6.95-7.00(3H, m), 7.04-7.09(1H, m), 7.29-7.35(2H, m), 7.38(1H, dd, J=8.8,
2.6Hz),
7.47(1H, d, J=2.6Hz), 8.19(1H, d, J=2.9Hz), 8.61(1H, brs), 11.92(1H, s).
Example 172: Preparation of the compound of Compound No. 172.
Using 5-chlorosalicylic acid and 3-amino-4-methylbiphenyl as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 47.7%.
1H-NMR(DMSO-ds): 8 2.33(3H, s), 7.06(1H, d, J=8.7Hz), 7.43-7.52(4H, m),
7.64-7.67(2H, m), 8.04(1H, d, J=2.7Hz), 8.19(1H, d, J=l.SHz), 10.40(1H, s),
12.22(1H,
s).
Example 173: Preparation of the compound of Compound No. 173.
Using 5-chlorosalicylic acid and 5-( a , a -dimethylbenzyl)-2-methoxyaniline
as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 89.0%.
1H-NMR(CDCIs): b 1.72(6H, s), 3.93(3H, s), 6.83(1H, d, J=8.8Hz), 6.93(1H, dd,
J=2.6,
8.8Hz), 6.96(1H, d, J=9.2Hz), 7.15-7.20(1H, m), 7.25-7.28(4H, m), 7.36(1H, dd,
J=2.6,
8.8Hz), 7.46(1H, d, J=2.6Hz), 8.35(1H, d, J=2.6Hz), 8.51(1H, s), 12.04(1H, s).
Example 174: Preparation of the compound of Compound No. 174.
Using 5-chlorosalicylic acid and 5-morpholino-2-nitroaniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 4.1%.
161
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): b 3.46-3.52(4H, m), 3.85-3.94(4H, m), 7.03(1H, d, J=8.8Hz),
7.47(1H, dd, J=2.9, 8.8Hz), 7.80(1H, dd, J=2.6, 8.8Hz), 7.82(1H, d, J=2.6Hz),
7.88(1H, d,
J=8.8Hz), 8.20(1H, d, J=2.2Hz), 10.70(1H, s), 11.43(1H, s)
Example 175: Preparation of the compound of Compound No. 175.
Using 5-chlorosalicylic acid and 5-fluoro-2-(1-imidazolyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 33.8%.
1H-NMR(DMSO-ds): b 6.99(1H, d, J=8.8Hz), 7.12-7.19(2H, m), 7.42-7.51(3H, m),
7.89(1H, d, J=2.8Hz), 7.93(1H, d, J=l.lHz), 8.34(1H, dd, J=11.4, 2.8Hz),
10.39(1H, s),
11.76(1H, brs).
Example 176: Preparation of the compound of Compound No. 176.
Using 5-chlorosalicylic acid and 2-butyl-5-nitroaniline as the raw materials,
the same operation as the Example 3 gave the title compound.
Yield: 15.3%.
1H-NMR(CDCIa): 8 0.99(3H, t, J=7.3Hz), 1.39-1.51(2H, m), 1.59-1.73(2H, m),
2.71-2.79(2H, m), 7.03(1H, d, J=8.9Hz), 7.41-7.49(3H, m), 7.92(1H, s),
8.07(1H, dd,
J=2.3, 8.4Hz), 8.75(1H, d, J=2.4Hz), 11.51(1H, s).
Example 177: Preparation of the compound of Compound No. 177.
Using 5-chlorosalicylic acid and 5-[(1,1-dimethyl)propyl]-2-hydroxyaniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 36.0%.
1H-NMR(CDCIa): 6 0.70(3H, t, J=7.4Hz), 1.28(6H, s), 1.63(2H, q, J=7.4Hz),
6.97(1H, d,
J=6.3Hz), 7.00(1H, d, J=6.6Hz), 7.08(1H, s), 7.14(1H, dd, J=2.5, 8.6Hz),
7.36(1H, d,
J=2.2Hz), 7.42(1H, dd, J=2.5, 8.8Hz), 7.57(1H, d, J=2.5Hz), 8.28(1H, s),
11.44(1H, s).
Example 178: Preparation of the compound of Compound No. 178.
Using 5-chlorosalicylic acid and 2-methoxy-5-methylaniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 74.2%.
1H-NMR(DMSO-ds): b 2.27(3H, s), 3.85(3H, s), 6.90(1H, dd, J=9.0, 2.4Hz),
6.98(1H, d,
J=9.OHz), 7.05(1H, d, J=9.OHz), 7.47(1H, dd, J=9.0, 3.OHz), 7.97(1H, d,
J=3.OHz),
8.24(1H, d, J=2.4Hz), 10.79(1H, s), 12.03(1H, s).
Example 179: Preparation of the compound of Compound No. 179.
Using 5-chlorosalicylic acid and 2,5-difluoroaniline as the raw materials, the
162
CA 02489091 2004-12-08
same operation as the Example 3 gave the title compound.
Yield: 81.5%.
1H-NMR(DMSO-ds): b 6.98-7.07(1H, m), 7.07(1H, d, J=9.OHz), 7.37-7.49(1H, m),
7.52(1H, dd, J=8.7, 3.OHz), 7.95(1H, d, J=2.7Hz), 8.15-8.22(1H, m), 10.83(1H,
s),
12.25(1H, s).
Example 180: Preparation of the compound of Compound No. 180.
Using 5-chlorosalicylic acid and 3,5-difluoroaniline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 82.0%.
1H-NMR(DMSO-ds): b 7.00(1H, tt, J=9.3, 2.1), 7.03(1H, d, J=9.OHz), 7.47(1H,
dd,
J=7.5, 2.7Hz), 7.49(1H, d, J=2.7Hz), 7.51(1H, d, J=2.lHz), 7.82(1H, d,
J=3.OHz),
10.63(1H, s), 11.43(1H, brs).
Example 181: Preparation of the compound of Compound No. 181.
Using 3-hydroxynaphthalene-2-carboxylic acid and 3,5-dichloroaniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 44.3%.
mp 254-255°C.
1H-NMR(DMSO-ds): b 7.34-7.39(3H, m), 7.49-7.54(1H, m), 7.76-7.79(1H, m),
7.89(2H,
d, J=l.8Hz), 7.92(1H, m), 8.39(1H, s), 10.75(1H, s), 11.01(1H, s).
Example 182: Preparation of the compound of Compound No. 182.
Using 2-hydroxynaphthalene-1-carboxylic acid and 3,5-dichloroaniline as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 51.2%.
mp 246-248°C.
1H-NMR(DMSO-ds): 8 7.26(1H, d, J=9.3Hz), 7.31-7.37(2H, m), 7.44-7.50(1H, m),
7.65-7.68(1H, m), 7.85-7.90(4H, m), 10.23(1H, s), 10.74(1H, s).
Example 183: The compound of Compound No. 183.
This compound is a commercially available compound.
Supplier: Sigma-Aldrich.
Catalog code number: 501361-8.
Example 184: Preparation of the compound of Compound No. 184.
Using 5-chloro-2-hydroxynicotinic acid and 3,5-bis[(1,1-dimethyl)ethyl]aniline
as the raw materials, the same operation as the Example 75 gave the title
compound.
163
CA 02489091 2004-12-08
Yield: 59.1%.
1H-NMR(DMSO-ds): b 1.29(18H, s), 7.18(1H, t, J=l.BHz), 7.52(2H.d, J=l.BHz),
8.07(1H, d, J=2.4Hz), 8.35(1H, d, J=3.3Hz), 11.92(1H, s), 13.10(1H, s).
Example 185: Preparation of the compound of Compound No. 185.
(1) 2-Amino-4-[(1,1-dimethyl)ethyl]thiazole.
A mixture of 1-bromo-3,3-dimethyl-2-butanone(5.03g, 28.lmmol),
thiourea(2.35g, 30.9mmo1) and ethanol(30mL) was refluxed for 1.5 hours. After
the
reaction mixture was cooled to room temperature, it was poured into saturated
aqueous sodium hydrogen carbonate and extracted with ethyl acetate. After the
ethyl
acetate layer was washed successively with water and brine, dried over
anhydrous
sodium sulfate, the residue obtained by evaporation of the solvent under
reduced
pressure was purified by column chromatography on silica gel(n-hexane:ethyl
acetate=2:1-X1:1) to give the title compound(3.99g, 90.9%) as an yellowish
white
powder.
1H-NMR(CDCIs):d 1.26(9H, s), 4.96(2H, brs), 6.09(1H, s).
When the method described in Example 185(1) is referred in the following
examples, solvents such as ethanol or the like were used as the reaction
solvent.
(2) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide.
Using 2-acetoxy-5-bromobenzoic acid and
2-amino-4-[(1,1-dimethyl)ethyl]thiazole as the raw materials, the same
operation as
the Example 75 gave the title compound.
Yield: 59.4%.
1H-NMR(CDCIa):d 1.31(9H, s), 2.44(3H, s), 6.60(1H, s), 7.13(1H, d, J=8.4Hz),
7.68(1H,
dd, J=8.7, 2.4Hz), 8.17(1H, d, J=2.4Hz), 9.72(1H, brs).
[2-Acetoxy-5-bromosalicylic acid: It was obtained, using 5-bromosalicylic acid
and
acetic anhydride as the raw materials, by the same operation as the Example
34(1)
with reference to "European Journal of Medicinal Chemistry", (France), 1996,
Vo1.31,
p.861-874. It was obtained by the same operation as the following Example
244(1).]
(3) 5-Bromo-N-{4-((1,1-dimethyl)ethyl]thiazol-2-yl}-2-
hydroxybenzamide(Compound
No. 185).
2N Sodium hydroxide(0.2mL) was added to a solution of
2-acetoxy-5-bromo-N-{4-(( 1,1-dimethyl)ethyl]thiazol-2-yl}benzamide( 100. lmg,
0.25mmol) in tetrahydrofuran(3mL), and the mixture was stirred at room
temperature
164
CA 02489091 2004-12-08
for 20 minutes. The reaction mixture was poured into diluted hydrochloric acid
and
extracted with ethyl acetate. After the ethyl acetate layer was washed with
brine,
dried over anhydrous sodium sulfate, the residue obtained by evaporation of
the
solvent under reduced pressure was crystallized by isopropyl ether/n-hexane to
give
the title compound(70.1mg, 78.9%) as a white powder.
1H-NMR(DMSO-ds): b 1.30(9H, s), 6.80(1H, brs), 6.95(1H, brs), 7.57(1H, brs),
8.06(1H,
d, J=2.4Hz), 11.82(1H, brs), 13.27(1H, brs).
Example 186: Preparation of the compound of Compound No. 186.
(1) 2-Acetoxy-5-bromo-N-{5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-
yl}benzamide.
N-Bromosuccinimide(97.9mg, 0.55mmo1) was added to a solution of
2-acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]thiazol-2-yl}benzamide(compound of
Example 185(2); 0.20g, 0.50mmo1) in acetonitrile(lOmL), and the mixture was
stirred
at room temperature for 1 hour. The residue obtained by evaporation of the
solvent
under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=3:1) to give the title compound as a crude product.
(2) 5-Bromo-N-{5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}-2-hydroxybenzamide
(Compound No. 186).
Using 2-acetoxy-5-bromo-N-{5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}-
benzamide as the raw material, the same operation as the Example 2 gave the
title
compound.
Yield: 90.9%(2 steps).
1H-NMR(DMSO-ds): b 1.42(9H, s), 6.99(1H, d, J=8.7Hz), 7.61(1H, dd, J=8.7,
2.7Hz),
8.02(1H, d, J=2.4Hz), 11.79(1H, brs), 12.00(1H, brs).
Example 187: Preparation of the compound of Compound No. 187.
Using 5-bromosalicylic acid and 2-amino-5-bromo-4-(trifluoromethyl)thiazole
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 22.4°/ .
mp 215°C(dec.).
1H-NMR(DMSO-ds): 8 7.00(1H, d, J=8.8Hz), 7.61(1H, dd, J=8.8, 2.8Hz), 7.97(1H,
d,
J=2.4Hz).
[2-Amino-5-bromo-4-(trifluoromethyl)thiazole: Refer to "Journal of
Heterocyclic
Chemistry", (USA), 1991, Vo1.28, p.1017.]
Example 188: Preparation of the compound of Compound No. 188.
165
CA 02489091 2004-12-08
(1) a-Bromo-pivaloylacetonitrile.
N-Bromosuccinimide(1.42g, 7.99mmol) was added to a solution of
pivaloylacetonitrile(l.OOg, 7.99mmo1) in carbon tetrachloride(l5mL), and the
mixture
was refluxed for 15 minutes. After the reaction mixture was cooled to room
temperature, the insoluble matter was filtered off, and the residue obtained
by
evaporation of the filtrate under reduced pressure was purified by column
chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title
compound(1.43g, 87.9%) as an yellowish brown oil.
1H-NMR(CDCIs): 8 1.33(9H, s), 5.10(1H, s).
When the method described in Example 188(1) is referred in the following
examples, N-bromosuccinimide was used as the brominating agent. As the
reaction
solvent, solvents such as carbon tetrachloride or the like were used.
(2) 2-Amino-5-cyano-4-[(1,1-dimethyl)ethyl]thiazole.
Using a -bromo-pivaloylacetonitrile and thiourea as the raw materials, the
same operation as the Example 185(1) gave the title compound.
Yield: 66.3%.
1H-NMR(CDCIs): b 1.41(9H, s), 5.32(2H, s).
(3) 5-Chloro-N-{5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl}-2-
hydroxybenzamide
(Compound No. 188).
Using 5-chlorosalicylic acid and 2-amino-5-cyano-4-[(1,1-dimethyl)-
ethyl]thiazole as the raw materials, the same operation as the Example 3 gave
the title
compound.
Yield: 63.4%.
1H-NMR(DMSO-ds): b 1.43(9H, s), 7.06(1H, d, J=8.7Hz), 7.51(1H, dd, J=8.7,
3.OHz),
7.85(1H, d, J=2.7Hz), 12.31(2H, br).
Example 189: Preparation of the compound of Compound No. 189.
Using 5-bromosalicylic acid and 2-amino-5-cyano-4-[(1,1-dimethyl)ethyl]-
thiazole(compound of Example 188(2)) as the raw materials, the same operation
as the
Example 3 gave the title compound.
Yield: 61.3%.
1H-NMR(DMSO-ds): b 1.43(9H, s), 7.00(1H, d, J=8.7Hz), 7.62(1H, dd, J=8.7,
2.7Hz),
7.97(1H, d, J=2.7Hz), 11.75(1H, br), 12.43(1H, br).
Example 190: Preparation of the compound of Compound No. 190.
166
CA 02489091 2004-12-08
Using 5-bromosalicylic acid and 2-amino-5-methylthiazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 12.9%.
1H-NMR(DMSO-ds): b 2.33(3H, s), 6.91(1H, d, J=7.6Hz), 7.26(1H, s), 7.54(1H, d,
J=9.6Hz), 8.03(1H, d, J=2.8Hz).
Example 191: Preparation of the compound of Compound No. 191.
Using 5-bromosalicylic acid and 2-amino-4,5-dimethylthiazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 14.4%.
1H-NMR(DMSO-ds): b 2.18(3H, s), 2.22(3H, s), 6.89(1H, d, J=8.8Hz), 7.51(1H, d,
J=6.8Hz), 8.02(1H, d, J=2.8Hz), 13.23(1H, brs).
Example 192: Preparation of the compound of Compound No. 192.
Using 5-bromosalicylic acid and 2-amino-5-methyl-4-phenylthiazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 27.7%.
mp 243-244°C.
1H-NMR(CDaOD): b 2.47(3H, s), 6.92(1H, d, J=8.7Hz), 7.36-7.41(1H, m), 7.44-
7.50(2H,
m), 7.53(1H, dd, J=9.0, 2.7Hz), 7.57-7.61(2H, m), 8.16(1H, d, J=2.7Hz).
[2-Amino-5-methyl-4-phenylthiazole: Refer to "Yakugaku Zasshi: Journal of The
Pharmaceutical Society of Japan", 1961, Vo1.81, p.1456.]
Example 193: Preparation of the compound of Compound No. 193.
Using (4-fluorophenyl)acetone as the raw material, the same operation as the
Examples 188(1)-(3) gave the title compound.
Yield: 28.8%(3 steps).
(1) a-Bromo-(4-fluorophenyl)acetone.
1H-NMR(CDCIs): b 2.33(3H, s), 5.41(1H, s), 7.07(2H, t, J=8.7Hz), 7.43(2H, dd,
J=8.7,
5.lHz).
(2) 2-Amino-4-methyl-5-(4-fluorophenyl)thiazole.
1H-NMR(CDCIa): b 2.27(3H, s), 4.88(2H, s), 7.07(2H, t, J=8.7Hz), 7.32(2H, dd,
J=8.7,
5.4Hz).
(3) 5-Bromo-N-[4-methyl-5-(4-fluorophenyl)thiazol-2-yl]-2-hydroxybenzamide
(Compound No. 193).
1H-NMR(DMSO-ds): b 2.36(3H, s), 6.95(1H, d, J=8.4Hz), 7.33(2H, t, J=8.7Hz),
167
CA 02489091 2004-12-08
7.52-7.59(3H, m), 8.06(1H, d, J=3.OHz), 12.01-13.65(2H, br).
Example 194: Preparation of the compound of Compound No. 194.
Using 3-(trifluoromethyl)phenylacetone as the raw material, the same
operation as the Examples 188(1)-(3) gave the title compound.
Yield: 39.8%(3 steps).
(1) a -Bromo-3-(trifluoromethyl)phenylacetone.
1H-NMR(CDCIa): 8 2.38(3H, s), 5.43(1H, s), 7.52(1H, t, J=7.8Hz), 7.61-7.66(2H,
m),
7.69-7.70(1H, m).
(2) 2-Amino-4-methyl-5-[3-(trifluoromethyl)phenyl]thiazole.
1H-NMR(CDCIs): 8 2.32(3H, s), 4.95(2H, s), 7.46-7.56(3H, m), 7.59-7.61(1H, m).
(3) 5-Bromo-N-{4-methyl-5-[3-(trifluoromethyl)phenyl]thiazol-2-yl}-2-hydroxy-
benzamide(Compound No. 194).
1H-NMR(DMSO-ds): b 2.40(3H, s), 6.97(1H, d, J=8.7Hz), 7.59(1H, dd, J=8.7,
2.4Hz),
7.71-7.84(4H, m), 8.06(1H, d, J=2.4Hz), 12.09(1H, br), 12.91-13.63(1H, br).
Example 195: Preparation of the compound of Compound No. 195.
Using 2,2-dimethyl-3-hexanone as the raw material, the same operation as the
Examples 188(1)-(3) gave the title compound.
Yield: 17.0%(3 steps).
(2) 2-Amino-4-[(l,l-dimethyl)ethyl]-5-ethylthiazole.
1H-NMR(CDCIa): 8 1.21(3H, t, J=7.5Hz), 1.32(9H, s), 2.79(2H, q, J=7.5Hz),
4.63(2H,
brs).
(3) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-ethylthiazol-2-yl}-2-hydroxybenzamide
(Compound No. 195).
1H-NMR(CDCls): b 1.32(3H, t, J=7.5Hz), 1.41(9H, s), 2.88(2H, q, J=7.5Hz),
6.84(1H, d,
J=9.OHz), 7.44(1H, dd, J=8.7, 2.4Hz), 8.05(1H, d, J=2.7Hz), 11.46(2H, br).
Example 196: Preparation of the compound of Compound No. 196.
Using 5-bromosalicylic acid and 2-amino-4-ethyl-5-phenylthiazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 17.4%.
mp 224-225°C.
1H-NMR(DMSO-ds): 8 1.24(3H, t, J=7.6Hz), 2.70(2H, q, J=7.6Hz), 6.95(1H, brd,
J=7.6Hz), 7.39-7.42(1H, m), 7.45-7.51(4H, m), 7.56(1H, brd, J=S.OHz), 8.06(1H,
d,
J=2.8Hz), 11.98(1H, brs).
168
CA 02489091 2004-12-08
Example 197: Preparation of the compound of Compound No. 197.
Using benzyl isopropyl ketone as the raw material, the same operation as the
Examples 188(1)-(3) gave the title compound.
Yield: 4.4%(3 steps).
(2) 2-Amino-4-isopropyl-5-phenylthiazole.
1H-NMR(CDCIa): b 1.23(6H, d, J=6.6Hz), 3.05(1H, m), 4.94(2H, s), 7.28-7.41(5H,
m).
(3) 5-Bromo-N-(4-isopropyl-5-phenylthiazol-2-yl)-2-hydroxybenzamide(Compound
No.
197).
1H-NMR(DMSO-ds): 8 1.26(6H, d, J=6.OHz), 3.15(1H, m), 6.98(1H, brs), 7.43-
7.53(5H,
m), 7.59(1H, brs), 8.08(1H, d, J=2.7Hz), 11.90(1H, brd), 13.33(1H, brd).
Example 198: Preparation of the compound of Compound No. 198.
Using 1-phenyl-2-hexanone as the raw material, the same operation as the
Examples 188(1)-(3) gave the title compound.
Yield: 52.6%(3 steps).
(1) a-Bromo-1-phenyl-2-hexanone.
1H-NMR(CDCIs): b 0.85(3H, t, J=7.2Hz), 1.19-1.32(2H, m), 1, 50-1.60(2H, m),
2.59(2H,
td, J=7.5, 3.9Hz), 5.44(1H, s), 7.34-7.45(5H, m).
(2) 2-Amino-4-butyl-5-phenylthiazole.
1H-NMR(CDCIs): b 0.89(3H, t, J=7.5Hz), 1.28-1.41(2H, m), 1.61-1.71(2H, m),
2.56-2.61(2H, m), 4.87(2H, s), 7.25-7.40(5H, m).
(3) 5-Bromo-N-(4-butyl-5-phenylthiazol-2-yl)-2-hydroxybenzamide(Compound No.
198).
iH-NMR(DMSO-ds): 8 0.85(3H, t, J=7.2Hz), 1.23-1.35(2H, m), 1.59-1.69(2H, m),
2.70(2H, t, J=7.2Hz), 6.96(1H, d, J=6.9Hz), 7.39-7.59(6H, m), 8.07(1H, d,
J=2.4Hz),
11.93(1H, br), 13.18-13.59(1H, br).
Example 199: Preparation of the compound of Compound No. 199.
(1) 4-Bromo-2,2,6,6-tetramethyl-3,5-heptanedione [ a -Bromo-
dipivaloylmethane].
N-Bromosuccinimide(965.8mg, 5.42mmo1) was added to a solution of
2,2,6,6-tetramethyl-3,5-heptanedione(dipivaloylmethane; l.OOg, 5.42mmo1) in
carbon
tetrachloride(lOmL), and the mixture was refluxed for 2 hours. After the
reaction
mixture was cooled to room temperature, the insoluble matter was filtered off,
and the
filtrate was evaporated under reduced pressure to give the title
compound(1.42g,
quant.) as a white crystal.
169
CA 02489091 2004-12-08
1H-NMR(CDCIs): b 1.27(18H, s), 5.67(1H, s).
When the method described in Example 199(1) is referred in the following
examples, N-bromosuccinimide was used as the brominating agent. As the
reaction
solvent, solvents such as carbon tetrachloride or the like were used.
(2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazole.
A mixture of 4-bromo-2,2,6,6-tetramethyl-3,5-heptanedione( a -bromo-
dipivaloylmethane; 1.42g, 5.40mmol), thiourea(451.8mg, 5.94mmo1) and
ethanol( l5mL) was refluxed for 2 hours. After the reaction mixture was cooled
to
room temperature, it was poured into saturated aqueous sodium hydrogen
carbonate
and extracted with ethyl acetate. After the ethyl acetate layer was washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was crystallized
by
dichloromethane/n-hexane to give the title compound(1.23g, 94.5%) as a white
crystal.
1H-NMR(CDCIs): 8 1.26(9H, s), 1.29(9H, s), 5.03(2H, s).
(3) 5-Chloro-N-{4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-
yl}-2-
hydroxybenzamide(Compound No. 199).
A mixture of 5-chlorosalicylic acid(143.6mg, 0.83mmo1),
2-amino-4-[(1,1-dimethyl)ethyl]ethyl-5-[(2,2-
dimethyl)propionyl]thiazole(200.Omg,
0.83mmo1), phosphorus trichloride(40 a L, 0.46mmo1) and chlorobenzene(4mL) was
refluxed for 3 hours. After the reaction mixture was cooled to room
temperature, the
residue obtained by concentration of the solvent under reduced pressure was
purified
by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the
title
compound(159.1mg, 48.4%) as a white powder.
1H-NMR(CDCIs): b 1.33(9H, s), 1.35(9H, s), 6.99(1H, d, J=8.7Hz), 7.43(1H, dd,
J=9.0,
2.7Hz), 7.70(1H, d, J=2.7Hz), 10.52(2H, br).
When the method described in Example 199(3) is referred in the following
examples, phophorus trichloride was used as the acid halogenating agent. As
the
reaction solvent, solvents such as monochlorobenzene, toluene or the like were
used.
Example 200: Preparation of the compound of Compound No. 200.
Using 5-chloro-N-{4-[(1,1-dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-
2-yl}-2-hydroxybenzamide(compound No. 199) and acetyl chloride as the raw
materials,
the same operation as the Example 5 gave the title compound.
Yield: 65.3%.
170
CA 02489091 2004-12-08
1H-NMR(CDCIa): b 1.32(9H, s), 1.33(9H,s),2.46(3H, s), 7.22(1H, d, J=8.4Hz),
7.56(1H,
dd, J=8.7, 2.4Hz), 8.05(1H, d, J=2.7Hz), 9.82(1H, brs).
Example 201: Preparation of the compound of Compound No. 201.
Using 5-bromosalicylic acid and 2-amino-4-[(1,1-dimethyl)ethyl]-5-
[(2,2-dimethyl)propionyl]thiazole(compound of Example 199(2)) as the raw
materials,
the same operation as the Example 199(3) gave the title compound.
Yield: 23.8%.
1H-NMR(CDCIa): b 1.33(9H, s), 1.35(9H, s), 6.94(1H, d, J=8, 7Hz), 7.55(1H, dd,
J=8.7,
2.lHz), 7.85(1H, d, J=2.lHz), 10.51(2H, br).
Example 202: Preparation of the compound of Compound No. 202.
Using pivaloylacetic acid ethyl ester as the raw material, the same operation
as the Examples 199(1)-(3) gave the title compound.
Yield: 45.7%(3 steps).
(1) a-Bromo-pivaloylacetic acid ethyl ester.
1H-NMR(CDCIs): b 1.28(9H, s), 1.29(3H, t, J=7.2Hz), 4.26(2H, q, J=7.2Hz),
5.24(1H,
s).
(2) 2-Amino-4-[(1,1-dimethyl)ethyl]thiazole-5-carboxylic acid ethyl ester.
1H-NMR(CDCIs): b 1.32(3H, t, J=7.2Hz), 1.43(9H, s), 4.24(2H, q, J=7.2Hz),
5.18(2H,
s).
(3) 2-(5-Bromo-2-hydroxybenzoyl)amino-4-[(1,1-dimethyl)ethyl]thiazole-5-
carboxylic
acid ethyl ester(Compound No. 202).
1H-NMR(DMSO-ds): b 1.30(3H, t, J=7.2Hz), 1.44(9H, s), 4.27(2H, q, J=6.9Hz),
7.00(1H,
d, J=8.7Hz), 7.63(1H, dd, J=8.7, 2.7Hz), 8.02(1H, d, J=2.4Hz), 11.80(1H, br),
12.12(1H,
br).
Example 203: Preparation of the compound of Compound No. 203.
Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-[(1,1-dimethyl)-
ethyl]thiazole-5-carboxylic acid ethyl ester(Compound No. 202) as the raw
material,
the same operation as the Example 36 gave the title compound.
Yield: 85.5%.
1H-NMR(DMSO-ds): b 1.44(9H, s), 7.00(1H, d, J=9.OHz), 7.62(1H, dd, J=9.0,
2.7Hz),
8.02(1H, d, J=2.4Hz), 11.83(1H, brs), 12.04(1H, brs), 12.98(1H, brs).
Example 204: Preparation of the compound of Compound No. 204.
(1) 2-Amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole.
171
CA 02489091 2004-12-08
N-Bromosuccinimide(l.OOg, 5.6mmo1) was added to a solution of
2-amino-4-[(1,1-dimethyl)ethyl]thiazole(compound of Example 185(1); 0.87g,
5.6mmo1)
in carbon tetrachloride(9mL), and the mixture was stirred at room temperature
for 1
hour. Hexane was added to the reaction mixture. The insoluble matter was
filtered
off, and the residue obtained by evaporation of the filtrate under reduced
pressure was
purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to
give
the title compound(1.23g, 93.7%) as an yellowish gray powder.
1H-NMR(CDCIa): b 1.39(9H, s), 4.81(2H, brs).
(2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-piperidinothiazole.
A mixture of 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole(O.lOg,
0.42mmo1), piperidine(O.ImL), potassium carbonate(0.20g) and acetonitrile(4mL)
was
refluxed for 3 hours. After the reaction mixture was cooled to room
temperature, it
was poured into water and extracted with ethyl acetate. After the ethyl
acetate layer
was washed successively with water and brine, dried over anhydrous sodium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(n-hexane:ethyl acetate=2:1) to give the
title
compound(80.7mg, 79.3%) as an yellow crystal.
1H-NMR(CDCIa): b 1.32(9H, s), 1.64(4H, t, J=5.7Hz), 1.71-1.77(2H, m), 2.35(2H,
brs),
2.99(2H, brs), 4.68(2H, s).
When the preparation method described in Example 204(2) is referred in the
following examples, bases such as potassium carbonate or the like were used as
the
base. As the reaction solvent, solvents such as acetonitrile or the like were
used.
(3) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-
yl}benzamide.
Phosphorus oxychloride(46 ~ L, 0.50mmo1) was added to a mixture of
2-acetoxy-5-bromobenzoic acid(90.3mg, 0.35mmol),
2-amino-4-[(1,1-dimethyl)ethyl]-5-piperidinothiazole(80.7mg, 0.34mmo1),
pyridine(O.lmL) and tetrahydrofuran(3mL) under argon atmosphere, and the
mixture
was stirred at room temperature for 2 hours. The reaction mixture was poured
into
2N hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate
layer
was washed successively with water and brine, dried over anhydrous sodium
sulfate,
the residue obtained by evaporation of the solvent under reduced pressure was
purified
by column chromatography on silica gel(n-hexane:ethyl acetate=3:1) to give the
title
compound(84.3mg) as a crude product.
172
CA 02489091 2004-12-08
When the preparation method described in Example 204(3) is referred in the
following examples, phosphorus oxychloride was used as the acid halogenating
agent.
As the reaction base, pyridine was used. As the reaction solvent, solvents
such as
dichloromethane, tetrahydrofuran or the like were used.
(4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl}-2-
hydroxybenzamide
(Compound No. 204).
2N Aqueous sodium hydroxide(O.lmL) was added to a solution of
2-acetoxy-5-bromo-N-{4-[( 1,1-dimethyl)ethyl]-5-piperidinothiazol-2-
yl}benzamide
(crude product, 84.3mg) in ethanol(3mL), and the mixture was stirred at room
temperature for 1 hour. The reaction mixture was poured into 2N hydrochloric
acid
and extracted with ethyl acetate. After the ethyl acetate layer was washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was purified by
column
chromatography on silica gel(n-hexane:ethyl acetate=4:1) to give the title
compound(54.1mg, 36.3%; 2 steps) as a white powder.
1H-NMR(CDCIs): b 1.41(9H, s), 1.56(2H, brs), 1.67-1.74(4H, m), 2.79(4H, brs),
6.85(1H,
d, J=9.OHz), 7.45(1H, dd, J=9.0, 2.4Hz), 8.06(1H, d, J=2.4Hz), 11.70(2H, br).
When the preparation method described in Example 204(4) is referred in the
following examples, inorganic bases such as sodium hydroxide, potassium
carbonate or
the like were used as the base. As the reaction solvent, solvents such as
water,
methanol, ethanol, tetrahydrofuran or the like were used alone or as a
mixture.
Example 205: Preparation of the compound of Compound No. 205.
Using 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole(compound of Example
204(1)) and morpholine as the raw materials, the same operation as the
Examples
204(2)-(4) gave the title compound.
Yield: 17.1%.
(2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-morpholinothiazole.
1H-NMR(CDCIs): b 1.33(9H, s), 2.76(4H, brs), 3.79(4H, brs), 4.66(2H, s).
(3) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-
yl}benzamide.
The product was used for the next reaction as a crude product.
(4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl}-2-
hydroxybenzamide
(Compound No. 205).
1H-NMR(CDCIs): b 1.24(9H, s), 2.89(4H, dd, J=4.8, 4.2Hz), 3.83(4H, dd, J=4.5,
4.2Hz),
173
CA 02489091 2004-12-08
6.89(1H, d, J=9.OHz), 7.49(1H, dd, J=9.0, 2.4Hz), 7.98(1H, d, J=2.lHz),
11.20(2H, br).
Example 206: Preparation of the compound of Compound No. 206.
Using 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole(compound of Example
204(1)) and 4-methylpiperazine as the raw materials, the same operation as the
Examples 204(2)-(4) gave the title compound.
Yield: 6.9%.
(2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazole.
1H-NMR(DMSO-ds): b 1.25(9H, s), 2.12(2H, brs), 2.19(3H, s), 2.57(2H, brs),
2.72(4H,
brs), 6.51(2H, s).
(3) 2-Acetoxy-N-{4-[(l,l-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-
yl}-
benzamide.
The product was used for the next reaction as a crude product.
(4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-(4-methylpiperazin-1-yl)thiazol-2-yl}-
2-
hydroxybenzamide(Compound No. 206).
1H-NMR(CDaOD): 8 1.41(9H, s), 2.55(3H, s), 2.87(4H, brs), 3.03(4H, brs),
6.88(1H, d,
J=8.7Hz), 7.49(1H, dd, J=8.7, 2.7Hz), 8.11(1H, d, J=2.7Hz).
Example 207: Preparation of the compound of Compound No. 207.
Using 2-amino-5-bromo-4-[(1,1-dimethyl)ethyl]thiazole(compound of Example
204(1)) and 4-phenylpiperazine as the raw materials, the same operation as the
Examples 204(2)-(4) gave the title compound.
Yield: 6.9%.
(2) 2-Amino-4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazole.
1H-NMR(CDCIa): 8 1.34(9H, s), 2.80(2H, brs), 3.03(4H, brs), 3.55(2H, brs),
4.69(2H, s),
6.88(1H, tt, J=7.2, l.2Hz), 6.95(2H, dd, J=9.0, l.2Hz), 7.28(2H, dd, J=8.7,
7.2Hz).
(3) 2-Acetoxy-5-bromo-N-{4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-
yl)thiazol-2-
yl}benzamide.
The product was used for the next reaction as a crude product.
(4) 5-Bromo-N-{4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1-yl)thiazol-2-yl}-
2-
hydroxybenzamide(Compound No. 207).
1H-NMR(DMSO-ds): 8 1.39(9H, s), 2.97(4H, s), 3.30(4H, s), 6.82(1H, t,
J=7.5Hz),
6.97(2H, brs), 6.99(2H, t, J=7.5Hz), 7.58(1H, brs), 8.05(1H, d, J=2.4Hz),
11.69(1H, brs),
11.82(1H, brs).
Example 208: Preparation of the compound of Compound No. 208.
174
CA 02489091 2004-12-08
Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole as the raw
materials, the same operation as the Example 199(3) gave the title compound.
Yield: 16.0%.
mp 239°C(dec.).
1H-NMR(DMSO-ds): b 7.02(1H, d, J=8.4Hz), 7.34(1H, t, J=7.6Hz), 7.44(2H, t,
J=7.6Hz), 7.62(1H, dd, J=8.4, 2.8Hz), 7.67(1H, s), 7.92(2H, d, J=7.2Hz),
8.08(1H, d,
J=2.8Hz), 11.88(1H, brs), 12.05(1H, brs).
Example 209: Preparation of the compound of Compound No. 209.
Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole-5-acetic acid methyl
ester as the raw materials, the same operation as the Example 199(3) gave the
title
compound.
Yield: 32.1%.
mp 288.5-229.5°C.
1H-NMR(DMSO-ds): b 3.66(3H, s), 3.95(2H, s), 6.99(1H, d, J=8.OHz), 7.42(1H, d,
J=6.OHz), 7.48(2H, brt, J=7.6Hz), 7.56-7.61(3H, m), 8.07(1H, d, J=2.4Hz),
11.85(1H,
brs), 11.98(1H, brs).
Example 210: Preparation of the compound of Compound No. 210.
2N Sodium hydroxide(0.5mL, lmmol) was added to a solution of
(2-[(5-bromo-2-hydroxybenzoyl)amino]-4-phenylthiazol-5-yl}acetic acid methyl
ester(Compound No. 209; 75mg, 0.17mmo1) in methanol(5mL), and the mixture was
stirred at room temperature for 12 hours. The reaction mixture was poured into
2N
hydrochloric acid and extracted with ethyl acetate. After the ethyl acetate
layer was
washed successively with water and brine, dried over anhydrous sodium sulfate,
the
residue obtained by evaporation of the solvent under reduced pressure was
washed
with n-hexane-ethyl acetate under suspension to give the title compound(56mg,
77.3%)
as a light yellow white crystal.
mp 284-286°C.
1H-NMR(DMSO-ds): 8 3.84(2H, s), 6.98(1H, d, J=8.8Hz), 7.42(1H, d, J=6.8Hz),
7.49(2H, t, J=7.6Hz), 7.58-7.61(3H, m), 8.07(1H, d, J=2.8Hz), 12.25(1H, brs).
Example 211: Preparation of the compound of Compound No. 211.
Using 5-bromosalicylic acid and 2-amino-4,5-diphenylthiazole as the raw
materials, the same operation as the Example 199(3) gave the title compound.
Yield: 25.9%.
175
CA 02489091 2004-12-08
mp 262-263°C.
1H-NMR(DMSO-ds): 8 7.02(1H, d, J=8.lHz), 7.34-7.47(lOH, m), 7.63(1H, d,
J=6.9Hz),
8.08(1H, d, J=2.4Hz), 11.88(1H, brs), 12.08(1H, brs).
[2-Amino-4,5-diphenylthiazole: Refer to "Nihon Kagaku Zasshi", 1962, Vo1.83,
p.209.]
Example 212: Preparation of the compound of Compound No. 212.
Using 5-bromosalicylic acid and 2-amino-4-benzyl-5-phenylthiazole as the raw
materials, the same operation as the Example 199(3) gave the title compound.
Yield: 28.1%.
mp 198-200°C.
1H-NMR(DMSO-ds): 8 4.08(2H, s), 6.95(1H, d, J=8.8Hz), 7.15-7.22(3H, m),
7.30(2H,
t, J=7.6Hz), 7.38-7.43(1H, m), 7.47(4H, d, J=4.4Hz), 7.57(1H, brd, J=8.8Hz),
8.05(1H,
d, J=2.4Hz), 11.98(1H, brs).
[2-Amino-4-benzyl-5-phenylthiazole: Refer to "Chemical and Pharmaceutical
Bulletin",
1962, Vo1.10, p.376.]
Example 213: Preparation of the compound of Compound No. 213.
Using 5-bromosalicylic acid and 2-amino-5-phenyl-4-(trifluoromethyl)thiazole
as the raw materials, the same operation as the Example 199(3) gave the title
compound.
Yield: 33.2%.
mp 250°C(dec.). 1H-NMR(DMSO-ds): b 7.02(1H, d, J=8.8Hz), 7.51(5H, s),
7.63(1H, dd,
J=8.8, 2.4Hz), 8.02(1H, d, J=2.8Hz), 12.38(1H, brs).
Example 214: Preparation of the compound of Compound No. 214.
Using 1-phenyl-1,3-butanedione as the raw material, the same operation as
the Examples 199(1)-(3) gave the title compound.
Yield: 8.9%(3 steps).
(1) a -Bromo-1-phenyl-1,3-butanedione.
1H-NMR(CDCIa): b 2.46(3H, s), 5.62(1H, s), 7.48-7.54(2H, m), 7.64(1H, tt,
J=7.5,
2.lHz), 7.97-8.01(2H, m).
(2) 2-Amino-5-acetyl-4-phenylthiazole.
1H-NMR(DMSO-ds): 8 2.18(3H, s), 7.50-7.55(2H, m), 7.59-7.68(3H, m), 8.69(2H,
brs).
(3) 5-Bromo-N-(5-acetyl-4-phenylthiazol-2-yl)-2-hydroxybenzamide(Compound No.
214).
1H-NMR(DMSO-ds): b 2.44(3H, s), 6.99(1H, d, J=9.OHz), 7.55-7.71(4H, m),
176
CA 02489091 2004-12-08
7.76-7.80(2H, m), 8.01(1H, d, J=2.4Hz), 12.36(2H, br).
Example 215: Preparation of the compound of Compound No. 215.
Using 1,3-diphenyl-1,3-propanedione as the raw material, the same operation
as the Examples 199(1)-(3) gave the title compound.
Yield: 49.7%.
(1) a-Bromo-1,3-diphenyl-1,3-propanedione.
1H-NMR(CDCIa): 8 6.55(1H, s), 7.45-7.50(4H, m), 7.61(2H, tt, J=7.2, 2.lHz),
7.98-8.01(4H, m).
(2) 2-Amino-5-benzoyl-4-phenylthiazole.
1H-NMR(DMSO-ds): 8 7.04-7.18(5H, m), 7.22-7.32(3H, m), 7.35-7.38(2H, m),
8.02(2H,
s).
(3) 5-Bromo-N-(5-benzoyl-4-phenylthiazol-2-yl)-2-hydroxybenzamide(Compound No.
215).
1H-NMR(DMSO-ds): 8 7.03(1H, d, J=8.7Hz), 7.17-7.30(5H, m), 7.39-7.47(3H, m),
7.57-7.60(2H, m), 7.64(1H, dd, J=8.7, 2.7Hz), 8.05(1H, d, J=2.4Hz), 11.82(1H,
brs),
12.35(1H, brs).
Example 216: Preparation of the compound of Compound No. 216.
Using 5-bromosalicylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid
ethyl ester as the raw materials, the same operation as the Example 199(3)
gave the
title compound.
Yield: 28.6%.
mp 197-199°C.
1H-NMR(DMSO-ds): b 1.21(3H, t, J=6.8Hz), 4.20(2H, q, J=6.8Hz), 7.01(1H, d,
J=8.8Hz), 7.43-7.48(3H, m), 7.63(1H, dd, J=8.8, 2.4Hz), 7.70-7.72(2H, m),
8.04(1H, d,
J=2.4Hz), 12.33(1H, brs).
Example 217: Preparation of the compound of Compound No. 217.
Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid
ethyl ester(compound No. 216) as the raw material, the same operation as the
Example
36 gave the title compound.
Yield: 67.0%.
1H-NMR(DMSO-ds): b 7.00(1H, d, J=8.8Hz), 7.42-7.44(3H, m), 7.62(1H, dd, J=8.8,
2.4Hz), 7.70-7.72(2H, m), 8.04(1H, d, J=2.4Hz), 12.31(1H, brs), 12.99(1H,
brs).
Example 218: Preparation of the compound of Compound No. 218.
177
CA 02489091 2004-12-08
Using 5-chlorosalicylic acid and 2-amino-4-phenylthiazole-5-carboxylic acid
ethyl ester as the raw materials, the same operation as the Example 199(3)
gave the
title compound.
Yield: 69.4°/ .
1H-NMR(DMSO-ds): b 1.22(3H, t, J=7.5Hz), 4.21(2H, q, J=7.5Hz), 7.07(1H, d,
J=8.7Hz), 7.43-7.47(3H, m), 7.53(1H, dd, J=8.7, 2.4Hz), 7.70-7.74(2H, m),
7.92(1H, d,
J=3.OHz), 11.88(1H, br), 12.29(1H, brs).
Example 219: Preparation of the compound of Compound No. 219.
Using pentafluorobenzoylacetic acid ethyl ester as the raw material, the same
operation as the Examples 199(1)-(3) gave the title compound.
Yield: 40.0%(3 steps).
(1) c~ -Bromo-pentafluorobenzoylacetic acid ethyl ester.
It was used for the next reaction as a crude product.
(2) 2-Amino-4-(pentafluorophenyl)thiazole-5-carboxylic acid ethyl ester.
1H-NMR(CDCIs): 8 1.23(3H, t, J=7.2Hz), 4.21(2H, q, J=7.2Hz), 5.41(2H, s).
(3) Ethyl 2-(5-bromo-2-hydroxybenzoyl)amino-4-(pentafluorophenyl)thiazole-5-
carboxylate(Compound No. 219).
1H-NMR(DMSO-ds): b 1.20(3H, t, J=7.2Hz), 2.51(2H, q, J=7.2Hz), 7.02(1H, d,
J=8.7Hz), 7.64(1H, dd, J=8.7, 2.7Hz), 7.90(1H, d, J=3.OHz), 11.92(1H, br),
12.58(1H,
br).
Example 220: Preparation of the compound of Compound No. 220.
A mixure of 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic
acid(Compound No. 217; 0.20g, 0.48mmo1), methylamine 40% methanol
solution(0.2m1),
1-hydroxybenzotriazole hydrate(96.7mg, 0.72mmo1), WSC ~ HC1(137.2mg, 0.72mmo1)
and tetrahydrofuran(l5mL) was stirred at room temperature for 18 hours. The
reaction mixture was poured into 2N hydrochloric acid and extracted with ethyl
acetate. After the ethyl acetate layer was washed successively with water and
brine,
dried over anhydrous sodium sulfate, the residue obtained by evaporation of
the
solvent under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=1:2), and crystallized by dichloromethane/n-hexane
to give
the title compound(87.9mg, 42.6%) as a white powder.
1H-NMR(DMSO-ds): b 2.70(3H, d, J=4.5Hz), 7.02(1H, d, J=9.OHz), 7.40-7.48(3H,
m),
7.63(1H, dd, J=9.0, 2.4Hz), 7.68-7.71(2H, m), 8.06(1H, d, J=2.4Hz), 8.16(1H,
t,
178
CA 02489091 2004-12-08
J=4.5Hz), 11.88(1H, br), 12.15(1H, brs).
When the method described in Example 220 is referred in the following
examples, WSC ~ HC1 and 1-hydroxybenzotriazole hydrate were used as the
dehydrocondensating agent. As the reaction solvent, solvents such as
tetrahydrofuran or the like were used.
Example 221: Preparation of the compound of Compound No. 221.
Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid
(Compound No. 217) and 70% aqueous ethylamine solution as the raw materials,
the
same operation as the Example 220 gave the title compound.
Yield: 62.5%.
1H-NMR(DMSO-ds): 8 1.05(3H, t, J=6.9Hz), 3.15-3.24(2H, m), 7.02(1H, d,
J=8.7Hz),
7.40-7.47(3H, m), 7.63(1H, dd, J=8.7, 3.OHz), 7.69-7.72(2H, m), 8.06(1H, d,
J=2.4Hz),
8.20(1H, t, J=5.4Hz), 11.84(1H, br), 12.14(1H, brs).
Example 222: Preparation of the compound of Compound No. 222.
Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid
(Compound No. 217) and isopropylamine as the raw materials, the same operation
as
the Example 220 gave the title compound.
Yield: 23.9%.
1H-NMR(DMSO-ds): 8 1.07(6H, d, J=6.3Hz), 4.02(1H, m), 7.02(1H, d, J=9.OHz),
7.40-7.52(3H, m), 7.64(1H, dd, J=8.7, 2.7Hz), 7.69-7.73(2H, m), 8.06(1H, d,
J=2.7Hz),
11.89(1H, br), 12.14(1H, brs).
Example 223: Preparation of the compound of Compound No. 223.
Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic acid
(Compound No. 217) and 2-phenethylamine as the raw materials, the same
operation
as the Example 220 gave the title compound.
Yield: 62.2 %.
1H-NMR(DMSO-ds): b 2.78(2H, t, J=7.5Hz), 3.43(2H, q, J=7.5Hz), 7.02(1H, d,
J=9.OHz), 7.19-7.24(3H, m), 7.27-7.33(2H, m), 7.39-7.41(3H, m), 7.61-7.65(3H,
m),
8.06(1H, d, J=2.4Hz), 8.25(1H, t, J=6.OHz), 11.85(1H, brs), 12.15(1H, brs).
Example 224: Preparation of the compound of Compound No. 224.
Using 5-bromosalicylic acid and 2-amino-4-(trifluoromethyl)thiazole-5-
carboxylic acid ethyl ester as the raw materials, the same operation as the
Example
199(3) gave the title compound.
179
CA 02489091 2004-12-08
Yield: 88.7%.
1H-NMR(DMSO-ds): b 1.32(3H, t, J=7.2Hz), 4.33(2H, q, J=7.2Hz), 7.01(1H, d,
J=8.7Hz), 7.63(1H, dd, J=8.7, 2.7Hz), 7.98(1H, d, J=2.4Hz), 12.64(1H, br).
Example 225: Preparation of the compound of Compound No. 225.
Using 4-hydroxybiphenyl-3-carboxylic acid and
2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials,
the same
operation as the Example 199(3) gave the title compound.
Yield: 61.7%.
mp 207-208°C.
1H-NMR(DMSO-ds): b 1.23(3H, t, J=7.2Hz), 4.22(2H, q, J=7.2Hz), 7.16(1H, d,
J=8.7Hz), 7.36(1H, t, J=7.5Hz), 7.45-7.50(5H, m), 7.69-7.76(4H, m), 7.85(1H,
dd, J=8.7,
2.4Hz), 8.31(1H, d, J=2.4Hz), 11.73(1H, brs), 12.60(1H, brs).
[4-Hydroxybiphenyl-3-carboxylic acid: Refer to "Tetrahedron", (USA), 1997,
Vo1.53,
p.11437.]
Example 226: Preparation of the compound of Compound No. 226.
Using (4'-fluoro-4-hydroxybiphenyl)-3-carboxylic acid and
2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials,
the same
operation as the Example 199(3) gave the title compound.
Yield: 62.7°/.
mp 237-238°C.
1H-NMR(DMSO-ds): b 1.22(3H, t, J=7.2Hz), 4.21(2H, q, J=7.2Hz), 7.13(1H, d,
J=8.4Hz), 7.28(2H, t, J=8.8Hz), 7.44-7.45(3H, m), 7.71-7.75(4H, m), 7.81(1H,
dd, J=8.8,
2.4Hz), 8.27(1H, d, J=2.4Hz), 11.67(1H, brs), 12.58(1H, brs).
[(4'-Fluoro-4-hydroxybiphenyl)-3-carboxylic acid: Refer to "Tetrahedron",
1997, Vo1.53,
p.11437.]
Example 227: Preparation of the compound of Compound No. 227.
Using (2',4'-difluoro-4-hydroxybiphenyl)-3-carboxylic acid and
2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials,
the same
operation as the Example 199(3) gave the title compound.
Yield: 45.6%.
mp 206-207°C.
1H-NMR(DMSO-ds): b 1.22(3H, t, J=7.2Hz), 4.22(2H, q, J=7, 2Hz), 7.17(1H, d,
J=9.OHz), 7.21(1H, td, J=8.7, 2.4Hz), 7.38(1H, ddd, J=11.7, 9.3, 2.4Hz), 7.44-
7.46(3H,
180
CA 02489091 2004-12-08
m), 7.60-7.75(4H, m), 8.13-8.14(1H, m), 11.86(1H, brs), 12.46(1H, brs).
Example 228: Preparation of the compound of Compound No. 228.
(1) [4-Hydroxy-4'-(trifluoromethyl)biphenyl]-3-carboxylic acid.
A mixture of 5-bromosalicylic acid(500mg, 2.30mmo1),
dihydroxy-4-(trifluoromethyl)phenylborane(488mg, 2.57mmo1), palladium
acetate(lOmg, 0.040mmo1) and lmol/L aqueous sodium carbonate(7mL) was stirred
at
80°C for 1 hour. After the reaction mixture was cooled to room
temperature, it was
poured into 2N hydrochloric acid and extracted with ethyl acetate. After the
ethyl
acetate layer was washed successively with water and brine, dried over
anhydrous
sodium sulfate, the residue obtained by evaporation of the solvent under
reduced
pressure was methyl-esterified by trimethylsilyldiazomethane and methanol
according
to the fixed procedure, and purified by column chromatography on silica
gel(n-hexane:ethyl acetate=5:1) to give a colourless liquid(563mg). 2N Sodium
hydroxide(3mL) was added to a solution of this liquid in methanol(lOmL), and
the
mixture was stirred at 60°C for 1 hour. After the reaction mixture was
cooled to room
temperature, it was poured into 2N hydrochloric acid and extracted with ethyl
acetate.
After the ethyl acetate layer was washed successively with water and brine,
dried over
anhydrous magnesium sulfate, the residue obtained by evaporation of the
solvent
under reduced pressure was washed with n-hexane/dichloromethane under
suspension
to give the title compound(458mg, 70.4%) as a white crystal.
mp 185°C(dec.).
1H-NMR(DMSO-ds): 8 7.09(1H, d, J=8.8Hz), 7.77(2H, d, J=8.OHz), 7.85(2H, d,
J=8.OHz), 7.90(1H, dd, J=8.8, 2.OHz), 8.10(1H, d, J=2.4Hz), 11.80(1H, brs).
(2) 2-{[4-Hydroxy-4'-(trifluoromethyl)biphenyl]-3-carbonyl}amino-4-
phenylthiazole-5-
carboxylic acid ethyl ester(Compound No. 228).
Using [4-hydroxy-4'-(trifluoromethyl)biphenyl]-3-carboxylic acid and
2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials,
the same
operation as the Example 199(3) gave the title compound.
Yield: 41.7%.
mp 236-237°C.
1H-NMR(DMSO-ds): 8 1.22(3H, t, J=7.2Hz), 4.21(2H, q, J=7.2Hz), 7.18(1H, d,
J=8.8Hz), 7.44-7.45(3H, m), 7.72-7.74(2H, m), 7.81(2H, d, J=8.4Hz), 7.91(1H,
dd,
J=8.8, 2.4Hz), 7.93(2H, d, J=8.4Hz), 8.36(1H, d, J=2.4Hz), 11.78(1H, brs),
12.62(1H,
181
CA 02489091 2004-12-08
brs).
Example 229: Preparation of the compound of Compound No. 229.
Using 2-hydroxy-5-(1-pyrrolyl)benzoic acid and
2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials,
the same
operation as the Example 199(3) gave the title compound.
Yield: 55.0°/.
iH-NMR(DMSO-ds): b 1.22(3H, t, J=7.2Hz), 4.22(2H, q, J=7.2Hz), 6.26(2H, t,
J=2.lHz),
7.13(1H, d, J=8.7Hz), 7.32(2H, t, J=2.lHz), 7.43-7.47(3H, m), 7.70-7.75(3H,
m),
8.09(1H, d, J=2.7Hz), 11.58(1H, brs), 12.55(1H, brs).
Example 230: Preparation of the compound of Compound No. 230.
(1) 2-Hydroxy-5-(2-thienyl)benzoic acid.
Tetrakis(triphenylphosphine)palladium(80mg, 0.07mmo1) was added to a
solution of 5-bromosalicylic acid(500mg, 2.30mmo1) in 1,2-dimethoxyethane(5mL)
under argon atmosphere, and the mixture was stirred at room temperature for 10
minutes. Then dihydroxy-2-thienylborane(324mg, 2.53mmo1) and 1M sodium
carbonate(7mL) were added to the mixture, and it was refluxed for 2 hours.
After the
reaction mixture was cooled to room temperature, it was poured into 2N
hydrochloric
acid and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was methyl-
esterified
by trimethylsilyldiazomethane and methanol according to the fixed procedure,
and
purified by column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to
give an
yellow liquid(277mg). 2N Sodium hydroxide(l.5mL) was added to a solution of
this
liquid in methanol(5mL), and the mixture was stirred at 60°C for 1
hour. After the
reaction mixture was cooled to room temperature, it was poured into 2N
hydrochloric
acid and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water and brine, dried over anhydrous magnesium sulfate, the
residue obtained by evaporation of the solvent under reduced pressure was
crystallized
from n-hexane/dichloromethane to give the title compound(58mg, 11.5%) as a
white
crystal.
1H-NMR(DMSO-ds): b 6.95(1H, d, J=8.8Hz), 7.09(1H, dd, J=4.8, 3.6Hz), 7.37(1H,
dd,
J=4.0, l.2Hz), 7.45(1H, dd, J=5.2, l.2Hz), 7.74(1H, dd, J=8.8, 2.8Hz),
7.96(1H, d,
J=2.8Hz).
182
CA 02489091 2004-12-08
(2) 2-[2-Hydroxy-5-(2-thienyl)benzoyl]amino-4-phenylthiazole-5-carboxylic acid
ethyl
ester(Compound No. 230).
Using 2-hydroxy-5-(2-thienyl)benzoic acid and
2-amino-4-phenylthiazole-5-carboxylic acid ethyl ester as the raw materials,
the same
operation as the Example 199(3) gave the title compound.
Yield: 58.2%.
mp 213-214°C.
1H-NMR(DMSO-ds): 8 1.22(3H, t, J=7.2Hz9, 4.21(2H, q, J=7.2Hz), 7.10(1H, d,
J=9.2Hz), 7.12(1H, dd, J=4.8, 3.6Hz), 7.44-7.46(4H, m), 7.50(1H, dd, J=4.8,
l.2Hz),
7.71-7.74(2H, m), 7.79(1H, dd, J=8.8, 2.4Hz), 8.21(1H, d, J=2.4Hz), 11.78(1H,
brs),
12.44(1H, brs).
Example 231: Preparation of the compound of Compound No. 231.
(1) 2-Amino-4-[3,5-bis(trifluoromethyl)phenyl]thiazole.
Phenyltrimethylammonium tribromide(753mg, 2mmo1) was added to a
solution of 3',5'-bis(trifluoromethyl)acetophenone(0.51g, 2.Ommo1) in
tetrahydrofuran(5mL) and the mixture was stirred at room temperature for 5
hours.
The reaction mixture was poured into water and extracted with ethyl acetate.
After
the ethyl acetate layer was washed with brine, dried over anhydrous sodium
sulfate,
ethanol(5mL) and thiourea(152mg, 2mmol) were added to the residue obtained by
evaporation of the solvent under reduced pressure, and the mixture was
refluxed for 30
minutes. After the reaction mixture was cooled to room temperature, it was
poured
into saturated aqueous sodium hydrogen carbonate and extracted with ethyl
acetate.
After the ethyl acetate layer was washed with brine and dried over anhydrous
sodium
sulfate, the residue obtained by evaporation of the solvent under reduced
pressure was
purified by column chromatography on silica gel(n-hexane:ethyl acetate=2:1)
and
washed with n-hexane under suspension to give the title compound(520.1mg,
83.3°/) as
a light yellow white crystal.
1H-NMR(CDCIa): b 5.03(2H, s), 6.93(1H, s), 7.77(1H, s), 8.23(2H, s).
(2) 5-Chloro-2-hydroxy-N-(4-[3,5-bis(trifluoromethyl)phenyl]thiazol-2-
yl}benzamide
(Compound No. 231).
A mixture of 5-chlorosalicylic acid(172.6mg, lmmol),
2-amino-4-[3,5-bis(trifluoromethyl)phenyl]thiazole(312.2mg, lmmol), phosphorus
trichloride(44 ,u L, 0.5mmo1) and monochlorobenzene(5mL) was refluxed for 4
hours.
183
CA 02489091 2004-12-08
After the reaction mixture was cooled to room temperature, it was poured into
water
and extracted with ethyl acetate. After the ethyl acetate layer was washed
with brine,
dried over anhydrous sodium sulfate, the residue obtained by evaporation of
the
solvent under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=3:1-->2:1) to give the title compound(109.8mg,
23.5°/) as a
pale yellow white powder.
IH-NMR(DMSO-ds): 8 7.08(1H, d, J=8.7Hz), 7.53(1H, dd, J=9.0, 3.OHz), 7.94(1H,
d,
J=3.OHz), 8.07(1H, s), 8.29(1H, s), 8.60(2H, s), 11.77(1H, s), 12.23(1H, s).
Example 232: Preparation of the compound of Compound No. 232.
Using 5-chlorosalicylic acid and
2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ethyl ester as
the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 49.6%.
1H-NMR(DMSO-ds): b 1.32(3H, t, J=7.2Hz), 1.74(4H, br), 2.63(2H, br), 2.75(2H,
br),
4.30(2H, q, J=7.2Hz), 7.05(1H, d, J=9.OHz), 7.50(1H, dd, J=8.7, 3.OHz),
7.92(1H, d,
J=3.OHz), 12.23(1H, s), 13.07(1H, s).
Example 233: Preparation of the compound of Compound No. 233.
Using 5-bromosalicylic acid and 3-amino-5-phenylpyrazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 9.2%.
1H-NMR(DMSO-ds): b 6.98(1H, d, J=8.8Hz), 7.01(1H, s),7.35(1H, t, J=7.6Hz),
7.46(2H,
t, J=7.6Hz), 7.58(1H, dd, J=8.8, 2.8Hz), 7.74-7.76(2H, m), 8.19(1H, s),
10.86(1H, s),
12.09(1H, s), 13.00(1H, brs).
Example 234: Preparation of the compound of Compound No. 234.
(1) 2-Amino-4,5-diethyloxazole.
Cyanamide(0.75g, 17.7mmo1) and sodium ethoxide(1.21g, 17.7mmo1) were
added to a solution of propioin(1.03g, 8.87mmol) in ethanol(lSmL), and the
mixture
was stirred at room temperature for 3.5 hours. The reaction mixture was poured
into
water and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was purified by
column
chromatography on silica gel(dichloromethane:methanol=9:1) to give the title
compound(369.2mg, 29.7%) as an yellow amorphous.
184
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): b 1.04(3H, t, J=7.5Hz), 1.06(3H, t, J=7.5Hz), 2.20(2H, q,
J=7.5Hz),
2.43(2H, q, J=7.5Hz), 6.15(2H, s).
(2) 2-Acetoxy-5-bromo-N-(4,5-diethyloxazol-2-yl)benzamide.
Using 2-acetoxy-5-bromobenzoic acid and 2-amino-4,5-diethyloxazole as the
raw materials, the same operation as the Example 5 gave the title compound.
Yield: 22.0%.
1H-NMR(CDCIs): b 1.22(3H, t, J=7.5Hz), 1.23(3H, t, J=7.5Hz), 2.38(3H, s),
2.48(2H, q,
J=7.5Hz), 2.57(2H, q, J=7.5Hz), 6.96(1H, d, J=8.7Hz), 7.58(1H, dd, J=8.7,
2.7Hz),
8.32(1H, s), 11.40(1H, br).
(3) 5-Bromo-N-(4,5-diethyloxazol-2-yl)-2-hydroxybenzamide(Compound No. 234).
Using 2-acetoxy-5-bromo-N-(4,5-diethyloxazol-2-yl)benzamide as the raw
material, the same operation as the Example 2 gave the title compound.
Yield: 70.2%.
1H-NMR(CDCIa) b :1.25(3H, t, J=7.5Hz), 1.26(3H, t, J=7.5Hz), 2.52(2H, q,
J=7.5Hz),
2.60(2H, q, J=7.5Hz), 6.84(1H, d, J=8.7Hz), 7.43(1H, dd, J=8.7, 3.OHz),
8.17(1H, d,
J=3.OHz), 11.35(1H, br), 12.83(1H, br).
Example 235: Preparation of the compound of Compound No. 235.
Using 5-bromosalicylic acid and 2-amino-4,5-diphenyloxazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 32.6%.
mp 188-189°C.
1H-NMR(DMSO-ds): b 6.98(1H, d, J=8.7Hz), 7.40-7.49(6H, m), 7.53-7.56(2H, m),
7.59-7.63(3H, m), 8.01(1H, d, J=2.4Hz), 11.80(2H, brs).
[2-Amino-4,5-diphenyloxazole: Refer to "Zhournal Organicheskoi Khimii: Russian
Journal of Organic Chemistry", (Russia), 1980, Vo1.16, p.2185.]
Example 236: Preparation of the compound of Compound No. 236.
(1) 2-Amino-4,5-bis(furan-2-yl)oxazole.
Cyanamide(218.8mg, 5.20mmol) and sodium ethoxide(530.8mg, 7.80mmo1)
were added to a solution of furoin(0.50g, 2.60mmo1) in ethanol(l5mL), and the
mixture
was stirred at room temperature for 2 hours. The reaction mixture was poured
into
water and extracted with ethyl acetate. After the ethyl acetate layer was
washed
successively with water and brine, dried over anhydrous sodium sulfate, the
residue
obtained by evaporation of the solvent under reduced pressure was purified by
column
185
CA 02489091 2004-12-08
chromatography on silica gel(n-hexane:ethyl acetate=1:11:2) to give the title
compound(175.Omg, 31.1%) as a dark brown crystal.
1H-NMR(DMSO-ds): b 6.59(1H, dd, J=3.3, 2.lHz), 6.62(1H, dd, J=3.3, 2.lHz),
6.73(1H,
dd, J=3.3, 0.6Hz), 6.80(1H, dd, J=3.3, 0.9Hz), 7.05(2H, s), 7.75-7.76(2H, m).
(2) 5-Bromo-N-[4,5-bis(furan-2-yl)oxazol-2-yl]-2-hydroxybenzamide(Compound No.
236).
Using 5-bromosalicylic acid and 2-amino-4,5-bis(furan-2-yl)oxazole as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 12.9%.
1H-NMR(DMSO-ds): b 6.65(1H, dd, J=3.6, l.BHz), 6.68(1H, dd, J=3.6, l.BHz),
6.75(1H,
d, J=8, 7Hz), 6.92(1H, dd, J=3.6, 0.9Hz), 6.93(1H, d, J=3.3Hz), 7.37(1H, dd,
J=8.7,
2.7Hz), 7.80(1H, dd, J=1.8, 0.9Hz), 7.84(1H, dd, J=1.8, 0.9Hz), 7.92(1H, d,
J=3.OHz),
14.88(2H, br).
Example 237: Preparation of the compound of Compound No. 237.
(1) 2-Acetoxy-N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)benzamide.
Using O-acetylsalicyloyl chloride and
2-amino-5-trifluoromethyl-1,3,4-thiadiazole as the raw materials, the same
operation
as the Example 1 gave the title compound.
Yield: 51.1%.
1H-NMR(DMSO-ds): b 2.23(3H, s), 7.32(1H, dd, J=8.0, l.2Hz),7.45(1H, td, J=7.6,
l.2Hz), 7.69(1H, td, J=8.0, 2.OHz), 7.87(1H, dd, J=8.0, 2.OHz), 13.75(1H,
brs).
(2) 2-Hydroxy-N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)benzamide(Compound
No.
237).
Using 2-acetoxy-N-(5-trifluoromethyl-1,3,4-thiadiazol-2-yl)benzamide as the
raw material, the same operation as the Example 2 gave the title compound.
Yield: 92.9%.
1H-NMR(DMSO-ds): b 7.00(1H, td, J=8.0, 0.8Hz),7.06(1H, d, J=8.4Hz), 7.51(1H,
ddd,
J=8.4, 7.6, 2.OHz), 7.92(1H, dd, J=8.0, l.6Hz), 12.16(1H, br).
Example 238: Preparation of the compound of Compound No. 238.
Using 5-bromosalicylic acid and 2-amino-5-trifluoromethyl-1,3,4-thiadiazole
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 80.2%.
1H-NMR(DMSO-ds): b 7.01(1H, d, J=9.OHz), 7.63(1H, dd, J=8.7, 2.7Hz), 7.97(1H,
d,
186
CA 02489091 2004-12-08
J=2.4Hz).
Example 239: Preparation of the compound of Compound No. 239.
Using 5-chlorosalicylic acid and 3-aminopyridine as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 23.2%.
1H-NMR(DMSO-ds): b 7.02(1H, d, J=9.3Hz), 7.42(1H, ddd, J=9.0, 4.8, 0.6Hz),
7.47(1H,
dd, J=8.7, 5.7Hz), 7.92(1H, d, J=2.7Hz), 8.15(1H, ddd, J=8.4, 2.4, l.SHz),
8.35(1H, dd,
J=7.8, l.SHz), 8.86(1H, d, J=2.4Hz), 10.70(1H, s).
Example 240: Preparation of the compound of Compound No 240.
Using 5-chlorosalicylic acid and 5-amino-2-chloropyridine as the raw
materials,
the same operation as the Example 3 gave the title compound.
Yield: 12.2%.
1H-NMR(DMSO-ds): 8 7.04(1H, d, J=9.OHz), 7.49(1H, dd, J=9.0, 3.OHz), 7.54(1H,
d,
J=8.4Hz), 7.88(1H, d, J=2.7Hz), 8.21(1H, dd, J=8.7, 2.7Hz), 8.74(1H, d,
J=2.7Hz),
10.62(1H, s), 11.57(1H, s).
Example 241: Preparation of the compound of Compound No. 241.
Using 5-chlorosalicylic acid and 2-amino-6-chloro-4-methoxypyrimidine as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 2.2%, white solid.
1H-NMR(DMSO-ds): 8 3.86(3H, s), 6.85(1H, s), 7.01(1H, d, J=9.OHz), 7.47(1H,
dd,
J=9.0, 3.OHz), 7.81(1H, d, J=3.OHz), 11.08(1H, s), 11.65(1H, s).
Example 242: Preparation of the compound of Compound No. 242.
Using 5-chlorosalicylic acid and 3-aminoquinoline as the raw materials, the
same operation as the Example 3 gave the title compound.
Yield: 4.3%.
1H-NMR(DMSO-ds): 8 7.07(1H, d, J=8.7Hz), 7.51(1H, dd, J=9.0, 3.OHz), 7.61(1H,
dt,
J=7.8, l.2Hz), 7.70(1H, dt, J=7.8, l.SHz), 7.98(2H, d, J=3.OHz), 8.01(1H, s),
8.82(1H, d,
J=2.4Hz), 10.80(1H, s), 11.74(1H, s).
Example 243: Preparation of the compound of Compound No. 243.
Using 5-chlorosalicylic acid and 2-amino-6-bromopyridine as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 12.3%.
1H-NMR(DMSO-ds): b 7.07(1H, d, J=8.7Hz), 7.42(1H, d, J=7.8Hz), 7.51(1H, dd,
J=8.7,
187
CA 02489091 2004-12-08
2.7Hz), 7.82(1H, t, J=7.5Hz), 7.94(1H, d, J=3.OHz), 8.24(1H, d, J=7.8Hz),
10.95(1H, s),
11.97(1H, s).
Example 244: Preparation of the compound of Compound No. 244.
(1) 2-Acetoxy-5-chlorobenzoic acid.
Concentrated sulfuric acid(0.08mL) was added slowly to a mixture of
5-chlorosalicylic acid(13.35g, 77mmo1) and acetic anhydride(20mL). After the
reaction mixture was solidified, it was poured into ice water and extracted
with ethyl
acetate. The organic layer was washed with water and brine, and dried over
anhydrous sodium sulfate. The residue obtained by evaporation of the solvent
under
reduced pressure was washed with n-hexane under suspension to give the title
compound(15.44g, 93.0%) as a white crystal.
1H-NMR(DMSO-ds): b 2.25(3H, s), 7.27(1H, d, J=8.7Hz), 7.72(1H, dd, J=8.7,
2.7Hz),
7.89(1H, d, J=2.7Hz), 13.47(1H, s).
(2) 2-Acetoxy-5-chloro-N-(pyridazin-2-yl)benzamide.
Using 2-acetoxy-5-chlorobenzoic acid and 2-aminopyridazine as the raw
materials, the same operation as the Example 204(3) gave the title compound.
Yield: 19.7%.
1H-NMR(CDCIs): b 2.42(3H, s), 7.19(1H, d, J=8.7Hz), 7.54(1H, dd, J=8.7,
2.7Hz),
8.01(1H, d, J=2.4Hz), 8.28(1H, dd, J=2.4, l.BHz), 8.42(1H, d, J=2.4Hz),
9.09(1H, s),
9.66(1H, d, J=l.BHz).
(3) 5-Chloro-2-hydroxy-N-(pyridazin-2-yl)benzamide(Compound No. 244).
Using 2-acetoxy-5-chloro-N-(pyridazin-2-yl)benzamide as the raw material,
the same operation as the Example 2 gave the title compound.
Yield: 72.6%.
1H-NMR(DMSO-ds): b 7.09(1H, d, J=9.OHz), 7.52(1H, dd, J=8.7, 2.7Hz), 7.96(1H,
d,
J=2.7Hz), 8.44-8.47(2H, m), 9.49(1H, s), 10.99(1H, s), 12.04(1H, s).
Example 245: Preparation of the compound of Compound No. 245.
Using 5-bromosalicylic acid and 2-amino-5-bromopyrimidine as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 10.3%.
iH-NMR(DMSO-ds): b 6.98(1H, d, J=8.8Hz), 7.59(1H, dd, J=8.8, 2.4Hz), 8.00(1H,
d,
J=2.8Hz), 8.86(2H, s), 11.09(1H, s), 11.79(1H, s).
Example 246: Preparation of the compound of Compound No. 246.
188
CA 02489091 2004-12-08
Using 2-(5-bromo-2-hydroxybenzoyl)amino-4-phenylthiazole-5-carboxylic
acid(Compound No. 217) and propylamine as the raw materials, the same
operation as
the Example 220 gave the title compound.
Yield: 23.1%.
1H-NMR(DMSO-ds): b 0.82(3H, t, J=7.5Hz), 1.39-1.51(2H, m), 3.13(2H, q,
J=6.6Hz),
7.02(1H, d, J=9.OHz), 7.40-7.48(3H, m), 7.63(1H, dd, J=8.7, 2.7Hz), 7.68-
7.72(2H, m),
8.06(1H, d, J=2.7Hz), 8.18(1H, t, J=5.7Hz), 11.87(1H, brs), 12.14(1H, brs).
Example 247: Preparation of the compound of Compound No. 247.
A mixture of 5-sulfosalicylic acid(218mg, lmmol),
3,5-bis(trifluoromethyl)aniline(229mg, lmmol), phosphorus trichloride(88 ~c L,
lmmol)
and o-xylene(5mL) was refluxed for 3 hours. After the reaction mixture was
cooled to
room temperature, it was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=3:1) to give the title compound(29mg, 9.2%) as a
white
solid.
1H-NMR(DMSO-ds): b 7.15(1H, d, J=8.8Hz), 7.65(2H, s), 7.73(1H, s), 7.81(1H,
s),
7.82(1H, dd, J=8.7, 2.5Hz), 8.23(1H, d, J=2.5Hz), 8.38(2H, s), 10.87(1H, s),
11.15(1H,
brs).
Example 248: Preparation of the compound of Compound No. 248.
A mixture of 5-chlorosalicylic acid(87mg, 0.5mmo1),
2,2-bis(3-amino-4-methylphenyl)-1,1,1,3,3,3-hexafluoropropane(363mg, lmmol),
phosphorus trichloride(44 ~ L, 0.5mmo1) and toluene(4mL) was refluxed for 4
hours.
After the reaction mixture was cooled to room temperature, it was purified by
column
chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the white
title
compound(l6mg, 4.9%). (The compound of Compound No. 251 described in the
following Example 251 was obtained as a by-product.)
1H-NMR(DMSO-ds): 8 2.34(6H, s), 7.04(4H, d, J=8.8Hz), 7.39(2H, d, J=8.4Hz),
7.48(2H, dd, J=8.8, 2.9Hz), 7.96(2H, d, J=2.9Hz), 8.19(2H, s), 10.44(2H, s),
12.17(2H,
s).
Example 249: Preparation of the compound of Compound No. 249.
Using 3-phenylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 64.6%.
1H-NMR(DMSO-ds): 8 7.12(1H, t, J=8.lHz), 7.37(1H, tt, J=7.5, l.SHz), 7.43-
7.48(2H,
189
CA 02489091 2004-12-08
m), 7.56-7.60(3H, m), 7.91(1H, s), 8.07, (1H, dd, J=8.1, l.SHz), 8.48(2H, s),
11.00(1H, s),
12.16(1H, s).
Example 250: Preparation of the compound of Compound No. 250.
Using 4-fluorosalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 65.7%.
1H-NMR(DMSO-ds): 8 6.81-6.90(2H, m), 7.84(1H, s, ), 7.93-7.98(1H, m, ),
8.45(2H, s, ),
10.78(1H, s), 11.81(1H, s, ).
Example 251: Preparation of the compound of Compound No. 251.
This compound was obtained by separation from the mixture with the
compound of Compound No. 248 described in the aforementioned Example 248.
Yield: 9.4%.
1H-NMR(CDaOD): b 2.16(3H, s), 2.34(3H, s), 6.69(1H, d, J=8.2Hz), 6.76(1H,
brs)6.95(1H, d, J=8.8Hz), 7.02(1H, d, J=8.OHz), ?.15(1H, d, J=8.2Hz), 7.29(1H,
d,
J=8.2Hz), 7.37(1H, dd, J=8.8, 2.6Hz), 7.97(1H, d, J=2.6Hz), 7.98(1H, s).
Example 252: Preparation of the compound of Compound No. 252.
Using 5-chlorosalicylic acid and 4-[2-amino-4-(trifluromethyl)phenoxy]-
benzonitrile as the raw materials, the same operation as the Example 3 gave
the title
compound.
Yield: 11.6%.
1H-NMR(CDsOD): b 6.88(1H, d, J=8.6Hz), 7.19(2H, d, J=8.9Hz), 7.24(1H, d,
J=8.6Hz),
7.33(1H, dd, J=8.8, 2.8Hz), 7.46(1H, dd, J=8.9, l.9Hz), 7.76(2H, d, J=8.9Hz),
7.98(1H, d,
J=2.7Hz), 8.96(1H, s).
Example 253: Preparation of the compound of Compound No. 253.
Using 5-chlorosalicylic acid and 3-amino-4-(4-methoxyphenoxy)-
benzotrifluoride as the raw materials, the same operation as the Example 3
gave the
title compound.
Yield: 88.1%.
1H-NMR(CDCIs): 8 3.85(3H, s)6.81(1H, d, J=8.5Hz), 6.97-7.02(3H, m), 7.08(2H,
d,
J=8.8Hz), 7.30(1H, m), 7.40(1H, dd, J=8.8, l.9Hz), 7.45(1H, d, J=2.2Hz),
8.70(1H, s),
8.78(1H, d, J=l.6Hz), 11.76(1H, s).
Example 254: Preparation of the compound of Compound No. 254.
Using salicylic acid and 2,5-bis(trifluoromethyl)aniline as the raw materials,
190
CA 02489091 2004-12-08
the same operation as the Example 3 gave the title compound.
Yield: 47.8%.
1H-NMR(CDsOD): b 7.00-7.06(2H, m), 7.48(1H, dt, J=1.5, 7.5Hz), 7.74(1H, d,
J=8.4Hz),
8.01-8.08(2H, m), 8.79(1H, s), 11.09(1H, s), 12.03(1H, s).
Example 255: Preparation of the compound of Compound No. 255.
(1) 2-Amino-4-(2,4-dichlorophenyl)thiazole.
Using 2',4'-dichloroacetophenone and thiourea as the raw materials, the same
operation as the Example 231(1) gave the title compound.
Yield: 97.1%.
1H-NMR(CDCIs): b 5.01(2H, s), 7.09(1H, s), 7.28(1H, dd, J=8.4, 2.lHz),
7.45(1H, d,
J=2.lHz), 7.82(1H, d, J=8.4Hz).
(2) 5-Chloro-2-hydroxy-N-[4-(2,4-dichlorophenyl)thiazol-2-
yl]benzamide(Compound No.
255).
Using 5-chlorosalicylic acid and 2-amino-4-(2,4-dichlorophenyl)thiazole as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 8.0%.
1H-NMR(DMSO-ds): b 7.08(1H, d, J=8.7Hz), 7.50-7.55(2H, m), 7.72-7.76(2H, m),
7.91(1H, d, J=8.4Hz), 7.95(1H, d, J=2.4Hz), 11.87(1H, brs), 12.09(1H, brs).
Example 256: Preparation of the compound of Compound No. 256.
Using 3-isopropylsalicylic acid and 3,5-bis(trifluoromethyl)aniline as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 99.2%.
1H-NMR(CDCIs): 8 1.26(6H, d, J=6.9Hz), 3.44(1H, Hept, J=6.9Hz), 6.92(1H, t,
J=7.8Hz), 7.38(1H, dd, J=8.1, l.2Hz), 7.44(1H, d, J=7.5Hz), 7.69(1H, s),
8.13(3H, s),
11.88(1H, s).
Example 257: Preparation of the compound of Compound No. 257.
Bromine(14.4 a L, 0.28mmo1) and iron powder(l.7mg, 0.03mmo1) were added to
a solution of N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-3-
isopropylbenzamide
(Compound No. 256; 100mg, 0.26mmo1) in carbon tetrachloride(5mL) under argon
atmosphere, and the mixture was stirred at room temperature for 2 hours. The
reaction mixture was diluted with ethyl acetate. The ethyl acetate layer was
washed
successively with water and brine, and dried over anhydrous magnesium sulfate.
The
residue obtained by evaporation of the solvent under reduced pressure was
crystallized
191
CA 02489091 2004-12-08
from n-hexane/ethyl acetate to give the title compound(110mg, 91.5%) as a
white solid.
1H-NMR(CDCIs): 8 1.25(6H, d, J=6.9Hz), 3.39(1H, Hept, J=6.9Hz), 7.49-7.51(2H,
m),
7.71(1H, brs), 8.11-8.14(3H, m), 11.81(1H, brs).
Example 258: Preparation of the compound of Compound No. 258.
N-Bromosuccinimide(88.2mg, 0.50mmo1) was added to a solution of
N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-3-methylbenzamide(Compound No.
58;
150mg, 0.41mmo1) in a mixed solvent of methanol/water(3:1; 5mL), and the
mixture
was stirred at room temperature for 10 minutes. The reaction mixture was
diluted
with ethyl acetate. The ethyl acetate layer was washed successively with 10%
aqueous sodium thiosulfate, water and brine, and dried over anhydrous
magnesium
sulfate. The residue obtained by evaporation under reduced pressure was
purified by
column chromatography on silica gel(n-hexane:ethyl acetate=5:1) to give the
title
compound(167mg, 91.5%) as a white powder.
1H-NMR(CDCIa): 8 2.28(3H, s), 7.47(1H, s), 7.50(1H, d, J=2.4Hz), 7.71(1H, s),
8.08(1H,
brs), 8.13(2H, s), 11.71(1H, s).
Example 259: Preparation of the compound of Compound No. 259.
Using N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-3-phenylbenzamide
(Compound No. 249), the same operation as the Example 258 gave the title
compound.
Yield: 67.5%.
1H-NMR(DMSO-ds): 8 7.36-7.50(3H, m), 7.55-7.59(2H, m), 7.71(1H, d, J=2.lHz),
7.93(1H, brs), 8.28(1H, d, J=2.lHz), 8.45(2H, s), 11.06(1H, brs), 12.16(1H,
brs).
Example 260: Preparation of the compound of Compound No. 260.
(1) 2-Amino-4-(3,4-dichlorophenyl)thiazole.
Using 3',4'-dichloroacetophenone and thiourea as the raw materials, the same
operation as the Example 231(1) gave the title compound.
Yield: 77.8%.
1H-NMR(DMSO-ds): b 7.17(2H, s), 7.24(1H, s), 7.62(1H, d, J=8.4Hz), 7.78(1H,
dd,
J=8.7, 2.7Hz), 8.22(1H, d, J=2.4Hz).
(2) 5-Chloro-2-hydroxy-N-[4-(3,4-dichlorophenyl)thiazol-2-
yl]benzamide(Compound No.
260).
Using 5-chlorosalicylic acid and 2-amino-4-(3,4-dichlorophenyl)thiazole as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 15.1%.
192
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): 8 7.08(1H, d, J=8.7Hz), 7.52(1H, dd, J=8.7, 2.7Hz), 7.71(1H,
d,
J=8.4Hz), 7.91(1H, d, J=l.BHz), ?.94(1H, s), 8.18(1H, d, J=l.SHz), 12.09(2H,
bs).
Example 261: Preparation of the compound of Compound No. 261.
(1) 2-Amino-4-[4-(trifluoromethyl)phenyl]thiazole.
Using 4'-(trifluoromethyl)acetophenone and thiourea as the raw materials, the
same operation as the Example 231(1) gave the title compound.
Yield: 77.5%.
1H-NMR(DMSO-ds): b 7.18(2H, s), 7.26(1H, s), 7.72(2H, d, J=8.4Hz), 8.00(2H, d,
J=8.lHz).
(2) 5-Chloro-2-hydroxy-N-{4-[4-(trifluoromethyl)phenyl]thiazol-2-yl?benzamide
(Compound No. 261).
Using 5-chlorosalicylic acid and 2-amino-4-[4-(trifluoromethyl)phenyl]thiazole
as the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 16.0%.
1H-NMR(DMSO-ds): b 7.09(1H, d, J=9.OHz), 7.53(1H, dd, J=8.7, 2.7Hz), 7.81(2H,
d,
J=8.4Hz), 7.96(1H, d, J=2.4Hz), 7.98(1H, s), 8.16(2H, d, J=8.lHz), 11.91(1H,
bs),
12.13(1H, bs).
Example 262: Preparation of the compound of Compound No. 262.
(1) Methyl 2-methoxy-4-phenylbenzoate.
Dichlorobis(triphenylphosphine)palladium(29mg, 0.04mmol) was added to a
solution of methyl 4-chloro-2-methoxybenzoate(904mg, 4.5mmo1), phenylboronic
acid(500mg, 4.lmmol) and cesium carbonate(2.7g, 8.2mmol) in
N,N-dimethylformamide(l5mL) under argon atmosphere, and the mixture was
stirred
at 120°C for 8 hours. After the reaction mixture was cooled to room
temperature, it
was diluted with ethyl acetate. The ethyl acetate layer was washed
successively with
water and brine, and dried over anhydrous sodium sulfate. The residue obtained
by
evaporation of the solvent under reduced pressure was purified by column
chromatography on silica gel(n-hexane:ethyl acetate=10:1) to give the title
compound(410mg, 41.2%) as a colourless oil.
1H-NMR(CDCIa): b 3.91(3H, s), 3.98(3H, s), 7.17(1H, d, J=l.SHz), 7.20(1H, dd,
J=8.1,
l.5Hz), 7.31-7.50(3H, m), 7.59-7.63(2H, m), 7.89(1H, d, J=8.lHz).
(2) 2-Methoxy-4-phenylbenzoic acid
2N Aqueous sodium hydroxide(5mL) was added to a solution of methyl
193
CA 02489091 2004-12-08
2-methoxy-4-phenylbenzoate(410mg, 1.69mmo1) in methanol(5mL), and the mixture
was refluxed for 1 hour. After the reaction mixture was cooled to room
temperature,
the solvent was evaporated under reduced pressure. 2N hydrochloric acid was
added
to the obtained residue and the separated crystal was filtered to give the
title
compound(371mg, 96.0%) as a crude product.
1H-NMR(DMSO-ds): 8 3.93(3H, s), 7.29(1H, dd, J=8.1, l.SHz), 7.34(1H, d,
J=l.SHz),
7.40-7.53(3H, m), 7.73-7.77(3H, m), 12.60(1H, s).
(3) N-[3,5-Bis(trifluoromethyl)phenyl]-2-methoxy-4-phenylbenzamide.
Using 2-methoxy-4-phenylbenzoic acid and 3,5-bis(trifluoromethyl)aniline as
the raw materials, the same operation as the Example 3 gave the title
compound.
Yield: 97.5%.
1H-NMR(CDCIa): b 4.19(3H, s), 7.25(1H, m), 7.38-7.53(4H, m), 7.62-7.65(3H, m),
8.12(2H, s), 8.35(1H, d, J=8.lHz), 10.15(1H, brs).
(4) N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-4-phenylbenzamide(Compound
No.
262).
1M Boron tribromide-dichloromethane solution(0.71mL, 0.71mmol) was added
to a solution of N-[3,5-bis(trifluoromethyl)phenyl]-2-methoxy-4-
phenylbenzamide(100mg, 0.24mmo1) in dichloromethane(5mL), and the mixture was
stirred at room temperature for 1 hour. The reaction mixture was diluted with
ethyl
acetate, washed successively with water and brine, and dried over anhydrous
magnesium sulfate. The residue obtained by evaporation of the solvent under
reduced pressure was purified by column chromatography on silica gel(n-
hexane:ethyl
acetate=5:1) to give the title compound(69.3mg, 71.6°/) as a white
powder.
1H-NMR(DMSO-ds): b 7.20(1H, dd, J=8.4.1.8Hz), 7.30(1H, d, J=l.BHz), 7.39-
7.51(3H,
m), 7.60-7.64(3H, m), 7.70(1H, brs), 8.15(2H, s), 8.19(1H, brs), 11.59(1H, s).
Example 263: Preparation of the compound of Compound No. 263.
(1) 2-Amino-4-(2,5-difluorophenyl)thiazole.
Using 2',5'-difluoroacetophenone and thiourea as the raw materials, the same
operation as the Example 231(1) gave the title compound.
Yield: 77.8%.
1H-NMR(DMSO-ds): b 7.45(1H, d, J=2.7Hz), 7.11-7.17(1H, m), 7.19(2H, s),
7.28-7.36(1H, m), 7.65-7.71(1H, m).
(2) 5-Chloro-2-hydroxy-N-[4-(2,5-difluorophenyl)thiazol-2-
yl]benzamide(Compound No.
194
CA 02489091 2004-12-08
263).
Using 5-chlorosalicylic acid and 2-amino-4-(2,5-difluorophenyl)thiazole as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 36.5%.
1H-NMR(DMSO-ds): b 7.09(1H, d, J=8.7Hz), 7.22-7.30(1H, m), 7.37(1H, m),
7.53(1H,
dd, J=8.7, 3.OHz), 7.72(1H, d, J=2.4Hz), 7.77-7.84(1H, m), 7.94(1H, d,
J=3.OHz),
11.89(1H, bs), 12.12(1H, bs).
Example 264: Preparation of the compound of Compound No. 264.
(1) 2-Amino-4-(4-methoxyphenyl)thiazole.
Using 4'-methoxyacetophenone and thiourea as the raw materials, the same
operation as the Example 231(1) gave the title compound.
Yield: 85.2%.
1H-NMR(DMSO-ds): 8 3.76(3H, s), 6.82(1H, s), 6.92(2H, d, J=9.OHz), 7.01(2H,
s),
7.72(2H, d, J=8.7Hz).
(2) 5-Chloro-2-hydroxy-N-[4-(4-methoxyphenyl)thiazol-2-yl]benzamide(Compound
No.
264).
Using 5-chlorosalicylic acid and 2-amino-4-(4-methoxyphenyl)thiazole as the
raw materials, the same operation as the Example 3 gave the title compound.
Yield: 16.4%.
1H-NMR(DMSO-ds): b 3.80(3H, s), 7.01(2H, d, J=9.OHz), 7.07(1H, d, J=8.7Hz),
7.50-7.55(2H, m), 7.86(2H, d, J=9.OHz), 7.96(1H, d, J=2.7Hz), 11.90(1H, bs),
12.04(1H,
bs).
Example 265: Preparation of the compound of Compound No. 265.
(1) 2-Amino-4-[3-(trifluoromethyl)phenyl]thiazole.
Using 3'-(trifluoromethyl)acetophenone and thiourea as the raw materials, the
same operation as the Example 231(1) gave the title compound.
Yield: 94.1%.
1H-NMR(DMSO-ds): 8 7.19(2H, s), 7.27(1H, s), 7.61(2H, dd, J=3.9, l.SHz),
8.07-8.13(2H, m).
(2) 5-Chloro-2-hydroxy-N-{4-[3-(trifluoromethyl)phenyl]thiazol-2-yl}benzamide
(Compound No. 265).
Using 5-chlorosalicylic acid and 2-amino-4-[3-(trifluoromethyl)phenyl]thiazole
as the raw materials, the same operation as the Example 3 gave the title
compound.
195
CA 02489091 2004-12-08
Yield: 31.0%.
1H-NMR(DMSO-ds): 8 7.13(1H, d, J=8.7Hz), 7.53(1H, dd, J=9.0, 2.7Hz), 7.70(1H,
d,
J=2.4Hz), 7.71(1H, d, J=l.2Hz), 7.95(1H, d, J=2.7Hz), 8.00(1H, s), 8.24-
8.27(2H, m),
12.16(2H, bs).
Example 266: Preparation of the compound of Compound No. 266.
(1) 2-Amino-4-(2,3,4,5,6-pentafluorophenyl)thiazole.
Using 2',3',4',5',6'-pentafluoroacetophenone and thiourea as the raw
materials,
the same operation as the Example 231(1) gave the title compound.
Yield: 86.7%.
1H-NMR(CDCIs): 8 5.19(2H, s), 6.83(1H, s).
(2) 5-Chloro-2-hydroxy-N-[4-(2,3,4,5,6-pentafluorophenyl)thiazol-2-
yl]benzamide
(Compound No. 266).
Using 5-chlorosalicylic acid and 2-amino-4-(2,3,4,5,6-pentafluorophenyl)-
thiazole as the raw materials, the same operation as the Example 3 gave the
title
compound.
Yield: 23.8%.
zH-NMR(DMSO-ds): b 7.08(1H, d, J=8.7Hz), 7.53(1H, dd, J=8.7, 2.7Hz), 7.73(1H,
s),
7.93(1H, d, J=2.7Hz), 11.85(1H, bs), 12.15(1H, bs).
Example 267: Preparation of the compound of Compound No. 267.
Using 5-chlorosalicylic acid and 2-amino-4-methylbenzophenone as the raw
materials, the same operation as the Example 3 gave the title compound.
Yield: 8.7%.
1H-NMR(CDCIs): b 2.50(3H, s), 6.98(1H, d, J=8.3Hz), 6.99(1H, d, J=7.3Hz),
7.39(1H,
dd, J=2.0, 8.6Hz), 7.48-7.64(4H, m), 7.72(2H, d, J=7.6Hz), 7.83(1H, d,
J=2.3Hz),
8.57(1H, s), 12.18(1H, s), 12.34(1H, br.s).
Example 268: Preparation of the compound of Compound No. 268.
Iron(3mg, 0.05mmo1) and bromine(129 ~ 1, 2.5mmo1) were added to a solution
of 2-hydroxy-N-[2,5-bis(trifluoromethyl)phenyl]benzamide(Compound No. 254;
175mg,
0.5mmo1) in carbon tetrachloride(5mL), and the mixture was stirred at
50°C for 12
hours. After the reaction mixture was cooled to room temperature, it was
washed
with saturated aqueous sodium hydrogen carbonate, water and brine, and dried
over
anhydrous magnesium sulfate. The residue obtained by evaporation of the
solvent
under reduced pressure was purified by column chromatography on silica
196
CA 02489091 2004-12-08
gel(n-hexane:ethyl acetate=2:1) to give the title compound(184.2mg, 72.7%) as
a white
crystal.
1H-NMR(DMSO-ds): b 7.92-7.98(1H, m), 8.06(1H, d, J=2.lHz), 8.09(1H, d,
J=8.4Hz),
8.22(1H, d, J=2.lHz), 8.27-8.32(1H, m), 11.31(1H, s).
Reference Example 1: Preparation of N-[2,4-bis(trifluoromethyl)phenyl]-5-
chloro-2-
hydroxybenzamide.
Phosphorus trichloride(44 ~ L, 0.5mmo1) was added to a mixture of
5-chlorosalicylic acid(173mg, lmmol), 2,4-bis(trifluoromethyl)aniline(229mg,
lmmol)
and toluene(5mL), and the mixture was refluxed for 4.5 hours. After the
reaction
mixture was cooled to room temperature, it was poured into water and extracted
with
ethyl acetate. After the ethyl acetate layer was washed with water and brine,
dried
over anhydrous magnesium sulfate, the residue obtained by evaporation of the
solvent
under reduced pressure was purified by column chromatography on silica
gel(n-hexane:ethyl acetate=2:1) to give the title compound(26.3mg, 6.9%) as a
white
powder.
1H-NMR(CDCls): 8 7.03(1H, dd, J=8.7, 0.6Hz), 7.43-7.48(2H, m), 7.91(1H, d,
J=9.OHz),
7.96(1H, s), 8.42(1H, s), 8.49(1H, d, J=8.7Hz), 11.26(1H, s).
Reference Example 2: Preparation of
N-[2-(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide.
A mixture of 5-chlorosalicylic acid(173mg, lmmol),
2-(trifluoromethyl)aniline(161mg, lmmol), phosphorus trichloride(44,u l,
0.5mmol) and
monochlorobenzene(5mL) was refluxed for 3 hours under argon atmosphere. After
the reaction mixture was cooled to room temperature, n-hexane was added and
the
separated crude crystal was filtered and dissolved in ethyl acetate(50mL).
After the
ethyl acetate solution was washed successively with water and brine, dried
over
anhydrous sodium sulfate, the solvent was evaporated under reduced pressure.
The
obtained residue was purified by column chromatography on silica gel(n-
hexane:ethyl
acetate=2:1) to give the title compound(183mg, 58.0%) as a white crystal.
1H-NMR(DMSO-ds): 8 7.07(1H, d, J=8.7Hz), 7.42(1H, t, J=7.5Hz), 7.52(1H, d,
J=8.7,
2.7Hz), 7.74(1H, t, J=8.lHz), 7.77(1H, t, J=8.lHz), 7.99(1H, d, J=2.7Hz),
8.18(1H, d,
J=8.lHz), 10.76(1H, s), 12.22(1H, s).
Reference Example 3: Preparation of N-[4-chloro-2-(trifluoromethyl)phenyl]-5-
chloro-2-hydroxybenzamide.
197
CA 02489091 2004-12-08
Using 5-chlorosalicylic acid and 4-chloro-2-(trifluoromethyl)aniline as the
raw
materials, the same operation as the Reference Example 2 gave the title
compound.
Yield: 21.5%.
1H-NMR(DMSO-ds): 8 7.07(1H, d, J=8.7Hz), 7.52(1H, dd, J=8.7, 2.7Hz), 7.80-
7.85(2H,
m), 7.97(1H, d, J=2.7Hz), 8.26(1H, d, J=8.4Hz), 10.80(1H, s), 12.26(1H, s).
Reference Example 4: Preparation of
N-[3-(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide.
Using 5-bromosalicylic acid and 3-(trifluoromethyl)aniline as the raw
materials, the same operation as the Reference Example 2 gave the title
compound.
Yield: 50.3%.
1H-NMR(DMSO-ds): 8 6.98(1H, d, J=8.7Hz), 7.48-7.52(1H, m), 7.59(1H, dd, J=8.7,
2.7Hz), 7.62(1H, t, J=8.lHz), 7.92-7.96(1H, m), 8.02(1H, d, J=2.4Hz), 8.20(1H,
s),
10.64(1H, s), 11.60(1H, s).
Reference Example 5: Preparation of N-[4-chloro-3-(trifluoromethyl)phenyl]-5-
bromo-2-hydroxybenzamide.
Using 5-bromosalicylic acid and 4-chloro-3-(trifluoromethyl)aniline as the raw
materials, the same operation as the Reference Example 2 gave the title
compound.
Yield: 37.4°/.
1H-NMR(DMSO-ds): b 6.98(1H, d, J=8.7Hz), 7.59(1H, dd, J=8.7, 2.4Hz), 7.73(1H,
d,
J=8.7Hz), 7.98(1H, d, J=2.4Hz), 8.00(1H, dd, J=8.7, 2.4Hx), 8.31(1H, d,
J=2.4Hz),
10.68(1H, s), 11.52(1H, brs).
Reference Example 6: Preparation of N-[4-(trifluoromethyl)phenyl]-5-
chloro-2-hydroxybenzamide.
Using 5-chlorosalicylic acid and 4-(trifluoromethyl)aniline as the raw
materials, the same operation as the Reference Example 2 gave the title
compound.
Yield: 75.0%, white solid
1H-NMR(DMSO-ds): 8 7.04(1H, d, J=9.OHz), 7.48(1H, dd, J=8.7, 2.7Hz), 7.74(2H,
d,
J=8.7Hz), 7.90(1H, d, J=2.7Hz), 7.95(2H, d, J=9.OHz), 10.65(1H, s), 11.59(1H,
s).
Reference Example 7: Preparation of N-[2-chloro-4-(trifluoromethyl)phenyl]-5-
bromo-2-hydroxybenzamide.
Using 5-bromosalicylic acid and 2-chloro-4-(trifluoromethyl)aniline as the raw
materials, the same operation as the Reference Example 2 gave the title
compound.
Yield: 34.9%.
198
CA 02489091 2004-12-08
1H-NMR(DMSO-ds): 8 7.04(1H, d, J=8.7Hz), 7.64(1H, dd, J=8.7, 2.7Hz), 7.79(1H,
dd,
J=9.0, 2.lHz), 7.99(1H, d, J=2.lHz), 8.11(1H, d, J=2.4Hz), 8.73(1H, d,
J=9.OHz),
11.15(1H, s), 12.42(1H, s).
Test Example 1: Measurement of Inhibitory Activity of NF- ~ B Activation.
Inhibitory activity of NF- ~ B activation was measured by referring to the
method of Hill et al. (Cell, (USA), in 1993, Vo1.73, No.2, p.395-406). Using a
transfection reagent(Effectene; QIAGEN), the human hepatoma cell strain HepG2
was
transfected with a plasmid(pNF r~ B-Luc Reporter Plasmid; STRATAGENE) which is
integrated with an oligonucleotide having five tandem copies of NF- rc B
binding
sequences(TGGGGACTTTCCGC) on a upstream region of firefly luciferase gene(Luc)
according to the QIAGEN's protocol, and the cells were incubated for 6 to 24
hours.
After the addition of TNF- a (40ng/ml) in the presence or absence of a test
compound,
the cells were incubated for 4 hours, and intracellular luciferase activity
was measured
by using PicaGene LT (TOYO INK MFG Co., Ltd.) and a chemical luminescence
measurement apparatus (SPECTRAFIuor Plus; TECAN). The inhibitory ratio was
measured as a ratio relative to the value of a luciferase activity in the
absence of the
test compound. The inhibitory ratio of NF- r~ B activity in the presence of
the test
compound at 10 a g/ml or 1 ~ g/ml are shown in the following table.
Inhibitory Ratio of
NF- r~ B Activation(%)
Compound Number Drug Concentration Drug Concentration
10 ~ g/mL 1 a g/mL
1 97.1 90.9
2 95.6 93.3
3 94.3 81.5
4 97.5 95.7
99.2 96.5
6 98.6 94.9
7 85.4 86.6
8 99.2 92.0
g 99.6 92.2
99.4 95.8
199
CA 02489091 2004-12-08
11 98.3 92.9
12 99.2 86.3
13 96.0 76.8
14 98.3 94.7
15 99.2 94.5
16 99.4 42.7
17 99.1 74.9
18 98.5 59.7
19 96.9 95.5
20 94.9 91.1
21 90.1 53.3
22 97.1 83.9
23 96.8 91.8
24 98.3 92.3
25 99.6 96.4
26 95.4 93.3
27 97.9 93.8
28 97.8 79.5
29 92.9 81.7
30 95.3 82.1
32 99.0 90.4
33 97.0 30.7
34 98.7 90.7
35 96.4 88.2
37 94.5 N.T.
38 87.1 16.0
39 82.2 23.7
40 96.0 44.9
41 95.9 42.2
42 98.1 84.4
44 67.5 N.T.
45 63.4 N.T.
200
CA 02489091 2004-12-08
46 88.4 20.5
47 97.2 51.8
48 98.7 96.2
49 89.1 19.4
50 96.0 69.9
51 98.2 90.5
52 97.3 96.4
53 94.5 93.3
54 86.5 N.T.
55 88.6 10.8
56 95.1 89.4
57 91.9 N.T.
58 95.0 88.2
59 94.7 41.9
60 99.1 94.0
61 97.2 95.1
62 86.9 37.0
63 85.0 85.4
64 94.1 84.9
65 89.8 83.3
71 95.0 89.6
72 95.0 94.6
73 97.9 93.1
74 97.5 64.0
75 82.2 58.1
80 73.0 46.3
81 96.3 95.0
82 96.8 94.0
83 98.3 95.7
I, 84 96.6 92.6
85 98.9 94.7
86 98.7 96.7
201
CA 02489091 2004-12-08
87 95.9 93.1
88 97.1 94.8
89 97.4 96.7
90 94.1 88.9
91 96.7 86.3
92 97.9 93.8
93 97.2 84.5
94 93.4 76.6
95 98.5 91.8
96 99.1 94.6
97 97.8 95.8
98 86.4 81.8
99 98.0 54.3
100 95.1 85.6
101 82.0 17.7
102 98.3 89.3
104 99.2 97.2
105 97.5 94.6
106 92.1 92.3
107 96.2 94.9
108 88.4 41.5
110 98.7 96.5
111 99.7 96.5
112 95.7 96.5
113 96.2 90.5
114 98.2 91.8
115 98.4 90.7
116 97.3 90.0
117 92.6 92.8
118 99.5 95.0
119 86.9 85.4
120 97.5 88.6
202
CA 02489091 2004-12-08
121 95.5 92.9
122 96.9 95.1
123 96.8 91.8
124 97.0 94.2
125 96.8 84.5
126 92.8 77.1
127 97.1 85.4
128 95.1 91.4
129 71.8 N.T.
130 70.6 N.T.
131 88.7 49.1
133 95.6 91.0
134 96.3 89.1
135 99.2 86.2
136 99.4 91.0
137 92.6 86.3
138 98.1 89.6
139 94.7 90.8
140 82.0 70.9
141 97.9 82.4
142 95.7 32.4
143 96.8 38.3
144 56.4 N.T.
146 98.5 91.2
147 91.0 38.9
149 87.1 37.4
151 98.2 85.8
152 95.3 35.1
153 97.1 88.3
154 93.3 83.0
155 90.2 11.2
156 95.7 93.8
203
CA 02489091 2004-12-08
157 98.8 52.6
158 96.8 52.4
160 96.5 69.6
161 97.6 94.2
162 97.9 93.8
163 97.4 92.1
164 98.3 97.6
165 99.4 95.9
166 96.4 94.1
167 98.7 76.4
168 97.8 46.7
169 95.9 31.6
171 98.1 90.6
172 96.4 93.7
173 98.3 86.4
174 89.6 N.T.
176 99.5 96.0
177 99.4 87.8
178 89.7 N.T.
179 93.4 92.5
180 93.7 90.7
181 95.1 N.T.
182 90.2 85.3
183 86.8 N.T.
184 63.8 53.6
185 95.2 88.4
186 98.7 96.5
187 94.4 85.3
188 92.4 92.6
189 93.8 20.0
190 69.7 N.T.
191 67.2 N.T.
204
CA 02489091 2004-12-08
192 94.4 83.6
193 82.0 N.T.
194 71.7 N.T.
195 98.1 90.5
196 87.6 28.8
197 96.1 70.1
198 88.7 46.1
199 98.4 96.4
200 97.7 95.0
201 97.5 86.8
202 92.4 84.5
204 97.8 93.6
205 96.8 87.8
206 89.6 36.3
207 95.9 92.5
208 78.8 N.T.
210 72.1 N.T.
211 67.0 N.T.
212 95.0 79.7
213 89.4 85.1
214 95.9 70.2
215 97.3 90.7
216 82.8 55.8
218 94.2 80.7
219 96.0 82.2
220 58.6 50.8
221 84.0 51.9
222 91.3 49.6
223 60.4 33.3
224 96.5 87.6
225 78.6 34.6
226 85.8 45.0
205
CA 02489091 2004-12-08
227 90.3 31.8
228 90.0 66.9
229 90.1
74.0
230 84.8 40.8
231 94.5 95.9
232 85.4 88.2
233 84.7 26.6
234 63.1 29.1
235 81.8 N.T.
236 56.0 21.4
237 81.9 N.T.
238 90.3 26.1
240 92.3 14.3
241 78.9 25.5
242 85.7 N.T.
243 95.1 84.2
247 >99.9 N.T.
248 >99.9 >99.9
249 90.7 86.6
250 95.4 94.2
251 96.8 93.6
252 96.3 93.9
253 99.5 96.3
255 N.T. >99.9
256 N.T. 92.1
257 N.T. >99.9
258 N.T. >99.9
259 N.T. >gg,g
260 N.T. >99.9
261 N.T. >99.9
262 N.T. >99.9
263 I N.T. >99.9
206
CA 02489091 2004-12-08
264 N.T. >99.9
265 N.T. >99.9
266 N.T. >99.9
267 N.T. 28.6
268 98.4 87.1
N.T.: not tested
A use of N-phenylsalicylamide derivatives as an NF- r~ B inhibitor is
disclosed
in the pamphlet of International Publication W099/65499. However, only a small
number of compounds were tested for inhibitory activity against NF- rc B, and
as for a
position of a substituent on the aniline moiety, studies were made on very
limited
substituents and their substituting positions. Although 2-mono-substituted
compounds, 4-mono-substituted compounds, and 2,4-di-substituted compounds are
referred to as preferred substituted aniline moieties, however, the
publication neither
suggests nor teaches the compounds represented by the general formula (I) (the
compounds whose aniline moiety is a 2,5-di-substituted or a 3,5-di-substituted
aniline)
contained in the medicament of the present invention. Moreover, among the
compounds represented by the aforementioned general formula (I), the
publication
does not describe the compounds having trifluoromethyl groups as substituents
on the
aniline moiety. A use of N-phenylsalicylamide derivatives as an anti-
inflammatory
agent is disclosed in the specification of European Patent No.0,221,211,
Japanese
Patent Unexamined Publication (KOKAI) No.(Sho)62-99329, and the specification
of
U.S. Patent No.6,117,859, and the publications disclose the introduction of
mono-trifluoromethyl group in the aniline moiety. However, inhibitory actions
of the
mono-substituted compounds against NF- rc B are disappeared at low
concentrations.
Therefore, the di-substituted compounds are far more advantageous.
Using typical compounds used as active ingredients of the medicament of the
present invention, a compound having the strongest inhibitory activity against
NF- ~c B
among the compounds described in the pamphlet of International Publication
W099/65499, typical compounds for which animal tests were carried out in the
pamphlet of International Publication W099165499, and mono-trifluoromethyl
substituted compounds, comparisons of inhibitory activities against NF- ~c B
were
carried out by using the reporter assay method. As a result, the medicament of
the
207
CA 02489091 2004-12-08
present invention was found to have about three to nine times stronger
inhibitory
activity against NF- ~c B at low concentration(0.1 ~ g/mL) than the compound
having
the strongest activity among the compounds disclosed in the pamphlet of
International
Publication W099/65499.
Inhibitory
Ratio
of
Compound NF- rc Remarks
B Activation(%)
10 ~c 1 ~ g/m 0 .1 ~
g/m 1 g/m 1
1
OH O CF3
97.5 95.7 60.9 Compound No.4
CI H CF3
OH O CFg
N - 96.3 95.0 27.0 Compound No.81
H
CI CFg
OH
O
N _.
N 0 98.4 96.4 19.6 Compound No.199
CI H
Compound described
in
H 0 c~ the pamphlet of
c' 92.7 88.7 6.8
International Publication
W099/65499
Compound described
in
off 0 the pamphlet of
N F 86.5 -63.8 -82.9
H International Publication
NOp
F
W099/65499
OH O CF3 Mono-trifluoromethyl
89.6 88.0 -20.9
substituted compound
off 0 Mono-trifluoromethyl
cF3 g5.0 85.3 -35.5
" substituted compound
cl
OH
Mono-trifluoromethyl
N 92.9 41.6 -18.44
" substituted compound
CF3
Test Example 2: Inhibitory Test against The Production of IL-6, IL-8 and PGE2
by TNF
208
CA 02489091 2004-12-08
a Stimulation Using Synovial Fibroblasts derived from a Rheumatoid Patient
Synovial fibroblasts (Human Synoviocyte (RA-Positive), Toyobo, T4040-05)
were cultured for 3 days in a medium containing lOnglml of TNF a and a test
compound. IL-6 and IL-8 in the supernatant were measured by the ELISA method,
and PGE2 (prostaglandin E2) was measured by the EIA method. The results are
shown in the following table.
Compound Inhibition against
Number Mediator Release
ICso(nM)
IL-6 IL-8 PGE 2
4 294 450 388
6 352 351 358
11 247 377 389
22 665 869 N.T.
23 540 876 809
24 593 N.T. N.T.
25 452 N.T. N.T.
27 355 527 532
51 874 832 863
63 513 786 439
73 337 670 662
83 <10 62 <10
86 565 N.T. 562
88 88 N.T. 33
90 24 373 38
93 130 753 47
94 N.T. N.T. 266
125 903 N.T. 966
135 61 N.T. 41
140 808 N.T. 21
187 649 N.T. 414
199 309 458 68
209
CA 02489091 2004-12-08
201 317 599 53
207 641 832 834
N.T.: not tested
Similarly, comparisons of inhibitory activities against the production of IL-
6,
IL-8 and PGE2 under TNF a stimulation were made for the compounds described in
the pamphlet of International Publication W099/65499, mono-trifluoromethyl
substituted compounds, and some di-substituted compounds having similar kind
of
substituents but substituted in different positions. As a result, the
compounds
described in the pamphlet of International Publication W099/65499 were found
to
have no strong inhibitory activity against the production of IL-8 in a manner
that 50%
inhibitory concentration was less than 1000nM. Moreover, mono-trifluoromethyl
substituted compounds disclosed in the specification of European Patent
No.0,221,211,
Japanese Patent Unexamined Publication (KOKAI) No.(Sho)62-99329, and the
specification of U.S. Patent No.6,117,859 were found to have no inhibitory
activity
against the production of IL-8 at concentrations less than 1000nM, and some of
the
compounds were found to have no inhibitory activity against the release of
inflammatory mediators at concentrations less than 1000nM. Furthermore, when
the
same kinds of substituents were used, some 2,4-disubstituted compounds, that
are
described to be preferable in the pamphlet of International Publication
W099/65499,
were found to have no inhibitory activity against the release of inflammatory
mediators at concentrations less than 1000nM. These results suggest that each
of 2-
or 4-substituted compound and 2,4-di-substituted compound, which are described
to be
preferable in the pamphlet of International Publication W099/65499, is not
optimum
for the inhibition against NF- ~c B activation and inhibition against the
production of
inflammatory mediators, whilst 2,5- or 3,5-di-substituted compounds according
to the
present invention are optimum as compounds to strongly inhibit the production
of
inflammatory mediators by the inhibition against NF- rc B activation.
The compounds of Compound No. 83, 88, 90, and 135, particularly the
compound of Compound No. 83 potently inhibited the production of IL-6, IL-8,
and
PGE2 under TNF a stimulation. A structural feature of these compounds is that
E is
a 2,5-di-substituted phenyl group in the aforementioned general formula (I).
Therefore, it is suggested that the compounds wherein E is a 2,5-di-
substituted phenyl
210
CA 02489091 2004-12-08
group in the aforementioned general formula (I), more preferably, compounds
wherein
E is a 2,5-di-substituted phenyl group (at least one of said substituents is
trifluoromethyl group), and most preferably, compounds wherein E is
2,5-bis(trifluoromethyl)ghenyl group are most suitable for the preventive
and/or
therapeutic treatment of diseases in which inflammatory mediators,
particularly, IL-6
and/or IL-8 and/or PGE2 are involved.
Inhibition
against
Mediator
Release
Compound ICso(nM) Remarks
IL-6 IL-8 PGE2
Compound described
in
off o c~ > 1000 the pamphlet of
c' 205 208
N
(-12%) International
e~
Publication W099/65499
Compound described
in
off o > 1000 the pamphlet of
N F 248 62
'~ (-4.5%) International
NO
F
y
Publication W099/65499
Compound described
in
off o > 1000 the pamphlet of
N F 85 730
a F (-23%) International
Publication W099/65499
Compound described
in
" 0 0 > 1000 > 1000 the pamphlet of
N ~ 82
(-5.9%) (-3.9%) International
Publication W099/65499
Compound described
in
> 1000 the pamphlet of
N 140 292
H (-67%) International
CF3
Publication W099/65499
OH O CF3 > 1000 Compound of
c' 91 57
N
(16/) Reference Example
5
211
CA 02489091 2004-12-08
o" o > 1000 > 1000 > 1000 Compound of
C
N
B~ " (27%) (16%) (10/) Reference Example
7
cl
OH
> 1000 > 1000 > 1000 Compound of
cl
N
CI " CF3 (-17/) (-43%) (20%) Reference Example
3
OH
> 1000 > 1000 Compound of
N cF3 202
CI " CF3 (-70/) (1.2%) Reference Example
1
o" o > 1000 Compound of
N 887 676
CI " CF3 (14%) Reference Example
2
off o cF3 > 1000 Compound of
N 690 413
" (16/) Reference Example
4
o" o > 1000 > 1000 > 1000 Compound of
CF3
N
cl " (36%) (4.2%) (-24%) Reference Example
6
Inhibitory ratios (%) at 1000nM are indicated in parentheses.
Test Example 3: Inhibitory Test against Collagen Induced Arthritis in Mice
6-Week-old mice were injected intravenously with mouse collagen antibody
cocktail(chondrex). After 3 days, arthritis was induced by an intravenous
injection of
LPS. From one day before the administration of LPS, a test substance suspended
in
an appropriate diluent or the diluent alone(negative control) was administered
orally
once a day, and clinical symptoms of each ankle joint of all foots were
recorded day
after day as numeral scores. The results of the medicaments of the present
invention(Compound No. 4 and 199) are shown in Fig. 1.
Test Example 4: Immediate Type Allergy Reaction Inhibitory Test(Ear swelling
test)
To NC/NGA mouse sensitized by an intravenous administration of anti
DNP-IgE, a test substance was administered intraperitoneally. Two hours after
the
administration, picryl chloride dissolved in olive oil was applied to auricle
to induce
allergic inflammatory response, and swelling of the auricle was measured with
passage
of time and a comparison was made between the drug administered group and the
control group. The results of the medicament of the present invention(Compound
No.
4) are shown in Fig. 2.
Test Example 5: Inhibitory Test against Type II Collagen Induced Arthritis in
Mice
212
CA 02489091 2004-12-08
Balb/c mice were immunized with heterologous type II collagen and Freund's
complete adjuvant by subcutaneous or intraperitoneal injection. At 21 days
after the
treatment, these mice were immunized again with heterologous type II collagen
and
Freund's incomplete adjuvant by subcutaneous or intraperitoneal injection to
develop
arthritis.
A test substance suspended in an appropriate diluent or the diluent alone
(negative control) was administered intraperitoneally once in two days from
the day of
the first immunization, and as for arthritis developed after the second
immunization,
clinical symptoms of each ankle joint of all foots were recorded day after day
as
numerous scores. When the score of the control measured on day 44 after
administration of lOmg/kg of the medicament of the present invention was
expresses
as 100%, rates of exacerbation(°/) of the clinical symptoms of
arthritis were
37.5(Compound No. 4), 76.5(Compound No. 90), 56.2(Compound No. 11),
64.0(Compound No. 88), and 0.0(Compound No. 83).
Test Example 6: Inhibitory Test against Myocardial Ischemia Reperfusion
Disorder in
Rats
Left coronary artery of 7 to 9 week-old rat was ligated to induce ischemic
state.
After 25 minutes, a test substance suspended in an appropriate diluent or the
diluent
alone(negative control) was intraperitoneally administered, and after 30
minutes, the
animal was reperfused. After 24 hours, a rate of necrosis of an ischemic part
of the
cardiac muscle was measured.
The medicament of the present invention(Compound No. 4) inhibited the
necrosis of the cardiac muscle by 60% with an administration at 5 mg/kg in
comparison
with the control.
Test Example 7: Inhibitory Test against The Proliferation of Vascular Smooth
Muscle
Cells of Normal Coronary Artery under Proliferation Stimulation
Vascular smooth muscle cells of normal coronary artery(Cryo CASMC) were
cultured for 2 hours in the presence or absence of a test substance in DMEM
medium
containing 0.5% of FBS and insulin(5 a g/ml). Then, FGF and EGF were added for
proliferation stimulation. The mixture was cultured for 72 hours and
proliferation of
the cells were measured by the MTS assay. The results aree shown in the
following
213
CA 02489091 2004-12-08
table.
Inhibitory Ratio of
Compound Proliferation(%)
Number Compound Concentration
500nM 250nM
4 92.2 87.9
6 94.8 88.0
23 89 31.6
29 90.4 52.2
19 88.6 34.0
90 95.2 89.5
140 86.1 4.3
71 92.4 81.6
11 91.4 86.7
51 86.6 26.2
201 84.4 59.8
93 87.2 12.1
199 84.6 35.1
207 84 52.5
253 91 84.1
268 9.8 5.6
83 87.9 27.1
Industrial Applicability
The medicament of the present invention is useful as medicament for
preventive and/or therapeutic treatment of diseases caused by NF- rc B
activation and
214
Image
